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ABSTRACT 
Objective 
To explore the effect of hypoglycaemia on adverse events in older people 
with diabetes and dementia and determine the feasibility of using 
continuous glucose monitoring in this patient group. 
Methods 
Systematic review on continuous glucose monitoring in older people with 
diabetes: Hypothesis-generating systematic review to inform my feasibility 
study and to identify gaps in the evidence. 
Feasibility study: I conducted a feasibility study of continuous blood 
glucose monitoring to explore continuous glucose monitoring in older 
people with diabetes and memory problems. 
Pharmacoepidemiological study: Retrospective cohort study using the 
Clinical Research Practice Datalink database to test the effect of exposure 
to hypoglycaemia in older patients with dementia.   
Systematic review and meta-analysis on the associations between 
hypoglycaemia and adverse events in older people treated with glucose-
lowering agents: Updated systematic review and meta-analysis of serious 
adverse events associated with hypoglycaemia in older patients treated 
with glucose-lowering agents. 
Findings 
Systematic review on continuous glucose monitoring in older people with 
diabetes: 9 studies were included with a total of nearly 1000 patients.   
Hypoglycaemic episodes occurred in a sizeable proportion and most of 
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these episodes were asymptomatic.  Some patients spent nearly 2 hours 
per day in the hypoglycaemic range. CGM is acceptable to patients and 
improved health-related well-being. 
Feasibility study:  12 participants completed the study and found using 
CGM device acceptable.  Data capture with this device varied considerably 
(3%-92%).  The device captured hypoglycaemic episodes in 6 participants, 
two of which lasted for over 300 minutes. 
Pharmacoepidemiological study:  Older people with dementia and diabetes 
who have had a hypoglycaemic event are at substantially higher risk of 
death, cardiovascular events, falls, fractures and emergency department 
attendances, than those who have not had a hypoglycaemic event. 
Systematic review and meta-analysis on the associations between 
hypoglycaemia and adverse events in older people treated with glucose-
lowering agents: 42 included studies with over 2 million patients.  
Hypoglycaemia is associated with an 80% increased risk in vascular 
complications, a doubling in risk of all-cause mortality, a 55% increased risk 
in dementia, and a 78% and 68% increased risk in falls and fractures 
respectively. 
Conclusions 
My research has highlighted the complications associated with 
hypoglycaemia in older people with diabetes and dementia and set the 
ground work for future studies using continuous glucose monitoring in this 
patient group. 
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STRUCTURE OF THESIS 
This thesis contains two systematic reviews, a pharmacoepidemiological study 
using a large primary care database and a feasibility study.  
 
The publications are listed on pages 17-19. 
 
Each publication is incorporated in separate chapters with preambles before 
each and edits to remove repetition. 
 
Chapter 2 presents a systematic review on the use of continuous glucose 
monitoring in older people with diabetes to consolidate the growing evidence 
base in that area 
 
Chapter 3 presents a feasibility study on the feasibility and acceptability of flash 
glucose monitoring in older people with diabetes and memory problems. 
 
Chapter 4 presents a pharmacoepidemiological study using the CPRD to 
evaluate the effect of hypoglycaemia on adverse events in older people with 
diabetes and dementia.  The adverse events of interest were all-cause 
mortality, cardiovascular events and falls and fractures. 
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Chapter 5 presents an updated systematic review on the association between 
hypoglycaemia and adverse events in older people with diabetes, which will 
incorporate the findings from chapter 4. 
 
Chapter 6 is the discussion chapter collating the core findings of my fellowship 
and setting out areas for future work. 
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AIMS OF THE THESIS 
The idea for this thesis developed from the lack of existing evidence and 
guidelines for standardised care for older people with diabetes and other 
complex health problems, in particular dementia.  Trials in diabetes have 
focused mainly on a younger, less complex population and do not take into 
account the clinical heterogeneity of older patients 1. 
Other researchers have highlighted the lack of standardised care in older 
patients with diabetes 2.  To compound matters, older people with multiple 
comorbidities are faced with polypharmacy and frailty 3.  Whilst for younger 
adults, tight glycaemic control is recommended in order to reduce the risk of 
long-term complications, there are no clear guidelines for older people with 
diabetes 4, especially those with multiple comorbidities, including dementia.  As 
a result, older people with diabetes are at risk of being overtreated with a view 
to achieving glycaemic control targets that are based on data from the younger 
population 5.  Consequently, they are at higher risk of hypoglycaemia, a side-
effect of some of the medications prescribed to manage diabetes. 
Studies involving older people with diabetes have identified significant 
associations between hypoglycaemia and subsequent cardiovascular events, 
falls, fractures and death 6.  In addition, those experiencing hypoglycaemia are 
at risk of worsening cognition 7.  However, we do not know the impact of 
hypoglycaemia in older people with co-existing dementia.   
Based on the lack of evidence and lack of standardised care, there is a strong 
case that steps need to be taken to improve the care of this vulnerable group 
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with complex healthcare needs.  Research into people living with dementia and 
diabetes is an area that has been identified as an area that should to be 
prioritised8. 
Hence, the aims of my thesis were to: 
1. Carry out a systematic review on the use of continuous glucose 
monitoring (CGM) in older people with diabetes to contribute to the 
growing evidence base in that area.  This was a hypothesis-generating 
systematic review to inform the design and conduct of my feasibility 
study and to identify gaps in the evidence and methodological 
challenges I might face when conducting my own study. 
2. Conduct a feasibility study of CGM to explore closer glucose monitoring 
in older people with diabetes and memory problems.  The specific 
question I was interested in was whether older people with diabetes 
and memory problems could tolerate wearing a CGM device for two 
weeks and the extent of data that I could capture. 
3. Complete a retrospective cohort study using the Clinical Practice 
Research Datalink (CPRD) database to test the effect of exposure to 
hypoglycaemia in older patients with dementia.  The question I was 
interested in answering was whether people with diabetes and 
dementia who experience a hypoglycaemic episode are at higher risk of 
adverse events (cardiovascular events, falls and fractures and all-cause 
mortality) compared to older patients with diabetes and dementia who 
do not have a hypoglycaemic episode.  As a secondary aim, I wanted to 
determine whether risk of complications after hypoglycaemia is 
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different in patients with dementia compared to those without 
dementia. 
4. Update previously published systematic reviews on the association 
between hypoglycaemia and adverse events in older people with 
diabetes, which will incorporate the findings from my retrospective 
cohort study.  Whilst my previously published systematic reviews have 
established that older people are at higher risk of adverse events, such 
as cognitive impairment, cardiovascular events, falls and fractures, and 
mortality, my updated review and meta-analysis will include the findings 
from my retrospective cohort study and other studies published in the 
last few years.  The updated review will provide the most up to date 
evidence on the associations of hypoglycaemia in older people and 
adverse events. 
 
The findings will guide clinicians, patients and their carers in making evidence-
based choices regarding intensity of drug therapy and strategies for better 
monitoring in this vulnerable and complex group of people. 
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CHAPTER 1 – INTRODUCTION 
In this introductory chapter, I will outline the basic principles of the 
management of diabetes and the challenges older people, carers and clinicians 
face.  In particular, I will discuss hypoglycaemia (a serious side effect of some 
medications used to manage diabetes) and the impact it has on older people 
with co-existing dementia. 
1.1 DIABETES AND DEMENTIA IN OLDER PEOPLE 
Diabetes mellitus is a very complex chronic illness often accompanied by co-
morbidities and polypharmacy.  It is characterised by a state of hyperglycaemia, 
due to insulin deficiency, insulin resistance or a mix of the two. 
Worldwide, there are about 425 million people living with diabetes, of whom 
approximately 123 million are aged between 65 to 99 years.  The figure for 
older people with diabetes is expected to rise to around 253 million in 20459.  
The cost of diabetes will increase in the older age bracket by over 100 billion 
USD from 2017 to 20459.  The aim of diabetes management is to achieve 
optimum glycaemic control, in order to prevent long-term microvascular, 
macrovascular and neurological complications 10 11.  Optimum control can be 
achieved through lifestyle modifications, oral and/or injectable hypoglycaemic 
medications.  The main classes of hypoglycaemic agents are: insulin, incretin 
mimics, sulfonylureas (SU), glucagon-like peptide-1 (GLP-1) analogues, 
dipeptidyl-peptidase-4 (DPP-4) inhibitors, sodium-glucose transport 2 (SGLT 2) 
inhibitors, biguanides, and thiazolidinediones. 
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1.1.2 DEMENTIA 
It is estimated that around 50 million people across the world are living with 
dementia, which is expected to rise to 125 million by 2050 12.  Dementia is a 
complex chronic progressive syndrome affecting the brain, in which there is 
disturbance of multiple brain functions, including the capacity to learn, 
language, calculation, planning and judgment 13. The syndrome is present when 
there is an effect on a person’s social and/or occupational functions.  Typically, 
Alzheimer’s dementia has an onset late in life with cognitive impairment and 
behavioural symptoms, all of which affect an individual’s day-to-day 
functioning.  The onset of symptoms is insidious and involves progressive loss of 
episodic memory due to hippocampal dysfunction (difficulty in acquiring and 
storing new information, whilst older memories are relatively spared).  
Language is affected, manifesting in word-finding difficulty, following a 
conversation, recognising and naming objects.  Visuospatial orientation can 
become affected and an individual may feel insecure in unfamiliar places and 
get lost driving or walking home.  As the disease progresses, individuals will find 
it difficult to use common objects (whilst retaining the motor skills to carry out 
these tasks).  They will find it difficult to dress, eat and wash by themselves 
without assistance.  Planning and carrying out tasks will become more and 
more challenging.  Currently, there is no cure for dementia.   
Non-pharmacological and pharmacological measures for cognition and 
behavioural and psychological symptoms of dementia can be employed to 
manage the disease. 
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Given that the proportion of older people with dementia who have co-existing 
diabetes is approximately 13-20% 14, these projections indicate that comorbid 
diabetes and dementia are likely to pose a major healthcare burden. 
Regarding life expectancy, Zilkens at al report that mean age of death was 82.4 
years in patients with dementia and diabetes, as compared to 85.0 years in 
those with dementia but no diabetes 15.  People with dementia aged 65 to 84, 
who have had more than 15 years duration of diabetes, have a 40-50% 
increased risk of death, compared to those without diabetes. 
1.1.3 DIABETES CARE IN OLDER PEOPLE 
The challenge regarding the management of diabetes in older people is that the 
evidence base is founded on studies that did not include older people, which 
unfortunately often is the case in clinical studies 10 16 17 18. 
As a result, the targets regarding glycaemic control are applied for young and 
older patients with diabetes alike.  Lipska et al highlighted that older people 
may not benefit from tight glycaemic control compared to younger adults and 
are more prone to hypoglycaemia as a result of intensive treatment strategies 4.  
Various guidelines for the management of diabetes in older people have been 
developed, which contain recurring themes such as adopting a personalised 
approach taking into account each person’s co-morbidities, frailty, 
polypharmacy and life expectancy 19 20.   The model below has been adapted 
from the Standards of Medical Care in Diabetes - 2019 abridged for Primary 
Care Providers 21 and was developed for the management of people with T2DM 
– it does not differentiate or take into account the complexities of older frail 
people with dementia.   
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Figure 1 Goals of diabetes care  
 
(adapted from American Diabetes Association (ADA) Standards of Medical Care – 
2019)21 
 
Whilst there is an emphasis on shared decision-making, it is an intensive model 
with a main goal of preventing complications, ie target-driven glycaemic control 
and monitoring of factors such as weight, blood pressure, cholesterol and 
glucose levels. 
Specific areas which can be more challenging in the management of older 
people with co-existing dementia are around shared-decision making (if they 
lack capacity), monitoring of glucose levels (they may not be able to carry out 
finger-prick testing themselves and have to rely on carers).  Older people might 
have to deal with administering insulin more than once per day and/or take a 
number of different oral medications to manage their diabetes, not taking into 
account any other co-morbidities for which they might be on a host of different 
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medications for.  People with dementia may have difficulty recognising 
symptoms and/or side-effects, adhering to medication and complying with 
treatment8.  In addition, older people with memory problems are at higher risk 
of hypoglycaemia, a serious side effects of some medications (in particular 
insulin and sulfonylureas) given to manage diabetes.  Other challenges older 
people might face in managing their health (or daily activities for that matter) 
include impaired vision due to cataract, impaired motor skills due to arthritis, 
neuropathies secondary to diabetes, or difficulty accessing their general 
practitioner (GP) due to living in rural or socio-economically deprived areas.  
This is mirrored in a French longitudinal observational study, which revealed 
that incident dementia was associated with less frequent diabetes monitoring 
and an increased risk of complications compared with older people without 
dementia 22. 
Despite all of this, there are as yet no standardised guidelines for older people 
who are having to juggle diabetes with co-existing dementia.  A realist synthesis 
to identify theories, frameworks, and processes of care for patients living with 
dementia and diabetes, highlighted the need for a flexible service model 
prioritising patients and carers and better alignment of workforce and 
organisations23.  The review included 89 papers, of which 79 were research 
papers and only ten out of the 89 focussed on people living with dementia and 
diabetes.  Themes emerging from the review relate to dealing with the stigma 
of dementia and how it can affect patients and families accessing diabetes-
related services, supporting and including families and carers in the 
management of each individual’s needs, empowering health care professionals 
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to have the confidence to simplify medication regimes, and empowering 
patients and carers in the management of diabetes and dementia.  Self-
management of diabetes should be encouraged, especially in the earlier stages 
of dementia.  Once the dementia progresses, there should be a shift to more 
monitoring by carers and healthcare professionals and making use of 
technological advances in the management of diabetes2. 
The American Geriatric Society (AGS) has also highlighted the lack of evidence 
in patients with diabetes and dementia. They remarked that older people were 
often excluded from trials in diabetes, resulting in guidelines not being based 
on reliable evidence in this group.  The AGS has called for more research “to 
better understand the risks and benefits of tighter glycaemic control among 
older patients and those with comorbidities” because of “increasing 
observational evidence … that clinicians often do not differentiate treatments 
for older patients who differ widely in health status”24. 
In 2019, an international panel of clinicians, researchers and individuals with 
diabetes developed a consensus statement on clinical targets for CGM data 
interpretation.  The need for a consensus statement arose to provide guidance 
to users of CGM, clinicians and researchers on how to interpret CGM data in 
clinical care and research 25. 
The panel of experts produced a table setting out targets for different diabetes 
groups.  Specifically, for older/high risk people they emphasised the need for 
minimizing the time spent in the hypoglycaemic range (ie <3.9 mmol/L).  The 
recommendation is that this group should spend <15 minutes per day in the 
hypoglycaemic range. 
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Figure 2 Suggested targets for assessment of glycaemic control 
 
(taken from Battelino et al 25) 
Of course, these targets have yet to be tested in a randomised controlled trial 
(RCT) or an observational study to evaluate whether they have a positive effect 
on patients’ health and service use (eg, GP visits, ED attendances). 
1.2 HYPOGLYCAEMIA AND ITS IMPACT 
Hypoglycaemia is a serious adverse event of medications prescribed to manage 
diabetes, which can be fatal.  It has been identified as one of the top three 
preventable adverse drug events by the US Department of Health and Human 
Services26.  
In the US, serious hypoglycaemic episodes resulted in nearly 300,000 
emergency department (ED) visits in adults with either Type 1 diabetes mellitus 
(T1DM) or Type 2 diabetes mellitus (T2DM)26.  Insulin has been shown to be the 
second most common medication associated with accident and emergency 
visits or hospitalisation27.  Population studies have confirmed that drug-induced 
hypoglycaemia is a growing burden in older patients with wide implications for 
patients, carers, healthcare professionals and healthcare service utilization.  In 
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the UK, the East Midlands Ambulance Trust responded to 523 call outs for 
severe hypoglycaemia over a 3-month period (mean age 76 years for the non-
insulin treated patients), with projected annual call out costs of over 
£235,00028.  This is mirrored by evidence in older people in Asia where, there 
has been a 10-fold increase over the last decade in the risk of hypoglycaemic 
episodes in older people needing hospital admission 29 30.  This upsurge has 
been attributed to increased intensity of medical treatment, as well as greater 
co-morbidities and frailty. 
A trend analysis on hypoglycaemia-related mortality in 109 countries from 
2000-2014 using the World Health Organisation (WHO) mortality database, 
showed a 60% increase in hypoglycaemia-related deaths until 2010 and stable 
trends onwards, with most countries in South America, Central America and the 
Caribbean showing the highest rates of hypoglycaemia-related deaths31. 
1.2.1 DEFINITION OF HYPOGLYCAEMIA 
One of the challenges in addressing hypoglycaemia is inconsistent and varied 
definitions.   
‘Hypoglycaemia’ can either be picked up biochemically by measuring glucose 
levels, or based on someone’s symptoms (eg dizziness, confusion, sweating).  
Another clinical example might be picking up seizures via an 
electroencephalogram (EEG) measuring brain wave activity, or be observing a 
person having a seizure (without the need for a test). 
Clinicians accept that certain conditions can be measured through doing a test, 
or through clinical diagnosis based on signs and symptoms (and this is reflected 
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in real-world epidemiology studies where laboratory verification may not be 
available at the time of the actual adverse event). 
With regard to glucose levels, it is accepted throughout the world that the cut-
off for the biochemical definition of the hypoglycaemic range is 3.9 mmol 
(70mg/dL) and below.”   
The 2017 Steering Committee on defining hypoglycaemia identified three 
levels32: 
 Level 1 between 3.9 mmol/L (70 mg/dL) and 3.0 mmol/L (54 mg/dL); 
 Level 2 <3.0 mmol/L (<54 mg/dL) 
 Level 3 severe hypoglycaemia – altered mental state and/or requiring 
third party assistance. 
A crude distinction used by clinicians is ‘mild’ hypoglycaemic events (which an 
individual self-treats) and ‘severe’ hypoglycaemic episodes, when an individual 
needs assistance from a third party in order to correct the glucose levels.  ‘Mild’ 
or ‘severe’ does not give an indication as to the precise glucose levels an 
individual might have at the time of the hypoglycaemic event or the duration of 
the hypoglycaemic event.  Someone might need help to treat their hypo at 3.9 
mmol/L, whereas other individuals are still able to self-treat at levels <3 
mmol/L. 
Interestingly, the cut off of <70 mg/dL (3.9mmol/L) for hypoglycaemia has been 
the subject of debate, as levels between 58-70 mg/dL (3.2-3.9 mmol/L) can be 
physiologically normal in a fasting non-diabetic person33. 
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1.2.2 CAPTURING HYPOGLYCAEMIA 
As with the definition of hypoglycaemia, there are a number of ways to capture 
these events, which in part will be influenced by whether a patient has T1DM or 
T2DM.  Existing research on glucose monitoring has focused on markers of long-
term efficacy or benefit34 35 for achieving optimum control to prevent long-term 
complications.  Patients with T1DM carry out self-monitoring of blood glucose 
(SMBG) by means of capillary finger-prick testing, or CGM.  SMBG in people 
with T1DM can range from a minimum of 4 times per day to 10 times per day 36.  
The disadvantage of SMBG is that it will only provide a snapshot of an 
individual’s glucose levels as and when that person makes a conscious decision 
to test.  It gives no insight into trends and there are no continuous 
measurements. 
SMBG accuracy is very much user and instrument-dependent 37. 
Figure 3 Capillary finger prick testing 
 
CGM is a device that sits just under a patient’s skin (either on the back of an 
arm or on the stomach).  The device has a sensor which can measure interstitial 
glucose (iG) levels continuously (day and night) throughout the lifetime of a 
sensor, which is usually around 10-14 days.  Results can either be accessed by 
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the patient through swiping a reader over the sensor or can be transmitted via 
Bluetooth.  Alarms can be set to indicate if glucose levels go too high or low and 
it is possible to see trends when glucose levels are rising or dropping.  Data can 
be downloaded via software and summarised in a report (ambulatory glucose 
report) setting out daily glucose and insulin patterns.  This can help in adjusting 
and optimising the management plan for that individual.  Newer CGM devices 
allow for the user to share his/her data with either a carer or parents (in 
children with T1DM) – readings are transmitted to the third person giving 
him/her real time updates about the patient’s glucose levels.  
Figure 4 CGM device with Bluetooth 
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Figure 5 CGM device (“flash glucose meter”) where readings are obtained by 
swiping the meter over the sensor 
 
 
The disadvantages with CGM are cost, possible triggering of anxiety due to data 
overload, finger-prick testing is not completely eliminated, it requires a lot of 
motivation to make the most of the device and the data it collects, and the 
sensor can cause discomfort or evoke feelings of self-consciousness. 
Whilst cost can be a barrier to access to CGM, recently, the National Health 
Service (NHS) announced its long-term plan, which included a pledge to 
enhance the support it offers people with diabetes.  As part of this pledge, 
people with T1DM will benefit from flash glucose monitoring (a version of 
CGM)38.  NHS England have published strict criteria for people with T1DM who 
might be able to get CGM on the NHS 39. 
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Studies have evaluated (and guidelines produced) the use of flash glucose 
monitoring in adults and children.  A consensus group of diabetes specialists 
within Europe agreed that it is an effective standard for analysing glucose data 
in diabetes management and can assist people (or their carers) with diabetes 
understand daily life with their conditions40 41.   
The majority of randomised trials that have been conducted on CGM are in 
T1DM, which demonstrated overall improvement in glycated haemoglobin 
(HbA1c) and a reduction of time spent in the hypoglycaemic range (<3.9 
mmol/L).   
Whilst patients with T2DM are only recommended to use SMBG if they are on 
insulin, there is evidence of hypoglycaemia or they are on oral medication that 
increases the risk of hypoglycaemia whilst driving or operating machinery 42.  
There is less evidence available about the use of CGM in type 2 diabetes, 
however, a few RCTs on CGM in T2DM have also shown improvement in time 
spent in hypoglycaemia and HbA1c 43 44, and a narrative review have 
highlighted that there are signals that its use promotes glycaemic and weight 
control and improves lifestyle45. 
Nevertheless, CGM use in T2DM is becoming more widespread, especially in the 
US.  Fonda et al looked at the long-term cost-effectiveness of CGM use in an 
RCT involving people with T2DM not on insulin who had a reduction in HbA1c.  
The authors found that CGM is a cost- effective disease management option 46. 
Anyone with T1DM or T2DM can opt to self-fund CGM. 
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Lastly, hypoglycaemic episodes requiring third party assistance, can be captured 
via capillary finger prick testing by a healthcare professional or venous sampling 
in a hospital setting. 
Monitoring glucose levels can prove challenging in older people with co-existing 
dementia, who face difficulties in recognizing and managing changes in glucose 
levels.  Recent studies of CGM technology in older adults (without dementia) 
have detected higher rates of hypoglycaemia compared to SMBG47 48, in 
addition to capturing asymptomatic hypoglycaemic episodes49.  However, to 
the best of my knowledge, there are no studies looking at the feasibility of the 
use of CGM technology in older people with memory problems and diabetes.   
In my thesis, the feasibility study captured hypoglycaemia based on CGM 
measured glucose levels.  The cohort study identified hypoglycaemic events 
based on clinical diagnoses (the clinician attending the patient with 
hypoglycaemia will in all likelihood have measured the glucose levels, but as a 
researcher, I am not able to access these results).  The studies in both 
systematic reviews used a mix of methods to identify hypoglycaemic episodes, 
ranging from capturing glucose levels, self-reporting by patients to review of 
healthcare records. 
1.2.3 INCIDENCE AND PREVALENCE OF HYPOGLYCAEMIA  
The true incidence of hypoglycaemia in the older population is tricky to 
establish, especially when looking at people with diabetes in the community as 
compared to inpatients. Hypoglycaemic episodes are more common in T1DM, 
however people with insulin-treated T2DM can be prone to frequent 
hypoglycaemia, particularly at night33.  Mild episodes of hypoglycaemia are 
 40 
dealt with by the affected person without recourse to any medical help.  In 
addition, such episodes may not have triggered measurement of glucose levels, 
via, for example, finger-prick testing.  Instead, people manage symptoms as 
opposed to an objective glucose level 50.  Furthermore, it is possible to have 
asymptomatic hypoglycaemic episodes, especially at night 33.  Studies looking at 
the incidence and prevalence of hypoglycaemia can also be difficult to compare 
due to different hypoglycaemia definitions, heterogeneity of populations and 
varied modes of capture of hypoglycaemic episodes33.   
Looking at the general population, the UK Hypoglycaemia Study group carried 
out an observational study in patients with T1DM and T2DM.  They relied on 
self-reporting of hypoglycaemic episodes and glucose capture via CGM.  Severe 
hypoglycaemia rates in patients with T2DM on sulfonylureas or insulin ranged 
between 0.1 to 0.2 episodes per subject year 51.  In a further study, participants 
with T1DM and T2DM on insulin were recruited from a diabetes register in 
Scotland and asked to prospectively record the number of mild and severe 
hypoglycaemic episodes experienced over a one-month period.  Patients with 
T1DM experienced hypoglycaemic events, at a rate of 43 events per patient per 
year.  Patients with T2DM on insulin had an incidence of 16 hypoglycaemic 
events per patient per year.  Duration of insulin treatment and previous 
hypoglycaemia were key predictors for hypoglycaemia in patients with T2DM52.  
Lastly, Akram et al carried out a questionnaire survey in Danish patients with 
insulin-treated T2DM asking about occurrence of hypoglycaemia, past 
hypoglycaemia awareness.  Based on this survey, the incidence of severe 
hypoglycaemia was 0.44 episodes per person per year53. 
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Focussing on the older population, Abdelhafiz et al carried out a comprehensive 
review exploring the relationship between hypoglycaemia, frailty and 
dementia3.  The authors argue that the incidence of hypoglycaemia in older 
people is in all likelihood underestimated, although a substantive evidence-base 
for this is lacking.  They put forward the argument that hypoglycaemia, frailty 
and dementia have a reciprocal relationship (Figure 6).  Many frail older people 
are overtreated and are on hypoglycaemic medications that convey a high risk 
of hypoglycaemic events (insulin and sulfonylureas) 54 55. 
Figure 6 Reciprocal relationship between hypoglycaemia, frailty and dementia  
 
(adapted from Abdelhafiz et al 2016) 3 
 
Cross-sectional studies have shown that severe hypoglycaemia was more 
prevalent in patients with dementia and diabetes, in particular those taking 
insulin56 57.  Feil et al’s database study found that in participants taking insulin, 
hypoglycaemia was more common in patients with dementia (26.5%) and 
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cognitive impairment (19.5%) compared to those with neither condition 
(14.4%)57.  Hypoglycaemia was identified from outpatient visits, emergency 
department and inpatient admission codes.  
In Abbatecola’s cross-sectional study, severe hypoglycaemic events were 
defined as a documentation of a plasma glucose of 50 mg/dL (2.8 mmol/L) or 
lower and symptoms requiring assistance from a third party to correct the low 
glucose.  Severe hypoglycaemia was more prevalent in patients with dementia 
on sulfonylureas 56.  A further study using a German/Austrian diabetes registry 
found that older people with diabetes and co-existing dementia had a higher 
rate of hypoglycaemia and used insulin more often compared to those without 
dementia.  Those with co-existing dementia and insulin therapy experienced 15 
severe hypoglycaemic episodes per 100 patient years and 8 per 100 patient-
years if taking sulfonylureas.  In contrast, patients without dementia 
experienced 10 severe hypoglycaemic episodes per 100 person-years if on 
insulin and 5 per 100 person-years when taking sulfonylureas58.   
In a retrospective cohort study using a US insurance database, the incidence of 
serious hypoglycaemia (defined as requiring hospitalisation, emergency 
department attendance or death) was 2 per 100 person-years in older people 
aged 65 and above.  The authors highlighted that increasing age, polypharmacy 
and frequent hospitalisations put patients at higher risk of severe 
hypoglycaemic episodes and that this vulnerable group needs close monitoring 
for adverse events59.  Chen et al reported a higher occurrence of any kind of 
hypoglycaemic events in patients living in care homes. 41.9% of care home 
residents with diabetes who were being treated with medication experienced 
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hypoglycaemic episodes over a one-year period (26 out of 62 care home 
residents with diabetes with a mean age of 76 years).60. 
1.2.4 RISK FACTORS FOR HYPOGLYCAEMIA 
Risk factors for hypoglycaemia for any person with diabetes include: use of 
insulin, sulfonylureas, kidney impairment, exercise, previous hypoglycaemic 
episodes, duration of diabetes and erratic meals 61.  Education around 
hypoglycaemia prevention, detection and management is essential both for 
patients and/or carers 20. 
1.2.5 PHYSIOLOGY AND SYMPTOMS 
Hypoglycaemia is a state of glucose deficiency, often as a result of diabetes 
medication such as insulin or sulfonylureas.   Counter-regulatory hormones 
(adrenaline, glucagon, glucocorticoids, growth hormone) are secreted in 
response to low glucose levels, in addition to the body suppressing endogenous 
insulin secretion (Figure 7). 
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Figure 7 Glucose concentrations and physiological changes 
(adapted from Zammitt et al)61 
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Symptoms of low glucose levels include irritability, hunger, sweating, light-
headedness, palpitations, confusion (Figure 8).  In the worst case scenario, it 
can lead to death, probably as a result of ventricular arrhythmias 20 33.  
However, symptoms of hypoglycaemia are person-specific and can change with 
advancing age, due to changes in the counterregulatory response61.  However, 
we do not know exactly at what age this occurs. 
Figure 8 Signs and symptoms of hypoglycaemia  
 
(taken from Diabetes UK webpage)62 
Being able to recognise falling glucose levels is crucial to self-management and 
preventing further deterioration. This recognition of hypoglycaemia and being 
able to efficiently self-manage hypoglycaemic events, becomes problematic in 
frail older people with co-existing dementia (and possibly further co-
morbidities).  They may experience reduced awareness of hypoglycaemic 
warning symptoms, reduced secretion of glucagon, may not be able to vocalize 
what they are experiencing, be impaired by altered psychomotor performance, 
all of which can lead to delays in treating the hypoglycaemic event63.   
Nocturnal hypoglycaemia is particularly tricky, as it is often asymptomatic and 
can last for hours 33.  
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1.2.6 MANAGEMENT OF HYPOGLYCAEMIA IN OLDER PEOPLE 
1.2.6.1 ACUTE MANAGEMENT 
A hypoglycaemic episode has to be treated with fast-acting carbohydrates (eg 
fruit juice, glucose tablets, jelly babies). 15-20g of quick-acting carbohydrates is 
usually an adequate amount. If the person experiencing the hypoglycaemic 
event is confused/uncooperative, but able to swallow, then 1.5-2 tubes of 
glucose gel is recommended.  If a person is unconscious and/or is having a 
seizure, intramuscular glucagon can be administered, or, in the hospital setting, 
intravenous 10-20% glucose64. 
Figure 9 Simplified pictorial guide for making treatment decisions using CGM 
(Dexcom G6) in an older person when glucose levels are falling 
 
1.2.6.2 LONG-TERM MANAGEMENT 
The cornerstone of the long-term management has to be striking the right 
balance between adequate glycaemic control and avoidance of hypoglycaemic 
events.  Patient education, glucose-monitoring and optimisation of prescribing 
will all play a part in this. However, Lash et al have identified a lack of resources 
to help clinicians and patients with diabetes reduce the risk of hypoglycaemic 
episodes26. 
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Striking the right balance is particularly pertinent in older frail adults with 
multiple co-morbidities and the concept of deprescribing is gaining ever 
increasing momentum.  Deprescribing consists of lowering doses of 
medications, switching medications or stopping medications altogether65.  
There is a lack of evidence, which shows that older, frail adults who have 
cognitive impairment or are nearing the end of life benefit from tight glycaemic 
control65.  Farrell et al recommend deprescribing medications known to 
contribute to hypoglycaemia in older adults at risk (especially those with 
multiple co-morbidities and cognitive impairment) and individualising targets65.  
Other researchers have recently published findings of a systematic review, 
which suggest that overtreatment is common in frail older people with multiple 
co-morbidities and that deintensification appears safe 55. 
There also needs to be a shift in how we carry out monitoring of glucose levels 
in older people with diabetes and dementia.  We need to explore the use of 
CGM in this vulnerable group and I will discuss this in more detail in later 
chapters. 
1.2.7 ADVERSE EFFECTS OF HYPOGLYCAEMIA  
The immediate effect of hypoglycaemia can be confusion, visual disturbance, 
alteration in mood and lack of concentration.  It also disrupts day-to-day 
activities, including exercise and driving.  Confusion and visual disturbance can 
trigger falls and resulting injuries, such as fractures.  There is also an increased 
risk in cardiovascular events, coma and death 6. 
Longer term, both hypoglycaemia and T2DM are risk factors for dementia66.  
Persistent or severe hypoglycaemic episodes can lead to permanent neuronal 
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damage3.  Gibas et al put forward the theory of “brain starvation” in patients 
with T2DM, due to concurrent hyperinsulinemia and relative hypoglycaemia 
due to insulin resistance resulting in apoptosis of healthy neurons from 
catabolic degeneration67.  Radiological studies in patients who had suffered 
profound hypoglycaemia have shown that neurons in the hippocampal and 
temporal areas, cerebral cortex, substantia nigra and basal ganglia are 
particularly sensitive to hypoglycaemia 66.  Lee et al have found that 
hypoglycaemia was associated with smaller total brain volume on MRI 68. 
Other studies have found a dose-response relationship between the frequency 
of severe hypoglycaemia and incidence of dementia69, and a nearly three-fold 
increase in risk of dementia in older patients with diabetes and hypoglycaemia 
in a seven-year follow-up study in older Taiwanese patients with diabetes70. 
I carried out a systematic review and meta-analysis of 12 studies and 1.4 million 
participants, which revealed significantly greater likelihood of hypoglycaemia in 
patients with impaired cognition compared to those without.  In addition, those 
affected by hypoglycaemia were more susceptible to worsening cognitive 
impairment and dementia, leading to a potentially vicious cycle of decline 7. 
In a further meta-analysis, I found a significant association between 
hypoglycaemia and falls (Odds Ratio (OR) 1.89; 95% Confidence Interval (CI) 
1.54, 2.32), or fractures (OR 1.92 95% CI 1.56, 2.38). Hypoglycaemia was also 
associated with cardiovascular complications, (OR 1.83; 95% CI 1.64, 2.05), 
microvascular complications (OR 1.77; 95% CI 1.49, 2.10), and increased 
likelihood of death, (OR 2.04; 95% CI 1.68, 2.47).  This second meta-analysis was 
based on patients with diabetes in general, and there was insufficient data to 
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directly evaluate serious consequences of hypoglycaemia in those with co-
morbid dementia 6. 
Two more recent studies have shown that severe hypoglycaemia may influence 
cardiovascular risk and death independently of diabetes severity and general 
vulnerability, in addition to there being an association with higher risk of hip 
fracture 71 72. 
1.3 WHAT NEEDS TO BE DONE 
The pressing need to address growing concerns about hypoglycaemia and its 
adverse effects, has led the Endocrine Society to develop a Hypoglycaemia 
Prevention Initiative 26.  Whilst clinical guidelines recommend personalised 
medicine and individualising goals in patients at risk of hypoglycaemia, this 
appears as yet not to have been translated into day-to-day clinical practice.  
Lash et al refer to a survey of healthcare professions carried out by the US 
Department of Veterans Affairs, in which 50% of the nearly 600 respondents 
reported no concerns over potential harms associated with tight glycaemic 
control in older people.  The authors recommend advancing better 
management of hypoglycaemia though use of risk assessment and clinical 
support tools, patient education and shared decision-making 26. 
It is becoming clear that new approaches or changes in mindset are needed 
when formulating monitoring strategies for older patients, aimed towards 
measuring harm from hypoglycaemia rather than just efficacy targets.    
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It is necessary to establish more robust evidence to support the principles set 
out in the figure below to guide the management of older people with diabetes 
and dementia. 
Figure 10 Factors for hypoglycaemia minimization 
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CHAPTER 2 - A SYSTEMATIC REVIEW OF CONTINUOUS GLUCOSE 
MONITORING IN OLDER PEOPLE WITH DIABETES MELLITUS 
 
2.1 PREAMBLE 
The first chapter outlined the basic principles of the management of diabetes 
and the specific challenges that older people, clinicians and carers encounter.  
This chapter presents a systematic review on continuous glucose monitoring in 
older people with diabetes consolidating the growing evidence base in this 
area.  It was published in Journal of Diabetes and its Complications in 201873.  
Chapter 2 is largely a replication of the publication, whilst also expanding on 
background, results and discussion sections. 
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2.2 CHAPTER SUMMARY 
2.2.1 BACKGROUND 
The presence of multiple comorbidities and cognitive decline poses major 
challenges for the self-management of older patients with diabetes.  The best 
way to monitor glucose levels in this population and the extent of harm from 
hypoglycaemia is not known.  The development of CGM over the last two 
decades has enabled a more comprehensive understanding of individual 
glycaemic profiles, however the focus has been on children and younger adults.  
Evidence on the use of CGM in older patients has started to emerge in recent 
years, but there has been no systematic review consolidating this growing 
evidence base. 
This was a hypothesis-generating systematic review to inform my feasibility 
study (chapter 3).  The parameters I was interested in were: 
 Methods used in the studies and extent of overall capture of glucose 
readings; 
 Quantitative estimates regarding time and depth of hypoglycaemia; 
 Acceptability of CGM to participants; 
 Adverse events and other patient outcomes associated with CGM use. 
2.2.2 METHODS 
The protocol was registered on the international database of pre-registered 
systematic reviews, PROSPERO (CRD42017068523) (Appendix 1). 
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A literature search of SCI Web of Science, Ovid SP MEDLINE and EMBASE from 
January 2010 to June 2017 was conducted for observational studies and 
randomized controlled trials of CGM in older patients (mean age 65 or older) 
with diabetes.  Studies that involved only hospitalized patients were excluded. 
Two reviewers independently extracted data (in particular, hypoglycaemic 
episodes) captured with the use of CGM.  Adverse events and acceptability of 
CGM were also assessed. 
2.2.3 RESULTS 
After screening 901 abstracts, I included nine studies with a total of 989 older 
patients with diabetes.   
The CGM studies reveal that hypoglycaemic episodes were occurring in a 
sizeable proportion (28-79%) of participants.  Most (80-100%) of these episodes 
were asymptomatic, with some patients spending nearly two hours per day in 
the hypoglycaemic range.  Older people with diabetes found CGM acceptable 
and experienced improved health-related well-being. 
2.2.4 CONCLUSIONS 
CGM frequently picks up asymptomatic hypoglycaemic episodes in older 
patients with diabetes. Users of CGM report improved well-being, and 
reduction of diabetes-related stress. 
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2.3 BACKGROUND 
Chapter 1 outlined the challenges of self-management of diabetes mellitus in 
older people with co-existing dementia, in addition to the growing concerns 
about hypoglycaemia and its adverse effects in this vulnerable group of people.  
I also discussed how recent advances in CGM technology may uncover the true 
extent of hypoglycaemia (including asymptomatic hypoglycaemic episodes). 
2.3.1 EVOLUTION OF CGM 
CGM first became available nearly 20 years ago and provides a way to 
continuously measure interstitial glucose levels, as opposed to intermittent 
finger-prick testing, which measures capillary blood glucose levels.  The overall 
goal of using CGM is to improve metabolic control and the evidence base to 
date is that it does lead to improvements in HbA1c, in addition to reducing 
hypoglycaemic events74 75.  An open-label randomized controlled trial using the 
FreeStyle Libre in people with type 2 diabetes on a basal-bolus regime showed a 
significant reduction of time spent in the hypoglycaemic range, but no 
significant change in HbA1c43.  More recently, Tyndall et al published a 
prospective observational study of 900 people with T1DM assessing change in 
HbA1c following flash glucose monitoring (compared to 518 not using flash 
glucose monitoring).  Whilst there were significant improvements in HbA1c, an 
increase in symptomatic and asymptomatic hypoglycaemic episodes were also 
reported, which the authors thought could be related to greater capture of 
previously unrecognised hypoglycaemia76. 
Despite this, it is still not the norm for individuals to use CGM over SMBG via 
finger stick tests.  Being relatively new and rapidly-evolving technology, barriers 
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to using CGM include cost, lack of standardised download of data, no 
standardised approach on how best to use the data, reliability of the glucose 
measurements and human factors77.   
2.3.1.1 TRANSMISSION OF DATA 
Depending on the manufacturer, CGM can transmit data continuously via 
Bluetooth to a receiver or smartphone, which then enables alarms to sound 
when readings are either high or low (Dexcom, Medtronic, Senseonics).  In 
addition, readings provide users with trend arrows, indicating whether glucose 
levels are predicted to rise, fall or remain steady.   
An alternative is ‘flash’ glucose monitoring such as the FreeStyle Libre (Abbott 
Diabetes Care), which has become available in 44 countries over the last few 
years and is licensed for adults and children.  It provides a cheaper alternative 
to other CGM devices and is based on similar sensor functionality.  The main 
differences are that whilst glucose levels are measured continuously, the data 
are not transmitted continuously from the sensor.  Instead, the user has to 
swipe/scan (‘flash’) the sensor with a reader (based on Near Field 
Communication technology) at least eight-hourly in order to capture 24-hour 
data every day throughout the life time of a sensor (14 days) 77.  Anyone using 
the FreeStyle Libre has to physically scan the sensor in order to see glucose 
readings.  Abbott have announced that they will be introducing a version 2, 
which includes a Bluetooth transmitter to enable optional alarms, although 
users will still need to scan the sensor regularly to obtain the full data. 
Finally, some CGM devices are ‘blinded’, whereby a user is not able to see the 
readings and the data is transmitted directly to a healthcare professional.  
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Examples include the Freestyle Libre Pro, the Medtronic iPro and the Dexcom 
Seven Plus (blinded mode).  Blinded CGM can be advantageous in a clinical trial 
setting, as trial participants will not be able to see their readings minimising any 
potential bias (‘Hawthorn effect’) that could arise.  In a healthcare setting, 
blinded mode could facilitate maintenance of an individual’s usual routines and 
behaviours. 
2.3.1.2 RELIABILITY OF CGM MEASUREMENTS 
CGM captures interstitial glucose levels, in contrast to capillary glucose.  
Interstitial glucose readings are known to lag behind capillary blood glucose 
readings, which relates to the diffusion time of glucose from capillaries to 
interstitial fluid and diffusion across sensor membranes 78.  There is an 
approximately 5-10 minute delay in interstitial fluid glucose response to 
changes in blood glucose79 80. 
A 2013 study concluded that the physiological delay of 5-6 minutes between 
blood glucose and interstitial glucose levels should not be an obstacle to CGM 
sensor use in real-world treatment settings 80.  A study of time delay with CGM 
devices reported that factors other than delay have a larger influence on the 
overall performance of a CGM device 81. 
Before 2016, CGM devices available in the US were only approved for use as 
adjunctive devices.  This meant that user had to confirm the interstitial glucose 
reading with a capillary reading, before making a decision about insulin 
adjustment, although a survey of adult patients in the US T1DM Exchange Clinic 
registry revealed that only 26% of 999 participants in the survey carried out a 
capillary blood glucose test before making treatment decisions82. 
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A randomized non-inferiority trial in adults with T1DM confirmed that it is safe 
to use CGM readings (Dexcom G4 Platinum) without confirmatory capillary 
blood glucose measurements.  It should be pointed out though that the 
participants in this trial all had well-controlled T1DM at low risk of severe 
hypoglycaemia82. 
Research has also shown that interstitial glucose measurement with the 
FreeStyle Libre device differed on average by around 11% compared to capillary 
blood glucose values 79.  However, Abbott, the manufacturer of FreeStyle Libre, 
has reported their sensor may have less accuracy in the lower glucose ranges.  
Abbott’s safety information discloses a clinical study showing that 40% of the 
time when the device indicated an interstitial glucose level of less than 3.3 
mmol/L, the capillary reading was between 4.5 mmol/L to 8.9 mmol/L. 
Older CGM devices required regular daily calibration (between 2 to 4 times per 
day) with capillary blood glucose measurements.  FreeStyle Libre and Dexcom 
G6 do not require any calibration, although the product information does state 
that should symptoms not match with the interstitial readings, then the user is 
advised to double-check with a capillary test.  The manufacturer of FreeStyle 
Libre point out that a capillary glucose reading is required during times of 
rapidly changing glucose levels when interstitial levels may not accurately 
reflect blood glucose, if hypoglycaemia or impending hypoglycaemia is reported 
or the symptoms do not match the interstitial reading (footnote 1 at 
https://freestylediabetes.co.uk/freestyle-libre/interstitial-vs-blood-glucose 83). 
Manufacturers of the newer CGM devices claim that their sensors are more 
accurate now at the extremes of glucose ranges. 
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The following factors influence the accuracy of CGM in a clinical setting:   
 Intrinsic technical ability of the hardware; 
 Performance of the software that picks up the sensor data and conducts 
processing to estimate the glucose concentrations; 
 Age and batch of the sensor; 
 Rate of change of glucose concentrations (which will be in turn be 
influenced by patient characteristics including age, physical activity, 
illness); 
 Absolute glucose value, whether at low or higher end. 
There is as yet no agreed standard for defining the performance of a CGM 
system. To start with, there are major methodological difficulties in obtaining a 
similarly large 'reference' set of glucose values from venous or capillary blood 
sampling concurrently for comparison against the hundreds of values captured 
by CGM over a 10-14-day period.  There is also no single 'diagnostic accuracy' 
summary statistic that can be presented as a valid and generalizable depiction 
of the CGM performance in a dynamic environment subject to influence by a 
constantly evolving multitude of internal and external factors. 
Performance of any glucose monitor (be it CGM or SMBG), can be described by 
either analytical or clinical accuracy.  Analytical accuracy describes the 
difference between the glucose value captured by a device compared to a 
reference glucose value.  Examples of measures that capture analytical accuracy 
are mean absolute relative difference (MARD) and diagnostic accuracy 
statistics.  Importantly, measures describing analytical accuracy do not take into 
account of the clinical importance of any discrepant measurements. 
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A consensus error grid can be used to depict and describe clinical accuracy. 
Here, paired results from a glucose meter and the reference method are 
plotted on an error grid (see Figure 11) and risk zones are superimposed on the 
graph.  The ‘error’ in this grid relates to the discrepancy between the referent 
value and the CGM value. The ‘consensus’ part relates to qualitative judgments 
(predefined by a consensus panel comprised of clinicians) about treatment 
decisions and clinical consequences that may arise due to the discrepancies 
between the CGM device and the referent glucose value. 
The different risk categories in the consensus error grid (zones A to E) are 
defined as: 
 A – no effect on clinical action (eg clinically accurate values within 20% 
of the reference sample); 
 B - altered clinical action or little or no effect on clinical outcome (eg 
values outside 20% of the reference sample but would not lead to 
inappropriate treatment); 
 C - altered clinical action (eg values that would lead to overcorrection of 
glucose levels); 
 D – altered clinical action – could have a significant clinical risk (eg, 
dangerous failure to detect and treat high or low glucose); 
 E – altered clinical action – could have dangerous clinical consequences 
(eg values that could lead to treatment contradictory to that needed) 84 
85 86. 
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MARD 
Put simply, MARD describes in percentage terms the disparity between the 
glucose level displayed by the CGM device compared to reference blood 
glucose results.  A lower MARD reflects a smaller discrepancy between the CGM 
device and referent value, and is considered to represent better sensor 
performance.  For example, if the CGM device consistently showed readings of 
10.0mmol/L when reference blood glucose readings were 9.0 mmol/L, then the 
MARD would be 10%.  Sophisticated statistical models are used in calculating 
and comparing single overall MARDs across studies based on summarizing the 
percentage difference seen in multiple samples across a wide range of glucose 
values. Typically, the MARD for CGM devices is better at normal glucose values, 
whereas the performance deteriorates outside range, thus resulting in larger 
MARDs79.  
Guidance published in the International Consensus on use of CGM, states that 
whilst “controversy exists regarding an exact cut-off point for accuracy, in silico 
testing has shown that a further lowering of MARD below 10% from reference 
values has little additional benefit for insulin dosing” 87 88.  Both the Freestyle 
Libre and Dexcom G6 CGM devices have MARD <10% and regulatory authorities 
have approved their use without having to conduct finger-prick tests (see Table 
1). 
The limitations of looking only at the overall MARD are that it does not tell us 
magnitude of errors at different glucose levels, nor the clinical importance of 
the discrepancies.  In addition, MARD can vary during sensor life, for example, it 
can be higher during the first few days of a new sensor 86. 
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Table 1 CGM devices, MARDs and calibration requirements 
Device MARD (%) Calibration requirements 
Abbott Freestyle Libre  9.7 None, although user advised to 
check their glucose levels with a 
capillary reading if interstitial 
reading does not reflect 
symptoms 
Dexcom G6 9.0 None, although user advised to 
check their glucose levels with a 
capillary reading if interstitial 
reading does not reflect 
symptoms 
Medtronic Enlite 13.6 Every 12 hours 
Medtronic Guardian 
Sensor 3 
9.6 (abdominal 
insertion with 3-4 
calibrations/day); 8.7 
(arm insertion with 3-
4 calibrations per day) 
Every 12 hours 
Professional Abbott 
Freestyle Libre 
(blinded) 
12.3 None 
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Medtronic iPro2 
(blinded) 
13.6 None (but at least one capillary 
glucose level entry every 12 hours 
required for system uploads) 
(adapted from ADA publication 89) 
 
By way of comparison, in 2015 Freckmann et al evaluated the accuracy of four 
SMBG systems based on two datasets.  One dataset evaluated 100 samples 
with blood glucose concentrations below 3.9 mmol/L and the second dataset 
evaluated 100 samples distributed following International Organization for 
Standardization (ISO) standard 15197 (in vitro diagnostic test systems – 
requirements for blood-glucose monitoring systems for self-testing in managing 
diabetes mellitus).  The authors reported MARD values ranging from 4%-13.4% 
for the first dataset that included low glucose value and 4.8% to 8.9% for the 
second ISO dataset 90. 
 
Diagnostic Accuracy statistics at specific ‘low’ thresholds 
For Freestyle Libre, the manufacturers report that 40% of the time when the 
device indicated an interstitial glucose level of less than 3.3 mmol/L, the 
capillary reading was between 4.5 mmol/L to 8.9 mmol/L. 
Wadwa et al have evaluated the alerts of the Dexcom G6 CGM system in a 
prospective multicentre study 91.  When the hypoglycaemia threshold alert was 
set to 3.9 mmol/L (70 mg/dL), the false alert rate was 15.6% whereas the false 
alert rate worsened to 30.1% when set to 3.3 mmol/L (60 mg/dL). 
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The main limitation of diagnostic accuracy statistics based on binary categories 
is that the actual size of the difference between the true and CGM value is not 
presented.   
 
Clinical consensus error grids 
A consensus error grid comparing CGM and the reference value has been 
reported for Freestyle Libre (Figure 11). 
 
Figure 11 Error grid analysis – FreeStyle Libre79 
 
In Figure 11, the percentage of results in Zone A (clinically accurate) of the 
consensus error grid was 86.7%.  The percentage of sensor results in Zones A 
and B (clinically acceptable) of the consensus error grid was 99.7% 79. 
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In summary, each method of evaluating and reporting performance of CGM 
gives different but useful information and experts consider that interpretation 
of the MARD together with consensus error grids will present a more complete 
picture90. 
  
Looking at the clinical context, for users of any glucose monitoring device, it is 
vital that clinically important differences are identified rather than just numbers 
relating to % deviation.  I recognise that CGM is a relatively new evolving 
technology that has limitations (like every evolving technology).  However, 
clinical practice and technology should also move forward to harness the 
strengths of CGM whilst working around the recognized limitations. 
CGM technology has evolved to address issues surrounding accuracy: 
1. The ability to take multiple readings of the real-time glucose value 
(thereby avoiding spurious one-off errors) interpreted together with the 
trend display showing change in glucose over time; 
2. Predictive software algorithms such as Urgent Low Soon (Dexcom G6) that 
analyse the pattern of change and generate alerts of impending 
hypoglycaemia. 
These elements empower a person with diabetes to take taking corrective 
action BEFORE, for example, hypoglycaemia actually happens. Clinicians 
advocate this method to act on an impending hypo, rather than wait for 
notification of an actual hypo.  
Hypoglycaemia has potentially very serious consequences, whereas corrective 
action is simple and likely to be very beneficial rather than harmful. The 
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predictive algorithm has also been implemented together with smart insulin 
pumps to suspend insulin delivery before low rather than stop only when the 
low has already occurred (discussed further in section 2.3.1.4.1). 
In these instances, the clinicians do not feel that there is a need for highly 
precise measurements – action should be taken if the glucose value is 4.05 
mmol/L or 3.75 mmol/L, or the true value of 3.9 mmol/L. There is no clinical 
rationale to wait until the exact threshold of 3.9 mmol/L is reached. 
As discussed above, it is also necessary to bear in mind that SMBG systems have 
MARDs between 4-13%.  Based on the currently accepted MARD of <10% with 
Dexcom G6 and FreeStyle Libre, the use of CGM would not necessarily be 
inferior to SMBG use because CGM has the added benefit of detecting 
asymptomatic hypoglycaemia, and can also sound alerts for impending 
hypoglycaemia. 
2.3.1.3 LIFESPAN OF SENSORS 
Depending on the manufacturer, sensors have a life span between 6 to 90 days, 
with implantable sensors (Eversense) lasting the longest. 
2.3.1.4 SOFTWARE AND INTEROPERABILITY 
The manufacturers of the various CGM devices provide free software, which 
enables users to download all the data that is collected throughout the life time 
of each sensor.  Non-standardised reporting of data makes it more difficult to 
analyse different CGM devices in a trial setting or carry or systematic reviews 
and meta-analyses 77.  Nevertheless, ambulatory glucose profiles provide a 
useful summary and overview of a user’s data. 
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Figure 12 Example of an ambulatory glucose profile 
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Users of CGM devices are unlikely to download data on a daily basis and it is not 
clear what information is used to make management decisions, eg based on an 
individual glucose level, the trend arrow (picture below), or the trend over the 
last few hours 77.  In addition to the software, users can download apps so that 
data can be viewed with their smartphone.  It is also possible to share data with 
relatives or carers. 
Figure 13 Picture of trend arrows – Dexcom G6 92 
 
Figure 14 Display of individual glucose reading on a smartphone 92 
 
 
A further advantage of CGM systems is the capability of alarms, which warn 
users of high and low glucose levels.   
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Pictures of the types of alarm provided by the Dexcom G6 system are below: 
Figure 15 Low glucose alert – Dexcom G6 92 
 
 
Figure 16 Urgent low soon alert – Dexcom G6 92 
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Figure 17 Urgent low alarm – Dexcom G6 92 
 
 
 
2.3.1.4.1 SENSOR AUGMENTED PUMP THERAPY SYSTEMS AND TANDEM PUMPS 
Medtronic have developed a system whereby a Medtronic CGM device is paired 
with a Medtronic pump (closed loop system – Medtronic 670G).  Research has 
shown that sensor-augmented pump therapy can result in significant 
improvement in HbA1C levels 93 in adults and children with T1DM.  The system 
is able to adjust basal (background) insulin rates every five minutes depending 
on the CGM reading and also has the feature of suspending insulin delivery up 
to 30 minutes before reaching hypoglycaemic levels. 
More recently, Dexcom has worked with Tandem Diabetes Care to develop a 
so-called tandem pump (t:slim x2).  The Dexcom G6 CGM device communicates 
in tandem with an insulin pump.  The pump itself incorporates Basal-IQ 
technology, whereby software is able to predict hypoglycaemic events 30 
minutes in advance resulting in automatic suspension of delivery of insulin, if 
glucose levels are expected to drop below a certain threshold.  Insulin delivery 
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is then automatically restarted once glucose levels have sufficiently recovered.  
A RCT of 24 schoolchildren in the US with T1DM showed that those using the 
t:slim X2 pump paired with Dexcom G6 had a significantly improved time in 
range without increasing hypoglycaemia compared to those on sensor 
augmented pump therapy (71% versus 53%)94. 
Interestingly, the online diabetes community posted in March 2019 that 
Tandem have suspended their Control-IQ trial due to concerns about the 
software’s behaviour resulting in hypoglycaemia. 
Features of the tandem pump software include: 
 An algorithm that is layered on top of the users’ pump settings; 
 Target range in normal use (6.25 mmol/L to 8.9 mmol/L); 
 Target range for night-time (6.25 mmol/L to 6.7 mmol/L); 
 Exercise settings; 
 Adjustments to basal rates and automated bolus only occur when the 
predicted glucose level is expected to be higher than 8.9 mmol/l; 
 Insulin delivery in a two-phase model, first adjusting basal rate every 
five minutes and then giving a single correction bolus per hour of 40% 
less than what the pump settings call for (but no bolus functionality 
when in sleep mode); 
 Basic learning capability using total daily dose compared to current 
settings and adjusting based on this information. 
In comparison, the closed loop Medtronic 670G uses a single target value 
instead of a range, there is no night time mode, there is no correction bolus and 
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the system learns about a user prior to being able to use auto mode (around 
two weeks). 
Figure 18 T:slim X2 tandem pump 
 
Figure 19 Medtronic 670G closed loop system 
 
2.3.1.5 COSTS 
Cost of CGM devices is a barrier to access and whilst the NHS’ long-term plan 
states that from April 2019, selected patients with T1DM will have access to 
flash glucose monitors, thus ending the variation patients in some parts of the 
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country are facing, many will still have to self-fund a CGM device especially if 
they have T2DM. 
Abbott’s FreeStyle Libre is the least expensive – the reader (which can be 
recharged) and each sensor cost around £50.  The monthly cost for sensors for 
someone using the device all the time is approximately £100.  The FreeStyle 
Libre has become so popular that its website is currently restricted to existing 
customers (https://www.freestylelibre.co.uk/libre/sign-in.html).  Existing 
customers are only able to order three sensors every 25 days. 
Dexcom have different payment plans for their G6 device.  Customers can 
choose to sign-up for 12 months at £159 per month, which provides a user with 
4 transmitters and 37 sensors over the 12-month period.  Individually, 
transmitters cost £200 (last for 3 months) and a three-pack of sensors costs 
£153.75. 
Patients who use the Medtronic Minimed 670G pump would have to pay 
between £210-£275 per box of five sensors.   
2.3.1.6 HUMAN FACTORS 
As alluded to above, human factors influence the use of CGM devices and there 
is a need to explore these more in a clinical trial setting.  Users can find wearing 
a sensor all the time a burden.  Inserting the sensor results in a small puncture 
site or may require a minor surgical procedure for implantable sensors 77.    
Thinking of the older population whose skin will be thinner and more prone to 
damage, there is to the best of my knowledge no evidence as to how that might 
affect sensor usage.  The impact of arthritis (in particular the hands) on an older 
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person’s dexterity and strength has also not been explored in relation to being 
able to use sensor insertion devices. 
Figure 20 Dexcom G6 insertion device 
 
 
Figure 21 Eversense insertion (implantable sensor which lasts for 90 days) 
 
 
The technology employed by the CGM manufacturers assume a high level of 
understanding and familiarity with smartphones, Bluetooth and apps.  Again, 
this might be a barrier to anyone (irrespective of age) who is not used to such 
technology or who lives in a less-developed country where the technology is 
not as widely available, compared to countries in Europe or the United States. 
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There is limited scope to personalize the interface, which some may perceive as 
a disadvantage.  Use of a CGM device will only be of benefit if the user and 
healthcare providers are able to analyse and interpret the data having had 
sufficient training.  Consultations between patients/carers and healthcare 
professionals take time, in order to ensure that useful management decisions 
are made based on the data collated by the device.  Such time, training and 
resources may be not available 77. 
To sum up, the technology around CGM devices has rapidly evolved over the 
last couple of decades.  Users are faced with an array of choices, but there are 
still a number of barriers preventing equitable access to this technology.  
Existing research in CGM has focussed on younger adults and children with 
diabetes and it is becoming clear that new approaches or changes in mindset 
are needed when formulating monitoring strategies for older patients, aimed 
towards measuring harm from hypoglycaemia rather than just efficacy targets.  
Hence, I conducted a systematic review on the role of CGM in older people, 
with specific focus on ascertainment of asymptomatic hypoglycaemia. 
This was a hypothesis-generating systematic to inform my feasibility study 
(chapter 3).  The parameters I was interested in were: 
 Methods used in the studies and extent of overall capture of glucose 
readings; 
 Quantitative estimates regarding time and depth of hypoglycaemia; 
 Acceptability of CGM to participants; 
 Adverse events and other patient outcomes associated with CGM use. 
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2.4 METHODS   
The protocol was registered on PROSPERO (CRD42017068523) (Appendix 1). 
2.4.1 STUDY SELECTION CRITERIA 
I included observational studies and RCTs.  Population of interest was older 
people, mean age >65 years.  Studies based solely on inpatients or laboratory 
settings were excluded. 
2.4.2 SEARCH STRATEGY 
I searched three electronic databases: Web of Science, Ovid SP MEDLINE and 
EMBASE from January 2010 to June 2017. 
No searches were conducted on unpublished or grey literature.  Only human 
studies were included in the search. 
The search strategy included terms related to the intervention (continuous 
glucose monitoring) and the population (older adults): 
(Aged OR "older adult" OR "older adults" OR elderly OR geriatric OR veteran? 
OR senior?) 
AND  
(continuous-glucose-monitoring or CGM) 
The full PubMed search strategy is reproduced below: 
("aged"[MeSH Terms] OR "older adult"[All Fields] OR "older adults"[All Fields] 
OR ("aged"[MeSH Terms] OR "aged"[All Fields] OR "elderly"[All Fields]) OR 
geriatric[All Fields] OR ("veterans"[MeSH Terms] OR "veterans"[All Fields] OR 
"veteran"[All Fields]) OR senior?[All Fields]) AND ("continuous glucose 
monitoring"[All Fields] OR CGM[All Fields]). 
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I also conducted a manual search by reviewing the reference lists of included 
studies and published systematic reviews on the same topic. The searches were 
also updated automatically on a monthly basis through electronic notifications 
from Pubmed. 
2.4.3 STUDY SELECTION AND DATA EXTRACTION 
Two reviewers (YKL and KM) independently screened titles and abstracts to 
remove those that clearly did not fulfil selection criteria. Both reviewers then 
proceeded to check full-text versions of articles that were either of uncertain 
suitability or were judged as potentially relevant.  Data extraction similarly 
involved two independent reviewers, with subsequent discussion to reach 
consensus. 
I extracted the following information onto a spreadsheet: study design, 
geographical location, sample size, mean age, diabetes duration, model/make 
of CGM, selection of patients, loss to follow-up, missing data, selective 
reporting, summary statistics of blood sugar values captured, definition and 
number of hypoglycaemic episodes captured, adverse events, acceptability and 
adherence (Tables 2 and 3). 
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Table 2. Study design and characteristics  
Study ID Study design, setting, country Patient Characteristics (numbers in each group, mean age 
overall, % male, type of diabetes, any inclusion/exclusion 
criteria, confounders adjusted for)  
Intervention (which model/make 
of CGM), blinded or not 
Argento 2014 95  Retrospective electronic health record 
review US adult endocrinology clinic. 
Any patient >65 years with CGM 15 June 
2013 
CGM (n=29) 
Age:68.8 (SD 3.5) years 
Male 12/29 (41%) 
T1DM 26/29 (90%) 
All patients used insulin 
Device not stated 
No blinding 
DuBose 2016 96 Post-hoc analysis of case-control study at 
the T1DM Exchange Clinic Network in US. 
Non-CGM users, T1DM >60 years age, diabetes duration 
>20years. Exclusions: chronic kidney disease stage 4 or 5, 
moderate or advanced dementia, or pancreatic 
transplant. 
N=199 
Mean age 68 
Male 53% 
Mean duration of diabetes 40 years 
Blinded participants using Dexcom 
SEVEN device, sampling glucose 
every 5 minutes for a week. Device 
replaced after that for further 7 
days. 
Ishikawa 2017 97 Retrospective observational study 
previously collected CGM data, Chiba 
University Hospital and Kashiwado 
Hospital Japan 2011-2016. 
N=170 (83% outpatients) type II DM age>65 years. 
Mean Age 74 
42.4% on DPP-4 inhibitors, 55.9% on 
with insulin) and 27.1% on SU. 
Medtronic iPro v2 or System Gold 
 78 
Litchman 2017 
98 
Two online surveys of CGM through 
Diabetes Online Community on Facebook. 
Convenience sample using snowball 
sampling technique 
N=11 users 
T1DM >65 years, able to read/write English. 
Mean age 70 
Male: 55% 
Diabetes duration 59.4 ± 6.4 y 
Control group N=11 who want to use CGM 
Dexcom Gen4 =8 
Dexcom Gen 5 =1 
Medtronic Revel=1 
Medtronic Enlite =1 
Munshi 2011 48 Prospective observational study, Tertiary 
care diabetes clinic, USA. 
N=40 
Community-living patients aged ≥69 years with HbA1C>8% 
 
blinded Medtronic iPro sampling 
every 5 minutes for a 3-day period 
Pistrosch 2015 99  Cross-sectional study of tertiary centre, 
Germany 
N=94 
Frail patients with type 2 diabetes with a proven 
cardiovascular event 
Mean age 68 years 
Medtronic iPro2 sampling every 5 
minutes for a 5-day period 
Polonsky 2016 
100 
Dexcom, Inc central database – email 
invites for participation in online survey in 
US 
N=210 
≥ 65 years of age with Medicare as primary insurance or no 
health insurance coverage. 
Mean age 70 years 
M: 52.9% 
Duration of diabetes 35.7 years 
T1DM: 93.8% 
T2DM: 6.2% 
Presumably Dexcom users 
Ruedy 2017 101 Post-hoc analysis of multicentre RCT in US 
and Canada 
N=63 on CGM, N =53 controls 
>60 years, receiving multiple daily insulin > 1 year, stable 
diabetes, compliant with self-monitoring. Excluded if recent 
use of CGM. 
Mean age 67 years 
Duration of diabetes 21 years 
T1DM: 20 (32%) 
T2DM: 43 (68%) 
Dexcom G4 Platinum, unblinded 
 
There were two periods of blinded 
CGM use at baseline and week 24 
follow-up to capture any change in 
hypoglycaemic episodes and their 
duration post-intervention 
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Complex intervention involving CGM guided treatment 
strategy vs. SMBG strategy implemented by clinicians for 24 
weeks 
Van Dijk 2017 49 Pilot study 
Primary care, Netherlands 
N=23 
Age ≥ 70 years, T2DM, HbA1c < 58 mmol/mol (7.5%), and a 
Groningen Frailty Indicator (GFI) score ≥ 4. 
Mean age 76 years 
Male 47% 
Median duration of diabetes 9 years 
Blinded Medtronic IPro2 
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Table 3. Outcomes 
Study ID Summary statistics of blood sugar 
values captured (mean, median, 
range, standard deviation) 
Recording time 
Definition and number of 
hypoglycaemic episodes 
captured  
What types 
of adverse 
events of 
interest 
were 
specified or 
defined? 
 
How and 
when were 
adverse 
events 
ascertained? 
 
How complete was 
follow-up and 
reporting of adverse 
events? (duration, 
numbers for loss to 
follow-up, or selected 
sample only) 
Was patient adherence 
and device 
acceptability 
ascertained? 
Argento 
2014 95 
CGM duration 36.8 (range 4-68) 
months 
Pre- vs. post-CGM outcomes: 
Percent with hypo pre: 79%  vs..31% 
(P = .0002).  No. of hypos: pre-  52 
episodes in 5 years prior vs. 12 
episodes after initiating personal 
real-time continuous glucose 
monitoring (PCGM).  (5 SH episodes 
occurred while patients not using 
PCGM).  
Yearly rate of SH 0.37 ± 0.38 vs. 0.12 
± 0.19 (P = .0007) 
Severe if patient 
required third-party 
assistance and counted as 
present 
if there was at least 1 
recorded episode. Individual 
reports 
of SH were counted as single 
episodes, and if plural or 
many episodes, then 
classified as several 
Not stated Not stated 38 prescribed PCGM; 
29 were still regularly 
using PCGM, 2 were 
using professional CGM 
intermittently, and 7  
never started PCGM (3 
patients) or 
discontinued  
 
Intermittent users 
excluded 
Not stated. 
DuBose 
2016 96 
Median 286 hours out of potential 
maximum of 336 hours CGM in two 
weeks. 
CGM recorded hypos; 
Minutes per 24 hrs (% time) 
<3.9 mmol: 91 (6.3%) 
<3.3 mmol: 55 (3.8%) 
<2.8 mmol: 31 (2.2%) 
 
Not stated Not stated Missing data varied 
from 3 – 15 
participants according 
to category of> 6 hours 
missing data per time 
Not stated 
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% days with at least one 
hypo event 38% 
period (24 h, day only, 
night only)  
 
199/201 patients 
followed-up 
Ishikawa 
2017 97 
Glucose recordings: 
< 3.9 mmol: 72/170 
% of time in hypo: 2.3% 
< 3.9 mmol, no mention of 
clinical event 
Not stated Not stated Not stated Not stated 
Litchman 
2017 98 
10/11 users said they had it on all 
the time. 
Hypoglycaemia 
glucose < 3.9 mmol;, 
severe hypoglycaemia 
hypoglycaemia episode 
requiring assistance form 
another person,  
hypoglycaemia 
unawareness is defined as 
occurring when an individual 
with 
diabetes is experiencing 
hypoglycaemia, but feels no 
symptoms. 
Hospitalizat
ion 
Online survey Selected sample – self-
identified as high 
technology users 
Yes. why participants 
were using/wanted to 
use real-time 
continuous glucose 
monitoring (RT-CGM), 
and how RT-CGM was 
affecting/might affect 
diabetes management 
and safety 
Munshi 
2011 48 
65% of patients 
with A1C >8% were found to have ≥1 
hypoglycaemic episode over a 3-day 
period. 
 
4 times a day finger-stick glucose 
checks did not coincide with CGM-
detected hypoglycaemia  
 
 
Symptoms – self-report. 
Analysis of CGM according to 
time, duration and 
magnitude of low glucose  
 
65% (26/40 patients) ≥1 
hypoglycaemia (median 
glucose 63 (42–69) mg/dl). 
12 (46%) had glucose levels 
<50 
Not stated Not stated Not stated Not stated 
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mg/dl, and 19 (73%) <60 
mg/dl. Average number of 
episodes 
4 with average duration of 
46 minutes. Of a total of 102 
hypoglycaemic episodes, 95 
(93%) were unrecognized, 
either by finger-stick 
monitoring or by symptoms.  
18/ 26 (69%) had ≥1 
nocturnal episode (average 
duration 56 minutes). 
Pistrosch 
2015 99 
Patients perceived 39 % of HE during 
the day and 
11 % of HE during the night. Patients 
with HE had significantly 
higher number of severe ventricular 
arrhythmias 
[ventricular tachycardia (VT) 32.8 ± 
60 vs. 0.9 ± 4.2, 
p = 0.019], and multivariate 
regression analysis revealed 
the duration of severe HE and TSH 
level as independent 
predictors of the occurrence of a VT 
<3.1mmol 
26/94 patients had hypo. 
Fifty-four episodes of 
hypoglycaemia (average of 
2.4 episodes per patient), 
with 171 minutes mean 
duration over 5 days. 
Eighteen events during 
daytime and 36 nocturnal 
<3.9 mmol 
4.2 episodes per patient with 
415 minutes mean duration 
over 5 days. 
 
Patients asked to record all 
symptoms of hypoglycaemia 
with date and time in diary 
 
Cardiovascu
lar events 
(VT)  
24-hour 
electrocardio
gram (ECG) 
monitoring 
Not stated Not stated 
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Polonsky 
2016 100 
154 (73.3%) in 6 months prior to 
CGM as compared to 
recent 6 months with CGM 121 
(57.6%). 
Drops in the incidence of events 
requiring the 
assistance of another, 
hypoglycaemia-related 
hospitalizations, 
ED visits, paramedic visits to the 
home, and car accidents. 
Hypoglycaemia  
frequency of 
low blood glucoses (<70 
mg/dl) in the past month, 
with and without symptoms; 
over the past 6 months, 
the frequency of moderate 
hypoglycaemic episodes 
(symptoms of confusion, 
disorientation, lethargy or 
being unable to treat 
oneself) and the number of a 
variety of events associated 
with severe hypoglycaemia, 
including episodes requiring 
assistance.  
Comparison of 
frequency/number of 
events during the 
“retrospective baseline 
period,” defined as the 6-
month period before they 
first started RT-CGM vs. 
current period. 
Healthcare 
use 
including 
paramedic 
visit, 
emergency 
department 
care, road 
accidents.  
Online survey Online survey 
conducted on behalf of 
Dexcom (CGM 
manufacturer) 
Not stated 
Ruedy 
2017 101 
Mean CGM use was 6.9 ± 0.2 
days/week in month one; and 6.8 ± 
1.1 in month 6. 
 
HbA1c reduction from baseline to 24 
weeks was greater in the CGM group 
than Control group (−0.9 ± 0.7% 
SH event that required 
assistance from another 
person to administer 
carbohydrates or other 
resuscitative action 
 
Not stated Not stated Post-hoc analysis of 
multicentre RCT 
Satisfaction with use of 
CGM mean score of 4.2 
± 0.4 on the CGM 
Satisfaction Survey 
(possible score range 1 
to 5), with mean 
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versus −0.5 ± 0.7%, adjusted 
difference in mean change −0.4 ± 
0.1%, P < .001). 
No hypos recorded during 
study. 
scores of 4.3 ± 0.5 on 
the Benefits subscale 
and 1.8 ± 0.5 on 
the Hassles subscale 
 
Van Dijk 
2017 49 
Monitoring period – 97 hours 
median (out of maximum of 120 
hours) 
Hypo < 3.0mmol: 5 patients 
had 15 events (245 minutes 
total) 
Hypo <3.5 mmol: 8 patients 
had 25 events (292 minutes 
total). 
None of the patients 
reported symptoms. 
Not stated Not stated Not stated Not stated 
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2.4.4 QUALITY ASSESSMENT 
Two reviewers (KM and YKL) assessed key parameters, including selection of 
patients, loss to follow-up, missing data, selective reporting and analysis. 
2.4.5 DATA SYNTHESIS/ANALYSIS  
I aimed to perform meta-analysis if there was sufficient quantitative data and 
similarity in the reported outcome measures. Assessment of statistical 
heterogeneity would be through the I2 statistic.  I aimed to assess publication 
bias by examining funnel plots, if there were more than 10 included studies for 
a particular outcome, and there was no evidence of significant heterogeneity.   
Where studies were too heterogeneous to be pooled, a narrative analysis of the 
data would be undertaken. 
2.5 RESULTS 
After de-duplication, we screened 902 citations and one citation from 
automated notification (Figure 23).  I included nine studies 95 48 49 96-101. 
The included studies had a total of 989 participants (sample size 22 to 285).  
Geographical locations were diverse and but were predominantly in 
economically developed countries such as North America, Japan, Canada, 
Germany and the Netherlands. 
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Figure 22. PRISMA Flow Diagram 
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2.5.1 PATIENT SELECTION 
Two studies used online surveys of already existing CGM users98 100.  Users who 
were not able to tolerate CGM were not included in the surveys.   
None of the studies included participants with cognitive impairment or 
dementia. 
2.5.2 AGE AND FRAILTY 
The mean age of all participants was 70 years, with six studies’ participants’ 
ages being between 67-69 years 101 99 48 98 95 96.   
Two studies discuss frailty of their participants 49 99.  Van Dijk et al included 
patients with a GFI score of 5 (a score of 4 or above indicates moderate to 
severe frailty) 49 102.  The GFI takes into account physical problems (co-
morbidities, mobility, hearing, eye sight), cognition, depression, anxiety and 
social factors.  Answers are given either a score of 0 or 1, with 1 indicating a 
problem.  The maximum score is 15 102.   
Pistrosch et al did not specify how they assessed frailty, but their participants 
had to have had a proven cardiovascular event99. 
2.5.3 TYPE OF DIABETES 
Two studies only included participants who had T1DM 96 98, three studies 
included patients with T2DM97 99 49 and the rest had a mix of T1DM and T2DM48 
95 100 101. 
2.5.4 CGM DEVICES 
A range of CGM devices were used in the included studies (manufacturers were 
Dexcom and Medtronic).  One study did not state which CGM device was used 
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95.  Whilst Polonsky et al also did not expressly state what device(s) participants 
were using, it is likely that they were Dexcom devices, as participants were 
emailed using the Dexcom central database100.  Four studies used blinded CGM, 
three of which used Medtronic iPro2 and one Dexcom SEVEN PLUS49 99 48 96.  
One study used both Medtronic iPro2 and Medtronic CGMS System Gold (also 
blinded) 97. 
The participants who took part in Litchman et al’s online survey used Dexcom 
G4, Dexcom G5, Medtronic Revel or Medtronic Elite 98, all unblinded.  Ruedy et 
al’s RCT used unblinded CGM (Dexcom G4 Platinum) 101. 
 
2.6 RISK OF BIAS OF INCLUDED STUDIES AND SELECTIVE OUTCOME REPORTING 
There was a mix of types of studies, including a RCT, retrospective health record 
reviews, cross-sectional studies, pilot study and mixed-method study.   
Most of the studies did not provide sufficient information on blinding of 
assessors and participants, drop-out rates, missing data and how missing data 
were addressed.   
2.6.1 DEFINITION OF HYPOGLYCAEMIA 
There was considerable variation in the definition of hypoglycaemia amongst 
the included studies.  Four studies looked at the occurrence of severe 
hypoglycaemia, defined as a patient requiring third party assistance 95 98 100 101.  
Two studies used online surveys and relied on self-reporting of glucose levels 
and symptoms 100 98.  
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2.6.2 PRE-SPECIFICATION OF ADVERSE EVENTS 
Six studies did not pre-specify any adverse events 95 96 97 48 101 49.  Polonsky et al 
captured healthcare use (paramedic visits, emergency department attendance) 
and road traffic accidents 100.  Pitrosch et al looked at the occurrence of 
ventricular arrhythmias 99 and Litchman et al’s survey asked about 
hospitalization 98. 
2.6.3 COMPLETENESS OF FOLLOW-UP 
Four studies did not address completeness of follow-up or missing data at all 97 
48 99 49.  One study was a post-hoc analysis of a randomized controlled trial 101, 
two studies were surveys which targeted already exciting CGM users or patients 
with diabetes who were keen to try out new technology 100 98.   DuBose et al 
provided incomplete information on missing data and follow-up 96.  Argento et 
al excluded intermittent users of CGM.  Out of 38 participants who were 
prescribed CGM, nine stopped using it regularly during the study period 95. 
2.6.4 ADHERENCE  
Seven studies did not state how patient adherence and acceptability were 
ascertained 95 96 97 48 99 100 49.  Ruedy et al evaluated acceptability with 
satisfaction surveys, and Litchman et al asked participants why they were using 
CGM and how CGM is affecting their diabetes management 101 98. 
 
2.7 EVIDENCE SYNTHESIS 
The nine included studies did not have sufficient quantitative data and 
similarity in the reported outcome measures for me to pool the data in a meta-
analysis. 
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I therefore carried out a narrative synthesis under the following headings: 
capture of hypoglycaemia, CGM satisfaction, association of adverse events with 
hypoglycaemia, pre-and post CGM outcomes. 
2.7.1 CAPTURE OF HYPOGLYCAEMIA 
Four studies report on the number of participants who had hypoglycaemic 
episodes recorded on CGM 48 49 97 99.  Figure 24 depicts the number of patients 
with and without hypoglycaemia. 
The proportion of participants affected by at least one or more hypoglycaemic 
event varied between 28%-79%.   This variation may have stemmed from 
differences in patient characteristics, nature of drug therapy and duration of 
monitoring (ranged from 3 to 5 days), nevertheless, the important unifying 
features of all of these studies is that CGM has demonstrated that a substantial 
proportion of older people are affected by hypoglycaemic events. 
I extracted data from three studies regarding the symptomatic or asymptomatic 
nature of the hypoglycaemic episodes 48 49 99.  Figure 25 illustrates number of 
hypoglycaemic events with and without symptoms.  
It is striking that between 80-100% of hypoglycaemic events were 
asymptomatic and arguably most if not all of these would have gone unnoticed 
had it not been for the use of CGM at that particular point in time. 
Finally, I estimated the length of time participants spent in the hypoglycaemic 
range in minutes per day (Figure 26) 96 101 49 48 99. 
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Figure 23. Number of patients with and without hypoglycaemia 
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Figure 24. Number of hypoglycaemic episodes with and without symptoms 
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Figure 25 Minutes per day in the hypoglycaemic range 
 
Participants in the observational studies spent between 34-112 minutes 
per day in the hypoglycaemic range, whereas those in the randomized trial 
spent only between 3-10 minutes in the hypoglycaemic range. 
 
The RCT by Ruedy et al is notable outlier - it is a post-hoc analysis of older 
participants in the multi-centre DIAMOND RCT comparing CGM versus 
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SMBG 103.  The objective was to determine effectiveness of CGM in older 
adults with T1DM or T2DM, who were on multiple daily insulin injections. 
Participants in the DIAMOND trial had to have a stable diabetes regime for 
three months prior to study entry, and were performing self-monitoring 
three or more times daily, with no history of recurrent hypoglycaemia 103.  
Co-morbidities such as recent cardiovascular disease, significant heart 
failure, conditions resulting in physical or cognitive decline, and renal 
impairment were listed as exclusion criteria.  The participants selected for 
the DIAMOND trial were not frail older people with multiple co-morbidities 
and possible cognitive impairment. For the post-hoc analysis, patients had 
to be 60 years or older with T1DM or T2DM treated with multiple daily 
injections of insulin for at least one year.  Exclusion criteria were use of 
CGM within three months of screening and any co-morbidities that would 
be deemed to make it unsafe to target an HbA1c of less than 7.0% - this 
was determined by the researchers.  Prior to randomization to CGM or 
control (SMBG), each participant used blinded CGM for two weeks.  After 
randomization, follow-up visits for both groups took place at 4, 12 and 24 
weeks.  The CGM group had an additional visit one week after 
randomization to troubleshoot potential use issues.  The SMBG group had 
two additional visits at weeks 11 and 23 to initiate blinded CGM for one 
week.   
Arguably, the participants were likely to have good hypoglycaemic 
awareness and ability to correct low blood sugars more quickly than those 
the frail older participants in, for example, van Dijk’s study where all of the 
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hypoglycaemic episodes were asymptomatic49.  In contrast to Ruedy et al, 
van Dijk et al’s study included frail patients with T2DM aged 70 or older 
who were treated with metformin and a sulfonylurea.  Pistrosch et al also 
included frail older patients with T2DM who already had a proven 
cardiovascular events, which included previous myocardial infarction (MI), 
ischaemic stroke, cardiac bypass surgery, peripheral artery disease with 
limb amputation or other endovascular procedures at the lower limb 
arteries99. 
The above three studies show how contrasting the included populations 
are – fit older patients with well-controlled diabetes versus frail older 
patients with multiple co-morbidities.  It is therefore not surprising that 
the findings of the studies are quite different. 
2.7.3 CGM SATISFACTION 
Two studies report on CGM satisfaction98 101. 
Litchman et al’s mixed-methods study, used convenience sample of older 
adults with T1DM aged 65 and older, using snowball sampling technique 
from the Diabetes Online Community within Facebook.  A total of 22 
participants were recruited – 11 who were using CGM and 11 ‘controls’ 
who wished to start CGM use.  Participants were asked to complete one of 
two online surveys about CGM.  The first survey was aimed at current CGM 
users, whilst the second survey (one month after the first) was completed 
by the control group.  The questions focussed on reasons for using CGM or 
wanting to use CGM and how it affected diabetes management.  The 
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surveys also asked participants about hypoglycaemia occurrence and 
unawareness. 
Emerging themes were that CGM use facilitates feelings of safety by 
preventing hypoglycaemia and improvement in well-being.  CGM users felt 
that they were able to function better in their daily activities and that the 
device could assist in prolonging life by preventing injury and complication 
98. 
In Ruedy et a’s study, CGM users (n=60) were asked to complete a CGM 
Satisfaction Survey at the 24-week follow-up visit.  The questionnaire 
consisted of 44 items on how satisfied the participant was with using CGM.  
As discussed above, this was a post-hoc analysis of the DIAMOND study 
and included participants with no major co-morbidities and well-controlled 
diabetes.  Overall satisfaction was high with mean score of 4.2 (range of 
scores 1-5), with mean scores of 4.3 on the Benefits subscale and 1.8 on 
the Hassles subscale, indicating that the perceived benefits outweighed 
the perceived hassles 101. 
2.7.4 ADVERSE EVENTS 
Three studies reported on adverse events, such as ED visits 100, falls, 
inability to operate a vehicle in the last year98 and ventricular 
arrhythmias99.  It is important to note that at this juncture, I cannot draw 
any conclusions regarding causality between the hypoglycaemic episodes 
and adverse events. 
Litchman et al asked participants to complete an online survey which 
included a question on whether hospitalization had occurred in relation to 
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a participant’s diabetes since they had started using CGM, which was 
compared to hospitalization on non-CGM users.  The results of that 
particular question are not reported.  However, CGM users (n=11) 
reported absence of severe hypoglycaemic episodes resulting in a fall or 
inability to operate a vehicle in the last year, compared to 6 non-CGM 
users (55%) 98. 
Pistrosch et al looked at the occurrence of ventricular arrhythmias in 
patients with T2DM, who had hypoglycaemic events.  The authors 
observed that 13 out of 26 patients in the hypoglycaemic group 
experienced ventricular arrhythmias, compared to 11 out of 68 
participants in the non-hypoglycaemic group 99. 
2.7.5 ADVERSE EVENTS PRE- AND POST-CGM 
Polonsky et al reported reduction of 5.3% of hospitalization in CGM users 
comparing hospitalization six months before starting CGM and over the 
past six months.  This reduction of hospitalization was a within-group 
comparison 100.  There was no reduction in hospitalization in the non-CGM 
users in the same period.  In addition, there was a 4.3% reduction in car 
accidents and 12.8% reduction in ED visits for CGM users within that time.  
This compares to a 4% increase in ED visits, 2.6% reduction in car accidents 
and 0% difference in hospitalization for non-CGM users within that same 
time period. The authors report unadjusted and adjusted ORs (and some p-
values), but no confidence intervals, so it is not possible to properly 
comment on the statistical significance of the results. 
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Argento et al’s study was a retrospective electronic health record review 
where the investigators looked at medically recorded hypoglycaemia 
(requiring assistance from a third party).  Here, CGM users were shown to 
have a reduction in the rate of severe hypoglycaemia from 0.37 to 0.12 per 
year.  Overall, the proportion of patients with any severe hypoglycaemia 
fell from 79% to 31% after initiation of CGM 95.  However, I am conscious of 
the major limitations of these studies which are non-randomized, 
unblinded, and without any specific treatment protocols involving glucose-
lowering drugs. 
 
2.8 DISCUSSION 
In this systematic review of CGM, I evaluated 9 studies with a total of 989 
participants who had type 1 or type 2 diabetes.   There were a diverse 
range of study designs, ranging from pilot studies, mixed method studies, 
database observational studies and one RCT.  Despite the variation in study 
populations and geographical locations, I found consistent evidence that 
CGM was able to detect hypoglycaemic episodes in a sizeable proportion 
of older patients, many of which were asymptomatic. In particular, van Dijk 
et al’s reported that 100% of the CGM recorded hypoglycaemic episodes 
were asymptomatic, with some patients having nearly two hours per day 
in hypoglycaemic range 49.   Munshi et al also highlighted that 95% of the 
captured hypoglycaemic episodes went unrecognized 48.  Clinicians and 
patients would probably have been completely unaware of these 
prolonged asymptomatic episodes in the pre-CGM era, and this may 
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represent a major unrecognized health burden in older people with 
diabetes. 
Since the publication of my systematic review, further data confirms my 
findings.  First, a Japanese study investigated the use of CGM in older 
people in an outpatient setting in Japan.  Out of 326 participants, 7 used 
CGM.  Asymptomatic hypoglycaemic episodes occurred in five out of the 
seven CGM users 104.  It was not possible to fully dissect the paper, other 
than the abstract, which is available in English.  Secondly, a conference 
abstract was presented at Endo 2019 in New Orleans 23-26 March 2019 on 
the exposure to hypoglycaemia in older adults with type 1 diabetes.  The 
authors analysed blinded CGM data in over 200 older adults (median age 
68 years) with T1DM collected at baseline in an RCT assessing the effect of 
CGM on hypoglycaemia.  The findings were that these older adults spent 
over one hour per day in the hypoglycaemic range and over 100 minutes 
per day in those with impaired hypoglycaemic awareness105.  
This supports my hypothesis that older patients (who may have cognitive 
problems and poor hypoglycaemic awareness) are spending longer in the 
hypoglycaemic range compared to patients with good hypoglycaemic 
awareness, who are able to correct their blood sugar levels in a short 
amount of time.  Following on from this, an important area for further 
research is whether an increased risk of serious harm is associated with 
duration of time in hypoglycaemic range rather than discrete episodes of 
hypoglycaemic events. 
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In addition to picking up hypoglycaemic events, the included studies have 
highlighted that older people with diabetes find the use of CGM 
acceptable101and that it improved well-being98.  Litchman et al also 
reported barriers regarding lack of accessibility, affordability and lack of 
insurance cover which can prevent older people from being able to make 
use of CGM technology98.  Although many of the studies do not directly 
draw a link between hypoglycaemia and subsequent serious events that 
affect quality of life, we have found three studies that venture the 
possibility of an association with emergency department visits and 
ventricular arrhythmias98 99 100. 
I recognize important limitations of our systematic review.  The data 
provided by the included studies was too heterogenous to provide an 
appropriate meta-analysis.  I have therefore not been able to provide a 
quantitative analysis of the data.  The included studies range to mixed-
method online surveys to RCTs, which makes it difficult to provide a robust 
analysis of the quality of the data and we only included English-language 
articles.  Some of the studies had a very select group of participants 
(Caucasian, highly educated and users of technological devices) and small 
sample sizes (<50).  This limits the generalizability to the general older 
population with diabetes.   
Rather than using CGM all-year round, it would be more cost-effective to 
use CGM to ‘troubleshoot’ (for example, two weeks every six months) and 
identify patterns in glucose variability (especially asymptomatic 
hypoglycaemia) in older patients.  Intermittent finger-prick testing is not 
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useful in this group, because the vast majority of hypoglycaemic episodes 
seem to be asymptomatic, and the older patient or carer may not be 
alerted to the need to do the finger-prick test at that point in time.  In 
addition, the duration of time spent in the hypoglycaemic range could not 
be reliably assessed through intermittent finger-prick testing.  A recently 
published consensus statement on clinical target for CGM data 
interpretation recommends that older people with diabetes should spend 
less than 1% (less than 15 minutes) of time per day in the hypoglycaemic 
range25. 
Further studies should explore possible associations between CGM 
recorded hypoglycaemic episodes, duration of time in hypoglycaemic 
range and cognitive and cardiovascular outcomes.  This could involve large 
cohorts of older people with diabetes (especially T2DM), with the aim of 
correlating asymptomatic hypoglycaemic episodes with subsequent 
serious adverse outcomes (for example patients could be asked to wear a 
14-day ECG recorder, in order to capture possible arrhythmias occurring at 
the time of hypoglycaemic episodes).  
In addition, trials of new glucose lowering therapies in older patients with 
diabetes should include the routine use of CGM, so that harmful effects 
are not missed. At present, the inconsistent definition and capture of 
hypoglycaemic episodes can lead to a misleadingly rosy picture of glucose 
lowering therapy in older people because the true extent of harm is 
difficult to analyse whilst the potential beneficial effects may be over-
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emphasized106.  CGM will make it possible to evaluate the cumulative 
effects of multiple minor hypoglycaemic episodes over the long-term. 
The monitoring strategy in older patients should focus on preventing 
imminent or acute harm, rather than long-term complications related to 
HbA1C which may only manifest in 10-20 years’ time – this could be 
beyond the lifespan of some patients. 
 
2.9 CONCLUSIONS 
CGM is an innovative technology that can detect otherwise unrecognized 
hypoglycaemic events in older patients.  CGM can provide more robust 
evidence to inform the careful balance of avoiding harm from 
hypoglycaemia and long-term diabetes control in such patients.  It is 
anticipated that over the next few years there will be rapid technological 
changes leading to improved interoperability, apps, software and 
affordability.  All of these factors should make CGM more accessible and 
potentially be a useful tool for older patients with diabetes and memory 
problems and their carers. 
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CHAPTER 3. CONTINUOUS GLUCOSE MONITORING IN OLDER PEOPLE WITH DIABETES 
AND MEMORY PROBLEMS – A FEASIBILITY STUDY 
 
3.1 PREAMBLE 
The second chapter outlined the findings of my systematic review on CGM in 
older people with diabetes.  I found evidence that CGM was able to detect 
hypoglycaemic episodes, many of which were asymptomatic.  The studies that 
were included in the systematic review also highlighted that older people found 
the use of CGM acceptable, in addition to experiencing improved well-being.  
However, my systematic review did not identify any studies of CGM specifically 
directed at older people with diabetes and co-existing memory problems, whilst 
at the same time exploring the experiences of these participants and their 
carers.  Chapter 3 presents a feasibility study on the feasibility and acceptability 
of a CGM device in older people with diabetes and memory problems. 
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3.2 CHAPTER SUMMARY 
3.2.1 BACKGROUND 
Older people with diabetes are at increased risk of harm from hypoglycaemia, 
particularly where there are co-existing memory problems.  CGM offers 
important benefits in terms of detecting hypoglycaemia, but the feasibility of 
use and extent of data capture has not been tested in this patient group.  The 
objective was to investigate the feasibility of trialling a CGM intervention in 
older people with diabetes and memory problems. 
3.2.2 METHODS 
I evaluated the Freestyle Libre CGM device for two weeks in patients aged ≥65 
with diabetes and abbreviated mini-mental test (AMT) score ≤8 or known 
dementia.  Participants could obtain on-the-spot glucose readings (as well as 
readings from preceding 8 hours) by swiping a reader over the sensor. 
Feasibility criteria were numbers of eligible patients, recruitment, attrition, 
extent of capture of glucose readings and adverse events. I conducted 
qualitative interviews with participants (and their carers) regarding CGM. 
3.2.3 RESULTS 
I identified 49 eligible participants.  17 subsequently consented, but 5 withdrew 
before recording of data because they, or their carers felt unable to manage 
study procedures. 12 participants (mean age 85 years) completed the study 
without any adverse events. Data capture across 14 days ranged between 3-
92% (mean 55%); 6 participants had <60% capture. Hypoglycaemic events 
(some prolonged) were recorded in 6 out of 9 insulin users. 
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Qualitative interviews found the following themes: the device does not 
interfere with daily activities, usability and comfort was positive, and it was 
helpful for carers in monitoring participants’ glucose concentrations. 
3.2.4 CONCLUSIONS 
The device was acceptable to participants, and carers reported greater ease in 
monitoring the participants’ glucose concentrations. However, completeness of 
data capture varied considerably with this device due to the need for users to 
conduct ≥3 scans per day. Real-Time devices with automated data transfer may 
be more suitable in older people with memory problems. 
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3.3 BACKGROUND 
Following on from the results of my systematic review in chapter 2, it became 
apparent that is necessary to investigate in more detail whether older people 
with diabetes and co-existing memory problems could tolerate wearing a CGM 
device, especially as conventional methods, such finger-prick testing may not be 
appropriate in this population.  These patients may not be able to recognise 
and/or act on symptoms stemming from major changes in blood sugars.  In any 
event, finger-prick testing only provides a snap-shot of the glucose level at a 
particular point in time and is not able to provide a complete picture of the 
variability throughout the day and night.   
A cohort study using registry data from German and Austrian diabetes centres, 
found that older people with diabetes and co-existing dementia had higher 
rates of severe hypoglycaemia (requiring third party assistance) and 
hypoglycaemia with coma compared to patients without dementia58.  Hence, 
the adverse effects of hypoglycaemia may be of far more pressing concern to 
frail older people, rather than strict glycaemic targets for reduction of vascular 
complications.   
Indications are the CGM can be a useful tool in uncovering the true magnitude 
of hypoglycaemia in older people.  However, my systematic review of the 
literature did not identify any studies that have investigated the feasibility of 
the use of CGM in older people with diabetes and co-existing memory 
problems, in addition to exploring the experiences of both the participants and 
carers (where applicable). 
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3.4 OBJECTIVE 
To investigate the feasibility of using CGM in older people with diabetes and 
memory problems.  Specifically, I investigated recruitment, retention, whether I 
could capture glucose data and what the participants’ (and carers’) experience 
was of the use of the device, and, finally, whether they experienced any 
adverse events. 
The study was approved by an ethics committee (REC reference 17/EE/0388).  
Please refer to Appendix 2 for full details of the approved research protocol. 
 
3.5 METHODS 
3.5.1 DESIGN 
I utilised mixed methods to conduct a feasibility study of CGM in older people 
with diabetes and co-existing diabetes living in the community. 
3.5.2 SETTING 
Participants were identified and recruited whilst an inpatient under the Older 
People’s Medicine and/or Acute Medicine Departments at the Norfolk and 
Norwich University Hospital Trust.  Recruitment took place between 1 February 
2018 to 31 January 2019.  Data collection took place in the Community and the 
device was only used post-discharge from the acute setting.   
3.5.3 CHOICE OF DEVICE 
At commencement of this feasibility study, there was only one CGM device 
(Abbott FreeStyle Libre), which does not require the user to conduct finger-
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prick testing for calibration, and so this was the intervention of choice for my 
study. This device is licensed for use in children and adults and available direct 
to consumer via the internet or from pharmacies.  The use of this device 
provides ambulatory glucose profiles, giving graphic and quantitative 
information on 24-hour glucose patterns.  This information can be viewed on a 
computer using the manufacturer’s software. 
The system consists of a reader (although Android phones and certain ioS 
devices can download an app, which replaces the need for a reader) and a 
sensor (35mm x 5mm), which exchange data through Near Field 
Communication technology.  The sensor is applied to the back of a person’s 
arm. It is able to store blocks of glucose data spanning 8 hours and will function 
for 14 days.  Whilst glucose levels are measured continuously, data are not 
transmitted continuously from the sensor.  Instead, the user has to swipe the 
sensor with a reader (hence the term ‘flash glucose monitoring’ used by the 
manufacturer) at least eight-hourly in order to achieve complete capture of 
data throughout the two-week life-span of a sensor.   
Figure 26 FreeStyle Libre sensor and reader 
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Figure 27 Illustration of attached sensor 
 
Figure 28 Illustration of obtaining a reading (‘flashing’ the reader over the 
sensor) 
 
3.5.4 RECRUITMENT OF PARTICIPANTS 
Eligible participants were 65 or older with T1DM or T2DM.  They needed to be 
on glucose-lowering medication (not diet or Metformin only), have an AMT 
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score equal or less than 8 (out of 10), or already have a formal diagnosis of 
dementia.  I aimed to recruit up to 20 participants.  As this was a feasibility 
study, there was no formal power calculation. 
Figure 29 Identification of potential participants and study flow 
 
Use of the AMT is mandated as a screening tool in the Norfolk and Norwich 
University hospital policy for all inpatients age 75 years and above.  The value of 
AMT in hospital settings was confirmed in a systematic review and meta-
analysis on screening for dementia in general hospital inpatients, where AMT 
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was reported to have good discriminant ability AUC 0.88107.  I acknowledge 
however that the use of the AMT only covers three cognitive domains 
(memory, orientation, attention/calculation) and there are more rigorous 
cognitive tests available.  The more rigorous test do not necessarily lend 
themselves to being carried out in an acute busy hospital setting 108.  However, 
my feasibility study was not about making new dementia diagnoses.  Rather, I 
wanted to identify inpatients with memory problems during their hospital 
admission who might benefit from the use of CGM. 
During the inpatient stay, information sheets were left at the bedside when it 
was not possible to speak to potential consultees (in cases where a patient did 
not have capacity) or a potential participant did not wish to discuss the study at 
the time of visit, but wanted to read the information sheet.  Participants were 
asked to continue with their usual diabetes management (including any finger-
prick monitoring) during the study period. 
3.5.5 MEASUREMENTS 
3.5.5.1 FEASIBILITY OUTCOMES (QUANTITATIVE) 
I investigated eligibility, recruitment, retention, reasons for withdrawal, data 
capture and adverse events.  For measure of “time in range” we set the reader 
to record it between 4mmol/L to 10mmol/L, which is similar to expert 
recommendations25 109. 
3.5.5.2 PATIENT OUTCOMES (QUALITATIVE) 
Semi-structured face-to-face interviews took place after the participants had 
worn the device for two weeks.  A topic guide was used (Appendix 6) to ensure 
the same domains were covered in each interview.  Participants and carers 
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were encouraged to talk about their experiences using the device.  Domains 
covered in the interview were acceptability of the device, exploration of 
expectations, effectiveness, including experience of scanning the device and 
immediate or longer-term consequences for the user and their diabetes 
management, consequences, including impact on wider health and wellbeing, 
and overall opinion of the device.  Detailed field notes were produced after 
each interview. 
3.5.6 DATA ANALYSIS 
For categorical variables, the number and percentage will be presented.  For 
continuous variables, the mean or median will be presented. 
Thematic analysis was used, once the interviews had been transcribed110.  
Familiarisation took place by listening to the interview recordings and reading 
of the transcripts. 
Framework analysis was applied to order111, chart and search the data manually 
and with software (NVivo 12, MSWord).  To ensure rigour and trustworthiness, 
coding was undertaken by two members of the research team (KM and KL) and 
transcripts were checked for accuracy. 
 
3.6 ETHICS 
The study was approved by an ethics committee (REC reference 17/EE/0388). 
The trial registration ID is ISRCTN29516623. 
 
 
 
 113 
3.7 RESULTS 
The patient recruitment flowchart is set out in Figure 31. 
Figure 30 Patient flowchart  
 
3.7.1 QUANTITATIVE RESULTS 
I identified 49 eligible participants.  17 people consented and twelve completed 
the study. 
The main reason for deciding not to participate after discharge home, was that 
the participant or carer felt it was too much to take on.  Participants living on 
their own were finding it challenging to cope with day to day life.  Carers felt 
overwhelmed by the challenges of looking after the participant. 
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Table 4 sets out baseline characteristics and data captured with the FreeStyle 
Libre device for participants who completed the study period.  12 participants 
(mean age 85 years) completed the study without any adverse events (skin 
reactions and/or pain).  All had T2DM apart from one participant with T1DM.  
Three participants had a formal diagnosis of dementia.  The AMT for the nine 
participants who did not have a formal diagnosis of dementia ranged between 
five to eight out of ten.   
Data capture across 14 days ranged between 3% to 92% (mean 55%); six 
participants had less than 60% capture.  Nine participants were insulin users, of 
which six (66%) experienced hypoglycaemic events (some prolonged).  The 
average duration of hypoglycaemic events ranged from 106 minutes to 437 
minutes. 
Figure 32 depicts the time in range for each participant, including the 
proportions spent below and above the target range (4-10 mmol/L).  Figure 33 
gives the FreeStyle Libre snapshot report for each participant who completed 
the study period. 
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Table 4. Baseline characteristics and data captured with FreeStyle Libre 
 1 2 3 4 5 6 7 8 9 10 11 12 
Gender M/F M M M M M M F F M M M M 
Age 90 79 82 80 86 87 84 92 84 81 90 90 
Type of diabetes 2 2 2 1 2 2 2 2 2 2 2 2 
Insulin user, Y/N Y Y Y Y N N Y Y Y N Y Y 
AMT, n/10 5 - 8 8 8 7 7 7 8 - - 7 
Dementia, Y/N N Y N N N N N N N Y Y N 
Days sensor worn 14 14 14 14 14 14 14 14 14 14 14 14 
Data capture, % 70 62 65 83 38 3 34 76 92 33 55 43 
Scans over 14 days 57 45 34 166 27 4 24 75 183 22 40 182 
Average glucose, mmol/L 16.8 8.8 8.4 11.9 10.8 9.6 12.2 7.3 6.6 16.0 6.6 10.4 
Hypo events (<4mmol/L) - - 1 11 - - - 13 21 - 4 1 
Average duration of low 
glucose events, min 
  109 113    106 182  437 348 
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Figure 31 Time in range (4-10mmol/L)   
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Figure 32 Participants’ snapshot reports 
Participant ID 001 
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Participant ID 002 
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Participant ID 003 
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Participant ID 004 
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Participant ID 005 
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Participant ID 006 
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Participant ID 007 
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Participant ID 008 
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Participant ID 009 
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Participant ID 010 
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Participant ID 011 
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Participant ID 012 
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3.7.2 RESULTS FROM THE INTERVIEWS 
All participants (and, where applicable, carers) agreed to take part in the semi-
structured interview.  The 12 interviews all took place in the participants’ homes, apart 
from three.  Two were nursing home residents (IDs 001 and 012), and one participant 
(004) was in a community hospital for rehabilitation during the study period.  The 
demographics of the participants who completed the study period are set out in Table 
5.  Analysis of the main findings are presented below under key domains including 
acceptability, expectations, effectiveness and consequences. Representative data 
extracts are presented verbatim (Table 6) with all participant and carer identifiers 
removed and replaced by the participants’ and carers’ IDs. 
 
Acceptability 
Participants and carers overwhelmingly found using the device acceptable.  Almost 
without exception participants reported not knowing or being conscious of wearing the 
device throughout the two weeks and that it did not interfere with day-to-day 
activities (Table 6).  In addition, participants confirmed that they were not aware of the 
device at night when they were sleeping.   
Many participants described what they considered advantageous about the device.  
The most common example given was the elimination of finger-pricking.  Participant 
007 described that her fingers got sore from doing finger prick tests. 
 
Exploration of expectations 
When asked about expectations they had about wearing the device, many participants 
stated that they had had none.  Participants were also asked if any expectations had 
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come to mind about what it meant for their diabetes: again, they replied they had 
none.   
One participant revealed an altruistic motivation to his joining the study (Table 6).  
Carer 011 also exhibited altruistic motivations when describing her expectations of 
being on the study, explaining that the findings will be positive for other people112. 
Other expectations showed an interest in contributing to science and a natural 
curiosity of being part of a research study (Table 6).  For another participant, joining 
the study meant that he had an opportunity to “join the 21st century” (Participant 
004). 
A distinct perspective was provided by the carer 002 - she admitted wondering if this 
was “a scam or something”, however, became reassured upon hearing details about 
the device and the feasibility study (Table 6). 
 
Effectiveness 
Interviews explored the experience of participants/carers using the device for two 
weeks and whether they felt they found any effectiveness for the user and their 
diabetes health.  Participants/carers found using the device effective, some preferring 
it over SMBG. 
Carers spoke favourably about the simplicity of the device, being “handy at night-
times” (Carer 002) for checking glucose levels without disturbing the participant and 
about the participant not being limited to the number of times they could check their 
glucose levels.   
 
Consequences 
The impact on participants’ and carers’ wider health and wellbeing was explored.  In 
particular, I was interested whether they found any aspects of the experience positive 
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or negative.  This included their views on whether the device had an impact on their 
symptoms, their experiences of living with diabetes and co-existing memory problems, 
and on their socialising and day-to-day activities.   
Although no participant reported anxiety or stress in wearing the device, a few 
reported that they wondered about the different results obtained from the device 
compared with finger-pricking.   Participant 012 expressed disappointment that the 
readings from the device did not always match the readings from the finger-prick test.   
Carers found the device particularly useful as it made them feel reassured and safer 
being able to check glucose levels, without having to use SMBG.  No reports of anxiety 
or stress in using the device were given by carers (Table 6). 
Another carer made the point of Participant 002 not always understanding the need 
for SMBG due to his underlying dementia (Table 6). 
One participant reported that wearing the device “made her feel confident” and, now 
that the two-week episode had ended, she would “miss it … it was a boon to have it” 
(Participant 008). 
 
Overall 
Participants were asked if they would recommend the device to others or what would 
they would say about their attitude to device to anyone who was considering it.  They 
all responded positively about recommending the device.   
One drawback mentioned was financial (Table 6).  Some participants remarked on 
discrepant readings provided by the device compared with finger-pricking.  One 
participant was explicit that he would like the device “to be more accurate”, comparing 
its readings less favourably with finger-pricking the results of which, he said, set his 
mind “more at rest” (Participant 009).  Nevertheless, his overall view of the device 
remained positive. 
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Table 5 Demographics and care arrangements of participants who completed the study period 
ID Age M/F Accommodation Social situation at time of interview 
1 90 M Room in Nursing Home Lives in nursing Home, nurse present at interview 
2 79 M House Lives with wife (present at interview); package of care four times per day 
3 82 M Bungalow Lives with wife (present at interview; she is his main carer 
4 80 M Bungalow In community hospital; wife present at interview 
5 86 M Cottage Lives alone, independent 
6 87 M Bungalow Lives alone, cleaner, supportive family 
7 84 F House Lives alone, daughter helps 
8 92 F House Lives alone, package of care three times per day 
9 84 M Bungalow Lives with wife (present at interview); she is main carer 
10 81 M House Lives with wife (present at interview); she is main carer 
11 90 M House Lives with wife (present at interview); she is main carer 
12 90 M Room in Nursing Home Nursing home 
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Table 6 Illustrative quotes 
Theme Illustrative quotes 
Acceptability 
 
“I don’t even know it’s on” (ID 007);  
“Easy to take a reading” and “it was silent and stayed in place” (ID 010). 
Exploration of expectations “What they do with it, they can do what they like with me” (ID 001);  
“You’ve got to work with science and progress” (ID 003);  
“I found out what it did and I thought, this is fantastic” (Carer ID 002). 
Effectiveness 
 
“Well it’s better than pricking your finger cos my fingers got like sore” (ID 007). 
“If I wanted to go and check [009’s] blood and say [009] was partly asleep I could check it and 
find out if everything was all right you know” (Carer ID 009) 
Consequences 
 
“…when it was low and then when I then give him something, it had then gone up so I knew it 
was working, so I was happy, more than happy with it.  Yes, I felt happy and I felt safer.” (Carer 
ID 011); 
“I just think it like I say with the whole package of the Alzheimer’s and dementia he’s not 
always understanding and doesn’t want it done and will pull his hand away and you know 
sometimes it’s just all too much” (Carer ID 002). 
Overall opinion 
 
“I’d tell them that it does away with the needle” (ID 003); 
“We both think it’s progress and it’s going to help people in the future” (Carer ID 003); 
“I’d do it [take part] again” because it had been a positive experience (ID 005); 
“I really can’t see any [drawbacks], apart from the price I can’t think of any drawbacks” (Carer 
ID 002). 
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3.8 DISCUSSION 
This study has shown that whilst the participants found wearing the sensor 
acceptable, data capture varied, depending on how many times the reader was 
used to scan the sensor during the study period.  Possible reasons for this 
include self-management skills, whether or not the participant had a carer living 
with them, and experience of glucose self-monitoring.  Nevertheless, some 
carers found it to be a useful and reassuring tool in managing this complex 
group of patients without having to resort to finger prick testing in a person 
who may not be able to understand the reasons for it. 
Only four of my twelve participants reached the target of 70% or more data 
capture in fourteen days as specified in a recently published international 
consensus on clinical targets for CGM data interpretation25.  
The living arrangements of the participants were not were not a clear-cut 
indicator regarding data capture.  4 of the 12 participants lived alone (data 
capture 3-76%), 2 were in a nursing home (data capture 57% and 43% 
respectively), 1 in a community hospital (data capture 83%), and 5 participants 
had the support of spouses at home during the study period (data capture 33-
92%).  Further work needs to be done to investigate which can of device can 
provide the most reliability regarding data capture.  For example, a CGM device 
with Bluetooth technology and continuous data transfer may result in higher 
data capture, irrespective of the living arrangements/packages of care. 
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The consensus statement for CGM targets in older people is that they should 
spend more than 50% in the target range (3.9-10 mmol/L), less than 1% below 
the target range (<3.9 mmol/L) and less than 10% above target (>13.9 
mmol/L)25.  In my study, six participants reached the above 50% time in range 
target and six reached the target of <1% below the target range. 
Figure 33  CGM targets as set out by international consensus on time in range 
 
(taken from Battelino et al)25 
Recruitment proved challenging in this vulnerable group, particularly because 
we chose to identify and recruit potential participants whilst they were 
inpatients in an acute hospital setting.  Challenges arose when a potential 
participant lacked capacity and consultee information sheets were left with the 
patient.  Often it was not possible to speak to next of kin, relatives or friends 
who could have been consultees, due to the unpredictability of visiting and 
some patients not being visited at all whilst in hospital.  In addition, it became 
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apparent that on discharge some participants found getting back into a daily 
routine and coping with day-to-day life overwhelming and therefore decided to 
withdraw from the study, despite showing interest in principle when 
approached in hospital. 
 
3.8.1 STRENGTHS AND LIMITATIONS 
My study used a mixed-methods approach exploring participants’ and carers’ 
experiences during the study period.   
With regards to the capture of hypoglycaemia, the manufacturer of FreeStyle 
Libre has reported their sensor may have less accuracy in the lower glucose 
ranges when compared to SMBG.  Abbott’s safety information discloses clinical 
study, which found that 40% of the time when the device indicated an 
interstitial glucose level of less than 3.3 mmol/L, the capillary reading was 
between 4.5 mmol/L to 8.9 mmol/L.  A further study carried out in France with 
older patients with type 2 diabetes (on insulin) in care homes, found that 51% 
of hypoglycaemic episodes captured with FreeStyle Libre were associated with 
values equal or greater than 3.9 mmol/L on capillary readings113. 
Despite limitations of the Freestyle Libre in data capture, our findings are 
supported by two recent pieces of research.  A conference abstract presented 
at Endo 2019 in New Orleans 23-26 March 2019 on the exposure to 
hypoglycaemia in older adults with T1DM analysed blinded CGM (Dexcom G4 
Platinum) data in over 200 older adults (median age 68 years) collected at 
baseline in a randomised controlled trial, assessing the effect of CGM on 
hypoglycaemia.  These older adults spend over one hour per day in the 
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hypoglycaemic range and over 100 minutes per day in those with impaired 
hypoglycaemic awareness105. 
In addition, a 2019 Japanese study investigated the use of blinded CGM 
(Medtronic iPro2) in older people in an outpatient setting in Japan.  Out of 326 
participants, 7 used CGM.  Asymptomatic hypoglycaemic episodes occurred in 5 
out of the 7 CGM users 104. 
Whilst the study took place within one area of the United Kingdom, I believe 
that the results are potentially generalizable to the rest of the older population 
in the UK with diabetes and memory problems.   
3.8.2 MEANING OF FINDINGS AND POTENTIAL FOR FUTURE WORK 
Meaning of findings and potential for future work 
CGM has gained momentum in the last few years, with more affordable devices 
being freely available for people with diabetes to purchase.  However, the focus 
has very much been on adults and children with T1DM and pregnant women.  
More recently, the National Health Service published its long-term plan, making 
reference to the fact that from April 2019, patients with T1DM benefit from 
flash glucose monitors ending the variation patients in some parts of the 
country are facing.  This includes patients T1DM, who are unable to routinely 
carry out finger prick testing due to disability (which would arguably include 
cognitive problems) and require carer support for their diabetes management 
(ie checking glucose levels and insulin administration).  No mention is made in 
the long-term plan of people with T2DM on medications which carry a high risk 
of hypoglycaemia (insulin, sulfonylureas), who may need carer support (for 
example due to underlying dementia) with the management of their diabetes.  
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There appears to be a disconnect by the commissioners by placing too much 
emphasis on the type of diabetes, rather than focussing on the class of anti-
diabetic medication a patient might be on.  One of the questions should be 
whether an individual is at high risk of hypoglycaemia and needs support with 
the management of their glucose levels, due to underlying frailty (including 
cognitive impairment), not what type of diabetes they have or how many times 
per day they carry out finger prick testing.  We know the older people with 
dementia and diabetes are at much higher risk of severe hypoglycaemia8. 
There is a need to seriously think about older frail people (especially those on 
insulin and/or with memory problems) and how best to manage diabetes in 
later life focussing on avoidance of hypoglycaemia and its adverse effects.  This 
will require an enormous shift in mindset by healthcare professionals and policy 
makers.   
A key area for investigation is what type of CGM (i.e. intermittent 
scanning/flash glucose monitoring, continuous transmission via Bluetooth or 
blinded and retrospective CGM) would be most appropriate in this group of 
patients?  Secondly, how often should CGM be employed (all the time, when 
there is a change in drugs, or intermittently for troubleshooting)? Thirdly, 
should it be limited to insulin and sulfonylurea users, which carry a higher risk 
of hypoglycaemia? 
In the first instance, it will be necessary to carry out a large-scale study using 
CGM to assess its true potential impact in this vulnerable group.  CGM would be 
used to capture hypoglycaemic episodes and guide the hypoglycaemia 
minimization strategy. In addition, CGM may be a useful and supportive tool for 
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carers in their day to day care of this vulnerable group of older people, 
especially those on drugs that carry a high risk of hypoglycaemia.  Further work 
is needed to explore whether older people with memory problems will be able 
to deal with the technology for continuous Bluetooth capture and reacting to 
the data that is produced by the software, including alarms for high and low 
glucose levels. 
 
3.9 CONCLUSIONS 
It is potentially feasible for older people with diabetes and memory problems to 
operate a CGM device that requires users to conduct intermittent scans. 
However, the added benefit of real-time transmission CGM devices that do not 
require active scanning needs to be explored further in this group of patients.    
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CHAPTER 4. THE EFFECTS OF HYPOGLYCAEMIA AND DEMENTIA ON CARDIOVASCULAR 
EVENTS, FALLS AND FRACTURES AND ALL-CAUSE MORTALITY IN OLDER PEOPLE – A 
RETROSPECTIVE COHORT STUDY  
 
4.1 PREAMBLE  
The second and third chapters outlined existing evidence regarding CGM use in 
older people and the detection of hypoglycaemia, in addition to my feasibility 
study of using the FreeStyle Libre CGM device in older people with memory 
problems.  Two-thirds of the insulin users in my feasibility study experienced 
hypoglycaemic events, two of which lasted over 300 minutes.  The 
consequences of hypoglycaemia in patients with co-morbid diabetes and 
dementia are unknown.  Hence, this fourth chapter presents a retrospective 
cohort study exploring the association between hypoglycaemia and serious 
adverse events in older patients with diabetes and dementia, and whether the 
consequences of hypoglycaemia were affected by presence of dementia.  It was 
published in Diabetes Obesity and Metabolism in 2019 
(https://www.ncbi.nlm.nih.gov/pubmed/31069922).  Chapter 4 is a more 
comprehensive and detailed expansion of the publication. 
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4.2 CHAPTER SUMMARY 
4.2.1 AIMS 
I aimed to test the association between hypoglycaemia and serious adverse 
events in older patients with diabetes and dementia, and whether the 
consequences of hypoglycaemia were affected by the presence of dementia.  
4.2.2 MATERIALS AND METHODS 
Retrospective cohort study using Clinical Practice Research Datalink in England 
(1997-2016).  I selected participants, intervention (exposure) and follow-up to 
mirror two hypothetical target randomised controlled trials.  Target trial 1’s 
exposure was hypoglycaemia in patients with dementia.  Target trial 2 
examined adverse effects of hypoglycaemia according to dementia status. 
I used Cox proportional hazard regression to estimate adjusted hazard ratios for 
falls, fractures, cardiovascular events and mortality.    
4.2.3 RESULTS 
In target trial 1, hypoglycaemia was associated with an increased risk during 12 
months follow-up of falls and fractures – adjusted Hazard Ratio (aHR) 1.94 (95% 
CI 1.67 to 2.24), cardiovascular events - aHR 2.00 (95% CI 1.61 to 2.48) and 
mortality - aHR 2.36 (95% CI 2.09 to 2.67). 
In target trial 2, presence of dementia was associated with increased risk of 
adverse events after hypoglycaemia (12 months follow-up): falls & fractures - 
aHR 1.72 (95% CI 1.51 to 1.96) and mortality - aHR 1.27 (95% CI 1.15 to 1.41), 
but had no effect on cardiovascular events - aHR 1.14 (95% CI 0.95 to 1.36).   
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4.2.4 CONCLUSIONS AND RELEVANCE 
Hypoglycaemia is associated with an early increased risk of serious adverse 
events in older people with diabetes and dementia. 
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4.3 INTRODUCTION 
In the preceding chapters, I have discussed the major healthcare burden 
comorbid diabetes and dementia are likely to pose over the next decades and 
how the self-management of diabetes is particularly challenging for older 
patients because they have limited recall of the dangers of hypoglycaemia and 
what remedial action to take114, and because they are more prone to 
hypoglycaemia from their medication115 6.  
Existing evidence has already highlighted the potentially serious consequences 
of hypoglycaemia (e.g. cardiovascular events, falls, fractures and death), 
however, none of the previous studies have specifically focused on the risks 
associated with hypoglycaemia among older people with dementia.   
My aim was to test the effect of hypoglycaemia in older people with dementia 
and diabetes on serious adverse events (myocardial infarction, ischaemic 
stroke, falls and fractures, and all-cause mortality).  I also examined whether 
dementia modified the effect of hypoglycaemia.  A more comprehensive 
understanding of the consequences of hypoglycaemia in this vulnerable and 
complex group will help optimise the clinical management. 
 
4.4 METHODS 
4.4.1 STUDY DESIGN 
I performed a retrospective cohort study using data from CPRD.  I designed two 
hypothetical target trials within a cohort of older patients with diabetes.  The 
concept of “target trials” was formalised by Hernan et al as a means of using 
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observational data to emulate a RCT116.  Whilst it would be preferable to carry 
out an RCT to assess or compare the effectiveness of an intervention, this is not 
always feasible, due to issues relating to time, funding, and/or ethics 
(particularly in studies of harmful effects). For instance, it would neither be 
feasible nor ethical to randomize participants to hypoglycaemia or no 
hypoglycaemia, for assessment of long-term adverse effects. Hence, 
researchers have to resort to observational data sets to try and emulate a 
target trial.  Hernan et al set out a framework which mimics the design and 
analysis of a target trial and tries to address potential sources of bias.  This 
enables a systematic and methodological evaluation of observational data, 
which will assist in analysing causal inferences116. 
My first target trial aimed to test the effect of hypoglycaemia among people 
with dementia and diabetes, with respect to subsequent serious adverse 
events.  I also conducted a second target trial to evaluate whether the effect of 
hypoglycaemia was affected by the presence or absence of dementia.  I 
selected participants, intervention (exposure) and follow-up to mirror the two 
hypothetical target randomised controlled trials116(Figure 35).  
 
   
 
 145 
Figure 34 Schematic presentation of study 
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4.4.2 STUDY DATA AND SETTING 
I chose to use CPRD because it holds anonymised primary care records from 
GPs, encompassing over 11 million patients from 674 practices in the UK and is 
broadly representative of the UK general population in terms of age, sex and 
ethnicity 117. Another advantage of CPRD is the data linkage with other 
databases, thus enabling me to ascertain hospital, national mortality, and 
socioeconomic data relating to the patient.  A subset of primary care datasets is 
linked with Hospital Episode Statistics (HES), which covers ED attendances and 
hospitalization. Linkage with the Office for National Statistics (ONS), allows me 
to record date of death of the participants, whilst the Index of Multiple 
Deprivation and Townsend scores is a record of socioeconomic deprivation 
status 117.   
The study protocol was approved by the Independent Scientific Advisory 
Committee (ISAC); protocol number 16_184R (Appendix 8).  I submitted 
proposed amendments to the Protocol in November 2017, which were 
approved in December 2017 (Appendix 9 and 10). 
I followed the Strengthening the Reporting of Observation Studies in 
Epidemiology (STROBE) guidelines in writing up the published manuscript118. 
4.4.2.1 SAMPLE SIZE CALCULATION 
Preliminary feasibility estimates were that there would be at least 960 patients 
with diabetes and dementia experiencing hypoglycaemia, and potentially up to 
9000 without hypoglycaemia.  Based on an estimated baseline event rate of 6% 
for fractures 119, my study had>99% power to detect a clinically important 
relative risk increase of 2.0 for fracture between groups (alpha 0.05) i.e. 
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absolute increase of 12% in the hypoglycaemic group.  I contacted CPRD 
beforehand to confirm that their database was potentially able to yield 
sufficient numbers of records to meet this sample size calculation. 
4.4.3 PARTICIPANTS 
The cohort consisted of patients aged 65 or older with diabetes, defined as a 
first ever prescription of any oral or injectable glucose-lowering agent between 
April 1997 and March 2016.  I considered initiation of a glucose-lowering drug 
to be a proxy for diagnosis and treatment of diabetes mellitus because there 
are no other clinical indications (e.g. polycystic ovary syndrome) for such drugs 
in this age group. 
Eligible participants also needed HES-linked data available. Dementia status was 
ascertained based on presence of CPRD Read Code or HES International 
Classification of Diseases (ICD) code (Appendix 11).   Brown et al showed that 
dementia recorded in routinely collected in HES has 85% diagnostic agreement 
with a GP survey120, and a recent systematic review has confirmed that large 
health-care datasets can achieve a high positive predictive value for dementia 
identification121. 
Read Codes have been used by the NHS since the 1980s and are a thesaurus of 
clinical terms. 
4.4.4 EXPOSURE AND OUTCOMES 
The exposure was defined as the first hypoglycaemic episode recorded on the 
primary (CPRD) or secondary (HES) healthcare database from April 1997 
onwards following initiation of a glucose-lowering agent.  Hypoglycaemic 
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episodes are recorded in primary care (CPRD) via Read codes and in secondary 
care (HES) via ICD codes: 
Hypoglycemia Read codes: C112100, C11y100, C116.00, C110z00, 
C112z00, C116000, C112000, C112.00, C110.00 
 
ICD9/10: 251.0, 251.1, 251.2, E249.8 and E250.8, 
E10.64, E11.64, E16.0, E16.1, E16.2 
Combined use of CPRD and HES broadens the capture of hypoglycaemia to 
include events recorded by medical personnel in both the primary and 
secondary care settings; a similar approach has been used in previous research 
on the association between hypoglycaemia and cardiovascular events in insulin 
users122.  I have to concede at this juncture that I am only able to capture 
hypoglycaemic episodes which have resulted in an entry on a patient’s medical 
record, which are those which require assistance from another person and are 
therefore flagged up to the medical team or result in an attendance in an 
emergency department.  I will further discuss the rationale and implications of 
this approach in the Strengths and Limitations section. 
For target trial 1, the exposed group’s (dementia, hypoglycaemia) first coded 
hypoglycaemic episode occurred a median of 13 (interquartile range: 2-34) 
months after meeting the study eligibility criteria.  The patients in the control 
group do not have hypoglycaemic events.  I therefore had to allocate the start 
date to be similar to the exposed group based on the time interval between 
meeting the study criteria and actually experiencing a hypoglycaemic event123.   
The outcomes were falls, fractures, cardiovascular events (myocardial infarction, 
ischaemic stroke) and all-cause mortality.  I chose these, based on a previous 
systematic review I published, which identified signals of elevated risk for these 
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outcomes in older people experiencing hypoglycaemic events6. 
In addition, I assessed the rate of ED attendances for patients who had their point 
of exposure after 1 April 2007 (HES Accident & Emergency data is only available 
for the time period April 2007 to 31 March 2016).   
The start of follow-up was the first hypoglycaemic episode, or the randomly 
allocated exposure date for the control group in target trial 1.  Follow-up 
continued for up to five years from the exposure, loss from database, death, or 
end of available database linkage (HES 31 March 2016 and ONS 17 April 2017), 
whichever was the earlier.   
4.4.5 COVARIATES 
The covariates I chose for the adjusted analysis are based on previous 
literature124 125.  Important confounders are the ones that are likely to affect 
the probability of the exposure and the outcome of interest, hence the adjusted 
models are specifically tailored to each outcome of interest.  For example, 
Hippisley-Cox et al used a specific list of confounders in their study assessing 
associations between risks of cardiovascular disease and all-cause mortality and 
different drugs used in the treatment of T2DM124.  My choice of covariates for 
the adjusted models assessing associations for those outcomes in my target 
trials was based on this paper.  
Driessen et al assessed bone fracture risk associated with the use of GLP-1 
receptor agonists and I was able to base my choice of covariates for the 
adjusted models assessing fracture risk in my target trials on Driessen’s 
study125. 
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I extracted information on a range of patient characteristics, including year of 
birth, gender, index of multiple deprivation quintile, year of glucose-lowering 
drug initiation, duration of dementia and diabetes, medications, co-morbid 
conditions (hypertension, peripheral vascular disease, valvular heart disease, 
cardiovascular disease, chronic kidney disease, atrial fibrillation), complications 
(severe kidney failure, amputation, blindness), body mass index (BMI) and 
HbA1c.  CPRD does not provide the month of birth for patients aged over 16, only 
the year of birth.  I therefore allocated the date of birth as the middle of the year 
of birth.    
Regarding ethnicity, Mathur et al demonstrated that in primary care there is 
good capture, which is largely comparable to the general population.  Linkage 
of datasets (ie HES inpatients) shows nearly 100% completeness, although there 
was poor completeness for HES A&E and poor consistency for HES outpatient 
records126.  I used HES categories, however, replaced with CPRD categories 
when HES was ‘other’, ‘unknown’ and ‘missing’.  Data extraction showed 10 
patients as ‘others’, which I then combined to make a ‘mixed/other’ category, 
in addition to ‘white’, ‘asian’, ‘black’, ‘unknown’. 
For alcohol, I extracted the last date on/before the exposure of drinking alcohol 
and the last date on/before the exposure of not drinking alcohol.  I then 
generated a variable for ‘alcohol status’ (yes/no). 
Looking at the smoking status for patients, I extracted three dates: last date 
on/before the exposure of being (a) current (b) ex or (c) non-smoker.  From those 
three dates, I generated a ‘smoking status’ variable with ‘yes’ being allocated to 
current and ex-smokers and ‘no’ allocated to non-smokers. 
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Covariates were measured at the point of exposure or the allocated index date 
for controls. I took into account the medication history for the past 90 days, most 
recent BMI within the last three years and most recent HbA1c within the last 18 
months. 
4.4.6 STATISTICAL ANALYSIS 
To estimate the association between the timing of hypoglycaemic episodes and 
defined outcomes, I used Cox proportional hazard regression models with 
adjustment for appropriate confounders to generate HRs and 95% CIs for each 
outcome.  Modelling the time for events (outcomes) to occur (survival time) is 
known as survival analysis.  The Cox proportional hazards model is a commonly 
used tool to investigate survival time and the relationship of predictor variables 
through the hazard function, for example, the hazard of the occurrence of 
myocardial infarction over a particular time period in relationship to various 
covariates127.  The assumption for this model is that the effect of predictors is 
constant over time.  However, the effect of the intervention (hypoglycaemia for 
target trial 1 and dementia for target trial 2) may be short-lasting or diminish 
with time, so it is necessary to check proportionality.  One way of doing this is, 
is to visually inspect log-log plots of survival to assess the proportional hazards 
assumption, ie the assumption that the relative effect of covariates on the 
hazard function does not change over time128.  If the proportional hazards 
assumption is met, then this should result in the log-log plot displaying parallel 
lines.  Log-log plots display the log survival versus log survival times. 
The proportional hazard assumption was not met in several of the outcomes, as 
a result of which I estimated the hazards at shorter and longer follow-up 
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periods.  An example of log-log plots where the proportional hazards 
assumption was met, and one were where it was not are in Figures 36 and 37. 
I used negative binomial regression to estimate the adjusted rate ratios of 
emergency department attendances for patients who had their point of 
exposure after 1 April 2007.  The aim of negative binomial regression is to 
model the relationships between predictors and the likelihood of a count 
outcome (ie here the emergency department attendances).   
It is similar to Poisson regression, however, the assumption with Poisson 
regression is that the mean and variance are the same, which often is not the 
case.  Negative binomial regression takes into account the variability of the 
counts.   
Analyses were performed with STATA version 14.2 software (StataCorp LP, 
College Station, TX). 
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Figure 35 Example where proportional hazards assumption was not met (target trial 1 – falls/fractures composite) 
 
  Number of events, n   Adjusted HR (95% CI) 
Up to one-year follow-up 
Adjusted HR (95% CI) 
12-60 months follow-up 
  Dementia, no hypoglycaemia 
(n=6134) 
Dementia, 
hypoglycaemia (n=1679) 
Complete case analysis (n=5607) 
  
Adverse events          
Falls & Fractures 
(composite) 
1771 555 1.94 (1.67 to 2.24)  1.16 (0.97 to 1.40) 
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Figure 36 Example where proportional hazards assumption was met (target trial 2 - falls/fractures composite) 
 
  Number of events, n   Adjusted HR (95% CI) 
Up to one-year follow-up 
Adjusted HR (95% CI) 
12-60 months follow-up 
  Dementia, hypoglycaemia 
(n=1679) 
No dementia, 
hypoglycaemia (n=12180) 
Complete case analysis (n=11683) 
  
Adverse events          
Falls & Fractures 
(composite) 
555 2642 1.72 (1.51 to 1.96) 1.71 (1.44 to 2.04) 
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4.4.7 MISSING DATA 
Missing data is unavoidable when analysing datasets, which can lead to bias 
and imprecise analysis.  Different approaches have been developed to address 
missing data and there is a lot of discussion around which technique is the most 
appropriate to employ dependent on the type of missing data. 
Data can be missing for different reasons: 
 Missing completely at random: there are no systematic differences 
between the missing and observed data 129, for example, people with 
missing blood pressure readings do not differ systematically from other 
people in the dataset 130. 
 Missing at random: there might be systematic differences between the 
observed and missing data, but they can be explained by other observed 
variables 129.  For example, if glycated haemoglobin (HbA1c) data are 
missing at random, conditional on age and gender, then the 
distributions of missing and observed HbA1c data will be similar among 
people of the same age and gender 130. 
 Missing not at random: associations with the observed data cannot 
explain systematic differences between observed and missing data 129. 
Two techniques which have been developed in order to address missing data 
are: 
 Complete case analysis: only individuals with complete information on 
all variables are considered in the main analysis; 
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 Multiple imputation:  missing values are imputed (replaced by plausible 
values – statistical packages create multiple datasets with imputed 
values to address uncertainty surrounding imputed values). 
There is no single optimal choice, however, researchers have argued that if data 
is not missing at random, then a complete case analysis can be a valid 
approach, whereas multiple imputation is valid for data missing at random and 
data missing completely at random 129. 
I used complete-case analysis for both hypothetical target trials, because I could 
not be certain that data were missing at random or not.  Due to not knowing 
the reason for missingness, I also carried out sensitivity analyses using different 
methods (multiple imputation, use of a missing data category, and exclusion of 
lifestyle covariates). 
 
4.5 RESULTS  
The cohort consisted of a total of 19,993 patients with diabetes.  The patient 
flowchart can be seen in Figure 38. 
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Figure 37 Patient flowchart 
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Patient demographics are set out in Table 7.   
 
Table 7 Baseline characteristics 
 
Dementia, no 
hypoglycaemia 
(n=6134) 
Dementia, 
hypoglycaemia 
(n=1679) 
Hypoglycaemia, 
no dementia 
(n=12180) 
Characteristics    
Age (years), mean (SD) 81.61 (6.88) 82.77 (6.59) 76.97 (7.31) 
Male gender, n (%) 2600 (42.39) 691 (41.16) 6105 (50.12) 
Ethnicity, n (%)    
Asian 188 (3.1) 59 (3.5) 541 (4.4) 
Black 156 (2.5) 59 (3.5) 261 (2.1) 
White 5409 (88.2) 1489 (88.7) 10787 (88.6) 
mixed/other 29 (0.5) 9 (0.5) 45 (0.4) 
unknown 352 (5.7) 63 (3.8) 546 (4.5) 
Documented smoking history, n 
(%)    
Yes 2984 (48.65) 852 (50.74) 7300 (59.93) 
No 3150 (51.35) 827 (49.26) 4880 (40.07) 
Body mass index (kg/m2), 
mean (SD) 26.63 (5.29) 26.32 (5.15) 28.67 (5.92) 
IMD quintile score, mean (SD)  2.88 (1.37) 3.03 (1.38) 3.01 (1.36) 
Documented alcohol history, n 
(%)    
Yes 3638 (59.31) 964 (57.42) 8601 (70.62) 
No 2496 (40.69) 715 (42.58) 3579 (29.38) 
Haemoglobin A1c (mmol/L), 
mean (SD) 56.71 (17.10) 62.46 (20.89) 60.51 (17.74) 
Haemoglobin A1c (%), mean 
(SD) 7.3 (3.7) 7.9 (4.1) 7.7 (3.8) 
Diabetes therapy duration 
(years), mean (SD) 5.22 (5.53) 8.55 (6.66) 8.62 (5.77) 
Dementia duration (years), 
mean (SD) 1.64 (2.24) 1.90 (2.31) N/A 
Comorbidities, n(%)    
Atrial fibrillation (AF) 951 (15.50) 309 (18.40) 1829 (15.02) 
Blindness 385 (6.28) 132 (7.86) 873 (7.17) 
Chronic obstructive pulmonary 
disease 448 (7.30) 138 (8.22) 1442 (11.84) 
Heart failure 482 (7.86) 190 (11.32) 1583 (13.00) 
Liver disease 89 (1.45) 31 (1.85) 258 (2.12) 
Hypertension 4023 (65.59) 1101 (65.57) 8515 (69.91) 
Inflammatory bowel disease 78 (1.27) 23 (1.37) 176 (1.44) 
Neuropathies 195 (3.18) 103 (6.13) 693 (5.69) 
Osteoporosis 405 (6.60) 137 (8.16) 725 (5.95) 
Parkinson’s disease 224 (3.65) 56 (3.34) 149 (1.22) 
Peripheral vascular disease 247 (4.03) 111 (6.61) 829 (6.81) 
Valvular heart disease 150 (2.45) 60 (3.57) 363 (2.98) 
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Renal disease 389 (6.34) 230 (13.70) 1524 (12.51) 
Rheumatoid arthritis 141 (2.30) 57 (3.39) 429 (3.52) 
Thyroid disease 884 (14.41) 267 (15.90) 1754 (14.40) 
Retinopathy 1438 (23.44) 653 (38.89) 4709 (38.66) 
Lower limb amputation 69 (1.12) 46 (2.74) 418 (3.43) 
Previous fractures 1143 (18.63) 397 (23.65) 1753 (14.39) 
Cancer that metastasizes to the 
bone 349 (5.69) 113 (6.73) 847 (6.95) 
History of previous MI 973 (15.86) 366 (21.80) 2643 (21.70) 
Prescription in past 90 days, n 
(%)    
Renin-angiotensin blockers 2790 (45.48) 825 (49.14) 7597 (62.37) 
Thiazide diuretic 763 (12.44) 137 (8.16) 2039 (16.74) 
Loop diuretics 1371 (22.35) 525 (31.27) 4165 (34.20) 
Betablocker 1304 (21.26) 367 (21.86) 3327 (27.32) 
Antiplatelets 3322 (54.16) 952 (56.70) 6367 (52.27) 
Anticoagulation 437 (7.12) 120 (7.15) 1154 (9.47) 
Lipid lowering medication 3608 (58.82) 974 (58.01) 7657 (62.87) 
Steroids 278 (4.53) 111(6.61) 1212 (9.95) 
Calcium channel blocker 1556 (25.37) 406 (24.18) 4011 (32.93) 
PD meds 216 (3.52) 54 (3.22) 185 (1.52) 
Antiarrhythmics 49 (0.80) 24 (1.43) 278 (2.28) 
Antidepressants 2006 (32.70) 598 (35.62) 2560 (21.02) 
Antipsychotics 904 (14.74) 253 (15.07) 468 (3.84) 
Hypnotics 429 (6.99) 121 (7.21) 565 (4.64) 
Drugs affecting bone 
metabolism 475 (7.74) 166 (9.89) 810 (6.65) 
Sulfonylureas 2511 (40.94) 786 (46.81) 5662 (46.49) 
Insulin 794 (12.94) 801 (47.71) 5974 (49.05) 
Other oral hypoglycaemics 3512 (57.25) 678 (40.38) 5528 (45.39) 
Dementia drugs 1027 (16.74) 180 (10.72) Not applicable 
 
1Bisphosphonates, Calcitonin, Calcium and Vitamin D supplements 
 
The mean age of the dementia group was 82 years and the non-dementia group 
was 77 years.  Insulin use was higher in those with dementia and 
hypoglycaemia compared to those with dementia and no hypoglycaemia (48% 
versus 13%). 
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In several instances, the proportional hazards assumption was not met in the 
statistical analysis. In order to identify any changes in the hazard during the 
follow-up period I have stratified the analysis according to less than or more 
than 12 months of follow-up (Tables 8 and 9). 
The number of events is reported in Tables 8 and 9 and the median time to 
event is reported in Table 10. 
Target trial 1 – the effect of hypoglycaemia on outcomes in patients with 
dementia (Table 8) 
During the first 12 months, adverse events occurred at about twice the rate 
among those with hypoglycaemia compared to those without - all-cause 
mortality (aHR 2.36 [95% CI 2.09 to 2.67]), cardiovascular events (aHR 2.00 
[95% CI 1.61 to 2.48)] and falls and fractures (aHR 1.94 [95%CI 1.67 to 2.24]). 
Hypoglycaemia was associated with an increase in subsequent myocardial 
infarction (MI) (aHR 2.24 [95% CI 1.59 to 3.15]) and ischaemic stroke (aHR 1.80 
[95% CI 1.37 to 2.36]) among people with dementia.  Falls and fracture risks 
individually were also both increased (aHR 1.96 [95% CI 1.69 to 2.29] and aHR 
1.62 [95% CI 1.25 to 2.08]). 
However, the associations diminished with longer follow-up.  During the 12-60 
months follow-up, there remained an association with mortality (aHR 1.33 [95% 
CI 1.19 to 1.48), but not the other outcomes. 
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Target trial 2 – the effect of co-morbid dementia on outcomes in patients with 
hypoglycaemia (Table 9) 
During the first 12 months, co-morbid dementia was associated with an 
increased risk of falls and fractures (aHR 1.72 [95% CI 1.51 to 1.96]) and 
mortality (aHR 1.27 [95% CI 1.15 to 1.41]) in older people with hypoglycaemia.   
The risk of mortality increased to more than double during the 12-60 months 
follow-up period (aHR 2.15 [95% CI 1.94 to 2.37]). 
Dementia did not show a statistically significant association on cardiovascular 
events (aHR 1.14 [95% CI 0.95 to 1.36]).  It was associated with a significant 
increase in the risk of ischaemic stroke (aHR of 1.41 [95% CI 1.12 to 1.78]), but 
not myocardial infarction (aHR 0.84 [95% CI 0.64 to 1.10]). 
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Table 8 Target trial 1 – effect of hypoglycaemia in patients with diabetes and dementia 
 
The model for cardiovascular events was adjusted for age, gender, ethnicity, BMI, duration of diabetes therapy, HbA1c, smoking status (ever/never), alcohol use 
(ever/never), index of multiple deprivation, co-morbidities (amputation history, atrial fibrillation, blindness, liver disease, heart failure, hypertension, neuropathies, 
Parkinson’s disease, peripheral vascular disease, renal disease, retinopathy, rheumatoid arthritis, valvular heart disease, h istory of MI), medications (insulin, sulfonylureas, 
other oral hypoglycaemics, beta blockers, calcium channel blockers, loop diuretics, thiazide diuretics, anticoagulants, antiplatelets, cholesterol-lowering medications, 
Angiotensin-converting enzyme inhibitor (ACEi), dementia drugs) 
 
The model for falls and fractures was adjusted for age, gender, ethnicity, BMI, duration of diabetes management, HbA1c, smoking status (ever/never), alcohol use 
(ever/never), index of multiple deprivation, co-morbidities (amputation history, atrial fibrillation, blindness, chronic obstructive pulmonary disease (COPD), liver disease, 
inflammatory bowel disease, heart failure, hypertension, neuropathies, osteoporosis, previous fractures, Parkinson’s disease, peripheral vascular disease, renal disease, 
retinopathy, rheumatoid arthritis, thyroid disease, valvular heart disease, history of cancer that metastasises to the bone), medications (bone protection medications, 
insulin, sulfonylureas, other oral hypoglycaemics, hypnotics, antipsychotics, antidepressants, beta blockers, calcium channel blockers, loop diuretics, thiazide diuretics, 
anticoagulants, antiplatelets, cholesterol-lowering medications, steroids, Parkinson’s medications, ACE-i), dementia drugs 
 Number of events, n Adjusted HR (95% CI) 
Up to one-year follow-up 
Adjusted HR (95% CI) 
12-60 months follow-up 
 Dementia, no 
hypoglycaemia (n=6134) 
Dementia, hypoglycaemia 
(n=1679) 
Complete case analysis (n=5607) 
Adverse events      
Cardiovascular (composite) 815 271 2.00 (1.61 to 2.48) 1.11 (0.85 to 1.47) 
MI 311 119 2.24 (1.59 to 3.15) 1.28 (0.86 to 1.91) 
Stroke 543 163 1.80 (1.37 to 2.36) 1.01 (0.71 to 1.43) 
Falls & Fractures (composite) 1771 555 1.94 (1.67 to 2.24)  1.16 (0.97 to 1.40) 
Falls 1640 514 1.96 (1.69 to 2.29) 1.10 (0.91 to 1.34) 
Fractures 720 207 1.62 (1.25 to 2.08) 1.09 (0.83 to 1.43) 
Mortality 3860 1370 2.36 (2.09 to 2.67)  1.33 (1.19 to 1.48) 
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The model for mortality was adjusted for age, gender, ethnicity, BMI, duration of diabetes management, HbA1c, smoking status (ever/never), alcohol use (ever/never), 
index of multiple deprivation, co-morbidities (amputation history, atrial fibrillation, blindness, COPD, liver disease, heart failure, hypertension, neuropathies, Parkinson’s 
disease, peripheral vascular disease, renal disease, retinopathy, rheumatoid arthritis, valvular heart disease, history of MI, history of cancer that metastasises to the bone), 
medications (insulin, sulfonylureas, other oral hypoglycaemics, beta blockers, calcium channel blockers, loop diuretics, thiazide diuretics, anticoagulants, antiplatelets, 
cholesterol-lowering medications, ACE-i), dementia drugs 
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Table 9 Target trial 2 – the effect of presence or absence of dementia 
 
The model for cardiovascular events was adjusted for age, gender, ethnicity, BMI, duration of diabetes therapy, HbA1c, smoking status (ever/never), alcohol use 
(ever/never), index of multiple deprivation, co-morbidities (amputation history, atrial fibrillation, blindness, liver disease, heart failure, hypertension, neuropathies, 
Parkinson’s disease, peripheral vascular disease, renal disease, retinopathy, rheumatoid arthritis, valvular heart disease, h istory of MI), medications (insulin, sulfonylureas, 
other oral hypoglycaemics, beta blockers, calcium channel blockers, loop diuretics, thiazide diuretics, anticoagulants, antiplatelets, cholesterol-lowering medications, ACE-
i). 
 
The model for falls and fractures was adjusted for age, gender, ethnicity, BMI, duration of diabetes management, HbA1c, smoking status (ever/never), alcohol use 
(ever/never), index of multiple deprivation, co-morbidities (amputation history, atrial fibrillation, blindness, COPD, liver disease, inflammatory bowel disease, heart failure, 
hypertension, neuropathies, osteoporosis, previous fractures, Parkinson’s disease, peripheral vascular disease, renal disease, retinopathy, rheumatoid arthritis, thyroid 
 Number of events, n Adjusted HR (95% CI) 
Up to one-year follow-up 
Adjusted HR (95% CI) 
12-60 months follow-up 
 Dementia, 
hypoglycaemia (n=1679) 
No dementia, 
hypoglycaemia, (n=12180) 
Complete case analysis (n=11683) 
Adverse events      
Cardiovascular (composite) 271 2297 1.14 (0.95 to 1.36) 0.91 (0.71 to 1.17) 
MI 119 1366 0.84 (0.64 to 1.10) 0.70 (0.75 to 1.00) 
Stroke 163 1097 1.41 (1.12 to 1.78) 1.22 (0.89 to 1.69) 
Falls & Fractures (composite) 555 2642 1.72 (1.51 to 1.96) 1.71 (1.44 to 2.04) 
Falls 514 2266 1.82 (1.59 to 2.09) 1.69 (1.40 to 2.03) 
Fractures 207 1208 1.36 (1.09 to 1.71) 1.39 (1.08 to 1.80) 
Mortality 1370 6142 1.27 (1.15 to 1.41)  2.15 (1.94 to 2.37) 
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disease, valvular heart disease, history of cancer that metastasises to the bone), medications (bone protection medications, insulin, sulfonylureas, other oral 
hypoglycaemics, hypnotics, antipsychotics, antidepressants, beta blockers, calcium channel blockers, loop diuretics, thiazide diuretics, anticoagulants, antiplatelets, 
cholesterol-lowering medications, steroids, Parkinson’s medications, ACE-i). 
 
The model for mortality was adjusted for age, gender, ethnicity, BMI, duration of diabetes management, HbA1c, smoking status (ever/never), alcohol use (ever/never), 
index of multiple deprivation, co-morbidities (amputation history, atrial fibrillation, blindness, COPD, liver disease, heart failure, hypertension, neuropathies, Parkinson’s 
disease, peripheral vascular disease, renal disease, retinopathy, rheumatoid arthritis, valvular heart disease, history of MI, history of cancer that metastasises to the bone), 
medications (insulin, sulfonylureas, other oral hypoglycaemics, beta blockers, calcium channel blockers, loop diuretics, thiazide diuretics, anticoagulants, antiplatelets, 
cholesterol-lowering medications, ACE-i) 
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Table 10 Median time to outcome 
 
 
 
 
 
 
 
 
 
 
 
  Median time to outcome, median days (25th to 75th percentile) 
  Dementia, no hypoglycaemia 
 
 
Dementia, 
hypoglycaemia 
 
 
Hypoglycaemia, no 
dementia 
Outcome 
  
  
Cardiovascular (composite) 
 
397 (152 to 762) 
 
153 (21 to 574) 
 
326 (53 to 793) 
Falls & Fractures (composite) 359 (136 to 751) 
 
145 (4 to 461) 
 
341 (50 to 863) 
Mortality 
 
618 (266 to 1047) 
 
334 (80 to 779) 
 
350 (80 to 877) 
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Sensitivity analyses (Tables 11 and 12) 
Certain lifestyle variables such as BMI, alcohol, smoking status and HbA1c were 
not regularly measured or necessarily measured close to the exposure.  My 
findings did not substantially change when using different methods to account 
for the missing data.  
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Table 11 Models used to investigate missing or incomplete data for target trial. 1 (12 months follow-up) 
 
 Unadjusted HR (95% CI) Model 1*†  
aHR (95% CI) 
Model 2*  
aHR (95% CI) 
Model 3* 
aHR (95% CI) 
Adverse events during follow-up 
 
   
Cardiovascular (composite) 2.11 (1.77 to 2.52) 1.79 (1.48 to 2.16) 
 
1.78 (1.48 to 2.16) 
 
1.77 (1.45 to 2.14) 
Falls & Fractures (composite) 1.98 (1.76 to 2.23) 1.80 (1.58 to 2.05) 
 
1.80 (1.59 to 2.06) 
 
1.79 (1.58 to 2.04) 
Mortality 2.58 (2.35 to 2.83) 2.34 (2.13 to 2.59) 
 
2.33 (2.11 to 2.57) 
 
2.32 (2.10 to 2.56) 
 
Model 1: Regression model excluding the following covariates: BMI, HbA1c, smoking status and alcohol status 
Model 2: Regression model with BMI and HbA1c as categorical covariates with missing category 
Model 3: Regression model with multiple imputation of continuous covariates HbA1C and BMI 
 
* The amount of missing lifestyle data for continuous variables was as follows: HbA1c within the last 18 months: 2042 (10.2%), BMI within the last three 
years: 2916 (14.6%). 
 
†An up to date (within 3 years of index date) record of smoking or alcohol history was not available in 2570 (12.9%) participants and 5667 (28%) 
participants respectively. 
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Table 12 Models used to investigate missing or incomplete data for target trial 2 (12 months follow-up) 
 
 Unadjusted HR (95% CI) Model 1* † 
 
aHR (95% CI) 
Model 2*  
aHR (95% CI) 
Model 3* 
aHR (95% CI) 
Adverse events during follow-up 
 
   
Cardiovascular (composite) 1.20 (1.03 to 1.40) 1.03 (0.88 to 1.21) 
 
1.00 (0.85 to 1.17) 
 
0.99 (0.84 to 1.16) 
Falls & Fractures (composite) 2.32 (2.07 to 2.60) 1.61 (1.43 to 1.82) 
 
1.62 (1.44 to 1.83) 
 
1.60 (1.42 to 1.81) 
Mortality 1.84 (1.69 to 1.99) 1.39 (1.28 to 1.51) 
 
1.35 (1.25 to 1.47) 
 
1.35 (1.24 to 1.47) 
 
Model 1: Regression model excluding the following covariates: BMI, HbA1c, smoking status and alcohol status 
Model 2: Regression model with BMI and HbA1c as categorical covariates with missing category 
Model 3: Regression model with multiple imputation of continuous covariates HbA1C and BMI 
 
* The amount of missing lifestyle data for continuous variables was as follows: HbA1c within the last 18 months: 2042 (10.2%), BMI within the last three 
years: 2916 (14.6%). 
 
† An up to date (within 3 years of index date) record of smoking or alcohol history was not available in 2570 (12.9%) participants and 5667 (28%) 
participants respectively. 
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Emergency department attendances (Table 13) 
The rate of ED attendances in patients with dementia and hypoglycaemia was 
113 per 100 patient-years.  The rate in those with dementia but no 
hypoglycaemia was 64 per 100 patient-years (aRR 1.43 [95% CI 1.30 to 1.57]). 
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Table 13 ED attendances across entire study duration 
 
 
 
 
Patients exposed 
 
 
Numbers of outcomes 
 
 
Events per 100- person years 
 
Target trial 1 
aRR (95% CI) 
 
Target trial 2  
aRR (95% CI) 
 
ED attendances       1.43 (1.30 to 1.57) 1.22 (1.10 to 1.34) 
Dementia, no 
hypoglycaemia 
6134 9156 64   
Dementia, 
hypoglycaemia 
1679 3110 113   
Hypoglycaemia, no 
dementia 
12180 16451 51   
 
Adjusted for age, gender, index of multiple deprivation quintile, ethnicity, HbA1c, medications (insulin, sulfonylureas, antipsychotics, hypnotics), co-morbid conditions 
(amputation, atrial fibrillation, blindness, COPD, liver disease, heart failure, hypertension, inflammatory bowel disease, neuropathies, osteoporosis, Parkinson’s disease, 
peripheral vascular disease, previous fractures, renal disease, rheumatoid arthritis, thyroid disease, retinopathy, cancers that metastasise to bone, diabetes duration) 
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4.6 DISCUSSION 
I have shown that older people with dementia and diabetes who have had a 
hypoglycaemic event have substantially higher risk of death, cardiovascular 
events, falls, fractures and emergency department attendances, than those 
who have not had a hypoglycaemic event. 
The hazard ratios of complications were found to be greatest within the first 12 
months of follow-up, which would be consistent with a clinically and biologically 
plausible relationship.  The magnitude of risk diminished with longer follow-up 
time, which indicates that our findings are probably not related to residual 
confounders.  This is because persistent residual confounding (such as greater 
frailty) would more likely be associated with constantly elevated hazard ratios 
for adverse outcomes across the entire duration of follow-up. 
The results underscore the importance of management strategies tailored 
towards avoidance of hypoglycaemic episodes rather than just chasing tight 
glycaemic targets in this vulnerable group.  This is of particular significance in 
the light of recent findings that asymptomatic hypoglycaemic episodes are 
often missed in older people with diabetes73, as this study may only be looking 
at the tip of the iceberg regarding the impact of hypoglycaemia.   
Furthermore, the higher risk in the first 12 months would be clinically 
consistent with the potential impact of an acute episode of hypoglycaemia, 
especially if the underlying harm stems from cardiac damage.  For example, 
Pistrosch et al’s study of CGM and ambulatory cardiac monitoring found a link 
between hypoglycaemia and the occurrence of ventricular arrhythmias99.  A 
recently published meta-analysis confirmed that hypoglycaemia can result in 
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ECG changes associated with cardiac arrhythmias that are markers of increased 
risk of mortality and cardiovascular events131.  Cardiac arrhythmias may be an 
underlying factor to explain our findings of increased risk of myocardial 
infarction, stroke, falls and death following hypoglycaemia.  Nevertheless, the 
effects of hypoglycaemia on the cardiovascular physiology of frail, multi-morbid 
older patients with diabetes remains unclear.   
More recent studies estimated the link between hypoglycaemia and 
accelerated cognitive decline.  Hypoglycaemia in older people is linked to an 
increased risk in cognitive decline7 and another recent study found that 
hypoglycaemia was associated with smaller total brain volume on MRI68.  
Cognitive decline may in turn pre-dispose older frail people to falls, fractures 
and death following hypoglycaemia.  This ties in with my findings that dementia 
contributes to greater hazards in terms of mortality, falls and fractures in older 
patients with hypoglycaemia.  My study demonstrates that co-morbid dementia 
and diabetes is a particularly challenging, high-risk condition in older people 
where carefully tailored strategies will be needed to minimize the serious 
consequences of hypoglycaemia. 
However, the effect of co-existing dementia on subsequent risk of myocardial 
infarction in older people with hypoglycaemia has not been established here.  
Diagnostic difficulty or misclassification may be a source of bias towards the 
null because of under-ascertainment of coronary events.  Older people with 
myocardial infarction can present with vague symptoms such as shortness of 
breath, nausea, sweating or collapse, which may result in an acute cardiac 
event going unrecognised. Alexander et al found that only 40% of over 85-year-
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olds presented with the typical symptom of chest pain when experiencing an 
acute myocardial infarction132 133.  Patients with co-morbid dementia may not 
be sufficiently able to communicate their symptoms, and symptoms such as 
shortness of breath and sweating could, for example, be misdiagnosed as 
pneumonia on initial presentation.  Bronchopneumonia is reported as the most 
common cause of death in older patients with dementia134 135.  Presence of 
cognitive impairment may also affect rates of diagnosis for other outcomes 
including fractures and strokes. 
4.6.1 STRENGTHS AND LIMITATIONS 
The strengths of this study include the size of the cohort of nearly 20,000 
patients and the number of covariates that I used to address confounding.  I am 
aware that differences in patient characteristics and medication could be 
potentially important contributors to risk of adverse outcomes.  Hence, the 
registered protocol specified the inclusion of several key variables (such as age, 
insulin use and co-morbidities) to reduce confounding in the adjusted statistical 
model.  As I am presenting the results of an observational study, I am not able 
to prove a causal link, however, this study does demonstrate that 
hypoglycaemia is a marker of risk for subsequent adverse events. 
The three areas which carry some risk of bias in my study are: reliability of 
capture of potential confounders, missing data and classification of 
intervention.  I am aware that in some patients, covariates such as BMI, HbA1c, 
smoking and alcohol status may not have been regularly documented in the 
preceding period before the exposure.  However, I used three different 
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methods to address this issue in our sensitivity analyses, all of which yielded 
similar results. 
My findings are principally applicable to severe hypoglycaemic events, which 
require medical assistance and hence result in an entry on an individuals’ 
medical records.  Large trials have used the same methodology in assessing 
severe hypoglycaemia and its complications, and my approach is therefore 
compatible with current research practice136 137.  I recognize that risk of 
subsequent complications may be of greater magnitude due to the severity of 
the hypoglycaemia and I cannot determine whether self-managed or 
asymptomatic hypoglycaemia are associated with a similar or lower risk of 
serious consequences.  However, in the absence of large CGM trials in older 
people with diabetes and dementia, there are no means of reliably detecting 
mild or asymptomatic hypoglycaemic episodes for research purposes.  
Hypoglycaemic episodes documented in primary and secondary care healthcare 
records are currently the only available source. 
In addition, I am not able to accurately ascertain from the database the precise 
timing of the hypoglycaemic episode and what the blood glucose 
concentrations were, although, by virtue of the fact that these hypoglycaemic 
episodes have been recorded on the medical database, one would assume that 
they were of a severity that warranted being brought to the attention of the 
patient’s healthcare team.  Moreover, I have not attempted to analyse the 
effects of recurrent hypoglycaemia because very few patients experienced 
recurrent events in previous studies using the same database 138 31.    
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Similarly, I am not able to accurately determine dementia severity or duration 
from onset due to the insidious onset and substantial variation in clinical 
presentation which makes it difficult to reliably capture and code in a GP 
database.   
A combination of less rigorous management regimes, but greater intensity of 
monitoring should be considered to reduce hypoglycaemia in this vulnerable 
population.  Simply changing or loosening HbA1c targets for the older frail 
population may not help in reducing hypoglycaemic events.  The risk of 
hypoglycaemia may also have some relationship to variability, rather than low 
absolute values of HbA1c, as demonstrated in a recent paper reporting that a 
slight change in HbA1c variability resulted in a more than five-fold risk of 
hospitalization due to hypoglycaemia138.   
Future research has to focus on a RCT (in older people with diabetes and 
dementia), where the treatment strategy would be aimed at minimizing 
hypoglycaemic episodes.  An essential component of the trial would be the use 
of CGM, in order to capture hypoglycaemic episodes that may otherwise go 
unrecorded and guide the hypoglycaemia minimization strategy (by means of 
analysing ambulatory glucose profiles obtained through CGM), in addition to 
being a useful and supportive tool for carers in their day to day care of this 
vulnerable group of older people.  
 
To sum up, hypoglycaemia is associated with greater risk of subsequent 
complications such as falls, fractures and death in patients with dementia.  
Future work should focus on personalized management of diabetes and 
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monitoring strategies in those with co-morbid dementia, aiming for an optimal 
balance of treatment effect whilst minimizing risk of hypoglycaemia. 
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CHAPTER 5 - META-ANALYSIS: ASSOCIATION BETWEEN 
HYPOGLYCAEMIA AND SERIOUS ADVERSE EVENTS IN OLDER PATIENTS 
TREATED WITH GLUCOSE-LOWERING AGENTS  
 
5.1 PREAMBLE 
The fourth chapter explored the association between hypoglycaemia and 
serious adverse events in older patients with diabetes and dementia.  I have 
previously published meta-analyses on adverse events (dementia, macro- and 
micro-vascular events, falls and fractures, and death associated with 
hypoglycaemia6 7.  However, since those publications in 2016, I am aware of the 
publication of several new studies on adverse events associated with 
hypoglycaemia, including my study discussed in the previous chapter.  Hence, I 
have updated my meta-analyses and present a comprehensive review of the up 
to date evidence regarding the association between hypoglycaemia and 
adverse events in older people. 
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5.2 CHAPTER SUMMARY 
 
5.2.1 AIMS:  
I aimed to conduct a meta-analysis of serious adverse events (dementia, macro- 
and micro-vascular events, falls and fractures, death) associated with 
hypoglycaemia in older patients treated with glucose lowering drugs. 
5.2.2 METHODS:  
Meta-analysis of studies reporting on hypoglycaemia and adverse events.  My 
search included searches from two previous systematic reviews I published, and 
I updated the search of MEDLINE and EMBASE for a five-year period between 
April 2014 to April 2019. I assessed study validity based on ascertainment of 
hypoglycaemia, adverse events and adjustment for confounders and conducted 
random effects inverse variance meta-analyses, assessing heterogeneity using 
the I2 statistic.  Hypoglycaemia was assessed in different ways by the included 
studies, from relying on hospital or claims data records for hypoglycaemia 
requiring hird party assistance, to relying on self-reported hypoglycaemic 
episodes or questionnaires completed by patients. 
5.2.3 RESULTS:  
I included 42 studies involving 2,137,211 participants.   
Meta-analysis of eight studies demonstrated that hypoglycaemic episodes were 
associated with dementia – pooled OR 1.55 (95% CI 1.33 to 1.79). 
Meta-analysis of eighteen studies demonstrated that hypoglycaemic episodes 
were associated with macrovascular complications, pooled OR 1.81 (95% CI 
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1.69 to 1.95), and microvascular complications in two studies pooled OR 1.77 
(95% CI 1.49 to 2.10).   
Meta-analysis of six studies demonstrated an association between 
hypoglycaemia and falls and fractures, pooled OR 1.78 (95% CI 1.44 to 2.21) and 
1.68 (95% CI 1.37 to 2.07) respectively.  
Hypoglycaemia was associated with increased likelihood of death in a meta-
analysis of eighteen studies, pooled OR 2.02 (95% Confidence Interval 1.75 to 
2.32).   
5.2.4 CONCLUSION:  
My meta-analysis raises major concerns about a range of serious adverse 
events associated with hypoglycaemia. Clinicians should prioritize individualized 
therapy and closer monitoring strategies to avoid hypoglycaemia in susceptible 
older patients. 
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5.3 INTRODUCTION 
I have previously conducted meta-analyses to analyse the evidence on the 
relationship between hypoglycaemia and adverse events in older patients 
treated with glucose lowering drugs6 7.   
My first systematic review looked at the bi-directional relationship between 
hypoglycaemia and dementia.  The key findings of my meta-analyses were a 
70% increased risk of deterioration in cognition following hypoglycaemia and 
conversely a 60% increased risk of hypoglycaemia in older people with 
dementia.  However, this review did not include other major adverse events 
that may be associated with hypoglycaemia.  Hence, I conducted a second 
systematic review which focused on vascular adverse events, falls and fractures 
and all-cause mortality.  I found a 1.5 times increased risk in macrovascular 
events (ischaemic strokes, myocardial infarctions) and a doubling of risk in falls, 
fractures and death. 
However, this second review did not find any studies that specifically looked at 
the effects of hypoglycaemia in older patients who also have dementia.  The 
gaps in the evidence, helped me design the CPRD study, which I discussed in 
chapter 4. 
I am now able to do a more comprehensive systematic review and meta-
analysis, which addresses the evidence gaps I identified. 
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5.4 MATERIAL AND METHODS 
I worked from the methods described in my previously published meta-
analyses6 7. 
5.4.1 DATA SOURCES AND SEARCHES 
The population I was interested in was older adults (above the age of 55 years, 
which is an arbitrary cut-off).  I used the arbitrary cut-off of 55 years because 
there is no accepted value, and I aimed to be broad rather than too restrictive. 
The intervention was ‘hypoglycaemia’ and the comparator ‘no hypoglycaemia’.  
The outcomes of interest were cardiovascular events, falls and fractures, death 
and dementia. 
The searches I ran only included terms for the population and the intervention.  
The outcomes are too diverse and non-specific for me to be confident that I 
would capture all the relevant papers if I focused on particular outcomes. For 
instance, myocardial infarction could be described under a multitude of terms 
as acute coronary syndrome, ST-elevation myocardial infarction (STEMI) or non-
ST elevated myocardial infarction (NSTEMI). 
Three searches fed into this systematic review and meta-analysis. 
For both previously published reviews, I searched MEDLINE and EMBASE for a 
ten-year period up to March 2015 with English language restriction and 
checked the bibliographies of included studies for any potentially suitable 
studies. In addition, I signed up for the PubMed automated update email 
notifications of any newly published articles on hypoglycaemia in older patients. 
The search strategies were as follows: 
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Search software: Ovid SP 
1. 
 
diabetes-mellitus.mp. [mp=title, abstract, subject headings, heading word, drug 
trade name, original title, device manufacturer, drug manufacturer, device trade 
name, keyword] 
   
2. 
older-patient?.mp. [mp=title, abstract, subject headings, heading word, drug 
trade name, original title, device manufacturer, drug manufacturer, device trade 
name, keyword] 
   
3. 
older-adult?.mp. [mp=title, abstract, subject headings, heading word, drug trade 
name, original title, device manufacturer, drug manufacturer, device trade name, 
keyword] 
   
4. 
elderly.mp. [mp=title, abstract, subject headings, heading word, drug trade 
name, original title, device manufacturer, drug manufacturer, device trade name, 
keyword] 
   
5. 
geriatric.mp. [mp=title, abstract, subject headings, heading word, drug trade 
name, original title, device manufacturer, drug manufacturer, device trade name, 
keyword] 
   
6. 
veterans.mp. [mp=title, abstract, subject headings, heading word, drug trade 
name, original title, device manufacturer, drug manufacturer, device trade name, 
keyword] 
   
7. 
hypoglyc?emia.mp. [mp=title, abstract, subject headings, heading word, drug 
trade name, original title, device manufacturer, drug manufacturer, device trade 
name, keyword] 
   
8. 2 or 3 or 4 or 5 or 6    
9. 1 and 7 and 8    
10. limit 9 to (english and last 10 years)    
 
PubMed update 
((("diabetes mellitus"[MeSH Terms] OR ("diabetes"[All Fields] AND "mellitus"[All Fields]) 
OR "diabetes mellitus"[All Fields]) AND ("hypoglycaemia"[All Fields] OR 
"hypoglycemia"[MeSH Terms] OR "hypoglycemia"[All Fields]) AND (("aged"[MeSH 
Terms] OR "aged"[All Fields] OR ("older"[All Fields] AND "adult"[All Fields]) OR "older 
adult"[All Fields]) OR ("aged"[MeSH Terms] OR "aged"[All Fields] OR "elderly"[All Fields]) 
OR geriatric[All Fields] OR ("veterans"[MeSH Terms] OR "veterans"[All Fields]) OR older-
patient?[All Fields])) 
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The updated search I ran was for a five-year period from April 2014 to April 
2019.  I decided to go back five-years, to make sure that I had not missed 
studies when conducting the previous two searches.  
The search strategy was as follows: 
PubMed 
("diabetes mellitus"[MeSH Terms] OR ("diabetes"[All Fields] AND "mellitus"[All Fields]) 
OR "diabetes mellitus"[All Fields]) AND ("older patients"[All Fields] OR "older 
patient"[All Fields] OR "elderly"[All Fields] OR geriatric?[All Fields] OR "veterans"[MeSH 
Terms] OR "Aged"[MeSH Terms] OR "veterans"[All Fields] OR "older adults"[All Fields]) 
AND ("hypoglycaemia"[All Fields] OR "hypoglycemia"[MeSH Terms] OR 
"hypoglycemia"[All Fields]) AND ("2014/04/10"[PDat] : "2019/04/08"[PDat] AND 
English[lang]). 
5.4.2 STUDY SELECTION 
In my analysis, I included cohort studies (prospective and retrospective), which 
examined the association between hypoglycaemia and serious adverse events 
in participants aged 55 years and older on glucose-lowering medications.  I 
treated post-hoc analyses of randomized controlled trials as cohort studies, as 
the analysis is no longer on a prospective randomized basis due to post-hoc 
classification of patients (with and without hypoglycaemia).  I excluded cross-
sectional studies.  The reason I excluded cross-sectional studies was that it 
would be impossible to determine whether the intervention (hypoglycaemia) or 
outcome (adverse events) occurred first. 
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I included only full journal publications because abstracts are limited in word 
count and cannot fully describe the statistical models and confounding 
variables that are of key interest in non-randomized studies. 
5.4.3 DATA EXTRACTION AND QUALITY ASSESSMENT 
Study screening and data extraction was performed by me and YKL, by 
independently scanning all titles and abstracts for relevant articles, before 
obtaining full text versions for further checking. YKL and I resolved uncertainties 
and discrepancies through discussion.   
Data collection was completed by using a standardized form, which included 
details of the study design, date of the study and country of origin, setting, 
selection criteria, participants’ characteristics and outcome measures.  I 
extracted relative measures of effect such as odds ratios, risk ratios, and hazard 
ratios for the outcomes of interest in the group with hypoglycaemia as 
compared to the controls. 
The outcomes (adverse events) of interest were dementia, falls and fractures, 
composite cardiovascular (macrovascular) and microvascular events and all-
cause mortality. 
In order to assess study validity, YKL and I independently checked the methods 
used for recording hypoglycaemia and determining serious adverse events, as 
well as adjustment for potential confounding factors. 
5.4.4 DATA SYNTHESIS AND ANALYSIS 
I performed a random effects meta-analysis of the relative effect measures 
using the generic inverse variance method (Revman 5.3, Nordic Cochrane 
Centre, Kobenhavn).  As adverse events are rare, odds ratios and risk or hazard 
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ratios will yield similar estimates of relative effect, and I have pooled all of them 
using a random effects model.  I chose to perform a random effects meta-
analysis, as this method takes heterogeneity into account.  The model estimates 
an average effect and considers differences in intervention effects as random, 
rather than the single true effect pooled estimate that arises from the fixed 
effect model.   
Heterogeneity is a description of the extent to which the results of studies are 
consistent with each other. 
Heterogeneity was assessed by using the I2 statistic and visual inspection of the 
forest plots.  The I2 test was developed to assess the potential extent of 
heterogeneity in the meta-analysis.  The Cochrane Collaboration139 has issued 
the following rough guide on interpreting heterogeneity using I2: 
 0% to 40%: might not be important; 
 30% to 60%: moderate heterogeneity; 
 50% to 90%: substantial heterogeneity; 
 75% to 100%: considerable heterogeneity. 
I planned to construct a funnel plot if I had more than 10 studies in the meta-
analysis (without evidence of statistical heterogeneity - I2 <50%).  Funnel plots 
are a means of assessing possible bias, in particular that intervention effects of 
smaller studies differ from intervention effects of bigger studies 139.  It presents 
a scatter plot of intervention effect estimates of studies included in the meta-
analysis and should resemble a funnel.  If there is bias, then the scatter plot will 
appear asymmetrical, although the interpretation/visual inspection of the 
scatter plots is inherently subjective. 
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5.5 RESULTS 
I screened 3134 citations in addition to the 29 papers that were included in the 
previous reviews.  I included 42 studies with a total of 2,137,211 participants 137 
140-146 147 148 149-151 152  68 70-72 122 153-159 160-169 69 170-174. 
The flow chart of the study selection is shown in Figure 39.  Characteristics of 
the included studies and participants are shown in Table 14.
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Figure 38 PRISMA Flow Diagram 
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Table 14 Study design and characteristics (new papers highlighted in bold) 
Study ID Design  Data source Number 
of patients, setting, 
dates 
How were the 
patients selected 
for study 
Diabetes definition & Patient Characteristics, 
age, sex (or Selection of Cases and Controls)  
Type of glucose lowering 
agents 
Bedenis 2014140 Prospective 
cohort 
Edinburgh type 2 
Diabetes Study, 1066 
participants, Lothian 
Region Scotland 
2006-2010 
Lothian Diabetes 
Register 
Type 2 diabetes, mean age 68 years, male 
51% 
31% previous coronary heart event, 8.7% 
previous cerebrovascular event, 14% previous 
MI, 5.8% previous stroke 
Oral hypoglycaemic agents, 
insulin  
Bonds 2010137 Post hoc analysis 
of RCT 
10,251 
77 clinical centres in 
North America  
RCT (ACCORD) in 
patients with 
Type 2  
Type 2 diabetes, mean age 62.2 years, male 
62%. Had either established cardiovascular 
disease or additional cardiovascular risk 
factors. Exclusions: past severe 
hypoglycaemia, BMI >45, serum creatinine 
>133 micromol/L, other serious illness 
Insulin, oral hypoglycaemic 
agents 
Cha 2016141 Prospective 
cohort  
Vincent Type 2 
Diabetes Registry 
enrolled between 
January 2000 to 
December 2010 
(follow-up until May 
2015), 
1260 participants, 
South Korea 
Consecutive 
patients 
attending 
Diabetes Centre 
at St. Vincent’s 
hospital 
Type 2 diabetes, mean age 55 years, female 
59% 
Exclusions: older than 75 years, mental health 
illness, unable to undertake self-care, 
previous episodes of SH, cognitive 
impairment, alcohol excess, malignancy, end-
stage renal disease, severe infection, liver 
cirrhosis 
Insulin, oral hypoglycaemic 
agents 
Chiba 2015142 Retrospective 211 
Tokyo, Japan, Dec 
2009-Apr 2011 
Outpatient 
diabetes clinic 
attended for 
≥one year. 
>60 years 
168 T2DM patients and 43 age-matched, non-
diabetic controls 
Oral hypoglycaemic agents 
Insulin 
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Exclusion: blindness, wheelchair/bedridden, 
end-stage renal disease, adrenal insufficiency, 
hypopituitarism, hypo/hyperthyroid, 
uncontrolled hypertension 
Chin 2016143 Prospective 
cohort  
Korea National 
Diabetes Program, 
1957 participants, 
Korea 
2006-2014 
Korea National 
Diabetes Program 
database and 
Health Insurance 
Review and 
Assessment 
Service of Korea 
(HIRAS) 
Type 2 diabetes, mean age 68 years, 47% 
male, mean diabetes duration 8 years 
Exclusions: history of hypoglycaemia. 
cognitive impairment, previous history of 
drug misuse, head injury, depression. 
Oral hypoglycaemic agents 
insulin 
Cukierman-Yaffe 
2019144 
Post-hoc analysis 
form ORIGIN trial 
(RCT) 
11,495 participants 
recruited between 
2003 to 2005, 573 
sites in 40 countries 
ORIGIN trial of 
insulin glargine 
versus standard 
care. 
Individuals with impaired fasting glucose, 
impaired glucose tolerance or early type 2 
diabetes who also had additional 
cardiovascular risk factors 
Mean age 66 years (SH), 63 years (non-SH), 
female 26% (SH), 33% (non-SH), baseline 
mini-mental state examination (MMSE) >24 
Median follow-up 6.2 years 
Oral hypoglycaemic agents 
insulin 
Davis 2019145 Post-hoc analysis 
of Veterans 
Affairs Diabetes 
Trial (VADT) 
1791 military 
veterans 
20 Veterans 
Administration 
Hospitals across the 
United States 
VADT trial Type 2 diabetes, 97% male, median follow-up 
5.6 years, inadequate response to maximal 
doses of oral agents or insulin therapy. 
Exclusions: HbA1c <7.5%, occurrence of a 
cardiovascular event during previous 6 
months, advanced congestive heart failure, 
severe angina, life expectancy <7 years, 
BMI>40, serum creatinine level >141 
Oral hypoglycaemic agents 
insulin 
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micromol/L, alanine aminotransferase level > 
three times the upper limit of normal 
Duckworth 2011146 Posthoc analysis 
of RCT 
1791 
US 
1 December 2000 – 
30 May 2008 
 
RCT (VADT) Mean age 60.3 years 
97% male 
T2DM 
Exclusions: recent cardiovascular event, 
serious co-morbidities, renal or liver 
impairment, BMI>40 
Insulin, oral hypoglycaemic 
agents 
Escalada 2016147 Retrospective 
cohort 
Medicare Advantage 
claims database 
31035 patients 
1 January 2007 to 31 
December 2012  
US 
Medicare 
Advantage claims 
database 
Patients with type 2 diabetes making first 
pharmacy claim for basal insulin, included if 
previously on GLP-1 analogs/ oral 
hypoglycaemic agentes and had at least 2 
years of Medicare Advantage coverage. 
Excluded: previous insulin use (prandial 
insulin use during follow-up was permitted) 
Oral hypoglycaemic agents, 
insulin 
Freemantle 2016148 Post hoc analysis 
of CREDIT study 
(longitudinal 
study in patients 
starting insulin in 
routine clinical 
practice) 
3601 participants 
enrolled between 4 
December 2006 and 
20 April 2008 
314 centres in 12 
countries 
 
 
CREDIT study Primary inclusion criteria: men and women 
with type 2 diabetes, age >40 years, who had 
started insulin therapy >1 month and <6 
months prior to study entry and who had 
HbA1c measurement within the 3 months 
prior to beginning insulin. 
Mean age 62 years, diabetes duration 11 
years, type 2 diabetes. 
Oral hypoglycaemic agents, 
insulin 
Goto 2016149 Retrospective 
cohort 
Health insurance 
database 
58223 patients 
Japan 
Japan Medical 
Data Centre Co 
Ltd database 
Inclusion criteria: T2DM or unspecified 
diabetes, prescription of glucose-lowering 
agent, observation for a continuous period of 
at least.6 months from January 2005 to July 
2014. 
Oral hypoglycaemic agents, 
insulin 
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Exclusions: <18 years or >75 years, type 1 
diabetes, severe hypoglycaemia, history of 
cardiovascular disease (CVD). 
Haroon 2015150 Prospective Canada, Ontario 
225045 with newly 
diagnosed diabetes 
668070 without 
diabetes 
Provincial health 
administrative 
databases 
Seniors with newly diagnosed diabetes and 
matched comparison cohort without diabetes 
aged 66-105 between 1 April 1995 to 31 
March 2007. 
Followed until 31 March 2012 for a new 
diagnosis of dementia. 
Exclusions: dementia at baseline, individuals 
living in long-term care facilities 
Insulin, oral agents 
Heller 2017151 Post-hoc analysis  
of EXAMINE trial 
(RCT) 
5380 patients 
49 countries 
 
EXAMINE trial of 
alogliptin versus 
standard care 
and placebo 
Type 2 diabetes requiring anti-
hyperglycaemic medications with a baseline 
HbA1c of 6.5% to 11.0% (48-97 mmol/mol or 
7.0%-10.0% [53-86 mmol/mol] if on insulin 
therapy). 
Oral hypoglycaemic agents, 
insulin 
Hsu 2013152 Prospective 
cohort 
77,611 
Taiwan, 1998-2009 
Enrolled in 
National Health 
Insurance  
>60 years, newly diagnosed T2DM (with ≥3 
outpatient claims ICD-9-CM code 250) 
Hypoglycaemic patients with randomly 
selected and matched non- hypoglycaemics. 
Insulin, SU, other drugs 
Hung 201772 Cohort  Insurance claims 
database 2001 to 
2009 
7761 patients 
Taiwan 
National health 
Insurance 
Research 
Database 
Type 2 diabetes, mean age 70 years, male 
43%. 
Controls were frequency matched on age 
within 5 years, on gender and on duration of 
diabetes at a ratio of 1:2. 
Exclusions: pathological fractures, 
transportation accident before the index 
date. 
Median follow-up 3.9 years. 
Oral hypoglycaemic agents, 
insulin 
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Johnston 2011154 Retrospective 
cohort 
860,845 
US, 30 September 
2006 to 30 
September 2008 
Thomson Reuters 
MarketScan 
Commercial 
Claims and 
Encounters 
(Commercial) 
database and 
Medicare  
database 
 
Age>65 years with T2DM (≥1 claim with 
diagnosis code) and ≥2 prescriptions claims 
for antidiabetic drugs. 
Continuous enrolment and pharmacy benefits 
 throughout 24-month study period, except in 
case of inpatient death due to acute 
cardiovascular event.  
Exclusion: claim with diagnosis code for 
T1DM. 
Oral glucose-lowering agents, 
insulin 
Johnston 2012153 Retrospective 
cohort  
361,210 
 
1 April 2008 to 31 
March 2010 
Thomson Reuters 
MarketScan 
Commercial 
Claims and 
Encounters 
(Commercial) 
database and 
Medicare  
Database. 
Mean age 75, 52% male, T2DM (≥1 claim with 
diagnosis code) and ≥2 prescriptions claims 
for antidiabetic drugs. 
Continuous enrolment and pharmacy benefits 
 throughout 24-month study period, except in 
case of disenrolment due to fracture. 
Any antidiabetic drugs 
Kacharoo 2015155 Retrospective 
cohort study 
43,226 
US, 2008-2011 
Truven Health 
Market Scan 
Medicare 
Supplemental 
Database, 21,613 
hypoglycaemia 
patients matched 
with 21,613 non-
hypoglycaemia 
patients. 
T2DM 
Randomly matched to controls 1:1 by age, 
gender. 
Age >65 at index date (first T2DM date in the 
study period). 
Male 48% 
Metformin, SU, 
Thiazolodinediones, Insulin 
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Khunti 2015122 Retrospective Total: 265,868 
T2DM: 10,422 
England & Wales, 
2001-2007 
CPRD with 
hospital episode 
statistics datalink.  
All insulin users, age >30 years. 
T2DM sample mean age 63, male 56% 
Exclusion: patient without linkage to HES, , 
pre-index period ≤180 days, hypoglycaemia 
before index, no diabetes classification, CV 
event at index. 
Insulin, with or without other 
hypoglycaemic drugs 
Kong 2014  - chronic 
kidney disease (CKD) 
156 
Post-hoc analysis 
of prospective 
cohort study 
Diabetes Registry 
8767 patients 
Hong Kong 
Hong Kong 
Diabetes Registry 
(Kong 2014 
cancer/mortality) 
Type 2 diabetes with and without SH in the 12 
months before enrolment 
Exclusions: type 1 diabetes, missing variables 
used in the analysis 
Oral hypoglycaemic agents, 
insulin 
Lee 2018 (CV 
mortality) 71 
Prospective 
cohort 
1209 patients with 
diabetes who had 
been recruited for 
the Artherosclerosis 
Risk in Communities 
study (ARIC) 
(4th study visit in 
1996-1998 Is 
baseline for this 
analysis) 
US 
ARIC study 
 
Participants with diabetes identified by self-
report of a physician diagnosis or use of 
glucose lowering medication at 4th ARIC study 
visit. 
No glucose lowering 
medications, oral 
hypoglycaemic agents, 
insulin 
Lee 2018 (dementia) 
68 
Cross-sectional 
study (cognitive 
status) 
 
‘Prospective 
study’-dementia 
2011 patients with 
diabetes who had 
been recruited for 
the Artherosclerosis 
Risk in Communities 
study (ARIC) 
ARIC study. Participants with diagnosed diabetes by self-
report of diagnosis or diabetes medication 
use at 4th ARIC study visit. 
No glucose lowering 
medications, oral 
hypoglycaemic agents, 
insulin 
   
 
 195 
‘Prospective incident 
dementia’ analysis 
included 
1263 participants; 
the baseline was visit 
4 (1996– 
1998), with follow-
up to the end of 
2013. 
Leong 2016157 Longitudinal 
cohort 
Primary care 
Network, 
9137 participants 
Massachusetts, US. 
Primary care 
Network. 
Type 1 or type 2 diabetes patients without 
coronary artery disease before 1 January 
2006; 
Follow-up until earliest incident of coronary 
artery disease (CAD), last clinic visit, death or 
30 June 2012.  
Patients with 1 or more hypoglycaemic 
events in 200-2005 considered exposed; 
patients without a reported hypoglycaemic 
episode before 1 January 2006 were 
considered unexposed. 
Exclusions: patients with CAD before 1 
January 2006. 
Oral hypoglycaemic agents, 
insulin 
Lin 201370 Prospective 
cohort 
Taiwan 
15404 
National Health 
Insurance 
Database 
 
Type 2 diabetes (ICD9-CM), no prior 
dementia. 
45% male, mean age 64. 
[2% had prior hypoglycaemia – not in baseline 
characteristics]. 
Oral hypoglycaemics or 
insulin 
Lu 2015158 Cohort study National Health 
Insurance Database 
Insurance 
database 
Type 1 and type 2 diabetes plus other group 
without diabetes.  
Medications not listed in 
Table 1 
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Taiwan 
31049 enrolled in 
each of three groups, 
2000 to 2008. 
covering those 
with at least two 
outpatient visits 
for diabetes. 
Mean age in patients with diabetes and 
hypoglycaemia 63 years, 46% male 
Exclusions: admissions to hospital with cancer 
or any diagnoses of accident between 1997 
and index date. 
Majumdar 2013159 Retrospective 
cohort 
85,810 
Canada, 2004-2009 
Alberta Kidney 
Disease Network 
and the 
provincial health 
ministry (Alberta 
Health) 
Outpatients age>66 years (mean 75) who had 
administrative data for both serum creatinine 
and HbA1c within 6 months of each other 
51% female 
50% diabetic 
Oral hypoglycaemic drugs 
(mono therapy or 
combination), insulin 
Mattishent 2019160 Retrospective 
cohort 
Primary care 
database 1997-2016 
 
19993 patients 
CPRD database Patients aged 65 or older with diabetes, 
defined as a first ever prescription of any oral 
or injectable glucose-lowering agent between 
April 1997 and March 2016. 
Eligible participants also needed HES-linked 
data available. 
Follow-up continued for up to five years from 
the exposure, loss from database, death, or 
end of available database linkage (HES 31 
March 2016 and ONS 17 April 2017), 
whichever was the earlier 
Insulin, oral hypoglycaemic 
drugs 
McCoy 2012161 Retrospective 
cohort 
1013 
Diabetes Clinic, 
single centre, US 
August 2005 – July 
2006 
Medical records Type 1 and Type 2 diabetes, mean age 60.5 
years, male 55%, history of hypoglycaemia 
established prior to index clinical encounter 
Exclusions: seven lost to follow-up 
Insulin, oral hypoglycaemic 
drugs 
Mehta 2017 162 Retrospective 
cohort 
Primary care 
database 
CPRD New diagnosis of type 2 diabetes from 2003-
2012, >65 years on drug therapy. 
Oral hypoglycaemic agents, 
insulin 
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53055 patients 
2003-2012 
UK 
Exclusions: dementia diagnosis in a year prior 
to index date. 
Mellbin 2013164 Posthoc analysis 
of RCT  
 
12,537 
40 countries, 2003-
2005 
International 
multicentre 
randomized 
controlled trial of 
two different 
interventions in 
dysglycaemic 
individuals with 
impaired fasting 
glucose (IFG), 
impaired glucose 
tolerance (IGT), 
newly detected 
diabetes, or 
established 
diabetes 
50 years or older (mean age 63.5, 65% male) 
with cardiovascular risk factors 
60% had prior cardiovascular event, 80% had 
prior diagnosis of diabetes, 6% had newly 
detected Type2 diabetes, 12% had impaired 
glucose tolerance or impaired fasting glucose.  
Median baseline HbA1c 6.4% and fasting 
plasma glucose 6.9mmol/L. 
Insulin glargine, oral 
hypoglycaemic drugs 
Ntouva 2019163 Retrospective 
cohort 
Primary care 
database 
1995-2016 
41163 participants 
UK 
The Health 
Improvement 
Network (THIN) 
 
Type 2 diabetes aged 18 and older, registered 
in general practices contributing to THIN 
between 1 January 1995 to 1 May 2016 
Follow-up:  earliest of transfer date, death 
date, first documentation of outcome 
(fracture) or study end date). 
History of hypoglycaemia=exposed cohort 
(follow-up from date of hypoglycaemic 
episodes=index date). 
Oral hypoglycaemic agents, 
insulin 
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No history of hypoglycaemia=unexposed 
cohort.  For each exposed patients up to 2 
unexposed controls were randomly selected 
Exclusions: history of fracture. 
Pieber 2018165 Post hoc analysis 
of RCT 
 
 
 
DEVOTE RCT – 
multicentre, double-
blind, cardiovascular 
outcomes trial 
7637 patients 
randomised to either 
insulin degludec or 
insulin glargine. 
DEVOTE trial Type 2 diabetes with at least one oral or 
injectable glucose-lowering agent with HbA1c 
>7.0% (53mmol/L) or with >20 units/day 
basal insulin. Eligible for trial if they either 
had at least one co-existing cardiovascular or 
renal condition and were aged >50 years or 
had at least one of a list of pre-specified 
cardiovascular risk factors and were aged >60 
years. 
NOT excluded if experienced SH prior to 
randomisation. 
Oral hypoglycaemic agents, 
insulin 
 
Rajpathak 2015166 Retrospective 
cohort 
42,747 
US, (1 January 2002 
to 31 December 
2005), with 13195 
propensity matched 
pairs 
OptumInsight, 
medical claims 
database 
 
>65 years (mean 72.5) with T2DM 
1:1 propensity matching score (Sulfonylurea v 
non-sulfonylurea users). 
Exclusion criteria: drug supply <30 days, 
insulin use, prior hip fracture, SU initiation 
among non-users or discontinuation among 
users after the index date. 
SU 
Rathmann 2013167 Retrospective 19184 DPP-4 and 
31110 SU users 
(total: 50294) 
Germany (1201 
general practices), 
April 2007 to July 
2010 
Primary care 
data: Disease 
Analyzer 
Database (IMS 
HEALTH) 
T2DM with first time prescription (index date) 
of either DPP-4 inhibitors or SU from  
Continuous treatment in same practice 
Mean age 64 (DPP-4) and 69 (SU) 
Excluded: use of both SU and DPP-4 inhibitor; 
insulin use at baseline or follow-up, or any 
other antidiabetic drugs except metformin. 
DPP-4 
SU 
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Signorovitch 2013168 Retrospective 33,492 
US, 1998-2010 
Claims database 
from self-insured 
companies 
T2DM who had filled ≥2 prescriptions for oral 
hypoglycaemic drugs 
Mean age 60; Male 50%. 
Random sample without hypoglycaemia 5:1 
ratio to hypoglycaemic patients 
Exclusion: evidence of insulin use 
Oral hypoglycaemic drugs 
Standl 2018169 Post-hoc analysis 
of RCT 
14671 participants; 
multi-national, 
double-blind, 
placebo-controlled, 
randomized, trial 
designed to assess 
CV safety of 
sitagliptin vs 
placebo. 
TECOS trial T2DM, pre-existing coronary, cardiovascular 
or peripheral atherosclerotic disease, >50 
years, baseline HBA1c 6.5-8% (48-64mmol/L) 
Exclusion: those on DPP4 inhibitor, GLP-1 
agonist, Rosiglitazone during the preceding 
three months, >2SH episodes in the previous 
12 months, estimated glomerular filtration 
rate (eGFR) <30mL/min 
Follow-up median of 3 years. 
Oral hypoglycaemic agents, 
insulin 
 
Whitmer 200969 Prospective US 
16667 
Kaiser 
Permanente 
Northern 
California 
Diabetes Registry 
(1980-2007) 
 
T2DM 
Mean age 66 
Male 55% 
No prior diagnoses of dementia, mild 
cognitive impairment, or general memory 
complaints. 
Insulin, oral agents 
Yaffe 2013170 Prospective US 
783 
Participants with 
DM enrolled in 
Health, Aging, 
and Body 
Composition 
Study.  Excluded 
those with 
DM (self-report, use of hypoglycaemia meds, 
or biochemical testing) 
Mean age 74 
47% black ethnicity 
52.4% male 
Baseline modified MMSE >80 (no pre-existing 
cognitive impairment) 
Insulin, oral agents  
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evidence of 
possible cognitive 
impairment at 
study baseline 
Zhao 2012171 Retrospective 
cohort study 
44,261 (unmatched 
sample), 761 
hypoglycaemia 
matched to 761 
controls 
US, January 2004- 
September 2010 
Electronic 
medical and 
pharmacy 
records Veteran 
Health 
Administration   
T2DM, mean age 63, male 96%. 
Excluded: patients with 1-year pre-index 
records of hypoglycaemia, cardiovascular, 
and microvascular diseases, patients with 
T1DM 
Oral glucose lowering agents, 
insulin 
Zhao 2015172 Retrospective 
cohort study 
Cohort 4215 with 
hypoglycaemia 
matched to controls 
US 
January 2004-July 
2010 
Electronic 
medical and 
pharmacy 
records Veteran 
Health 
Administration   
Mean age 76.5, T2DM  
Excluded: patients with T1DM, patients with 
6-month pre-index record of fall. 
Oral glucose lowering agents, 
insulin 
Zinman 2018173 Post-hoc analysis 
of RCT 
9430 patients 
Multi-centre, 
double-blind, 
placebo-controlled 
RCT of liraglutide 
LEADER trial Type 2 diabetes; age 50 years or older and 
established CV disease or chronic renal failure 
OR age >60 years and risk factors for CV 
disease, HbA1c >7%. 
Patients were randomized 1:1 to receive 
liraglutide or placebo both in addition to 
standard-of-care treatment and followed for 
3.5-5 years. 
Exclusions: type 1 diabetes, use of GLP-1 
agonist, DDP-4 inhibitors, pramlintide, or 
rapid-acting insulin, history of MEN type 2 or 
medullary thyroid cancer and occurrence of 
Oral hypoglycaemic agents, 
insulin 
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an acute coronary or cerebrovascular event 
within 14 days before screening and 
randomization. 
Zoungas 2010174 Posthoc analysis 
of RCT  
 
11,140,  
215 centres in 20 
countries 
June 2001 to March 
2003 
ADVANCE 
randomized 
controlled trial of 
intensive glucose 
lowering 
(between) 
T2DM, age ≥55 years, diagnosis after the age 
of 30 and had a history of macrovascular or 
microvascular disease or at least one other 
cardiovascular risk factor.  Excluded if clear 
indication for long-term insulin at baseline. 
Gliclazide together with 
other oral glucose lowering 
agents 
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The included studies consist of nineteen retrospective, eleven prospective and 
twelve post-hoc analyses.  The studies had a total of 2,137,211 participants 
(sample size from 211 to 860,845).  Geographical locations were diverse and 
included North America, Canada, Asia and Europe. 
Twenty-seven studies focused on patients with T2DM, whereas the remaining 
studies had a mix of T1DM, T2DM and impaired glucose tolerance/impaired 
fasting glucose.  Four studies looked only at oral agents 166 167 174 168.  The 
remaining studies included patients with injectable as well as oral antidiabetic 
drugs. 
I report details of study validity (ascertainment of adverse outcomes, and 
confounding factors) in Table 15 and summarize the key features below. 
5.5.1 MEASUREMENT OF HYPOGLYCAEMIC EVENTS 
Most of the studies relied on hospital or claims data records for severe 
hypoglycaemic events, ie hypoglycaemia that requires help from another 
person to be managed/treated. 
Eleven studies rely on either a history of self-reported hypoglycaemic episodes, 
questionnaires, or provided participants with diaries and glucometers 164 137 142 
161  173 151 169 148 140 141 145.  These studies would be considered to be lower quality 
because of lack of medical documentation and high risk of recall bias. 
5.5.2 MEASUREMENT OF ADVERSE EVENTS 
Twelve studies used pre-specified outcomes from RCTs and one non-
interventional study148 137 144-146 148 156 164 165 169 173 174. 
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27 studies measured adverse events through database or medical records 
codes, one study relied on a professional interviewer with questionnaire 142and 
one study on self-report/GP questionnaires 140. 
A diverse variety of tests were used to ascertain dementia for the research 
studies, which reflects the reality of there not being one single agreed 
diagnostic test for dementia.  Some studies relied on diagnostic coding in 
medical or insurance records, where it was unclear if any specific validation 
based on cognitive testing had taken place.  
5.5.3 CONFOUNDING FACTORS 
All studies attempted to account for potential confounding through the use of 
multivariate logistic regression models, and in addition four studies used 
Propensity Score Matching 152 164 171 175. 
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Table 15 Study outcomes, results and risk of bias (new papers highlighted in bold) 
Study ID Method of diagnosing each type of 
adverse event 
Method of diagnosing or 
determining that patients had 
hypoglycaemia 
Statistical adjustments for 
confounding factors (if any) 
Results  
Bedenis 2014 140 Primary outcomes were MI (fatal or 
nonfatal), angina, transient ischaemic 
attack (TIA), stroke (fatal or nonfatal).  
Composite macrovascular disease 
outcome defined as one or more 
episodes of MI, angina, TIA or stroke.  
Coronary heart disease defined by 
occurrence of MI or angina.  
Cerebrovascular disease defined by 
occurrence of stroke or TIA. 
 
Self-report questionnaire or via GP 
questionnaire, WHO chest pain 
questionnaire, ECG and hospital 
discharge data linkage from 
Information and Services Division of 
NHS Scotland 
Self-report questionnaire of 
events within past 12 months 
(severe hypoglycaemia only) 
Univariate and multivariate-
adjusted regression models 
adjusting for age, sex, blood 
pressure, HbA1c, total 
cholesterol, HDL cholesterol, 
BMI, eGFR, duration of 
diabetes, smoking status, 
diabetes treatment, 
cardiovascular medications, 
microalbuminuria. 
Macrovascular disease events 
aOR 2.11 (1.06 to 4.21);  
Coronary heart disease events 
aOR 2.44 (1.13 to 5.26);  
Cerebrovascular disease events 
aOR 1.01 (0.29 to 3.61);  
MI aOR 4.02 (1.54 to 10.48);  
Stroke aOR 0.86 (0.21 to 3.56). 
Bonds 2010 137 Pre-specified primary outcome: non-
fatal MI or non-fatal stroke and 
cardiovascular (CV) death 
 
Pre-specified secondary outcome: all 
cause mortality 
 
Investigators asked patients 
about hypoglycaemic events at 
each visit. Patients were given 
home glucose monitors: 
-symptomatic severe 
hypoglycaemic event requiring 
medical assistance (HMA); 
Cox regression models 
(stepwise procedure) 
Confounders: baseline 
covariates, age, gender, 
ethnicity, education, BMI, 
alcohol, smoking, 
cardiovascular disease, diabetes 
Association between any 
hypoglycaemic event and 
mortality  
intensive arm aHR 1.41 (1.03, 
1.93); 
standard care arm aHR 2.30 
(1.46, 3.65). 
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Blinded independent adjudication of 
outcomes 
blood glucose <2.8mmol/L or 
symptoms resolved with 
treatment 
-symptomatic severe 
hypoglycaemic event requiring 
any assistance (HA) 
duration, diabetic 
complications, cardiovascular 
risk factors, medication, trial 
treatment assignment 
Cha 2016 141 Primary outcome: death from any 
cause or cardiovascular death (deaths 
resulting from acute MI, sudden 
cardiac death, death due to heart 
failure, other CV causes) 
CVD based on review of medical 
records and diagnosis confirmed by 
cardiologist, neurologist or 
neurosurgeon. 
Causes of death determined from 
death certificates, clinical records and 
hospital records 
SH – hypoglycaemic episodes 
requiring medical care in an 
emergency department or 
hospitalization. Patients were 
asked if they had experienced 
SH and medical records were 
reviewed for confirmation. 
Cox proportional hazards 
regression with adjustments 
for: sex, age, duration of 
diabetes, hypertension, diabetic 
nephropathy, mean HbA1c, 
insulin, ACE inhibitor, 
Angiotension Receptor Blocker 
(ARB), CVD history 
Cardiovascular mortality aHR 6.34 
(2.02 to 19.87) 
All-cause mortality aHR 2.64 (1.39 
to 5.02). 
Chiba 2015 142 Professional interviewer with 
questionnaire about frequency and 
type of falls (defined as unexpected 
event in which the person came to rest 
on the ground, floor, lower level.  
Complicated with a head injury or 
fractures).   
Professional interviewer with 
validated questionnaire 
regarding hypoglycaemic 
symptoms. 
Severe: coma, convulsion, 
inability of self-management 
and recovery from symptoms. 
Mild: hypoglycaemic symptoms 
with recovery within 10 
minutes by self-administered 
sugar or glucose. 
Multiple regression analysis: 
age, sex, cognitive impairment 
(MMSE <26), Timed up and go 
test (TUG) score, Geriatric 
Depression Scale (GDS)-15 
scores, Falls Risk Index, 
presence of hypoglycaemia. 
Presence of hypoglycaemia OR 
3.62 (1.24, 10.53), associated 
with presence of multiple falls, 
and any fall OR 2.05 (0.93-4.535). 
Prevalence of falls increased as 
the frequency of hypoglycaemia 
increased. 
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Chin 2016 143 Incident cases of dementia and organic 
mental disorder were identified form 
HIRAS claim database (ICD-10 codes) 
HIRAS claims database (ICD-10 
codes). Data on severity or 
need for hospital admission was 
not captured. 
Cox proportional hazards 
regression models adjusting for 
age, sex, smoking status, 
alcohol status, BMI, diastolic 
blood pressure, medications, 
diabetes duration, 
dyslipidaemia, CVD, 
cerebrovascular disease 
Any events of hypoglycaemia and 
risk of dementia aHR 2.689 (1.080 
to 6.694). 
Two or more hypoglycaemic 
events and risk of dementia 
aHR 4.065 (1.099 to 15.039) 
Cukierman-Yaffe 2019 
144 
Incident cognitive dysfunction defined 
either as reported dementia (first 
occurrence of an affirmative answer to 
a case report form question) or a post-
randomization MMSE score of <24.   
Sensitivity analysis conducted using a 
more restrictive definition of cognitive 
dysfunction (reported dementia or two 
consecutive MMSE scores <24 or last 
available MMSE score <24) 
Self-reported, based on 
questioning of participants and 
patient diary of capillary 
glucose.   
Non-severe hypoglycaemia 
defined as an event associated 
with symptoms consistent with 
hypoglycaemia and confirmed 
by a capillary glucose reading of 
<54mg/dL (3mmol/L).  SH 
defined as a symptomatic 
events requiring assistance of 
another person and there was 
prompt recovery after oral 
carbohydrate, IV glucose or 
glucagon and/or documented 
self-measure or laboratory-
measured plasma glucose level 
of <36 mg/dL (2 mmol/L) 
Cox proportional hazards 
regression adjusting for 
baseline CVD, diabetes status, 
allocation to glargine, allocation 
to b-3 fatty acids, HbA1c as a 
time-varying covariate, age. 
Accounted for competing risk of 
death. 
Relationship between SH and 
incident cognitive impairment 
after adjusting for baseline CVD, 
diabetes status, treatment 
allocation: aHR 1.16 (0.89 to 
1.52) Model with propensity 
score for SH: aHR 1.00 (0.76 to 
1.31). 
Sensitivity analysis with more 
restrictive definition of cognitive 
impairment: aHR 1.21 (0.90 to 
1.63). 
Non-SH and risk of incident 
cognitive impairment aHR 0.59 
(0.52 to 0.68); 
Model with propensity score for 
non-SH aHR 0.58 (0.51 to 0.67). 
Sensitivity analysis with more 
restrictive definition of cognitive 
impairment aHR 0.62 (0.52 to 
.073). 
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Davis 2019 145 Primary outcome:   adjudicated by an 
end point committee that was 
unaware of study group assignments. 
Cardiovascular events were 
documented MI, stroke, death as a 
result of cardiovascular causes, new or 
worsening congestive cardiac failure, 
surgical intervention for cardiac, 
cerebrovascular, or peripheral vascular 
disease, inoperable coronary artery 
disease and amputation for ischaemic 
gangrene. 
Total mortality pre-specified 
secondary outcome. 
SH defined as a self-reported 
episode of a low blood glucose 
value accompanied by 
confusion requiring assistance 
from another person of loss of 
consciousness. 
Cox proportional hazards 
regression adjusting for 
treatment group, overall 
cardiovascular risk (including 
factors such as diabetes 
duration, HbA1c), prior 
cardiovascular event, insulin 
use, eGFR 
SH within prior three months and 
association with cardiovascular 
events and mortality 
Cardiovascular events aHR 1.90 
(1.06 to 3.52); 
Cardiovascular mortality aHR 3.7 
(1.30 to 10.40); 
All-cause mortality aHR 2.40 (1.10 
to 5.10). 
Duckworth 2011 146 Cardiovascular event is pre-specified 
composite: MI, stroke, CV death, 
cardiac failure, vascular surgery, 
inoperable coronary artery disease, 
amputation for gangrene 
Blinded independent adjudication of 
outcomes 
Routine trial monitoring Multivariate regression analysis 
Confounders: prior 
cardiovascular event, age, 
baseline insulin, ethnicity, 
smoking status, HbA1c, lipids, 
creatinine, diabetes treatment 
and duration 
HR for composite cardiovascular 
event 1.88 (1.03, 3.43). 
Escalada 2016 147 Hospitalization 
Secondary outcome: mortality 
Medically attended 
hypoglycaemia events 
identified from claims database 
– ICD-9 codes 
Cox proportional hazards 
regression for risk of 
hospitalization with medically 
attended hypoglycaemia as the 
time-varying covariate, 
adjusting for demographic, 
comorbidity and medication 
history factors 
Medically attended 
hypoglycaemia after initiation of 
basal insulin and risk of 
hospitalization aHR 1.59 (1.53 to 
1.65). 
Hypoglycaemia and risk of death 
aHR 1.50 (1.40 to 1.60) 
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Three sensitivity analyses for 
mortality modelling after 
hypoglycaemia: 1) mortality risk 
amongst the population with an 
MI, congestive heart failure, 
peripheral vascular disease or 
stroke; 2) population with MI, 
CHF, peripheral vascular disease 
(PVD), stroke, dementia or 
renal disease,3)  population 
without cancer 
Sensitivity analyses of 
hypoglycaemia in patients with 
different baseline comorbidities: 
1) aHR 1.46 (1.34 to 1.58) 
2) aHR 1.44 (1.34 to 1.56) 
3) 1.48 (1.37 to 1.58) 
Freemantle 2016 148 Primary outcomes: composite of 
stroke of myocardial infarction or 
cardiovascular-specific death;  
Outcome events reported by 
investigator in clinical report forms at 
6-month intervals; supportive 
documents requested and adjudicated 
by three reviewers (ECG, hospital 
records, biochemistry, radiology 
reports, medication charts) 
Cardiovascular events:  MI, stable 
angina, severe unstable angina leading 
to hospitalization, stroke, TIA, PVD, 
limb amputation, myocardial 
revascularization. 
Reported by participants based 
on symptoms, recorded 
capillary values, and need for 
assistance. 
Data were gathered in routine 
clinical practice, and treating 
physicians were asked to report 
updated participant data every 
6 months 
Cox proportional hazards 
regression 
Time-to-event endpoints 
calculated from date of insulin 
initiation and were restricted to 
54 months 
Relationship between reported 
severe hypoglycaemia and CV 
death or all-cause mortality 
CV death and SH aHR 1.10 (0.34 
to 3.57) 
All-cause mortality and SH 1.22 
(0.59 to 2.53). 
Goto 2016 149 Primary outcome: CVD 
CVD defined as conditions during 
hospitalization with both a diagnosis of 
Severe hypoglycaemia defined 
by ICD 10 code and prescription 
Cox proportional hazards 
models to evaluate association 
of SH with CVD risk, adjusted 
Association between SH and CVD 
risk 
aHR 3.39 (1.25 to 9.18); 
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CVD (ischaemic heart disease, stroke, 
peripheral artery disease) and either a 
medical procedure performed or a 
prescription to treat CVD 
for either 50% dextrose or 
glucagon infusion 
for age, sex, duration of 
diabetes, history of 
microvascular disease, Charlson 
Co-morbidity index, 
medications. 
5:1 propensity score matching 
Propensity-score matched 
cohort: aHR 7.31 (1.87 to 28.6). 
Haroon 2015 150 Dementia: defined based on one or 
more hospitalisation records or two 
outpatient physician billing claims 
(within six months) listed relevant ICD-
9 claim 
Healthcare administrative 
database records of 
hospitalisation or emergency 
department visits for 
hypoglycaemia  
Cox proportional hazard 
modelling 
Sensitivity Analyses to examine 
whether detection bias could 
explain elevated risk of 
dementia 
Models were adjusted for 
baseline income and co-
morbidities, including 
hypertension, chronic kidney 
disease and vascular diseases of 
varying aetiologies. 
Cumulative incidence functions 
were used to estimate the 
probability of occurrence of 
dementia 
Hospitalisation and emergency 
department visits for 
hypoglycaemia were significant 
predictors of dementia aHR 1.73 
(1.62 to 1.84) based on 
comparison of one or more 
episodes versus none. 
Heller 2017 151 Primary endpoint in EXAMINE trial: 
composite of death from 
cardiovascular causes, nonfatal MI or 
non-fatal stroke.   
 
Independent central adjudication 
committee adjudicated all suspected 
Assessed at study visits at 1, 3, 
6, 9 and 12 months post-
randomization during the first 
year of the study and every 4 
months during subsequent 
years of participation.  
Hypoglycaemic events 
Cox proportional hazards 
models with adjustments for 
age, sex, treatment, HbA1c, 
glycaemic medication and 
stratified by screening renal 
function and geographic region 
Risk of major adverse 
cardiovascular events (MACE) 
after reported serious 
hypoglycaemia  
aHR 1.60 (0.80 to 3.20); 
MACE after any hypoglycaemia 
aHR 1.05 (0.79 to 1.40). 
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primary end-point events and other 
cardiovascular and points, as well as all 
deaths. 
characterised by local 
investigators according to their 
intensity (mild to severe) and 
seriousness (hospitalization or 
ED management) 
Hsu 2013 152 Cancer, stroke, coronary heart disease 
and cardiovascular disease identified 
from hospital claims dataset, ICD-9-CM 
codes 
 
Death status ascertained according to 
discharge reasons with death or 
critically ill at discharge, or if insurance 
cover stopped due to death. 
Hospital claims dataset for 
severe hypoglycaemia 
Outpatient claims dataset for 
mild hypoglycaemia 
ICD-9-CM codes 
Propensity score, Cox 
proportional hazard model, 
Kaplan-Meier 
 
Variables in propensity score 
matching: age, sex, diabetes 
duration, hypertension, heart 
disease, renal and liver disease, 
cancer, mental disease, socio-
economic status, treatment 
adherence. 
 
HR 2.09 (1.63, 2.67) for 
cardiovascular diseases, HR 2.51 
(2.00, 3.16) for all-cause 
hospitalisation, HR 2.48 (1.41, 
4.38) for total mortality 
Hung 2017 72 Primary outcome:  hip fracture after 
SH 
Insurance claims ICD-9 
 
 
 
Index date was first date of 
hospitalization or ED 
hypoglycaemic visit 
Insurance claims ICD-9. 
Cox proportional hazards 
regression models adjusted for 
sex, ESRD, COPD, epilepsy, CAD, 
stroke, dementia, Parkinson’s, 
osteoporosis, retinopathy, 
neuropathy, alcohol misuse, 
TZD, oestrogen, acarbose, 
glinide, metformin, SU, DPP4i, 
beta blocker, corticosteroid, 
anti-depressants, NSAIDs, anti-
osteoporosis 
Risk of hip fracture higher in 
relation to SH  
 aHR 1.71 (1.35 to 2.16) 
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Johnston 2011 154 Acute cardiovascular events: coronary 
artery bypass graft, revascularisation, 
percutaneous coronary intervention –
≥one inpatient or outpatient claim ICD-
9-CM code 
Acute MI, incident unstable angina – 
≥1 inpatient claim with an ICD-9-CM 
code 
≥1 outpatient claim with ICD-9-
CM diagnosis code for 
hypoglycaemia (hypoglycaemic 
events were allowed to occur at 
any time during the evaluation 
period, including after acute 
cardiovascular events) 
Multiple logistic regression and 
backwards stepwise selection 
Adjusted for age, sex, 
geography, insurance type, 
comorbidity scores, 
cardiovascular risk and prior 
events, diabetes complications, 
total baseline medical 
expenditures. 
OR 1.79 (1.69, 1.89) for acute 
cardiovascular events; 
Patients >age 65 years OR1.78 
(1.65, 1.92) 
Johnston 2012 153 Emergency department claim with 
ICD-9-CM diagnosis code 
≥1 outpatient claim with ICD-9-
CM diagnosis code for 
hypoglycaemia (hypoglycaemic 
events allowed to occur at any 
time during evaluation period, 
including after fracture) 
Multiple logistic regression 
Confounders: patient 
demographics, baseline co-
morbid conditions, baseline 
medications, Charlson Co-
morbidity Index (CCI), medical 
encounters for diabetes, total 
baseline medical expenditures, 
number of medical codes 
aOR for fall-related fractures 1.70 
(1.58, 1.83). 
Kacharoo 2015 155 Admin claim data 
Fall-related events defined as ICD-9-
CM codes 800.x-995.x, with a fall being 
the external cause defined as ICD-9-
CM E-codes E880-E888 which were 
recorded within +/-2 days of each 
other in any order. 
Composite fall events (e.g. fall with 
head injury or fracture) identified 
based on two or more claims codes 
occurring within 2 days. 
Admin claim data 
ICD-9-CM codes 250.8, 251.0, 
251.1 and 251.2 
Logistic regression analysis 
Patients matched on age and 
gender; statistical adjustment 
on CCI  
Risk of fall-related events aOR 
1.95 (1.70, 2.2); 
Fracture – aOR 2.16 (1.74 -2.67). 
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Khunti 2015 122 Cardiovascular event defined as a 
composite of MI, stroke or 
cardiovascular death (cause of death 
obtained through linkage to Office for 
National Statistics).   
Data on hypoglycaemic 
episodes were obtained from 
HES via ICD-10 codes 9E16.0, 
E16.2). 
Mutivariate Cox regression 
models 
Covariates: age, sex, smoking 
status, geographical region, 
history of cardiovascular events 
before index date, use of oral 
antidiabetic medications, 
Charlson comorbidity index, 
BMI, HbA1c 
 
All-cause mortality for T2DM: HR 
1.94 (1.52, 2.47) and 2.39 (2.13, 
2.67) for those with and without 
a history of CVD. 
Cardiovascular events for T2DM: 
HR 1.70 (1.09, 2.64) and 1.50 
(1.19, 1.88) for those with and 
without a history of CVD. 
Kong 2014 156 Ascertained though Hospital Authority 
Central Computer Management 
System, which records diagnoses of all 
hospital discharges, including mortality 
based on ICD-9 codes.  Mortality data 
cross-checked with Hong Kong Death 
Registry.   
SH defined as one or more 
hospitalizations for 
hypoglycaemia in the 12 
months before enrolment or 
during the follow-up period 
from enrolment to death or 31 
January 2009. 
Cox proportional hazards 
regression models with 
adjustments for age, sex, BMI, 
smoking satus, alcohol use, low-
density lipoprotein cholesterol 
(LDL-C), high-density 
lipoprotein cholesterol (HDL-C), 
systolic blood pressure (BP), 
HbA1c, duration of diabetes, 
urinary albumin to creatinine 
ratio, prior CVD, prior cancer, 
medications at enrolment. 
 
Hazard ratios of severe 
hypoglycaemia for the risk of all-
cause death in 
patients without CKD 
aHR 1.81 (1.38 to 2.37). 
Lee 2018 71 An expert committee adjudicated 
all coronary heart disease and stroke 
events (ICD-9 codes).   
Mortality was assessed via proxy, 
coroner reports, and the National 
Death Index through 2013.   
Severe hypoglycaemic events 
were identified from 
hospitalizations, emergency 
department visits, and 
ambulance calls with a 
validated algorithm, using ICD-9 
Cox proportional hazards 
regression models adjusting for 
age, sex race-centre, diabetes 
medication use, duration of 
diabetes, tertiles of 
fructosamine, low eGFR, 
Association between SH and CV 
events and all-cause mortality 
(Model 3); 
Coronary heart disease aHR 2.02 
(1.27 to 3.20); 
Stroke aHR 0.81 (0.40 to 1.63) 
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codes in the primary position 
through 31 December 2013. 
Hospitalization records were 
available from ARIC surveillance 
of local hospitals. Linked 
Medicare claims for were also 
assessed. 
albumin-urea ratio, income, 
disability, systolic BP, 
hypertension, LDL-C, HDL-C, 
medications, smoking status 
(Model 3) 
All-cause mortality aHR 1.73 (1.38 
to 2.17). 
Lee 2018 68  Assessment of cognitive status 
(normal, mild cognitive impairment 
or dementia) was based on available 
cognitive test scores from visits 2 
(1990–1992), 4 (1996–1998) and 5 
(2011–2013), the Clinical Dementia 
Rating (CDR), based on interviews with 
participants and informants, the 
Modified Telephone Interview for 
Cognitive Status (TICS), hospitalisation 
records and death certificates. 
Diagnoses standardised using 
algorithm, with expert panel review 
who could clinically over-ride 
algorithm. 
For the analysis of incident dementia, 
a date of dementia diagnosis was 
assigned as the date of hospitalisation 
with a dementia ICD-9 code or, if no 
hospitalisation with dementia 
occurred, the first date of detection 
via the TICS or CDR, or visit 5. 
Severe hypoglycaemic episodes 
were identified from 
hospitalisations, emergency 
department visits and 
ambulance calls by a widely 
used algorithm that employs 
primary position ICD-9 codes. 
Multinomial logistic 
regression to compare the odds 
of having mild cognitive 
impairment or dementia by 
history of severe hypoglycaemia 
Prospective incident dementia 
analysis, based on 
Cox regression model for the 
outcome of incident dementia, 
with severe hypoglycaemia as a 
time-varying exposure 
(4 models used, adjusting for 
covariates). 
Prospective association of severe 
hypoglycaemia with incident 
dementia among ARIC 
participants with diagnosed 
diabetes at visit 4 in the 
prospective incident dementia 
analysis 
Model 4 aHR 2.28 (1.58 to 3.29). 
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Leong 2016 157 Electronic health record repository, 
including outpatients, emergency 
department and inpatient visits. iCD-9 
code-cased algorithm 
Hypoglycaemia defined as 
hypoglycaemia brought to 
medical attention. ICD-9 code-
based algorithm capturing 
healthcare use. 
Three Cox models for incident 
CAD constructed,  Model 3 fully 
adjusted adjusting for sex, age, 
educational attainment, CAD 
risk factors, insulin, oral 
hypoglycaemics, total 
medication count, retinopathy, 
neuropathy, renal failure, eGFR, 
LDL < HDL, cancer, dementia, 
dysrhythmias, hospitalizations, 
weight loss within a year, 
HbA1c measurements per year. 
Hypoglycaemia and associated 
CAD risk 
aHR 1.90 (1.09 to 3.31) 
Risk diminished with time after 
event. 
Fully adjusted model 
aHR 1.65 (0.95 to 2.87). 
Lin 2013 70 Dementia: ICD9-CM 
Method of diagnosing not stated 
ICD9-CM 
Method of diagnosing not 
stated 
Multivariable Cox proportional 
hazard analysis 
Age, gender, co-morbidities 
(Ischaemic heart 
disease, cardiovascular disease, 
hyperlipidaemia, 
chronic renal disease, 
hypertension), insulin use. 
 
Adult diabetic patients with prior 
hypoglycaemia had a significantly 
increased risk dementia: aHR 
1.45 (1.07 to 1.97);  
Lu 2015158 Falls needing admission to hospital – 
fall-related diagnosis code in discharge 
diagnosis during the follow-up (ICD-9 
codes).  Unable to distinguish between 
the falls occurring before or during 
hospitalization. 
SH defined as presence of ICD-9 
codes in outpatient and 
inpatient visits before the index 
date. 
Proportional hazards regression 
models. 
Fine & Gray competing risks 
model to account for mortality. 
Sequential construction of 
multivariate regression.  
Adjustments for age, sex, type 
of diabetes, geographic area, 
Risk of falls in diabetes with 
hypoglycaemia group - 
Patients with diabetes but 
without hypoglycaemia as 
referent category: 
Age>65 years aHR 1.35 (1.25 to 
1.45) 
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urbanization status, obesity, 
mental health problems, 
neurological, cardiovascular, 
endocrine, renal, ophthalmic 
disorders epilepsy, stroke, 
substance abuse. 
Majumdar 2013159 Primary outcome: all-cause mortality 
Secondary end points included all-
cause hospitalisations and 
hypoglycaemia-associated 
hospitalisations. 
Mortality and dates of hospitalisation 
determined by linkage to provincial 
health ministry databases. 
Defined severe hypoglycaemia 
by the presence of any 
inpatient discharge diagnosis of 
hypoglycaemia (ICD-10 code 
E15 or E16) 
Multivariable Cox proportional 
hazard methods 
Adjusted for age, sex, 
socioeconomic status (based on 
individual health insurance 
premium level and median 
neighbourhood income), index 
eGFR, prevalent hypoglycaemia, 
co-morbidities, use of diabetes 
medications 
Mortality associated with any 
hospitalisation with 
hypoglycaemia in 
patients with diabetes: aHR 2.46 
(2.17 to 2.80) 
 
Mattishent 2019 160 Outcomes were falls, fractures, 
cardiovascular events (myocardial 
infarction, ischaemic stroke) and all-
cause mortality. Data obtained from 
CPRD using Read codes and HES with 
ICD codes 
First hypoglycaemic episode 
recorded on the primary (CPRD) 
or secondary (HES) healthcare 
database from April 1997 
onwards following initiation of 
a glucose-lowering agent.  Data 
on hypoglycaemic episodes 
were obtained from CPRD using 
Read codes and HES with ICD 
codes 
Cox proportional hazard 
regression models with 
adjustments for medications, 
age, gender, co-morbidities, 
Townsend deprivation index 
Hypoglycaemia was associated 
with an increased risk during 12 
months follow-up of:  
Falls 1.96 (1.69 to 2.29) 
Fractures 1.62 (1.25 to 2.08) 
Cardiovascular events - aHR 2.00 
(1.61 to 2.48) 
Mortality - aHR 2.36 (2.09 to 
2.67) 
McCoy 2012 161 Ascertainment of mortality from 
medical records and social security 
death index 
Investigator asked patients 
about hypoglycaemic events 
Logistic regression 
 
OR 3.38 (1.55 to 7.39) 
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-mild hypoglycaemia: 
symptoms consistent with 
hypoglycaemia not requiring 
any assistance 
-severe hypoglycaemia: similar 
symptoms requiring external 
assistance 
Confounders: age, gender, type 
of diabetes and duration, CCI, 
HbA1c 
Association between severe 
hypoglycaemia and 5-year 
mortality 
Mehta 2017 162 Outcome variable was time to 
dementia – defined by diagnosis codes 
from electronic medical records.  
Hypoglycaemia defined based 
on previously defined algorithm 
for CPRD using Read and Med 
codes. 
Cox multivariable model taking 
into account competing risks. 
 
Adjustments for: age, sex, 
HbA1c, alcohol use, smoking 
status, diabetes treatment, co-
morbidities associated with 
dementia. 
Association of hypoglycaemia 
with dementia 
 
Fully adjusted model 
aHR 1.27 (1.06 to 1.51)  
Mellbin 2013 164 -Composite of cardiovascular death 
(any death for which no non-
cardiovascular cause could be 
identified), non-fatal MI (based on 
clinical presentation, elevated cardiac 
markers, and /or new 
electrocardiographic changes), or 
stroke (based on clinical presentation 
and imaging) 
-Mortality 
Blinded independent adjudication of 
outcomes 
Participants recorded 
hypoglycaemic events with 
glucose meters and diaries.  
Investigators asked patients 
about hypoglycaemic events at 
each study visit. 
Non-severe hypoglycaemia: 
relevant symptoms confirmed 
by glucose reading <3mmol/L. 
-severe hypoglycaemia: 
symptomatic hypoglycaemia 
requiring assistance of another 
person with (i) prompt recovery 
after oral carbohydrate and/or 
Propensity score matching, as 
well as Cox regression models 
addressing 
potential confounders: age, 
gender, ethnicity, education, 
prior cardiovascular events, 
hypertension, depression, 
current smoking, alcohol intake, 
albumin/creatinine ratio >30 
mg/g, diabetes and 
cardiovascular drugs, BMI, 
waist-hip ratio, HbA1c, fasting 
plasma glucose, lipids, serum 
In those with severe 
hypoglycaemia aHR 1.58 (1.24 to 
2.02) for composite event. 
aHR 1.71 (1.27 to 2.30) for 
cardiovascular death. 
HR 1.74 (1.39 to 2.19) for total 
mortality. 
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(ii) documented plasma glucose 
level <2mmol/L 
creatinine, mini-mental status, 
prior diabetes mellitus 
Ntouva 2019 163 Primary outcome: any fracture; 
secondary outcome: fragility fracture 
Read codes obtained from database 
Read codes obtained from 
database 
Incidence Rate Ratios derived 
using Poisson regression 
adjusting for covariates: age, 
sex, BMI, Townsend deprivation 
index, smoking, CCI, HbA1c, 
insulin, bisphosphonates, 
steroid, hyperthyroidism, 
Graves disease, renal 
impairment, antihypertensive 
medications. 
Risk of all fractures in patients 
with documented hypoglycaemia 
compared to those without 
aIRR 1.20 (1.12 to 1.30) 
Pieber 2018 165 Primary outcome: MACE 
(cardiovascular death, non-fatal MI, 
non-fatal stroke) 
 
 
Adjudication-confirmed SH was 
pre-specified, multiplicity-
adjusted secondary outcome as 
defined by ADA as an episode 
requiring the assistance of 
another person to actively 
administer carbohydrates or 
glucagon, or to take other 
corrective action. 
Cox regression models  
Adjustments for age, sex, 
HbA1c, BMI, diabetes duration, 
insulin, hepatic impairment, 
renal status, cardiovascular risk 
group 
Risk of MACE for individuals who 
had vs those who had not 
experienced SH aHR 1.38 (0.96 to 
1.96); 
All-cause mortality aHR 2.51 (1.79 
to 3.50). 
Rajpathak 2015 166 Hip fracture defined as an ICD-9 code 
820.xx 
ICD-9 codes based on validated 
algorithm 
Multivariable logistic regression  
based on propensity score as 
well as adjustment for 
confounders:: age, sex, 
Medicare cover, region, 
coronary heart disease, stroke, 
osteoporosis, dementia, CKD 
aOR 2.42 (1.35 to 4.34) for hip 
fractures in those with 
documented hypoglycaemia 
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Rathmann 2013 167 Macrovascular complications were 
determined based on primary care 
diagnoses (ICD-10 codes) for coronary 
heart disease (I20, I24 and I25), MI 
(I21, I22, I23 and I25.2), stroke (I63, 
I64, G45) and peripheral vascular 
disease (E10.5, E11.5, E14.5 and I73.9) 
ICD-10 coding (E16.0, E16.1, 
E16.2) 
Frequency of patients with >1 
hypoglycaemic event assessed 
30, 90, 183, 365 and 730 days 
after index date 
Adjusted for age, sex, type of 
practise (diabetologist), practise 
region, health insurance status 
(private), antidiabetic co-
medication, episodes of 
hypoglycaemia, microvascular 
complications, hypertension, 
hyperlipidaemia, 
antihypertensive, lipid-lowering 
and antithrombotic drugs and 
Charlson co-morbidity index 
aHR 1.6 (1.1 to 2.2) for incident 
macrovascular complications 
Signorovitch 2013 168 Inpatient and emergency department 
claims based on ICD9-CM codes, 
grouped into three codes: accidental 
falls, motor vehicle accidents and 
other accidents 
ICD-9-CM codes for 
hypoglycaemia at any place of 
service 
Multivariable Cox-proportional 
hazard models adjusted for age, 
gender, demographics, co-
morbidities of diabetes, 
accident risk factors, CCI, 
inpatient admissions, use of 
oral hypoglycaemics. 
Hypoglycaemia associated with 
accidental falls aHR 1.36 (1.13 to 
1.65) 
For age >65: aHR 1.52 (1.18 to 
195) 
Standl 2018 169 Primary 4-point composite MACE: first 
confirmed event of CV death, non-fatal 
MI, nonfatal stroke or hospitalization 
for unstable angina 
 
Secondary outcome: 3-point MACE (CV 
death, nonfatal MI/nonfatal stroke), 
fatal/nonfatal MI, fatal/nonfatal 
stroke, all-cause death, hospitalization 
for heart failure 
 
Proactive enquiry at 
screening/enrolment, 4-month, 
8-month visits and then annual 
visits.  SH episodes were 
recorded systematically as 
prespecified events of clinical 
interest: episodes in which a 
participant was sufficiently 
disorientated or incapacitated 
as to require help.   
Cox regression models 
Adjustments for age, sex, race, 
ethnicity, HbA1c, New York 
Heart Association (NYHA) class, 
smoking, MI, COPD, CAD, 
stroke, >50% stenosis of carotid 
artery, atrial flutter/fibrillation, 
insulin, amputation, diabetic 
neuropathy, foot ulcer, blood 
pressure, heart rate, height, 
BMI, eGFR, randomized 
SH association with primary 
composite CV end point aHR 1.55 
(1.06 to 2.28); 
All-cause mortality aHR 1.83 (1.22 
to 2.75); 
CV death aHR 1.72 (1.02 to 2.87). 
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Adjudicated by independent clinical 
events classification committee 
 
treatment, diabetes duration, 
geographical region. 
Whitmer 2009 69 Dementia: inpatient and outpatient 
databases based on ICD9-CM 
Hospitalisation and ED 
diagnoses of hypoglycaemia 
using hospital/ED databases 
ICD9-CM 
Cox proportional hazard 
regression models, adjusted for 
age, sex, race/ethnicity, 
education, BMI, duration of 
diabetes, 7-yr mean HbA1c, 
diabetes treatment, 
History of severe hypoglycaemic 
episodes was associated with a 
greater risk of dementia: aHR 
1.44 (1.25 to 1.66) 
Yaffe 2013 170 Dementia: hospital records indicating 
an admission associated with 
dementia or the use of prescribed 
dementia medications 
Hospital records: severe hypos 
requiring admission and 
identified as primary or 
secondary diagnosis related to 
overnight hospitalisation.  No 
information on milder hypos 
not requiring admission 
Cox Proportional Hazard 
Regression. Adjustments for 
age, educational level, 
race/ethnicity, and any other 
covariates significantly 
associated with severe 
hypoglycaemia or dementia in 
bivariate analysis 
Hypoglycaemia associated with 
increased risk of dementia: aHR 
2.09 (1.00 to 4.35) 
 
Zinman 2018 173 Primary composite outcome: first 
occurrence of death from 
cardiovascular causes, nonfatal 
myocardial infarction, or nonfatal 
stroke. 
 
Adjudicated by blinded, external, 
independent committee. 
Self-reported hypoglycaemia 
was a secondary safety 
endpoint, reported using 
patient diaries and transcribed 
into case report form.  SH 
defined as requiring assistance 
of another person to administer 
fast-acting carbohydrates, 
glucagon or other resuscitative 
action – reported as a medical 
event of special interest. 
Cox regression to analyse time 
to first MACE, CV death, non-CV 
death or all-cause mortality 
with either SH at any time 
(yes/no) as a factors or with 
hypoglycaemia (SH or 
confirmed, yes/no) as a time-
dependent covariate. 
Adjustments for randomized 
treatment, baseline covariates, 
concomitant insulin use, HbA1c 
during trial, concomitant 
MACE up to one year with SH 
aHR 1.90 (1.30 to 2.90) 
All-cause death up to one year 
with SH 
aHR 2.70 (1.90 to 3.90). 
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Confirmed hypoglycaemia 
defined as SH or minor 
hypoglycaemia (<3.1mmol/L).  
Nocturnal hypoglycaemia 
defined as episodes occurring 
between 00:01 and 05:59h.  
Patients asked to check blood 
glucose whenever a 
hypoglycaemic episode was 
suspected. 
sulfonylurea/glinide use, eGFR 
and event adjudication 
committee-confirmed 
hospitalization for heart failure 
during the trial (time-
dependent covariates) 
Zhao 2012 171 ICD-9-CM codes. 
Macrovascular: MI, stroke, congestive 
heart failure, peripheral vascular 
disease. 
Microvascualr: renal, ophthalmic or 
neurologic manifestations with 
diabetes. 
ICD-9-CM codes Propensity score matching 
(greedy 5 to 1 method) for 
noncomparable baseline 
characteristics  
Cox proportional hazard 
regression models controlling 
for covariates, including  
baseline demographic and 
illness characteristics, vital 
signs, prior medication, and 
index drug 
aHR 2.00 (1.63 to 2.44) for 
cardiovascular events, aHR 1.76 
(1.46 to 2.11) for microvascular 
complications 
aHR 1.29 (0.94 to 1.77) for 
mortality. 
 
Zhao 2015 172 ICD-9-CM codes for fall-related events 
(fractures, head injuries) with a fall 
being the external cause within a two-
day window. 
ICD-9-CM codes McNemar tests, Generalised 
estimating equation (GEE). 
Matching on age, gender, 
ethnicity and medical service. 
Adjustments for social 
demographic and illness 
characteristics, vital signs and 
medication use. 
aOR 2.70 (1.64 to 4.47) for fall-
related events in the 
hypoglycaemia group 
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Zoungas 2010 174 First major macrovascular event=death 
from cardiovascular cause, non-fatal 
MI, non-fatal stroke 
First major microvascular event=new 
or worsening nephropathy or 
retinopathy 
Secondary outcomes=death from any 
cause and death from a cardiovascular 
event 
 Independent adjudication by blinded 
committee 
 
Blood glucose level <2.8 
mmol/L or typical 
symptoms/signs without other 
apparent cause.  Those with 
transient neurological 
dysfunction who required help 
from 3rd party were considered 
to have severe hypoglycaemia.  
Minor hypoglycaemia if 
transient dysfunction of CNS 
and able to treat themselves. 
Cox proportional-hazard 
models adjusted for covariates. 
Baseline: sex, duration of 
diabetes, treatment allocation, 
history of macrovascular or 
microvascular disease, 
ever smoker.  
Time dependent covariates 
during follow-up: age, HbA1c, 
body mass index, creatinine, 
urine albumin to creatinine 
ratio, systolic blood pressure, 
diabetes and blood pressure 
drugs. 
aHR 2.88 (2.01 to 4.12) major 
macrovascular events, aHR 1.81 
(1.19 to 2.74) major 
microvascular events, aHR 2.68 
(1.7 to 4.19) death from 
cardiovascular cause, aHR 2.69 
(1.97t o 3.67) death from any 
cause 
 
 
   
 
 222 
5.5.4 META-ANALYSIS 
5.5.4.1 ASSOCIATION BETWEEN HYPOGLYCAEMIA AND VASCULAR DISEASE  
I included eighteen studies in the meta-analysis for macrovascular 
complications140 145 146 149 151 152 71 122 154 157 160 164 165 167 169 171 173 174. The pooled 
odds ratio was 1.81 (95% CI 1.69 to 1.95).  There was low heterogeneity 
(I2=10%).  Hypoglycaemia was significantly associated with macrovascular 
complications.  There are two studies in the meta-analysis which reported on 
the association between hypoglycaemia and microvascular complications 174 171.  
The microvascular complications covered in the study were nephropathy or 
retinopathy 174 and a composite endpoint of several complications 171. The 
pooled odds ratio was 1.77 (95% CI 1.49 to 2.10) with no evidence of 
heterogeneity (I2=0%) (Figure 40). 
Figure 39  Meta-analysis of association between hypoglycaemia and vascular 
events 
 
Study or Subgroup
1.1.1 Macrovascular
Bedenis 2014
Davis 2019
Duckworth 2011
Goto 2016
Heller 2017
Hsu 2013
Johnston 2011
Khunti 2015
Lee CV 2018
Leong 2016
Mattishent 2019
Mellbin 2013
Pieber 2018
Rathmann 2013
Standl 2018
Zhao 2012
Zinman 2018
Zoungas 2010
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 18.93, df = 17 (P = 0.33); I² = 10%
Test for overall effect: Z = 16.69 (P < 0.00001)
1.1.2 Microvascular
Zhao 2012
Zoungas 2010
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.01, df = 1 (P = 0.90); I² = 0%
Test for overall effect: Z = 6.55 (P < 0.00001)
Weight
1.0%
1.3%
1.3%
0.5%
1.0%
7.0%
34.2%
7.9%
2.2%
1.6%
8.9%
7.3%
3.7%
3.3%
3.1%
9.7%
2.6%
3.5%
100.0%
83.5%
16.5%
100.0%
IV, Random, 95% CI
2.11 [1.06, 4.21]
1.90 [1.03, 3.52]
1.88 [1.03, 3.43]
3.39 [1.25, 9.18]
1.60 [0.80, 3.20]
2.09 [1.63, 2.68]
1.78 [1.65, 1.92]
1.50 [1.19, 1.89]
2.02 [1.28, 3.20]
1.65 [0.95, 2.87]
2.00 [1.61, 2.48]
1.58 [1.24, 2.01]
1.38 [0.97, 1.96]
1.60 [1.10, 2.33]
1.55 [1.05, 2.28]
2.00 [1.63, 2.45]
1.90 [1.25, 2.90]
2.88 [2.01, 4.13]
1.81 [1.69, 1.95]
1.76 [1.46, 2.12]
1.81 [1.19, 2.75]
1.77 [1.49, 2.10]
Odds Ratio Odds Ratio
IV, Random, 95% CI
0.1 0.2 0.5 1 2 5 10
Hypoglycemia not harmful Hypoglycemia harmful
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5.5.4.2 ASSOCIATION BETWEEN HYPOGLYCAEMIA AND FALLS OR FRACTURES  
There are six studies reporting on falls142 155 160 158 168 172with a pooled odds ratio 
of 1.78 (95% CI 1.44 t0 2.21) and substantial heterogeneity (I2=87%). 
I included six studies for fractures with a pooled odds ratio of 1.68 (95% CI 1.37 
to 2.07) and considerable heterogeneity (I2=91%) 160 72 153 155 163 166 (Figure 41). 
 
Figure 40 Meta-analysis of association between hypoglycaemia and falls and 
fractures 
 
 
Study or Subgroup
2.1.1 Falls
Chiba 2015
Kacharoo 2015
Lu 2015
Mattishent 2019
Signorovitch 2013
Zhao 2015
Subtotal (95% CI)
Heterogeneity: Tau² = 0.05; Chi² = 39.42, df = 5 (P < 0.00001); I² = 87%
Test for overall effect: Z = 5.24 (P < 0.00001)
2.1.2 Fractures
Hung 2017
Johnston 2012
Kacharoo 2015
Mattishent 2019
Ntouva 2019
Rajpathak 2015
Subtotal (95% CI)
Heterogeneity: Tau² = 0.05; Chi² = 56.24, df = 5 (P < 0.00001); I² = 91%
Test for overall effect: Z = 4.90 (P < 0.00001)
Weight
5.7%
21.5%
23.0%
21.0%
17.8%
11.0%
100.0%
16.8%
20.8%
17.4%
16.3%
20.7%
8.0%
100.0%
IV, Random, 95% CI
2.05 [0.93, 4.52]
1.95 [1.70, 2.24]
1.35 [1.26, 1.45]
1.96 [1.68, 2.29]
1.52 [1.18, 1.96]
2.70 [1.67, 4.36]
1.78 [1.44, 2.21]
1.71 [1.35, 2.16]
1.70 [1.58, 1.83]
2.16 [1.74, 2.68]
1.62 [1.26, 2.08]
1.20 [1.11, 1.30]
2.42 [1.35, 4.34]
1.68 [1.37, 2.07]
Odds Ratio Odds Ratio
IV, Random, 95% CI
0.1 0.2 0.5 1 2 5 10
Hypoglycaemia not harmful Hypoglycaemia harmful
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5.5.4.3 ASSOCIATION BETWEEN HYPOGLYCAEMIA AND MORTALITY 
There are eighteen studies reporting on overall mortality with a pooled odds 
ratio of 2.02 (95% CI 1.75 to 2.32) with substantial heterogeneity (I2=86%)71 122 
137 141 145 147 148 152 156 159-161 164 165 169 171 173 174 (Figure 42). 
Despite the heterogeneity, the direction of association was consistent across all 
the studies in the Forest plot. 
Two studies did not find a statistically significant association between 
hypoglycaemia and mortality 148 171.  I explored the contribution of these two 
studies to the heterogeneity, by removing them, one at a time, and found that 
it made no difference to the heterogeneity.   
 
Figure 41 Meta-analysis of association between hypoglycaemia and mortality 
 
 
Study or Subgroup
Bonds Intensive 2010
Bonds Standard 2010
Cha 2016
Davis 2019
Escalada 2016
Freemantle 2016
Hsu 2013
Khunti 2015
Kong 2014
Lee CV 2018
Majumdar 2013
Mattishent 2019
McCoy 2012
Mellbin 2013
Pieber 2018
Standl 2018
Zhao 2012
Zinman 2018
Zoungas 2010
Total (95% CI)
Heterogeneity: Tau² = 0.07; Chi² = 129.83, df = 18 (P < 0.00001); I² = 86%
Test for overall effect: Z = 9.78 (P < 0.00001)
Weight
5.6%
4.3%
3.0%
2.4%
7.7%
2.5%
3.5%
7.5%
6.1%
6.5%
7.4%
7.4%
2.3%
6.5%
5.5%
4.7%
6.3%
5.1%
5.7%
100.0%
IV, Random, 95% CI
1.41 [1.03, 1.93]
2.30 [1.46, 3.62]
2.64 [1.39, 5.03]
2.40 [1.13, 5.10]
1.50 [1.41, 1.60]
1.22 [0.59, 2.53]
2.48 [1.41, 4.36]
2.39 [2.13, 2.68]
1.81 [1.38, 2.37]
1.73 [1.38, 2.17]
2.46 [2.17, 2.79]
2.36 [2.09, 2.67]
3.38 [1.55, 7.39]
1.74 [1.39, 2.18]
2.51 [1.80, 3.50]
1.83 [1.22, 2.75]
1.20 [0.94, 1.53]
2.70 [1.87, 3.90]
2.69 [1.97, 3.67]
2.02 [1.75, 2.32]
Odds Ratio Odds Ratio
IV, Random, 95% CI
0.1 0.2 0.5 1 2 5 10
Hypoglycaemia not harmful Hypoglycaemia harmful
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5.5.4.4 HYPOGLYCAEMIA AS A PREDICTOR FOR DEMENTIA  
I identified eight relevant studies that evaluated the relationship of 
hypoglycaemia as a predictor of dementia 143 144 68 69 150 162 170.  The meta-
analysis shows an increased risk of dementia in patients known to suffer from 
hypoglycaemic episodes, with a pooled odds ratio of 1.55 (95% CI 1.33 to 1.79).  
I detected substantial heterogeneity with I2 = 70% (Figure 43). 
Figure 42 Meta-analysis of association between hypoglycaemia and dementia 
 
5.5.5 PUBLICATION BIAS AND SELECTIVE OUTCOME REPORTING 
I constructed a funnel plot for the meta-analysis on the association between 
hypoglycaemia and vascular events, as more than ten studies were included in 
the analysis.  On visual inspection of the funnel plot there are very few small 
studies that contributed to the meta-analysis, and it is difficult to judge 
presence or absence of asymmetry. As such, I cannot rule out the possibility of 
selective reporting or publication bias. 
 
 
 
 
Study or Subgroup
Chin 2016
Cukierman-Yaffe 2019
Haroon 2015
Lee Dementia 2018
Lin 2012
Mehta 2017
Whitmer 2009
Yaffe 2013
Total (95% CI)
Heterogeneity: Tau² = 0.02; Chi² = 23.28, df = 7 (P = 0.002); I² = 70%
Test for overall effect: Z = 5.81 (P < 0.00001)
Weight
2.3%
12.1%
23.0%
9.6%
11.8%
18.0%
19.7%
3.4%
100.0%
IV, Random, 95% CI
2.69 [1.08, 6.69]
1.21 [0.90, 1.63]
1.73 [1.62, 1.85]
2.28 [1.58, 3.29]
1.45 [1.07, 1.97]
1.27 [1.07, 1.51]
1.44 [1.25, 1.66]
2.09 [1.00, 4.37]
1.55 [1.33, 1.79]
Odds Ratio Odds Ratio
IV, Random, 95% CI
0.05 0.2 1 5 20
Hypoglycaemia not harmful Hypoglycaemia harmful
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Figure 43 Funnel plot 
 
For completeness, at Appendix 14, I have produced a supplemental table listing 
the pooled odds ratios using both random and fixed effects methods.  Effect 
estimates were not substantially altered whether a fixed effect model was 
used, or a random effects model that distributed a greater proportion of weight 
to smaller studies. 
 
5.6 DISCUSSION 
My meta-analysis of 42 observational studies (involving a total of over 2 million 
participants) confirms the major concerns about a range of serious adverse 
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events associated with hypoglycaemia in older patients treated with glucose-
lowering drugs.  I found consistent evidence of an 80% relative increase in the 
likelihood of vascular events (both macro- and microvascular complications) 
with hypoglycaemic episodes.   
My meta-analysis also reveals a significant relationship between hypoglycaemia 
and risk of falls and fractures, as well as a doubling in the likelihood of death.  
There is also evidence from eight studies identifying the increased likelihood of 
dementia in those with a history of hypoglycaemic events. 
The abundance and consistency of evidence regarding serious harm supports 
my argument that treatment strategies aimed at minimizing hypoglycaemia 
should be prioritized in older patients who are already prone to suffer from 
cardiovascular events, falls, and fractures.  In addition, an international 
consensus on clinical targets for continuous glucose monitoring data was 
published in June 2019, which highlights that older adults with diabetes should 
spend less than 15 minutes per day in the hypoglycaemic range (<3.9mmol/L)25. 
What is still debated is the physiological mechanism behind the adverse impact 
of hypoglycaemia on, for example, the cardiovascular system and cognition.  I 
have discussed different theories in chapters 1 and 4.  Of course, 
hypoglycaemia may simply be a surrogate marker/indicator for greater disease 
burden or frailty in older patients, and there may actually be no direct 
mechanistic pathway linking hypoglycaemia to cardiovascular events or 
death137 164.  Given the multi-factorial nature of adverse events in older people, 
it seems prudent to consider that hypoglycaemia may be one factor amongst a 
host of others that can contribute to serious harm, and that all efforts should be 
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made to reduce this risk.  It is also tempting to speculate whether 
hypoglycaemia episodes that trigger acute cardiovascular events may be the 
unifying factor in explaining the associated falls and increased mortality. 
5.6.1 STRENGTHS 
My systematic review and meta-analysis provide a comprehensive synthesis of 
the most up to date evidence covering a range of adverse events that are a 
major burden in older patients with diabetes.  
My review also extends to assessing adverse events in two subgroups of older 
people; those with chronic kidney disease156 and dementia160. 
5.6.2 LIMITATIONS 
I am aware of limitations in my meta-analyses, in particular the inability to 
prove causality due to the observational nature of the studies. However, I do 
not consider it ethical or feasible to conduct a randomized trial in older patients 
to expose them to hypoglycaemia.  There is some heterogeneity, especially 
regarding the association between hypoglycaemia and mortality and falls and 
fractures.  Factors which could be influencing heterogeneity include different 
classes of medications, different geographical locations, different study designs 
and ascertainment of hypoglycaemic episodes.  The temporal relationships are 
not always clear and my search was limited to English-language articles.  
Detection of hypoglycaemia is a major issue that may have biased the estimates 
in either direction. For instance, poor recording or failure to accurately capture 
hypoglycaemia can bias the results towards the null. 
Another limitation is the studies included in the systematic review employ a 
very wide definition of adverse events, particularly when constructing a 
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composite endpoint.  This stems from the variation in the use of administrative 
codes for the definition of cardiovascular events, as well as hypoglycaemia.   
I considered summarizing the evidence using GRADE, however, this tool is 
mainly designed for recommendations on healthcare intervention and not for 
aetiology and prognostic studies.  The two main areas within GRADE that 
cannot be applied here are ‘measure of indirectness’ and ‘estimation of 
absolute effect size’. 
Finally, I am conscious of potential publication and selective outcome reporting 
biases where null or negative findings are not fully reported, thus resulting in 
inflated estimates of association in the meta-analyses.  However, the funnel 
plot analysis I performed in relation to cardiovascular events, did not show 
obvious asymmetry, which can be interpreted as no definite evidence of 
underlying publication bias, or bias due to missing studies.   
 
5.7 CONCLUSIONS  
My updated systematic review and meta-analysis provide a strong evidence 
base to support and strengthen my argument about the importance of adopting 
a hypoglycaemia minimization strategy.  The new search added 21 studies to 
my already existing systematic reviews.   
Adopting a hypoglycaemia minimization strategy is especially true in older 
patients with diabetes mellitus and other co-morbidities, as they are at risk of 
serious adverse events associated with hypoglycaemic episodes.  With regard to 
patients with co-morbid diabetes and cognitive impairment, they may find 
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themselves in an awkward spiral descent resulting in ever-worsening cognitive 
decline and more frequent hypoglycaemic episodes at the same time, which is 
something I highlighted in my previously published review.  In addition, older 
people with dementia and diabetes may have difficulty with self-management 
due to their cognitive decline, greater susceptibility to hypoglycaemia and 
having poorer access to diabetes services and monitoring 2. 
The next big step has to be to conduct an RCT in older people with diabetes.  
The intervention arm would be managed with a hypoglycaemia minimization 
strategy (using continuous glucose monitoring) and the control arm with 
standard care.  I envisage a follow-up for 6 months and the outcomes would be 
adverse events, such as cardiovascular events leading to hospitalization. 
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CHAPTER 6. DISCUSSION 
This chapter presents an overall discussion of my research, how it should be 
interpreted by the clinical community and its impact for future work.   
I have highlighted the complexities of hypoglycaemia in older people with 
diabetes and dementia and the take home messages from my research are: 
 This vulnerable group is at higher risk of cardiovascular events, falls and 
fractures and mortality following hypoglycaemia, especially in the first 
12 months after a medically recorded hypoglycaemic episode (requiring 
third party assistance), compared to those without medically recorded 
hypoglycaemia.   
 I have demonstrated through my feasibility study that it is feasible to 
pick up hypoglycaemic episodes through the use of CGM in older people 
with memory problems and diabetes.  
My work should also contribute to the growing evidence around managing 
diabetes and dementia in older people leading to the implementation of a 
common pathway, rather than trying to manage each condition in isolation. 
Whilst I have discussed strengths and limitations for each aspect of my research 
in the individual chapters (chapters 2-5), here I will also discuss overarching 
areas for improvement and further development. 
6.1 HOW SHOULD MY FINDINGS BE INTERPRETED BY THE CLINICAL COMMUNITY? 
My findings should help guide clinicians, patients and their carers in making 
evidence-based choices regarding intensity of drug therapy, and strategies for 
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better monitoring in this vulnerable and complex group.  There are important 
implications for different sectors covering the provision of healthcare: 
6.1.2 HEALTH ECONOMICS 
My research has focussed on medical adverse events, however, the cost 
implications of hypoglycaemic events and the effect on quality of life are also 
crucial to consider.  Studies have shown that hypoglycaemia impacts heavily on 
a person’s quality of life and my systematic review on CGM in older people also 
flagged up papers which commented on an improvement in quality of life when 
using CGM176 73.  In addition, existing evidence has demonstrated the high 
economic burden and healthcare utilization resulting from hypoglycaemia177-179.   
Between December 2014 and April 2016, there were more than 2000 
ambulance call-outs for severe hypoglycaemia in the East of England, 24% of 
which were from callers aged over 80 years and 44% from callers aged over 70 
years.  The severe hypoglycaemic events in the older population were 
associated with insulin use180.  In the East Midlands, the annual estimated costs 
of call-outs for hypoglycaemia is approximately £235,00028. 
With this in mind, the main driver from an economics point of view should be 
minimising the risk of hypoglycaemia.  There needs to be an enormous shift in 
thinking by commissioners regarding how we can best minimise hypoglycaemia, 
especially in frail older people, combined with the use of CGM.  We know that 
the use of CGM can significantly reduce the time spent in the hypoglycaemic 
range43. 
At this point in time, there is a general perception that older people do not 
need to test their glucose levels as much and I have already argued that 
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intermittent finger-prick testing is not helpful to fully capture hypoglycaemic 
episodes. The work that I will need to carry out in the future will have to include 
health economic modelling to show that the costs of using CGM technology will 
be recouped due to reduction in ED attendances, hospitalisations, falls and 
fractures and cardiovascular events, in addition to the improvement in quality 
of life for patients and carers.  I would like to assess whether the benefits of 
intermittent use of CGM could outweigh the costs of it.  CGM technology has 
seen so much development in the last two decades, I would expect the devices 
to become more affordable and user-friendly over the next 10 years. 
Older people with dementia are at higher risk of hypoglycaemic episodes8 and I 
alluded to this already in my discussion in chapter 3.  It should not matter what 
type of diabetes a person has or how often he or she checks glucose levels.  The 
important question has to be whether an individual is at high-risk of 
hypoglycaemia, be it because of the medication they are on (insulin and 
sulfonylureas) and/or the fact that they are frail, have memory problems or 
other disabilities, which makes the management of their diabetes more 
complex. 
6.1.3 SOCIAL CARE 
An advantage of using CGM in frail older people would be less need for District 
Nurses to drive to lots of homes to carry out finger-prick testing, although 
chances are that they may still need to administer insulin. It is already possible 
to remotely share CGM data via smartphone apps. 
In order to be able to implement the use of CGM effectively, areas that need to 
be explored are around who (if the patient is unable to, due to, for example, 
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dementia) would monitor glucose levels and react to alarms: a next of kin, 
doctors, carers?  Cloud-based services enable patients and carers to set up 
“followers” to share the data.  For example, parents of young children can set 
up their smartphone so that they receive their child’s glucose readings and 
alarms.  By analogy, similar scenarios with relatives and/or carers could apply to 
older frail people who need support with the management of their diabetes.  
What would need to be explored is how the care network can be set up to deal 
with low glucose alerts that need addressing sooner rather than later.  Ideally (if 
NHS and Social Care resources were not an issue), older people with memory 
problems and high-risk of hypoglycaemia would have access to tailored 
packages of care, taking into account nutrition (composition of meals, in 
particular carbohydrates, timing of meals) and hydration (avoiding 
dehydration), in addition to CGM.  The ADA recommends that the composition 
of meals (carbohydrates, protein and fat) should be individualised, reflecting 
eating patterns, personal preferences, the individual’s culture, traditions and 
religion, economics and metabolic goals 21. 
There are interesting developments around remote monitoring in the home, led 
by the Care Research & Technology Centre at Imperial College, using artificial 
intelligence and robotics to enable people with dementia to live in their own 
home for longer.  It involves monitoring aspects such as sleep, behaviour, 
possible markers of impending infection and even EEG which is transmitted 
from encrypted home storage to Cloud Computing leading to data integration 
and intelligent decision-making (Figure 45).  It would be fascinating to explore 
whether CGM could also be incorporated into such a set up.  
   
 
 235 
Figure 44 The ‘Healthy Home’ 
(taken from Imperial College website)181  
 
6.1.4 CLINICAL CARE 
For clinicians, when managing a frail older person with diabetes and other 
complex co-morbidities, the focus has to be on minimisation of hypoglycaemia 
rather than achieving a HbA1c target.  This can be achieved by deintensification 
of medications and also (paradoxically) greater monitoring through CGM.  A 
recently published systematic review found that the benefits of 
deintensification outweigh the harms in older people with type 2 diabetes with 
or without co-morbidities182.  The outcomes the authors were interested 
included measures of glycaemia, admission rates, hospitalizations, 
complications, mortality, quality of life and patient satisfaction.  Most of the 
data in the review appears to relate to glycaemic outcomes.  Only two studies 
report adverse events and three reported on mortality.  It would be more 
accurate to state that the relative paucity of data of adverse events and 
mortality outcomes means that we cannot conclusive make statements on 
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deintensification outweighing harms.  The authors acknowledge that the 
studies were of poor methodological quality with short follow-up durations of 
only a few months, which makes it impossible to draw robust conclusion. 
Using CGM is really the only way to pick up hypoglycaemic episodes, especially 
at night, in addition to variability in glucose readings throughout day and night.  
In older frail patients I envisage that CGM could be used as a troubleshooting 
tool, for example, if someone on insulin or sulfonylureas has required the help 
of another person to manage a hypoglycaemic episode, or when there has been 
a change in dose of medications.  In those cases, CGM could be used over a 
period of, for example, a month, in order to obtain an ambulatory glucose 
profile.  Treatment decisions, including deintensification of medication can then 
be made with the help of the ambulatory glucose profile before and/or after 
any planned changes in management.   
I concede that for healthcare professionals this may result in more and longer 
consultation times with this group of patients, which poses a challenge in itself 
in an already stretched NHS.  However, the benefits of this approach in the long 
term are likely outweigh the challenges (however, this again will need to be 
assessed). 
 
6.2 AREAS FOR IMPROVEMENT 
The strengths and limitations for each aspect of my fellowship are discussed in 
chapters 2-5.  Here I will outline more generally some limitations that still need 
to be overcome in future research. 
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I have not yet assessed the optimal strategy of hypoglycaemia minimization.  
Should this be done through modification of pharmacotherapy or better 
monitoring, or better social care, or a combination of all of these factors. 
With regard to better monitoring, I need to assess which device is most 
acceptable to older people and their carers. The different CGM devices are 
constantly undergoing modifications and innovations and my thesis data relate 
to a device that has since been made more accurate and refined. 
I have not assessed whether reduction of hypoglycaemia leads to improved 
patient and health service use outcomes, or indeed adverse effects.  I will also 
need to assess which older patient group is the most appropriate to target, for 
example, should it be nursing home residents, older people who are still living 
alone, those on insulin and/or sulfonylureas or those with carers. 
I have not yet been able to assess the factors that can lead to older people not 
being able to use a CGM device, for example, the presence or absence of carers, 
past experience of self-monitoring glucose levels, type and severity of memory 
problems, other co-morbidities such as arthritis and visual problems.  I have not 
been able to confirm improvements in diabetes-related psychological and 
physical health. 
 
6.2.1 PHARMACOEPIDEMIOLOGICAL STUDY 
Whilst I can only work with the data that is available through a particular 
dataset, I would have liked to have been able to gather information on the 
following aspects: 
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 A&E data (other than being able to extract that someone has attended 
A&E) - A&E is good at coding for trauma injuries, but not specific enough 
for hypoglycaemia. 
Figure 45 Extracts from HES Data Dictionary – Accident & Emergency 
 
 
 
 
 Free text written by GPs for individual patient visits: I would have liked 
to have been able to check free text, as this may have revealed further 
hypoglycaemic episodes, which I would have missed due to not being 
able to do that. 
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 Data on social care packages and whether or not someone has had to 
move into a care/nursing home as these can be interpreted as proxies 
for frailty. 
 Information on aspects such as delayed discharges (which are often 
linked to the challenges of finding and starting a care package). 
 Severity of dementia: this is a tricky area and impossible to reliably code 
on a database, however, ideally it would be useful to be able to extract 
information on whether an individual is not able to live independently 
anymore, has limited communication, whether or not they are still able 
to wash/dress/eat themselves and what their mobility is like. 
During the preparatory work of extracting raw data from the database, I 
noticed that the date of death in CPRD at times did not match the date of death 
in ONS, or HES dates occurred after the death date.  This could be a reflection 
of the time it can take for discharge letters to be completed and sent to primary 
care and for primary care then to code the diagnoses listed in the discharge 
documentation. 
6.2.2 FEASIBILITY STUDY 
One of the findings of my feasibility study was the variability of data capture, as 
some participants did not remember to scan the sensor.  Data capture was less 
than 60% in six participants.  Since my study started, a new CGM device became 
widely available, which is licensed for use in adults and children (Dexcom G6).  
With this device, data is constantly being transmitted to a reader via Bluetooth 
and does not require active scanning.  It also does not require any calibration 
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via finger-prick testing and has greater accuracy in glucose measurements than 
the older Freestyle Libre.   
I would have liked to have used the Dexcom G6 device to assess whether data 
capture improved and whether participants (and carers) were able to work with 
the Bluetooth technology.  Another aspect to investigate is the use of alarms 
(for high/low glucose readings) which Dexcom employs and how this may or 
may not have affected participants and carers.  I am however planning a new 
study using Dexcom G6, which is discussed below. 
 
6.3 PERSONAL REFLECTIONS 
6.3.1 FEASIBILITY STUDY 
The feasibility study was my first opportunity to carry out a clinical trial from 
start to finish.  The entire process was fascinating and at times frustrating, 
especially regarding the bureaucracy that is involved in setting up any study, 
from inception through to getting paperwork signed off by the sponsor before 
submitting to and attending an Ethics Committee.  It made me realise how 
much of a challenge it is to try and get a study up and running and why 
clinicians who do not have protected research time and do not understand/are 
not aware of the intricacies of the different steps involved might be put off 
carrying out research.   
A further aspect I found challenging on a personal level was the recruitment of 
participants.  I felt quite conflicted when approaching potential participants, 
especially as I was very aware of their vulnerability exacerbated by being in an 
acute hospital, which in itself can be a stressful and scary experience for each 
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affected individual.  If anything, I probably discouraged some participants from 
taking part, as I did not want them to feel pressured. 
Saying that, once participants had consented and I carried out study visits, this 
gave me a chance to build rapport and trust, which in turn resulted in getting to 
know fascinating individuals.  I felt quite humbled being able to spend time with 
them and incredibly grateful that the participants were prepared to take part in 
my study.  It highlighted to me how much older people still want to be involved 
in furthering scientific and medical advances and that they are so often wrongly 
excluded from primary research.  On the flip side, in some cases it was also a 
stark reminder of just how vulnerable this patient population is, especially in 
rural Norfolk, where access to anything from food shops to social clubs to GP 
surgeries can be extremely limited when someone does not have a car or 
friends/family who could provide transport.  On a few occasions, I visited a 
participant whose front door was left unlocked leaving them incredibly 
vulnerable to anyone walking into their house. 
Despite all the bureaucratic hurdles that have to be overcome (and that is after 
the hurdles of securing funding in the first place), I am determined to carry out 
further studies which naturally flow on from my fellowship, which I discuss 
below.   
As a research community I feel there needs to be a much greater effort in 
including older frail people in research studies. 
6.3.2 PHARMACOEPIDEMIOLOGICAL STUDY 
I was keen to carry out a database study, partly because of the intellectual 
challenge of dealing with a big dataset.  It was a very steep learning curve, 
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especially as I am not naturally drawn to complex statistical models or large sets 
of numbers.  This is exactly why I wanted to incorporate such a study into my 
fellowship.   
Learning about how to approach a large dataset and all the groundwork 
(around carefully examining the data) before any statistical models can be 
applied was a real eye-opener for me.  
A huge amount of preparatory work went into extracting raw data and putting 
it into a format that is suitable for software analysis.  I spent a lot of time 
putting together lists using the CRPD code browser to collate codes for 
hypoglycaemia (exposure), co-morbidities, lifestyle factors, outcomes (all Read 
codes), medications (BNF codes).  I also had to identify ICD-10 codes for the 
A&E/HES data (Appendix 11). 
Working with a big dataset also made me realise just how imperfect they are 
and how much we rely on the accuracy of coding of diseases, medications and 
patient characteristics.  Any dataset is only going to be as good as the coding, 
which is inconsistent.    
My view is that observational research continues to be a very important part of 
evidence synthesis, especially as it may not always be feasible to carry out an 
RCT due to time, funding and/or ethical issues.  However, rigour around the 
construct of observational studies is vital.  In that context, I was fascinated by 
the theoretical constructs created by Miguel Hernan (target trials to emulate a 
theoretical RCT). 
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6.4 FUTURE RESEARCH  
My research to date has set the ground work for future studies on CGM in frail 
older people with diabetes.  I am already working on a pilot study where I will 
capture data on the time spent in range using CGM in older people with 
diabetes living in care and/or nursing homes.  I am setting up the research team 
and have consulted lay members of the Alzheimer’s Society Research Network 
about the planned study.  I will submit an application for Research for Patient 
Benefit funding within the next 12 months. 
A key area for investigation is what type of CGM (i.e. intermittent 
scanning/flash glucose monitoring, continuous transmission via Bluetooth or 
blinded and retrospective CGM) would be most appropriate in older people 
with memory problems?  Can older people with memory problems (or their 
carers) deal with the technology for continuous Bluetooth capture and react to 
the data that is produced by the software, including alarms for high and low 
glucose levels. 
Secondly, how often should CGM be employed (all the time, when there is a 
change in drugs, or intermittently for troubleshooting)?  
Thirdly, should it be limited to insulin and sulfonylurea users, which carry a 
higher risk of hypoglycaemia?   
Finally, it would be important to identify facilitators and barriers to CGM use in 
older people with memory problems, with specific focus on factors such as 
dementia severity, functional status, availability of carers, familiarity with self-
monitoring etc. that can influence extent of data capture. 
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There is a clear need for a large-scale prospective study using CGM to assess its 
true potential impact in this vulnerable group.  CGM would be used to capture 
hypoglycaemic episodes and guide a hypoglycaemia minimization strategy.  In 
addition, CGM may be a useful and supportive tool for carers in their day to day 
care of this vulnerable group of older people, especially those on insulin.   
 
With regards to patient outcomes and hypoglycaemia, I would need to conduct 
a cluster-randomised trial.  This could be done either at GP practice level or 
nursing home level.  The population of interest would be older people with 
diabetes treating either with insulin and/or sulfonylureas, which confer a higher 
risk of hypoglycaemia.  CGM would be part of a complex intervention in 
combination with implementing a hypoglycaemia minimisation strategy.  The 
control group would continue with their standard diabetes care (plus blinded 
CGM).  The main outcome would be health service use (including ambulance 
call-outs and emergency department visits).  The secondary outcome would be 
time in range. 
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6.5 STATEMENT OF IMPACT 
Based on my work on diabetes and dementia, I presented oral and written 
evidence at the All-Party Parliamentary Group (APPG) on Dementia, which led 
to the publication (and launch in Parliament) of their report in 2016: ‘Dementia 
rarely travels alone: Living with dementia and other conditions’ 
(https://www.alzheimers.org.uk/sites/default/files/migrate/downloads/appg_o
n_dementia_2016_report.pdf). 
More recently, two of my systematic reviews on adverse events of 
hypoglycaemia in older people with diabetes formed part of the evidence 
behind a Position Statement of Primary Care Diabetes Europe on the 
management of type 2 diabetes in older people (Factors influencing safe 
glucose-lowering in older adults with type 2 diabetes: a PeRsOn-centred 
ApproaCh To IndiVidualisEd (PROACTIVE) Glycemic Goals for older people.  A 
position statement of Primary Care Diabetes Europe ( https://www.primary-
care-diabetes.com/article/S1751-9918(18)30300-0/pdf). 
 
  246 
REFERENCES  
1. Kirkman MS, Briscoe VJ, Clark N, et al. Diabetes in older adults: a consensus 
report. J Am Geriatr Soc 2012;60(12):2342-56. doi: 10.1111/jgs.12035 
[published Online First: 2012/10/31] 
2. Bunn F, Goodman C, Jones PR, et al. Managing diabetes in people with 
dementia: a realist review. Health Technol Assess 2017;21(75):1-140. 
doi: 10.3310/hta21750 [published Online First: 2017/12/14] 
3. Abdelhafiz AH, McNicholas E, Sinclair AJ. Hypoglycemia, frailty and dementia 
in older people with diabetes: Reciprocal relations and clinical 
implications. J Diabetes Complications 2016;30(8):1548-54. doi: 
10.1016/j.jdiacomp.2016.07.027 
4. Lipska KJ, Ross JS, Miao Y, et al. Potential overtreatment of diabetes mellitus 
in older adults with tight glycemic control. JAMA Intern Med 
2015;175(3):356-62. doi: 10.1001/jamainternmed.2014.7345 
5. Abdelhafiz AH, Sinclair AJ. Deintensification of hypoglycaemic medications-
use of a systematic review approach to highlight safety concerns in older 
people with type 2 diabetes. J Diabetes Complications 2018;32(4):444-
50. doi: 10.1016/j.jdiacomp.2017.11.011 
6. Mattishent K, Loke YK. Meta-analysis: Association between hypoglycaemia 
and serious adverse events in older patients. J Diabetes Complications 
2016;30(5):811-8. doi: 10.1016/j.jdiacomp.2016.03.018 [published 
Online First: 2016/04/17] 
7. Mattishent K, Loke YK. Bi-directional interaction between hypoglycaemia and 
cognitive impairment in elderly patients treated with glucose-lowering 
agents: a systematic review and meta-analysis. Diabetes Obes Metab 
2016;18(2):135-41. doi: 10.1111/dom.12587 
8. Snowden MB, Steinman LE, Bryant LL, et al. Dementia and co-occurring 
chronic conditions: a systematic literature review to identify what is 
known and where are the gaps in the evidence? Int J Geriatr Psychiatry 
2017;32(4):357-71. doi: 10.1002/gps.4652 
9. International Diabetes Federation. IDF DIABETES ATLAS 2017 [8th:[Available 
from: http://www.diabetesatlas.org accessed 7 January 2019. 
10. Intensive blood-glucose control with sulphonylureas or insulin compared 
with conventional treatment and risk of complications in patients with 
type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) 
Group. Lancet 1998;352(9131):837-53. [published Online First: 
1998/09/22] 
11. Effect of intensive blood-glucose control with metformin on complications 
in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective 
Diabetes Study (UKPDS) Group. Lancet 1998;352(9131):854-65. 
[published Online First: 1998/09/22] 
12. Alzheimer’s Disease International. World Alzheimer Report 2018 2018 
[Available from: 
https://www.alz.co.uk/research/WorldAlzheimerReport2018.pdf 
accessed 7 January 2019. 
  247 
13. Woodford H. Essential Geriatrics. 3rd ed: CRC Press Taylor & Francis Group 
2016. 
14. Bunn F, Burn AM, Goodman C, et al. Comorbidity and dementia: a scoping 
review of the literature. BMC Med 2014;12:192. doi: 10.1186/s12916-
014-0192-4 
15. Zilkens RR, Davis WA, Spilsbury K, et al. Earlier age of dementia onset and 
shorter survival times in dementia patients with diabetes. Am J 
Epidemiol 2013;177(11):1246-54. doi: 10.1093/aje/kws387 [published 
Online First: 2013/04/02] 
16. Action to Control Cardiovascular Risk in Diabetes Study G, Gerstein HC, 
Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes. 
N Engl J Med 2008;358(24):2545-59. doi: 10.1056/NEJMoa0802743 
[published Online First: 2008/06/10] 
17. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and 
cardiovascular disease in patients with type 1 diabetes. N Engl J Med 
2005;353(25):2643-53. doi: 10.1056/NEJMoa052187 [published Online 
First: 2005/12/24] 
18. Dluhy RG, McMahon GT. Intensive glycemic control in the ACCORD and 
ADVANCE trials. N Engl J Med 2008;358(24):2630-3. doi: 
10.1056/NEJMe0804182 [published Online First: 2008/06/10] 
19. Gosney M. HA, Conroy S. Oxford Desk Reference Geriatric Medicine: Oxford 
University Press 2012:172-181. 
20. Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: a report 
of a workgroup of the American Diabetes Association and the Endocrine 
Society. Diabetes Care 2013;36(5):1384-95. doi: 10.2337/dc12-2480 
21. Association AD. Standards of Medical Care in Diabetes—2019 Abridged for 
Primary Care Providers. Clinical Diabetes 2019;37(1):11-34. 
22. Wargny M, Gallini A, Hanaire H, et al. Diabetes Care and Dementia Among 
Older Adults: A Nationwide 3-Year Longitudinal Study. J Am Med Dir 
Assoc 2018 doi: 10.1016/j.jamda.2017.12.006 
23. Bunn F, Goodman C, Reece Jones P, et al. What works for whom in the 
management of diabetes in people living with dementia: a realist 
review. BMC Med 2017;15(1):141. doi: 10.1186/s12916-017-0909-2 
24. Huang ES, Davis AM. Glycemic Control in Older Adults With Diabetes 
Mellitus. Jama 2015;314(14):1509-10. doi: 10.1001/jama.2015.8345 
[published Online First: 2015/10/16] 
25. Battelino T, Danne T, Bergenstal RM, et al. Clinical Targets for Continuous 
Glucose Monitoring Data Interpretation: Recommendations From the 
International Consensus on Time in Range. Diabetes Care 2019 doi: 
10.2337/dci19-0028 [published Online First: 2019/06/10] 
26. Lash RW, Lucas DO, Illes J. Preventing Hypoglycemia in Type 2 Diabetes. J 
Clin Endocrinol Metab 2018 doi: 10.1210/jc.2017-02804 
27. Budnitz DS, Lovegrove MC, Shehab N, et al. Emergency hospitalizations for 
adverse drug events in older Americans. N Engl J Med 
2011;365(21):2002-12. doi: 10.1056/NEJMsa1103053 
28. Khunti K, Fisher H, Paul S, et al. Severe hypoglycaemia requiring emergency 
medical assistance by ambulance services in the East Midlands: a 
  248 
retrospective study. Prim Care Diabetes 2013;7(2):159-65. doi: 
10.1016/j.pcd.2013.01.001 [published Online First: 2013/02/05] 
29. Kim JT, Oh TJ, Lee YA, et al. Increasing trend in the number of severe 
hypoglycemia patients in Korea. Diabetes Metab J 2011;35(2):166-72. 
doi: 10.4093/dmj.2011.35.2.166 
30. Chen YJ, Yang CC, Huang LC, et al. Increasing trend in emergency 
department visits for hypoglycemia from patients with type 2 diabetes 
mellitus in Taiwan. Prim Care Diabetes 2015;9(6):490-6. doi: 
10.1016/j.pcd.2015.04.002 
31. Zaccardi F, Davies MJ, Dhalwani NN, et al. Trends in hospital admissions for 
hypoglycaemia in England: a retrospective, observational study. Lancet 
Diabetes Endocrinol 2016;4(8):677-85. doi: 10.1016/S2213-
8587(16)30091-2 
32. Agiostratidou G, Anhalt H, Ball D, et al. Standardizing Clinically Meaningful 
Outcome Measures Beyond HbA1c for Type 1 Diabetes: A Consensus 
Report of the American Association of Clinical Endocrinologists, the 
American Association of Diabetes Educators, the American Diabetes 
Association, the Endocrine Society, JDRF International, The Leona M. 
and Harry B. Helmsley Charitable Trust, the Pediatric Endocrine Society, 
and the T1D Exchange. Diabetes Care 2017;40(12):1622-30. doi: 
10.2337/dc17-1624 
33. Frier BM. Hypoglycaemia in diabetes mellitus: epidemiology and clinical 
implications. Nature reviews Endocrinology 2014;10(12):711-22. doi: 
10.1038/nrendo.2014.170 [published Online First: 2014/10/08] 
34. Malanda UL, Welschen LM, Riphagen, II, et al. Self-monitoring of blood 
glucose in patients with type 2 diabetes mellitus who are not using 
insulin. Cochrane Database Syst Rev 2012;1:CD005060. doi: 
10.1002/14651858.CD005060.pub3 
35. Young LA, Buse JB, Weaver MA, et al. Glucose Self-monitoring in Non-
Insulin-Treated Patients With Type 2 Diabetes in Primary Care Settings: 
A Randomized Trial. JAMA Intern Med 2017 doi: 
10.1001/jamainternmed.2017.1233 
36. NICE. Type 1 diabetes in adults; diagnosis and management 2015 [Available 
from: https://www.nice.org.uk/guidance/ng17/chapter/1-
recommendations#blood-glucose-management-2 accessed 30 January 
2019. 
37. ADA. Standards of Medical Care in Diabetes. Diabetes Care 2005;28:S4-S26. 
38. NHS. The NHS Long Term Plan 2019 [Available from: 
https://www.longtermplan.nhs.uk/wp-content/uploads/2019/01/nhs-
long-term-plan.pdf accessed 28 January 2019. 
39. UK D. Can I get access to Flash? The situation in England 2019 [Available 
from: https://www.diabetes.org.uk/resources-s3/2019-
05/Flash%20England%20Criteria%201st%20May%202019.pdf accessed 
5 November 2019. 
40. Bergenstal RM, Ahmann AJ, Bailey T, et al. Recommendations for 
standardizing glucose reporting and analysis to optimize clinical decision 
  249 
making in diabetes: the ambulatory glucose profile. J Diabetes Sci 
Technol 2013;7(2):562-78. doi: 10.1177/193229681300700234 
41. Matthaei SD RB, E. Evans, M. Geelhoed-Duijvestijn, N. Joubert, M. 
Consensus recommendations for the use of Ambulatory Glucose Profile 
in clinical practice. Br J Diabetes Vasc Dis 2014;14:153-7. 
42. NICE. Type 2 diabetes in adults: management 2015 [Available from: 
https://www.nice.org.uk/guidance/ng28/resources/type-2-diabetes-in-
adults-management-pdf-1837338615493 accessed 27 January 2019. 
43. Haak T, Hanaire H, Ajjan R, et al. Flash Glucose-Sensing Technology as a 
Replacement for Blood Glucose Monitoring for the Management of 
Insulin-Treated Type 2 Diabetes: a Multicenter, Open-Label Randomized 
Controlled Trial. Diabetes Ther 2017;8(1):55-73. doi: 10.1007/s13300-
016-0223-6 [published Online First: 2016/12/22] 
44. Ehrhardt NM, Chellappa M, Walker MS, et al. The effect of real-time 
continuous glucose monitoring on glycemic control in patients with type 
2 diabetes mellitus. J Diabetes Sci Technol 2011;5(3):668-75. doi: 
10.1177/193229681100500320 [published Online First: 2011/07/05] 
45. Taylor PJ, Thompson CH, Brinkworth GD. Effectiveness and acceptability of 
continuous glucose monitoring for type 2 diabetes management: A 
narrative review. Journal of diabetes investigation 2018;9(4):713-25. 
doi: 10.1111/jdi.12807 [published Online First: 2018/01/31] 
46. Fonda SJ, Graham C, Munakata J, et al. The Cost-Effectiveness of Real-Time 
Continuous Glucose Monitoring (RT-CGM) in Type 2 Diabetes. J Diabetes 
Sci Technol 2016;10(4):898-904. doi: 10.1177/1932296816628547 
[published Online First: 2016/02/05] 
47. Pazos-Couselo M, Garcia-Lopez JM, Gonzalez-Rodriguez M, et al. High 
incidence of hypoglycemia in stable insulin-treated type 2 diabetes 
mellitus: continuous glucose monitoring vs. self-monitored blood 
glucose. Observational prospective study. Canadian Journal of Diabetes 
2015;39(5):428-33. doi: https://dx.doi.org/10.1016/j.jcjd.2015.05.007 
48. Munshi MN, Segal AR, Suhl E, et al. Frequent hypoglycemia among elderly 
patients with poor glycemic control. Arch Intern Med 2011;171(4):362-4. 
doi: https://dx.doi.org/10.1001/archinternmed.2010.539 
49. van Dijk P, Bouma A, Landman GW, et al. Hypoglycemia in Frail Elderly 
Patients With Type 2 Diabetes Mellitus Treated With Sulfonylurea. J 
Diabetes Sci Technol 2017;11(2):438-39. doi: 
10.1177/1932296816668873 
50. Ahren B. Avoiding hypoglycemia: a key to success for glucose-lowering 
therapy in type 2 diabetes. Vasc Health Risk Manag 2013;9:155-63. doi: 
10.2147/VHRM.S33934 [published Online First: 2013/05/03] 
51. Hypoglycaemia Study Group UK. Risk of hypoglycaemia in types 1 and 2 
diabetes: effects of treatment modalities and their duration. 
Diabetologia 2007;50(6):1140-7. doi: 10.1007/s00125-007-0599-y 
[published Online First: 2007/04/07] 
52. Donnelly LA, Morris AD, Frier BM, et al. Frequency and predictors of 
hypoglycaemia in Type 1 and insulin-treated Type 2 diabetes: a 
population-based study. Diabetic medicine : a journal of the British 
  250 
Diabetic Association 2005;22(6):749-55. doi: 10.1111/j.1464-
5491.2005.01501.x [published Online First: 2005/05/25] 
53. Akram K, Pedersen-Bjergaard U, Carstensen B, et al. Frequency and risk 
factors of severe hypoglycaemia in insulin-treated Type 2 diabetes: a 
cross-sectional survey. Diabetic medicine : a journal of the British 
Diabetic Association 2006;23(7):750-6. doi: 10.1111/j.1464-
5491.2006.01880.x [published Online First: 2006/07/18] 
54. Abdelhafiz AH, Koay L, Sinclair AJ. The effect of frailty should be considered 
in the management plan of older people with Type 2 diabetes. Future Sci 
OA 2016;2(1):FSO102. doi: 10.4155/fsoa-2015-0016 
55. Abdelhafiz AH, Sinclair AJ. Deintensification of hypoglycaemic medications-
use of a systematic review approach to highlight safety concerns in older 
people with type 2 diabetes. J Diabetes Complications 2017 doi: 
10.1016/j.jdiacomp.2017.11.011 
56. Abbatecola AM, Bo M, Barbagallo M, et al. Severe hypoglycemia is 
associated with antidiabetic oral treatment compared with insulin 
analogs in nursing home patients with type 2 diabetes and dementia: 
results from the DIMORA study. J Am Med Dir Assoc 2015;16(4):349 e7-
12. doi: 10.1016/j.jamda.2014.12.014 
57. Feil DG, Rajan M, Soroka O, et al. Risk of hypoglycemia in older veterans 
with dementia and cognitive impairment: implications for practice and 
policy. J Am Geriatr Soc 2011;59(12):2263-72. doi: 10.1111/j.1532-
5415.2011.03726.x 
58. Prinz N, Stingl J, Dapp A, et al. High rate of hypoglycemia in 6770 type 2 
diabetes patients with comorbid dementia: A multicenter cohort study 
on 215,932 patients from the German/Austrian diabetes registry. 
Diabetes Res Clin Pract 2016;112:73-81. doi: 
10.1016/j.diabres.2015.10.026 [published Online First: 2015/11/14] 
59. Shorr RI, Ray WA, Daugherty JR, et al. Incidence and risk factors for serious 
hypoglycemia in older persons using insulin or sulfonylureas. Arch Intern 
Med 1997;157(15):1681-6. [published Online First: 1997/08/11] 
60. Chen LK, Lin MH, Lai HY, et al. Care of patients with diabetes mellitus in 
long-term care facilities in Taiwan: diagnosis, glycemic control, 
hypoglycemia, and functional status. J Am Geriatr Soc 2008;56(10):1975-
6. doi: 10.1111/j.1532-5415.2008.01904.x 
61. Zammitt NN, Frier BM. Hypoglycemia in type 2 diabetes: pathophysiology, 
frequency, and effects of different treatment modalities. Diabetes Care 
2005;28(12):2948-61. 
62. Diabetes UK. Signs and symptoms of hypoglycaemia  [Available from: 
https://www.diabetes.org.uk/guide-to-diabetes/complications/hypos 
accessed 9 April 2019. 
63. Meneilly GS, Tessier DM. Diabetes, Dementia and Hypoglycemia. Can J 
Diabetes 2016;40(1):73-6. doi: 10.1016/j.jcjd.2015.09.006 
64. JBDS. The Hospital Management of Hypoglycaemia in Adults with Diabetes 
Mellitus, 2013. 
  251 
65. Farrell B, Black C, Thompson W, et al. Deprescribing antihyperglycemic 
agents in older persons: Evidence-based clinical practice guideline. Can 
Fam Physician 2017;63(11):832-43. 
66. Sheen YJ, Sheu WH. Association between hypoglycemia and dementia in 
patients with type 2 diabetes. Diabetes Res Clin Pract 2016;116:279-87. 
doi: 10.1016/j.diabres.2016.04.004 [published Online First: 2016/06/21] 
67. Gibas KJ. The starving brain: Overfed meets undernourished in the 
pathology of mild cognitive impairment (MCI) and Alzheimer's disease 
(AD). Neurochem Int 2017;110:57-68. doi: 10.1016/j.neuint.2017.09.004 
68. Lee AK, Rawlings AM, Lee CJ, et al. Severe hypoglycaemia, mild cognitive 
impairment, dementia and brain volumes in older adults with type 2 
diabetes: the Atherosclerosis Risk in Communities (ARIC) cohort study. 
Diabetologia 2018;61(9):1956-65. doi: 10.1007/s00125-018-4668-1 
[published Online First: 2018/07/02] 
69. Whitmer RA, Karter AJ, Yaffe K, et al. Hypoglycemic episodes and risk of 
dementia in older patients with type 2 diabetes mellitus. Jama 
2009;301(15):1565-72. doi: 10.1001/jama.2009.460 
70. Lin CH, Sheu WH. Hypoglycaemic episodes and risk of dementia in diabetes 
mellitus: 7-year follow-up study. Journal of internal medicine 
2013;273(1):102-10. doi: 10.1111/joim.12000 
71. Lee AK, Warren B, Lee CJ, et al. The Association of Severe Hypoglycemia 
With Incident Cardiovascular Events and Mortality in Adults With Type 2 
Diabetes. Diabetes Care 2018;41(1):104-11. doi: 10.2337/dc17-1669 
72. Hung YC, Lin CC, Chen HJ, et al. Severe hypoglycemia and hip fracture in 
patients with type 2 diabetes: a nationwide population-based cohort 
study. Osteoporos Int 2017;28(7):2053-60. doi: 10.1007/s00198-017-
4021-4 [published Online First: 2017/04/05] 
73. Mattishent K, Loke YK. Detection of asymptomatic drug-induced 
hypoglycemia using continuous glucose monitoring in older people - 
Systematic review. J Diabetes Complications 2018;32(8):805-12. doi: 
10.1016/j.jdiacomp.2018.05.005 [published Online First: 2018/06/12] 
74. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring 
Study G, Tamborlane WV, Beck RW, et al. Continuous glucose 
monitoring and intensive treatment of type 1 diabetes. N Engl J Med 
2008;359(14):1464-76. doi: 10.1056/NEJMoa0805017 [published Online 
First: 2008/09/10] 
75. Charleer S, Mathieu C, Nobels F, et al. Effect of Continuous Glucose 
Monitoring on Glycemic Control, Acute Admissions, and Quality of Life: 
A Real-World Study. J Clin Endocrinol Metab 2018;103(3):1224-32. doi: 
10.1210/jc.2017-02498 [published Online First: 2018/01/18] 
76. Tyndall V, Stimson RH, Zammitt NN, et al. Marked improvement in HbA1c 
following commencement of flash glucose monitoring in people with 
type 1 diabetes. Diabetologia 2019 doi: 10.1007/s00125-019-4894-1 
[published Online First: 2019/06/10] 
77. Petrie JR, Peters AL, Bergenstal RM, et al. Improving the Clinical Value and 
Utility of CGM Systems: Issues and Recommendations: A Joint 
Statement of the European Association for the Study of Diabetes and 
  252 
the American Diabetes Association Diabetes Technology Working Group. 
Diabetes Care 2017;40(12):1614-21. doi: 10.2337/dci17-0043 [published 
Online First: 2017/10/27] 
78. Staal OM, Hansen HMU, Christiansen SC, et al. Differences Between Flash 
Glucose Monitor and Fingerprick Measurements. Biosensors (Basel) 
2018;8(4) doi: 10.3390/bios8040093 [published Online First: 
2018/10/20] 
79. Bailey T, Bode BW, Christiansen MP, et al. The Performance and Usability of 
a Factory-Calibrated Flash Glucose Monitoring System. Diabetes 
technology & therapeutics 2015;17(11):787-94. doi: 
10.1089/dia.2014.0378 [published Online First: 2015/07/15] 
80. Basu A, Dube S, Slama M, et al. Time lag of glucose from intravascular to 
interstitial compartment in humans. Diabetes 2013;62(12):4083-7. doi: 
10.2337/db13-1132 [published Online First: 2013/09/07] 
81. Sinha M, McKeon KM, Parker S, et al. A Comparison of Time Delay in Three 
Continuous Glucose Monitors for Adolescents and Adults. J Diabetes Sci 
Technol 2017;11(6):1132-37. doi: 10.1177/1932296817704443 
[published Online First: 2017/05/02] 
82. Aleppo G, Ruedy KJ, Riddlesworth TD, et al. REPLACE-BG: A Randomized 
Trial Comparing Continuous Glucose Monitoring With and Without 
Routine Blood Glucose Monitoring in Adults With Well-Controlled Type 
1 Diabetes. Diabetes Care 2017;40(4):538-45. doi: 10.2337/dc16-2482 
[published Online First: 2017/02/18] 
83. Abbott. FLASH GLUCOSE MONITORING  [Available from: 
https://freestylediabetes.co.uk/freestyle-libre/interstitial-vs-blood-
glucose accessed 5 November 2019. 
84. Parkes JL, Slatin SL, Pardo S, et al. A new consensus error grid to evaluate 
the clinical significance of inaccuracies in the measurement of blood 
glucose. Diabetes Care 2000;23(8):1143-8. doi: 
10.2337/diacare.23.8.1143 [published Online First: 2000/08/11] 
85. Clarke WL, Cox D, Gonder-Frederick LA, et al. Evaluating clinical accuracy of 
systems for self-monitoring of blood glucose. Diabetes Care 
1987;10(5):622-8. doi: 10.2337/diacare.10.5.622 [published Online First: 
1987/09/01] 
86. Ajjan RA, Cummings MH, Jennings P, et al. Accuracy of flash glucose 
monitoring and continuous glucose monitoring technologies: 
Implications for clinical practice. Diab Vasc Dis Res 2018;15(3):175-84. 
doi: 10.1177/1479164118756240 [published Online First: 2018/02/16] 
87. Danne T, Nimri R, Battelino T, et al. International Consensus on Use of 
Continuous Glucose Monitoring. Diabetes Care 2017;40(12):1631-40. 
doi: 10.2337/dc17-1600 [published Online First: 2017/11/23] 
88. Kovatchev BP, Patek SD, Ortiz EA, et al. Assessing sensor accuracy for non-
adjunct use of continuous glucose monitoring. Diabetes technology & 
therapeutics 2015;17(3):177-86. doi: 10.1089/dia.2014.0272 [published 
Online First: 2014/12/02] 
89. Association AD. Role of Continuous Glucose Monitoring in Diabetes 
Treatment 2018 [Available from: 
  253 
https://professional.diabetes.org/sites/professional.diabetes.org/files/
media/final_ada-abbott_cgm_compendium_final.pdf accessed 5 
November 2019. 
90. Freckmann G, Pleus S, Link M, et al. Accuracy Evaluation of Four Blood 
Glucose Monitoring Systems in Unaltered Blood Samples in the Low 
Glycemic Range and Blood Samples in the Concentration Range Defined 
by ISO 15197. Diabetes technology & therapeutics 2015;17(9):625-34. 
doi: 10.1089/dia.2015.0043 [published Online First: 2015/06/11] 
91. Wadwa RP, Laffel LM, Shah VN, et al. Accuracy of a Factory-Calibrated, Real-
Time Continuous Glucose Monitoring System During 10 Days of Use in 
Youth and Adults with Diabetes. Diabetes technology & therapeutics 
2018;20(6):395-402. doi: 10.1089/dia.2018.0150 [published Online First: 
2018/06/15] 
92. Dexcom. Dexcom G6 School Nurse Guide  [Available from: 
https://www.uclh.nhs.uk/OurServices/ServiceA-
Z/CYPS/PDIAB/Documents/Dexcom%20G6%20School%20Guide.pdf 
accessed 5 November 2019. 
93. Bergenstal RM, Tamborlane WV, Ahmann A, et al. Effectiveness of sensor-
augmented insulin-pump therapy in type 1 diabetes. N Engl J Med 
2010;363(4):311-20. doi: 10.1056/NEJMoa1002853 [published Online 
First: 2010/07/01] 
94. Forlenza GP, Ekhlaspour L, Breton M, et al. Successful At-Home Use of the 
Tandem Control-IQ Artificial Pancreas System in Young Children During a 
Randomized Controlled Trial. Diabetes technology & therapeutics 
2019;21(4):159-69. doi: 10.1089/dia.2019.0011 [published Online First: 
2019/03/20] 
95. Argento NB, Nakamura K. PERSONAL REAL-TIME CONTINUOUS GLUCOSE 
MONITORING IN PATIENTS 65 YEARS AND OLDER. Endocrine Practice 
2014;20(12):1297-302. doi: 10.4158/ep14017.or 
96. DuBose SN, Weinstock RS, Beck RW, et al. Hypoglycemia in Older Adults 
with Type 1 Diabetes. Diabetes technology & therapeutics 
2016;18(12):765-71. doi: 10.1089/dia.2016.0268 [published Online First: 
2016/12/21] 
97. Ishikawa T, Koshizaka M, Maezawa Y, et al. Continuous glucose monitoring 
reveals hypoglycemia risk in elderly patients with type 2 diabetes 
mellitus. Journal of diabetes investigation 2017 doi: 10.1111/jdi.12676 
[published Online First: 2017/04/12] 
98. Litchman ML, Allen NA. Real-Time Continuous Glucose Monitoring 
Facilitates Feelings of Safety in Older Adults With Type 1 Diabetes: A 
Qualitative Study. J Diabetes Sci Technol 2017:1932296817702657. doi: 
10.1177/1932296817702657 [published Online First: 2017/04/06] 
99. Pistrosch F, Ganz X, Bornstein SR, et al. Risk of and risk factors for 
hypoglycemia and associated arrhythmias in patients with type 2 
diabetes and cardiovascular disease: a cohort study under real-world 
conditions. Acta Diabetol 2015;52(5):889-95. doi: 
https://dx.doi.org/10.1007/s00592-015-0727-y 
  254 
100. Polonsky WH, Peters AL, Hessler D. The Impact of Real-Time Continuous 
Glucose Monitoring in Patients 65 Years and Older. J Diabetes Sci 
Technol 2016;10(4):892-7. doi: 10.1177/1932296816643542 [published 
Online First: 2016/03/30] 
101. Ruedy KJ, Parkin CG, Riddlesworth TD, et al. Continuous Glucose 
Monitoring in Older Adults With Type 1 and Type 2 Diabetes Using 
Multiple Daily Injections of Insulin: Results From the DIAMOND Trial. J 
Diabetes Sci Technol 2017:1932296817704445. doi: 
10.1177/1932296817704445 [published Online First: 2017/04/30] 
102. Peters LL, Boter H, Buskens E, et al. Measurement properties of the 
Groningen Frailty Indicator in home-dwelling and institutionalized 
elderly people. J Am Med Dir Assoc 2012;13(6):546-51. doi: 
10.1016/j.jamda.2012.04.007 [published Online First: 2012/05/15] 
103. Beck RW, Riddlesworth T, Ruedy K, et al. Effect of Continuous Glucose 
Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using 
Insulin Injections: The DIAMOND Randomized Clinical Trial. Jama 
2017;317(4):371-78. doi: 10.1001/jama.2016.19975 
104. Soma Y, Oka R, Fujii S, et al. [The status of glycemic control and 
hypoglycemia in elderly patients visiting the outpatient department 
specializing in diabetes]. Nihon Ronen Igakkai Zasshi 2018;55(2):268-75. 
doi: 10.3143/geriatrics.55.268 [published Online First: 2018/05/22] 
105. Carlson AL KL, Miller K et al. Exposure to Hypoglycemia in Older Adults 
with Type 1 Diabetes: Baseline Characteristics Using Continuous Glucose 
Monitoring Data. Endo 2019. New Orleans, LA, 2019. 
106. Balijepalli C, Druyts E, Siliman G, et al. Hypoglycemia: a review of 
definitions used in clinical trials evaluating antihyperglycemic drugs for 
diabetes. Clin Epidemiol 2017;9:291-96. doi: 10.2147/CLEP.S129268 
107. Jackson TA, Naqvi SH, Sheehan B. Screening for dementia in general 
hospital inpatients: a systematic review and meta-analysis of available 
instruments. Age Ageing 2013;42(6):689-95. doi: 10.1093/ageing/aft145 
[published Online First: 2013/10/09] 
108. Woodford HJ, George J. Cognitive assessment in the elderly: a review of 
clinical methods. QJM 2007;100(8):469-84. doi: 10.1093/qjmed/hcm051 
[published Online First: 2007/06/15] 
109. Wright LA-C, Hirsch IB. Metrics Beyond Hemoglobin A1C in Diabetes 
Management: Time in Range, Hypoglycemia, and Other Parameters. 
Diabetes technology & therapeutics 2017;19(S2):S16-S26. doi: 
10.1089/dia.2017.0029 [published Online First: 2017/05/01] 
110. Braun V, Clarke V. Using thematic analysis in psychology. Qualitative 
Research in Psychology 2006;3:77-101. 
111. Ritchie J, J L. Qualitative research practice : a guide for social science 
students and researchers. . London: Sage Publications 2003  
112. Neugroschl J, Sano M, Luo X, et al. Why They Stay: Understanding Research 
Participant Retention in Studies of Aging, Cognitive Impairment and 
Dementia. J Gerontol Geriatr Res 2014;3(4) doi: 10.4172/2167-
7182.1000170 [published Online First: 2014/12/19] 
  255 
113. Alitta Q, Grino M, Adjemout L, et al. Overestimation of Hypoglycemia 
Diagnosis by FreeStyle Libre Continuous Glucose Monitoring in Long-
Term Care Home Residents With Diabetes. J Diabetes Sci Technol 
2018;12(3):727-28. doi: 10.1177/1932296817747887 [published Online 
First: 2017/12/19] 
114. Harsch IA, Kaestner RH, Konturek PC. Hypoglycemic side effects of 
sulfonylureas and repaglinide in ageing patients - knowledge and self-
management. J Physiol Pharmacol 2018;69(4) doi: 
10.26402/jpp.2018.4.15 
115. Hambling CE, Seidu SI, Davies MJ, et al. Older people with Type 2 diabetes, 
including those with chronic kidney disease or dementia, are commonly 
overtreated with sulfonylurea or insulin therapies. Diabetic medicine : a 
journal of the British Diabetic Association 2017;34(9):1219-27. doi: 
10.1111/dme.13380 
116. Hernan MA, Robins JM. Using Big Data to Emulate a Target Trial When a 
Randomized Trial Is Not Available. Am J Epidemiol 2016;183(8):758-64. 
doi: 10.1093/aje/kwv254 [published Online First: 2016/03/20] 
117. Herrett E, Gallagher AM, Bhaskaran K, et al. Data Resource Profile: Clinical 
Practice Research Datalink (CPRD). Int J Epidemiol 2015;44(3):827-36. 
doi: 10.1093/ije/dyv098 
118. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of 
Observational Studies in Epidemiology (STROBE) statement: guidelines 
for reporting observational studies. Lancet 2007;370(9596):1453-7. doi: 
10.1016/S0140-6736(07)61602-X 
119. Wang HK, Hung CM, Lin SH, et al. Increased risk of hip fractures in patients 
with dementia: a nationwide population-based study. BMC Neurol 
2014;14:175. doi: 10.1186/s12883-014-0175-2 
120. Brown A, Kirichek O, Balkwill A, et al. Comparison of dementia recorded in 
routinely collected hospital admission data in England with dementia 
recorded in primary care. Emerg Themes Epidemiol 2016;13:11. doi: 
10.1186/s12982-016-0053-z 
121. Wilkinson T, Ly A, Schnier C, et al. Identifying dementia cases with 
routinely collected health data: A systematic review. Alzheimers Dement 
2018;14(8):1038-51. doi: 10.1016/j.jalz.2018.02.016 
122. Khunti K, Davies M, Majeed A, et al. Hypoglycemia and risk of 
cardiovascular disease and all-cause mortality in insulin-treated people 
with type 1 and type 2 diabetes: a cohort study. Diabetes Care 
2015;38(2):316-22. doi: 10.2337/dc14-0920 
123. Harvey RDJ, D.; Mosley, D.; UnitedHealthcare®. Random assignment of 
proxy event dates to unexposed individuals in observational studies: An 
automated technique using SAS®. Midwest SAS Users Group. 
Minneapolis, 2012. 
124. Hippisley-Cox J, Coupland C. Diabetes treatments and risk of heart failure, 
cardiovascular disease, and all cause mortality: cohort study in primary 
care. BMJ 2016;354:i3477. doi: 10.1136/bmj.i3477 
125. Driessen JH, Henry RM, van Onzenoort HA, et al. Bone fracture risk is not 
associated with the use of glucagon-like peptide-1 receptor agonists: a 
  256 
population-based cohort analysis. Calcif Tissue Int 2015;97(2):104-12. 
doi: 10.1007/s00223-015-9993-5 
126. Mathur R, Bhaskaran K, Chaturvedi N, et al. Completeness and usability of 
ethnicity data in UK-based primary care and hospital databases. J Public 
Health (Oxf) 2014;36(4):684-92. doi: 10.1093/pubmed/fdt116 
127. George B, Seals S, Aban I. Survival analysis and regression models. J Nucl 
Cardiol 2014;21(4):686-94. doi: 10.1007/s12350-014-9908-2 [published 
Online First: 2014/05/09] 
128. Austin PC. Statistical power to detect violation of the proportional hazards 
assumption when using the Cox regression model. J Stat Comput Simul 
2018;88(3):533-52. doi: 10.1080/00949655.2017.1397151 [published 
Online First: 2018/01/13] 
129. Hughes RA, Heron J, Sterne JAC, et al. Accounting for missing data in 
statistical analyses: multiple imputation is not always the answer. Int J 
Epidemiol 2019 doi: 10.1093/ije/dyz032 [published Online First: 
2019/03/18] 
130. Bhaskaran K, Smeeth L. What is the difference between missing completely 
at random and missing at random? Int J Epidemiol 2014;43(4):1336-9. 
doi: 10.1093/ije/dyu080 [published Online First: 2014/04/08] 
131. Fitzpatrick C, Chatterjee S, Seidu S, et al. Association of hypoglycaemia and 
risk of cardiac arrhythmia in patients with diabetes mellitus: A 
systematic review and meta-analysis. Diabetes Obes Metab 
2018;20(9):2169-78. doi: 10.1111/dom.13348 
132. Alexander KP, Newby LK, Cannon CP, et al. Acute coronary care in the 
elderly, part I: Non-ST-segment-elevation acute coronary syndromes: a 
scientific statement for healthcare professionals from the American 
Heart Association Council on Clinical Cardiology: in collaboration with 
the Society of Geriatric Cardiology. Circulation 2007;115(19):2549-69. 
doi: 10.1161/CIRCULATIONAHA.107.182615 
133. Alexander KP, Newby LK, Armstrong PW, et al. Acute coronary care in the 
elderly, part II: ST-segment-elevation myocardial infarction: a scientific 
statement for healthcare professionals from the American Heart 
Association Council on Clinical Cardiology: in collaboration with the 
Society of Geriatric Cardiology. Circulation 2007;115(19):2570-89. doi: 
10.1161/CIRCULATIONAHA.107.182616 
134. Brunnstrom HR, Englund EM. Cause of death in patients with dementia 
disorders. Eur J Neurol 2009;16(4):488-92. doi: 10.1111/j.1468-
1331.2008.02503.x 
135. Magaki S, Yong WH, Khanlou N, et al. Comorbidity in dementia: update of 
an ongoing autopsy study. J Am Geriatr Soc 2014;62(9):1722-8. doi: 
10.1111/jgs.12977 
136. Heller SR, Bergenstal RM, White WB, et al. Relationship of glycated 
haemoglobin and reported hypoglycaemia to cardiovascular outcomes 
in patients with type 2 diabetes and recent acute coronary syndrome 
events: The EXAMINE trial. Diabetes, obesity & metabolism 
2017;19(5):664-71. doi: 10.1111/dom.12871 [published Online First: 
2017/02/27] 
  257 
137. Bonds DE, Miller ME, Bergenstal RM, et al. The association between 
symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: 
retrospective epidemiological analysis of the ACCORD study. BMJ 
2010;340:b4909. doi: 10.1136/bmj.b4909 [published Online First: 
2010/01/12] 
138. Zhong VW, Juhaeri J, Cole SR, et al. HbA1C variability and hypoglycemia 
hospitalization in adults with type 1 and type 2 diabetes: A nested case-
control study. J Diabetes Complications 2018;32(2):203-09. doi: 
10.1016/j.jdiacomp.2017.10.008 
139. The Cochrane Collaboration. Cochrane Handbook for Systematic Reviews 
of Interventions. London: Cochrane 2019. 
140. Bedenis R, Price AH, Robertson CM, et al. Association between severe 
hypoglycemia, adverse macrovascular events, and inflammation in the 
Edinburgh Type 2 Diabetes Study. Diabetes Care 2014;37(12):3301-8. 
doi: 10.2337/dc14-0908 [published Online First: 2014/09/23] 
141. Cha SA, Yun JS, Lim TS, et al. Severe Hypoglycemia and Cardiovascular or 
All-Cause Mortality in Patients with Type 2 Diabetes. Diabetes Metab J 
2016;40(3):202-10. doi: 10.4093/dmj.2016.40.3.202 [published Online 
First: 2016/04/22] 
142. Chiba Y, Kimbara Y, Kodera R, et al. Risk factors associated with falls in 
elderly patients with type 2 diabetes. J Diabetes Complications 
2015;29(7):898-902. doi: 10.1016/j.jdiacomp.2015.05.016 
143. Chin SO, Rhee SY, Chon S, et al. Hypoglycemia is associated with dementia 
in elderly patients with type 2 diabetes mellitus: An analysis based on 
the Korea National Diabetes Program Cohort. Diabetes Res Clin Pract 
2016;122:54-61. doi: 10.1016/j.diabres.2016.09.027 [published Online 
First: 2016/11/05] 
144. Cukierman-Yaffe T, Bosch J, Jung H, et al. Hypoglycemia and Incident 
Cognitive Dysfunction: A Post Hoc Analysis From the ORIGIN Trial. 
Diabetes Care 2019;42(1):142-47. doi: 10.2337/dc18-0690 [published 
Online First: 2018/11/15] 
145. Davis SN, Duckworth W, Emanuele N, et al. Effects of Severe Hypoglycemia 
on Cardiovascular Outcomes and Death in the Veterans Affairs Diabetes 
Trial. Diabetes Care 2019;42(1):157-63. doi: 10.2337/dc18-1144 
[published Online First: 2018/11/21] 
146. Duckworth WC, Abraira C, Moritz TE, et al. The duration of diabetes affects 
the response to intensive glucose control in type 2 subjects: the VA 
Diabetes Trial. J Diabetes Complications 2011;25(6):355-61. doi: 
10.1016/j.jdiacomp.2011.10.003 
147. Escalada J, Liao L, Pan C, et al. Outcomes and healthcare resource 
utilization associated with medically attended hypoglycemia in older 
patients with type 2 diabetes initiating basal insulin in a US managed 
care setting. Curr Med Res Opin 2016;32(9):1557-65. doi: 
10.1080/03007995.2016.1189893 [published Online First: 2016/05/14] 
148. Freemantle N, Danchin N, Calvi-Gries F, et al. Relationship of glycaemic 
control and hypoglycaemic episodes to 4-year cardiovascular outcomes 
in people with type 2 diabetes starting insulin. Diabetes Obes Metab 
  258 
2016;18(2):152-8. doi: 10.1111/dom.12598 [published Online First: 
2015/10/30] 
149. Goto A, Goto M, Terauchi Y, et al. Association Between Severe 
Hypoglycemia and Cardiovascular Disease Risk in Japanese Patients With 
Type 2 Diabetes. J Am Heart Assoc 2016;5(3):e002875. doi: 
10.1161/JAHA.115.002875 [published Online First: 2016/03/11] 
150. Haroon NN, Austin PC, Shah BR, et al. Risk of Dementia in Seniors With 
Newly Diagnosed Diabetes: A Population-Based Study. Diabetes Care 
2015 doi: 10.2337/dc15-0491 [published Online First: 2015/07/29] 
151. Heller SR, Bergenstal RM, White WB, et al. Relationship of glycated 
haemoglobin and reported hypoglycaemia to cardiovascular outcomes 
in patients with type 2 diabetes and recent acute coronary syndrome 
events: The EXAMINE trial. Diabetes Obes Metab 2017;19(5):664-71. 
doi: 10.1111/dom.12871 [published Online First: 2017/01/07] 
152. Hsu PF, Sung SH, Cheng HM, et al. Association of clinical symptomatic 
hypoglycemia with cardiovascular events and total mortality in type 2 
diabetes: a nationwide population-based study. Diabetes Care 
2013;36(4):894-900. doi: 10.2337/dc12-0916 [published Online First: 
2012/12/12] 
153. Johnston SS, Conner C, Aagren M, et al. Association between 
hypoglycaemic events and fall-related fractures in Medicare-covered 
patients with type 2 diabetes. Diabetes Obes Metab 2012;14(7):634-43. 
doi: 10.1111/j.1463-1326.2012.01583.x 
154. Johnston SS, Conner C, Aagren M, et al. Evidence linking hypoglycemic 
events to an increased risk of acute cardiovascular events in patients 
with type 2 diabetes. Diabetes Care 2011;34(5):1164-70. doi: 
10.2337/dc10-1915 [published Online First: 2011/03/23] 
155. Kachroo S, Kawabata H, Colilla S, et al. Association between hypoglycemia 
and fall-related events in type 2 diabetes mellitus: analysis of a u.s. 
Commercial database. Journal of managed care & specialty pharmacy 
2015;21(3):243-53. [published Online First: 2015/03/03] 
156. Kong AP, Yang X, Luk A, et al. Hypoglycaemia, chronic kidney disease and 
death in type 2 diabetes: the Hong Kong diabetes registry. BMC Endocr 
Disord 2014;14:48. doi: 10.1186/1472-6823-14-48 [published Online 
First: 2014/06/15] 
157. Leong A, Berkowitz SA, Triant VA, et al. Hypoglycemia in Diabetes Mellitus 
as a Coronary Artery Disease Risk Factor in Patients at Elevated Vascular 
Risk. J Clin Endocrinol Metab 2016;101(2):659-68. doi: 10.1210/jc.2015-
3169 [published Online First: 2015/12/18] 
158. Lu CL, Hsu PC, Shen HN, et al. Association Between History of Severe 
Hypoglycemia and Risk of Falls in Younger and Older Patients With 
Diabetes. Medicine (Baltimore) 2015;94(33):e1339. doi: 
10.1097/MD.0000000000001339 [published Online First: 2015/08/20] 
159. Majumdar SR, Hemmelgarn BR, Lin M, et al. Hypoglycemia associated with 
hospitalization and adverse events in older people : Population-based 
cohort study. Diabetes Care 2013;36(11):3585-90. doi: 
http://dx.doi.org/10.2337/dc13-0523 
  259 
160. Mattishent K, Richardson K, Dhatariya K, et al. The effects of hypoglycemia 
and dementia on cardiovascular events, falls and fractures and all-cause 
mortality in older people - a retrospective cohort study. Diabetes Obes 
Metab 2019 doi: 10.1111/dom.13769 [published Online First: 
2019/05/10] 
161. McCoy RG, Van Houten HK, Ziegenfuss JY, et al. Increased mortality of 
patients with diabetes reporting severe hypoglycemia. Diabetes Care 
2012;35(9):1897-901. doi: 10.2337/dc11-2054 
162. Mehta HB, Mehta V, Goodwin JS. Association of Hypoglycemia With 
Subsequent Dementia in Older Patients With Type 2 Diabetes Mellitus. J 
Gerontol A Biol Sci Med Sci 2017;72(8):1110-16. doi: 
10.1093/gerona/glw217 [published Online First: 2016/10/28] 
163. Ntouva A, Toulis KA, Keerthy D, et al. Hypoglycaemia is associated with 
increased risk of fractures in patients with type 2 diabetes mellitus: a 
cohort study. Eur J Endocrinol 2019;180(1):51-58. doi: 10.1530/EJE-18-
0458 [published Online First: 2018/11/08] 
164. Origin Trial Investigators, Mellbin LG, Ryden L, et al. Does hypoglycaemia 
increase the risk of cardiovascular events? A report from the ORIGIN 
trial. Eur Heart J 2013;34(40):3137-44. doi: 10.1093/eurheartj/eht332 
165. Pieber TR, Marso SP, McGuire DK, et al. DEVOTE 3: temporal relationships 
between severe hypoglycaemia, cardiovascular outcomes and mortality. 
Diabetologia 2018;61(1):58-65. doi: 10.1007/s00125-017-4422-0 
[published Online First: 2017/09/16] 
166. Rajpathak SN, Fu C, Brodovicz KG, et al. Sulfonylurea use and risk of hip 
fractures among elderly men and women with type 2 diabetes. Drugs 
Aging 2015;32(4):321-7. doi: 10.1007/s40266-015-0254-0 [published 
Online First: 2015/04/01] 
167. Rathmann W, Kostev K, Gruenberger JB, et al. Treatment persistence, 
hypoglycaemia and clinical outcomes in type 2 diabetes patients with 
dipeptidyl peptidase-4 inhibitors and sulphonylureas: a primary care 
database analysis. Diabetes Obes Metab 2013;15(1):55-61. doi: 
10.1111/j.1463-1326.2012.01674.x 
168. Signorovitch JE, Macaulay D, Diener M, et al. Hypoglycaemia and accident 
risk in people with type 2 diabetes mellitus treated with non-insulin 
antidiabetes drugs. Diabetes Obes Metab 2013;15(4):335-41. doi: 
10.1111/dom.12031 
169. Standl E, Stevens SR, Armstrong PW, et al. Increased Risk of Severe 
Hypoglycemic Events Before and After Cardiovascular Outcomes in 
TECOS Suggests an At-Risk Type 2 Diabetes Frail Patient Phenotype. 
Diabetes Care 2018;41(3):596-603. doi: 10.2337/dc17-1778 [published 
Online First: 2018/01/10] 
170. Yaffe K, Falvey CM, Hamilton N, et al. Association between hypoglycemia 
and dementia in a biracial cohort of older adults with diabetes mellitus. 
JAMA Intern Med 2013;173(14):1300-6. doi: 
10.1001/jamainternmed.2013.6176 [published Online First: 2013/06/12] 
171. Zhao Y, Campbell CR, Fonseca V, et al. Impact of hypoglycemia associated 
with antihyperglycemic medications on vascular risks in veterans with 
  260 
type 2 diabetes. Diabetes Care 2012;35(5):1126-32. doi: 10.2337/dc11-
2048 [published Online First: 2012/03/21] 
172. Zhao Y, Kachroo S, Kawabata H, et al. Association between Hypoglycemia 
and Fall-Related Fractures and Health Care Utilization in Older Veterans 
with Type 2 Diabetes. Endocr Pract 2015 doi: 10.4158/EP15640.OR 
173. Zinman B, Marso SP, Christiansen E, et al. Hypoglycemia, Cardiovascular 
Outcomes, and Death: The LEADER Experience. Diabetes Care 
2018;41(8):1783-91. doi: 10.2337/dc17-2677 [published Online First: 
2018/06/16] 
174. Zoungas S, Patel A, Chalmers J, et al. Severe hypoglycemia and risks of 
vascular events and death. N Engl J Med 2010;363(15):1410-8. doi: 
10.1056/NEJMoa1003795 
175. Goto A, Arah OA, Goto M, et al. Severe hypoglycaemia and cardiovascular 
disease: systematic review and meta-analysis with bias analysis. BMJ 
2013;347:f4533. doi: 10.1136/bmj.f4533 [published Online First: 
2013/08/01] 
176. Ahammed A, Pathan F, Afsana F, et al. The Burden of Severe Hypoglycemia 
on Quality of Life among Diabetes Mellitus Patients in a Tertiary Level 
Hospital of Bangladesh. Indian J Endocrinol Metab 2018;22(4):499-504. 
doi: 10.4103/ijem.IJEM_338_17 [published Online First: 2018/08/28] 
177. de Groot S, Enters-Weijnen CF, Geelhoed-Duijvestijn PH, et al. A cost of 
illness study of hypoglycaemic events in insulin-treated diabetes in the 
Netherlands. BMJ open 2018;8(3):e019864. doi: 10.1136/bmjopen-
2017-019864 [published Online First: 2018/03/28] 
178. Barranco RJ, Gomez-Peralta F, Abreu C, et al. Incidence and care-related 
costs of severe hypoglycaemia requiring emergency treatment in 
Andalusia (Spain): the PAUEPAD project. Diabetic medicine : a journal of 
the British Diabetic Association 2015;32(11):1520-6. doi: 
10.1111/dme.12843 [published Online First: 2015/06/30] 
179. Alemayehu B, Liu J, Rajpathak S, et al. Healthcare resource use and 
associated costs of hypoglycemia in patients with type 2 diabetes 
prescribed sulfonylureas. J Diabetes Complications 2017;31(11):1620-23. 
doi: 10.1016/j.jdiacomp.2017.07.012 [published Online First: 
2017/08/29] 
180. Sampson M, Bailey M, Clark J, et al. A new integrated care pathway for 
ambulance attended severe hypoglycaemia in the East of England: The 
Eastern Academic Health Science Network (EAHSN) model. Diabetes Res 
Clin Pract 2017;133:50-59. doi: 10.1016/j.diabres.2017.08.017 
[published Online First: 2017/09/12] 
181. Wighton K. £20m centre to enable people with dementia to live in own 
homes for longer 2019 [Available from: 
https://www.imperial.ac.uk/news/190934/20m-centre-enable-people-
with-dementia/ accessed 16 July 2019. 
182. Seidu S, Kunutsor SK, Topsever P, et al. Deintensification in older patients 
with type 2 diabetes: A systematic review of approaches, rates and 
outcomes. Diabetes Obes Metab 2019 doi: 10.1111/dom.13724 
[published Online First: 2019/04/03] 
  261 
Appendix 1 Protocol: CGM in older patients: systematic review 
 
 
 
 
 
  262 
 
 
 
 
 
 
 
  263 
 
 
 
 
 
  264 
 
 
 
 
 
 
  265 
 
 
 
 
 
 
 
 
 
 
 
 
  266 
Appendix 2 Protocol: Feasibility study 
 
    
 
Feasibility and acceptability of monitoring ambulatory glucose 
profile in older patients living with memory problems and 
diabetes (EAGLE) 
Version Version 3.0 
Date March 2018 
Sponsor University of East Anglia 
 
Authorisation: Chief Investigator 
Name Dr Katharina Mattishent 
Role Chief Investigator 
 
Authorisation: Sponsor  
Name Sarah Green  
Role Project Officer  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  267 
1 Administrative information 268 
1.1 Compliance ................................................................................................. 268 
1.2 Sponsor ....................................................................................................... 268 
1.3 Structured trial summary ............................................................................. 269 
1.4  Roles and responsibilities ............................................................................ 271 
2 Flow Diagram 275 
3 Abbreviations 2760 
4 Introduction 278 
4.1 Background and Rationale ........................................................................... 278 
4.3 Trial Design ................................................................................................. 282 
5 Methods 283 
5.1 Site Selection .............................................................................................. 283 
5.2 Participants ................................................................................................. 283 
5.6 Outcomes.................................................................................................... 285 
5.8 Sample Size ................................................................................................. 287 
5.9 Recruitment and Retention .......................................................................... 287 
5.10 Data Collection, Management and Analysis .................................................. 288 
5.11 Data Monitoring .......................................................................................... 290 
6Ethics and Dissemination 294 
6.1 Research Ethics Approval ............................................................................. 294 
6.2 Protocol Amendments ................................................................................. 294 
6.3 Consent or Consultation .............................................................................. 294 
6.4 Confidentiality............................................................................................. 295 
6.5 Declaration of Interests ............................................................................... 295 
6.6 Indemnity ................................................................................................... 295 
6.7 Finance ....................................................................................................... 296 
6.8 Archiving ..................................................................................................... 296 
6.9 Access to Data .................................................................................................. 296 
6.10 Ancillary and Post-trial Care ......................................................................... 296 
6.11 Publication Policy ........................................................................................ 296 
7 Protocol Amendments 297 
 
 
 
 
 
  268 
 
1 Administrative information  
This document describes the Feasibility study: feasibility and acceptability of 
ambulatory glucose profile (AGP) in older patients with memory problems and 
diabetes, sponsored by the University of East Anglia.  
It provides information about procedures for entering participants into the trial, and 
provides sufficient detail to enable: an understanding of the background, rationale, 
objectives, trial population, the medical device, methods, statistical analyses, ethical 
considerations, dissemination plans and administration of the trial; replication of key 
aspects of trial methods and conduct. 
1.1 Compliance  
The trial will be conducted in compliance with the approved protocol, the Declaration 
of Helsinki (2008), the principles of Good Clinical Practice (GCP) as laid down by the 
Commission Directive 2005/28/EC with implementation in national legislation in the 
UK by Statutory Instrument 2004/1031 and subsequent amendments, the UK Data 
Protection Act, and the National Health Service (NHS) Research Governance 
Framework for Health and Social Care (RGF).  
1.2 Sponsor 
The University of East Anglia is the trial sponsor and has delegated responsibility for 
the overall management of the EAGLE study to the Chief Investigator. Queries 
relating to sponsorship of this trial should be addressed to the Chief Investigator, or 
via the trial team. 
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1.3 Structured trial summary 
 
Primary Registry and Trial 
Identifying Number 
TBC 
Date of Registration in 
Primary Registry 
TBC 
Secondary Identifying 
Numbers 
Funding reference number: Grant number 324 
(AS-CTF-16-001) 
IRAS reference number: 221757 
Source of Monetary or 
Material Support 
Clinician and Healthcare Professional Training 
Fellowship, Alzheimer’s Society 
Sponsor University of East Anglia 
Contact for Scientific Queries Dr Katharina Mattishent 
Norwich Medical School 
University of East Anglia 
Bob Champion Research and Education Building 
Norwich 
NR4 7TJ. 
e-mail: k.mattishent@uea.ac.uk  
Public Title EAGLE study 
Scientific Title Feasibility and acceptability of monitoring 
ambulatory glucose profile in older patients living 
with memory problems and diabetes 
Countries of Recruitment England 
Health Condition(s) or 
Problem(s) Studied 
Patients with memory problems and diabetes 
Intervention(s) Use of ambulatory glucose profile system (AGP – 
FreeStyle Libre Flash Glucose Monitoring System, 
Abbott) 
 
Key Inclusion and Exclusion 
Criteria 
Inclusion Criteria: Patients 65 years and older, Type 1 
or Type 2 Diabetes mellitus, on glucose-lowering 
medication, Abbreviated Mental Test (AMT) equal to 
or less than 8 or formal diagnosis of dementia. 
 
Exclusion criteria: treatment with metformin 
only, not willing to participate, terminal illness 
(less than one-year life expectancy), AMT>8.  
Evidence of bruising, bleeding, cellulitis and/or 
skin tears on the upper arms 
  
 
Study Type Feasibility study of a medical device 
Date of First Enrolment Anticipated 01/02/2018 
Target Sample Size 20 participants 
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Feasibility objectives  Estimate size of eligible patient population 
 Estimate recruitment and retention 
pattern of patients 
 Estimate proportion of captured blood 
glucose readings 
Feasibility Outcome(s) 1. Numbers of potentially eligible patients 
who meet the selection criteria 
2. Number of participants subsequently 
recruited into the study 
3. Extent of capture of blood glucose 
readings 
4. Attrition rate and reasons for withdrawal 
5. Adverse events      
 
 
Patient outcome measure This is a feasibility study, as such no primary 
outcome has been defined.  The following 
patient outcomes will be collected by means of a 
qualitative interview 
 Acceptability of ambulatory glucose 
profile system to patients 
 Acceptability of ambulatory glucose 
profile system to family and carers (both 
informal and formal) 
 Patient and carer experience 
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1.4  Roles and responsibilities 
These membership lists are correct at the time of writing; please see terms of 
reference documentation in the TMF for current lists. 
Protocol contributors 
Name Affiliation Role  
Professor Yoon Loke, 
Professor of 
Medicine and 
Pharmacology 
 
Norwich 
Medical School, 
UEA 
Initiated and developed the trial question 
and study development. 
Lead the writing of the protocol and 
funding application. 
Dr Katharina 
Mattishent, 
Alzheimer’s Society 
Doctoral Research 
Fellow 
Norwich 
Medical School, 
UEA 
Contributed significantly to the 
development of the trial question, and the 
drafting of the protocol. 
Dr Ketan Dhataryia, 
Consultant in 
Endocrinology and 
Diabetes 
Norfolk & 
Norwich 
University 
Hospital NHS 
Trust 
Contributions on the study design with 
emphasis on the clinical aspects of 
management of diabetes. 
Dr Sankalpa 
Neupane, Consultant 
in Endocrinology and 
Diabetes 
Norfolk & 
Norwich 
University 
Hospital NHS 
Trust 
Contributions on the study design with 
emphasis on the clinical aspects of 
management of diabetes. 
Professor Chris Fox, 
Professor of Clinical 
Psychiatry and 
Honorary Consultant 
Psychogeriatrician 
 
Norwich 
Medical School, 
UEA 
Contributions on the study design with 
emphasis on the clinical aspects of 
management of dementia. 
Professor John 
Potter, Professor of 
Ageing and Stroke 
Medicine 
 
Norfolk & 
Norwich 
University 
Hospital NHS 
Trust 
Contributions on the study design with 
emphasis on the clinical aspects of 
management of older people with 
multiple co-morbidities. 
Dr Helen May, 
Consultant 
Geriatrician 
 
Norfolk & 
Norwich 
University 
Hospital NHS 
Trust 
Contributions on the study design with 
emphasis on the clinical aspects of 
management of older people with 
multiple co-morbidities. 
Dr Charlotte Salter Social 
Gerontologist, 
Norwich 
Medical School, 
UEA 
Contributions on the study design with 
emphasis on the qualitative data 
collection 
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Dr George Savva Senior Lecturer 
Applied 
Statistics, School 
of Health 
Sciences, UEA 
Contributions on the study design with 
emphasis on the quantitative data 
collection 
Matthew Lariviere 
Dr Kathleen Lane 
Anthropologist 
of Health, 
Ageing & 
Technology, 
Senior Research 
Associate, 
School of Health 
Sciences, UEA 
Contributions on the study design with 
emphasis on the qualitative data 
collection 
 
Role of trial sponsor and funders 
Name Affiliation Role  
Trial sponsor   University of 
East Anglia 
Approval of: trial design, data collection 
methods, conduct and monitoring with 
ultimate authority over these.  
Funder Alzheimer’s 
Society 
Approval of: trial design, data collection 
methods, conduct, monitoring and analysis 
with ultimate authority over these the 
responsibility of the sponsor.  
Trial Team 
Name Affiliation Role and responsibilities 
Dr Katharina 
Mattishent, 
Alzheimer’s Society 
Doctoral Research 
Fellow 
Norwich 
Medical 
School 
Chief investigator with responsibility for the: 
conduct, data analysis, interpretation and 
reporting. Recruitment of participants. 
Professor Yoon 
Loke, 
Professor of 
Medicine and 
Pharmacology 
 
Norwich 
Medical 
School 
Co-Chief investigator with overall 
responsibility for the: design, conduct, 
monitoring, analysis, interpretation and 
reporting of the trial. Recruitment of 
participants. 
Dr Ketan Dhataryia, 
Consultant in 
Endocrinology and 
Diabetes 
Norfolk & 
Norwich 
University 
Hospital NHS 
Trust 
Clinical advisor on management of patients in 
the trial.  
Dr Sankalpa 
Neupane, Locum 
Consultant in 
Endocrinology and 
Diabetes 
Norfolk & 
Norwich 
University 
Hospital NHS 
Trust 
Clinical advisor on management of patients in 
the trial. Recruitment of participants. 
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Dr Helen May, 
Consultant 
Geriatrician 
 
Norfolk & 
Norwich 
University 
Hospital NHS 
Trust 
Clinical advisor on management of patients in 
the trial. Recruitment of participants. 
Dr Charlotte Salter Norwich 
Medical 
School, UEA 
Advisor on the study design with emphasis on 
the qualitative data collection. 
Dr George Savva Senior 
Lecturer 
Applied 
Statistics, 
School of 
Health 
Sciences, UEA 
Study Statistician 
Trial Steering Committee 
Name Affiliation Role and responsibilities 
Dr Chris Atkins, 
NIHR Doctoral 
Research Fellow 
Norwich 
Medical 
School 
Independent Chair Person 
Professor Yoon 
Loke, 
Professor of 
Medicine and 
Pharmacology 
 
Norwich 
Medical 
School 
Co-chief research investigator with overall 
responsibility for the: development, conduct, 
progress, administration and monitoring of the 
work in all centres, plus analysis and production 
of the final manuscript.  
Dr Katharina 
Mattishent, 
Alzheimer’s Society 
Doctoral Research 
Fellow 
Norwich 
Medical 
School 
Chief investigator with responsibility, with the 
trial manager, for the management of the trial 
including: conduct and progress, responding to 
clinical inquiries, data analysis and 
interpretation and production of the final 
manuscript. 
Dr Helen May, 
Consultant 
Geriatrician 
 
Norfolk & 
Norwich 
University 
Hospital NHS 
Trust 
Clinical advisor on management of patients in 
the trial, particularly in relation to older people 
with multiple co-morbidities 
Dr Ketan Dhataryia, 
Consultant in 
Endocrinology and 
Diabetes 
Norfolk & 
Norwich 
University 
Hospital NHS 
Trust 
A clinical advisor on aspects of management of 
participants in the trial particularly relation to 
the management of diabetes and 
hypoglycaemia  
Paul Miliac Alzheimer’s 
Society 
Patient Representative 
Dick Abbott Alzheimer’s 
Society 
Patient Representative 
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Sarah Green University of 
East Anglia 
Sponsor Representative 
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2 Flow Diagram 
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3 Abbreviations 
AGP Ambulatory glucose profile 
AMT Abbreviated Mental Test  
AR  Adverse reaction 
CA Consultee agreement 
CI Chief Investigator 
CIS Consultee Information Sheet 
CRF Case Report Form 
CRO  Contract Research Organisation 
CT Clinical Trials 
CTA Clinical Trials Authorisation 
CTCAE Common Terminology Criteria for Adverse Events 
CTRG Clinical Trials and Research Governance 
EAGLE 
Feasibility and acceptability of ambulatory 
glucose profile in older patients living with 
memory problems and diabetes. 
GCP Good Clinical Practice 
GP General Practitioner 
HRA Health Research Authority 
ICF Informed Consent Form 
IRAS Integrated Research Application System 
NHS National Health Service 
NMS Norwich Medical School 
NNUH Norfolk and Norwich University Hospital 
NRES National Research Ethics Service  
PI Principal Investigator 
PIS Participant/ Patient Information Sheet 
R&D NHS Trust R&D Department 
RCT Randomised Controlled Trial 
REC Research Ethics Committee 
SAE Serious Adverse Event 
SAR Serious Adverse Reaction 
SC Safety Committee 
SOP Standard Operating Procedure 
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SSAR Suspected Serious Adverse Reaction 
SUSAR Suspected Unexpected Serious Adverse Reactions 
TMF Trial Master File 
TSC Trial Steering Committee 
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4 Introduction 
4.1 Background and Rationale 
Older patients living with memory problems and diabetes face a specific burden due 
to the high cognitive load in self-management of diabetes, resulting in substantially 
increased risks of low blood sugars (hypoglycaemia) from decreased food intake or 
inability to adjust drug doses. Patients and carers have to recognize and respond to 
acute, dangerous changes in blood sugar (e.g. hypoglycaemia) necessitating urgent 
treatment, but this is difficult because patients with memory problems may not be 
able to relay how unwell they feel.  
Harm from hypoglycaemia is a rapidly growing problem for health services. Older 
people have a 10-fold increased risk of hypoglycaemic episodes needing hospital 
admission (1) (2), whereas East Midlands Ambulance Trust had 523 call outs for 
severe hypoglycaemia (mainly in older people) over a 3-month period, with projected 
costs > £235,000 per year (3). Severe hypoglycaemia has serious health 
consequences, but even mild episodes can cause significant distress and disruption 
to quality of life and daily activities.  
Mattishent et al have identified the potentially enormous impact of hypoglycaemia 
on patients with memory problems and diabetes and their carers.  Their systematic 
review and meta-analysis of 12 studies and 1.4 million participants revealed 
significantly greater likelihood of hypoglycaemia in patients with impaired cognition 
(pooled odds ratio (OR) 1.61 (95% Confidence Interval (CI) 1.25, 2.06)) compared to 
those without.  In addition, those affected by hypoglycaemia were more susceptible 
to worsening cognitive impairment and dementia (OR 1.68; 95% CI 1.45, 1.95), 
leading to a potentially vicious cycle of decline. (4) 
The National Institute of Health Research has also funded a realist (literature) 
synthesis on theories, frameworks, and processes of care for patients with diabetes 
and memory problems. The American Geriatric Society has called for more research 
“to better understand the risks and benefits of tighter glycaemic control among older 
patients and those with comorbidities” because “clinicians often do not differentiate 
treatments for older patients who differ widely in health status. (5)   
Management of comorbid diabetes in people with memory problems is challenging, 
because the extent of harm from hypoglycaemia, and the best way to monitor blood 
glucose in this population is not known. The development of continuous glucose 
monitoring (CGM) has paved the way to better understanding individuals’ glycaemic 
profiles.  A study of CGM technology in 40 older adults (mean age 75 years, no 
dementia) picked up 102 hypoglycaemic events over a 3-day period, whereas 
conventional monitoring failed to detect 95/102 (93%) of these hypoglycaemic 
events. (6) 
A more recent study employed CGM in 23 well-controlled older patients (mean age 
76 years) with Type 2 diabetes mellitus and monitored them for a median period of 
97 hours.  Subsequent analysis found that five patients had a total of 15 
hypoglycaemic events with a glucose level <3.0mmol/L recorded with the CGM 
device (the cut-off for a hypoglycaemic episode is <4mmol/L).  Eight patients 
experienced a total of 25 events with a glucose level <3.5mmol/L.  None of these 
patients reported experiencing symptoms of hypoglycaemia. (7)  This study shows 
that asymptomatic hypoglycaemic episodes (which might otherwise go unnoticed 
unless CGM was performed) are an issue in older people. 
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Ishikawa et al published the findings of their study in April 2017, in which CGM 
technology was used to analyse the relationship between low blood sugars and 
diabetes treatment in older patients (>65 years) with Type 2 diabetes.  They 
concluded that patients aged 65 and older with Type 2 diabetes had a higher risk of 
low blood sugars if they had higher blood sugar variability and lower average glucose 
levels(8) . 
Noteably, neither of these recent studies explored CGM’s value in patients with 
memory problems and diabetes.  The technology is under-researched in this 
vulnerable group. 
More recently, flash glucose monitoring has been introduced, which obtains 
ambulatory glucose profiles (AGP) as a novel method of analysing glycaemic profiles.  
The device enables patients and healthcare professionals to retrospectively look at 
data collected over a two-week period.  It stores glucose readings every 15 minutes 
over the last eight hours (for a complete picture, the sensor should be scanned 
approximately three times a day).  It is possible to download all the glucose readings 
via free software.  The downloaded report enables identification of patterns in the 
glucose levels and when they are occurring. 
The main advantages of the flash glucose monitoring system compared to standard 
CGM are: 
 Cost: Flash glucose monitors are significantly cheaper than CGM systems (see 
below section 4.1.2). 
 AGP systems do not require finger-prick testing for calibration, whereas CGM 
systems do. 
 The sensor for the AGP system lasts for 14 days.  Standard CGM sensors last 
for a maximum of seven days (there has been a development of a recently 
approved implantable sensor (Eversense), which lasts for up to 90 days, but 
still requires finger-prick testing for calibration)(9). 
Studies have already evaluated and guidelines produced for the use of flash glucose 
monitoring with adults and children (10).  A consensus group of diabetes specialists 
within Europe agreed that AGP is an effective standard for analysing glucose data in 
diabetes management and can assist people (or their carers) with diabetes 
understand daily life with their conditions (11). 
However, to date there are no studies looking at the feasibility of this device in adults 
with memory problems and diabetes. 
Technology can be liberating offering enhanced safety and freedom but can also 
leave people vulnerable, create increased expectation of services and be 
stigmatising (Kang et al., 2010). Whilst older people are known to be far from 
passive when it comes to using and adapting technology to suit their needs (12) 
there are some important issues in relation to personal health monitoring 
technologies (PHM) such as the AGP System. Research suggests PHM can lead to 
social isolation and over reliance on technology can give a false sense of safety 
especially where resources remain scarce (13).  A recent review of the literature 
found issues such as privacy, autonomy, visibility and impact on health providers 
were all highlighted as potential consequences of PHM (14).  
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It will therefore be important to try to understand the patients’ experiences as well 
the carers’ (both informal and paid). Interviews will cover personal experience of 
the AGP System and seek to understand longer-term issues regarding the value of 
using such devices in patients with diabetes and memory problems. Different 
personal situations and their contextual elements that affect the use of the APG 
System will be explored.  
This feasibility study of new technology for flash glucose will pave the way for further 
development and implementation of improved monitoring in this vulnerable group.  
This research will help develop strategies for better monitoring. 
Before a full RCT to assess efficacy of the use of the AGP system in patients with 
memory problems and diabetes can be conducted, important feasibility criteria 
need to be assessed to justify its development and inform its design and conduct, 
which include eligibility, recruitment, retention, successful capture of blood glucose 
readings and qualitative assessment of value and acceptability.   
Topics for discussion are likely (but not exclusively) to include: factors that have had 
an impact on the acceptability of the AGP System including design and usability; 
and, the impact of the device on daily life and routines including physical, 
emotional and social health; current and perceived practical, emotional and 
theoretical issues with wearing the device and the associated health monitoring. In 
addition, we will gather participants’ views on the quality and quantity of 
communication received concerning information, explanations and on-going and 
follow-up care needs; and, recommendations for inclusion in the design of future 
patient and carer-facing information and explanations. 
The feasibility criteria will determine whether a full RCT could be conducted, which 
would look at whether patients with memory problems and diabetes can correctly 
use the device and act on the results to potentially improve clinical outcomes and 
quality of life. 
4.1.1 Background to the fellowship  
This feasibility study forms part of an Alzheimer’s Society funded doctoral research 
fellowship, which commenced in January 2017.  The focus of the fellowship is to 
investigate hypoglycaemia and serious adverse events in older people living with 
memory problems and diabetes.   
The feasibility study is complementary to a pharmacoepidemiological (database) 
study that looks at the consequences of hypoglycaemia in patients with dementia 
and diabetes.  The results of both studies will provide a multi-faceted approach 
towards tackling the difficult challenges faced by patients with dementia and 
diabetes, and their carers.   
4.1.2 Explanation for choice of device  
The introduction of flash glucose monitoring using the factory-calibrated meter has 
emerged as a novel method to study glycaemic patterns.  The system that is 
currently publicly available for patients to purchase is the FreeStyle Libre Flash 
Glucose Monitoring System-Abbott. The website also provides video tutorials on 
the use of the system (https://www.freestylelibre.co.uk/libre/). 
The use of the flash glucose system provides AGP, giving graphic and quantitative 
information on 24-hour glucose patterns. This can enable patients, carers and 
clinicians to identify patterns in glycaemic control and when they are occurring. The 
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use of the AGP system has been evaluated and recommended both in adults and 
children aged 4-17. 
The system consists of a reader (although Android phones can download an app, 
which replaces the need for a reader) and a sensor (approximately the size of a £2 
coin): 
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The starter pack consists of the reader and two sensors (each sensor lasts for two 
weeks) and costs £159.95.  Each subsequent sensor costs £57.95.  Patients with 
diabetes ordering the products will be exempt from VAT.  Importantly, if a patient 
or carer owns an Android smartphone, it will not be necessary to purchase a 
reader, as they can download a free app instead. 
The flash glucose monitoring system does not require finger-prick testing for 
calibration (in contrast to CGM systems, which do require calibration via finger-
prick testing). 
This feasibility study has not received any sponsorship from Abbott.  The device 
received the CE mark for use in adults in 2014 and for children (4-17 years) in 2016. 
4.2 Objectives 
The objectives of this study are to assess if the use of AGP system is feasible and 
acceptable for older patients with memory problems and diabetes. 
 Participant eligibility: how many patients with memory problems and 
diabetes are potentially eligible? 
 Participant recruitment: how many patients are subsequently enrolled in the 
study? 
 Participant retention:  what proportion of participants will take part until the 
end of the study?  For withdrawals, what are the reasons? 
 How many hours of glucose data will successfully be recorded? 
 Do participants find the use of the AGP system acceptable? 
 Are there any adverse events related to wearing the sensor (for example pain 
or skin reactions)? 
 Are there any other adverse events, for instance, hospitalisation or events 
that require medical attention? 
The data from this feasibility study will help guide further plans for a RCT, including 
recruitments plans and power calculations. 
 
4.3 Trial Design 
This study is a single-centre medical device study to determine the feasibility and 
acceptability of the use of the AGP system in older patients with memory problems 
and diabetes.   
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We will invite and recruit patients aged 65 and over, whilst they are inpatients 
under the Older People’s Medicine Department, Acute Medicine Unit, or the 
Diabetes and Endocrinology Department.  The use of the AGP system will take place 
around one-month after discharge from the acute setting, to ensure that the 
participants have had a chance to fully recover from their hospital admission and 
are settled back into their usual routine at their usual place of residence.  We aim 
to recruit up to 20 participants.   
The AGP system will be given to the participants for up to two weeks.  At the first 
home visit, the researcher will fit the sensor and provide training on how to use the 
device.  The research team will contact the participants one week after the first 
home visit (telephone call) to check whether any questions have arisen and 
whether the participant is still happy to be part of the study.  At the end of the 
study period, participants and/or their carers will take part in an in-depth interview 
to explore the acceptability of the medical device. 
5 Methods 
5.1 Site Selection 
5.1.1 Study Setting  
Participants will be identified & recruited whilst an inpatient under the Older 
People’s Medicine and/or Acute Medicine Departments at the Norfolk and Norwich 
University Hospital Trust.  The trial itself will take place in the Community and AGP 
system will only be used post-discharge from the acute setting. 
5.2 Participants 
5.2.1 Eligibility Criteria 
The population of interest is older people (≥65 years old) with memory problems 
and diabetes. 
5.2.2 Participant Inclusion Criteria 
 Patients aged 65 and older 
 Type 1 or Type 2 diabetes mellitus 
 On glucose-lowering medication 
 Abbreviated Mini-Mental Test (AMT) score equal or less than 8 (out of 10) 
or already has formal diagnosis of dementia 
With regard to the use the AMT, this is part of standard clinical care at the NNUH 
where it has been implemented as a short screening test to identify memory 
problems in inpatients.  If a patient scores 8 or less out 10 on the AMT, this triggers 
an established Trust protocol called Memory Matters.  The result of the AMT is 
logged on the Trust’s reporting software (ICE) and automatic referrals to the 
Memory Matters Team and GP are triggered for further follow-up in the 
Community post-discharge.  The value of AMT in hospital settings was confirmed in 
a systematic review and meta-analysis on screening for dementia in general 
hospital inpatients, where AMT was reported as a reasonable tool with good 
discriminant ability AUC 0.88 (15). 
5.2.3 Participant Exclusion Criteria 
The participant may not enter the trial if any of the following apply: 
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 Treatment with Metformin only; 
 Not willing to participate; 
 Terminal illness (less than one-year life expectancy); 
 AMT above 8  
 Evidence of bruising, bleeding, cellulitis and/or skin tears on the upper arms 
 
5.2.4 Eligibility Criteria for Individuals Performing the Interventions 
The Co-chief investigator will provide hands on teaching to participants and/or their 
carers on the use of the AGP system, including how to fit the sensor.  She has met 
with the local Abbot representative who provided hands-on teaching.  In addition, 
there are freely available instruction videos available at 
http://www.freestylelibre.co.uk. 
 
5.3 Intervention 
This is a one-arm feasibility study on the acceptability of wearing the Freestyle Libre 
AGP system.  All participants will be issued with the AGP system.  The trial team will 
buy the readers and sensors from the Freestyle Libre website and provide the 
participants with all the necessary equipment. 
Participants will be shown how to wear the Freestyle Libre AGP system, which they 
will be asked to wear for up to two weeks (=the lifespan of one sensor).   This two-
week period will commence one month of discharge from the acute setting.  The 
period between discharge and starting to wear the AGP system is intended to give 
participants time to recover from their acute admission and settle back into their 
normal daily routines.  The blood glucose readings that are captured will, therefore, 
be a more realistic reflection of usual care (as opposed to capturing blood glucose 
readings whilst a participant is being treated or recovering from an acute illness). 
There will be no change in the standard care of the participants’ diabetes 
management.  
 In order to gain the most information about the acceptability of use of the AGP 
system, there will be no blinding of the blood glucose readings.  If participants 
and/or carers have any concerns about prolonged or recurrent blood glucose 
trends that indicate the patient is running significantly out of their individual target 
range, they can either contact their usual clinical team (e.g. GP or diabetes team) 
that provides their care, or alternatively alert the trial team (via a helpline) who will 
then assess the readings and make appropriate referrals. The trial team includes 
two Consultants in Diabetes who will be able to evaluate glucose patterns and 
make recommendations for any further care through usual channels. 
We will encourage participants (and/or caregivers) to keep a diary of events, when 
there were concerns about blood sugar readings and the clinical or research team 
was contacted. 
No adjustment to the diabetes medication should be made by the 
participants/carers, unless advised by a medical practitioner. 
The trial team will look at the data retrospectively (after the participant has worn 
the device for up to two weeks).  The readings that the Flash Glucose Monitor 
records are not real-time, as  the blood sugar readings are taken from the 
interstitial fluid (thin layer that surrounds the cells of the tissues below the skin), as 
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opposed to blood.  There is an approximate 10-minute delay in interstitial fluid 
glucose response to changes in blood glucose.  Nevertheless, glucose readings on 
interstitial fluid have been shown to reliably reflect glucose levels(16). 
5.4 Discontinuation 
Participation in this study is completely voluntary and participants can choose to 
discontinue at any stage. If so, they (or their nominated consultee) will be informed 
they: do not need to give a reason (although they will be voluntarily asked to supply 
one) and that their medical and legal rights are not affected.  In addition, if a 
participant is admitted to hospital during the study period, we would stop the 
glucose data collection from the date of the admission onwards. 
5.5 Concomitant Care 
This medical device study is testing the feasibility of the use of the Freestyle Libre 
AGP system.  Whilst wearing the sensor, participants will be advised to continue 
with the standard care for their diabetes as recommended by their healthcare 
team. 
5.6 Outcomes 
Feasibility outcome measures 
 Numbers of potentially eligible patients who meet the selection criteria 
 Number of participants subsequently recruited into the study 
 Extent of capture of blood glucose readings 
 Attrition rate and reasons for withdrawal 
 Adverse events related to wearing device and other adverse events       
Patient outcome measures 
Participants and/or their carers will be asked to take part in one interview, which 
will take place during the second home visit. It will focus on the acceptability of use 
of the AGP system following completion of the study period. 
5.7 Participant Timeline  
Participants will remain in the study for 6-8 weeks from providing consent. 
Participants will undergo the following steps: 
 Receipt of invitation letter and PIS/CIS whilst an inpatient at Norfolk and 
Norwich University Hospital, which will cover taking part in the study and one 
interview. 
 If interested, the research team will fully explain the study and answer and 
questions. The chief investigator will assess whether there is any evidence of 
bruising, bleeding, cellulitis and/or skin tears on the upper arms.  Should that 
be the case, then the potential participant will not be eligible to take part in 
the study.   
 Consent will be taken (or consultee agreement sought) prior to discharge 
from hospital. 
a. In case of discharge before consent is obtained, potential participants 
will also have been given a reply slip and pre-paid envelope to confirm 
whether or not they are prepared to be contacted about the study. 
  286 
 An introduction to the AGP system will be given to the patient and or carer 
by the co-chief investigator prior to discharge. 
 Within one month after discharge, participants (or their carers) will be 
contacted to check willingness to continue with the study 
a. If no, then participant will be withdrawn and this will be the end of 
involvement for that particular person 
b. If yes, the chief investigator will arrange a home visit to deliver the 
AGP system and fit the sensor. Prior to fitting the senor, the chief 
investigator will again assess whether there is any evidence of 
bruising, bleeding, cellulitis and/or skin tears on the upper arms.  
Should that be the case, then the potential participant will not be 
eligible to take part in the study.  The home visit will also be an 
opportunity to provide refresher teaching on the use of the AGP 
system. Understanding and health literacy may well be barriers to 
usability and participants (and care givers) will be encouraged to ask 
questions and be given a contact name and number in the event of 
any subsequent questions arising or concerns.   
 After one week, the research team will telephone the participant (or carer) 
to check how they are getting on with the AGP system and whether they are 
still happy to continue being part of the study.  If not, the participant will be 
withdrawn, however, the data collected by the AGP system up to the date of 
withdrawal will still be analysed.  The reason for withdrawal will be 
documented on the case record form (anonymised). 
 After wearing the sensor for two weeks, members of the trial team will 
contact the participant to arrange a convenient time for a 2nd home visit, in 
order to collect the AGP system and carry out a semi-structured face-to-face 
interview (lasting up to one hour) to explore patient and carer experiences of 
using the AGP system and the acceptability of the medical device and the 
participant’s/carer’s experiences. 
5.7.1 Withdrawal 
Participants will have the right to withdraw from the study at any time without giving 
reason. Identifiable data already collected with consent will be retained and used in 
the study. 
5.7.2 Participant Transfers 
If a participant moves from the area during the trial period, this will be considered a 
discontinuation from the study.  Identifiable data already collected with consent will 
be retained and used in the study. 
5.7.3 Trial Closure 
Trial closure will be after the last participant has returned the AGP system. 
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5.8 Sample Size 
This feasibility study aims to estimate the important parameters for the sample size 
calculation for a full trial; no sample size calculation has been undertaken at this 
stage.  We aim to recruit up to 20 participants.  This is a size that the research team 
consider to be pragmatic and sufficient as indicative quantitative data upon which 
to base the sample size for a full trial.                                                                                                                                                                                                                                                                                                               
5.9 Recruitment and Retention 
5.9.1 Recruitment  
Potential participants will be identified whilst an inpatient under either the Acute 
Medicine or Older People’s Medicine Departments: 
 Patients aged 65 years and older 
 Type 1 or Type 2 diabetes mellitus 
 On glucose-lowering medication 
 AMT equal or less than 8 (out of 10) or already has formal diagnosis of 
dementia 
The research team will liaise with their colleagues on the clinical teams to identify if 
there are any potentially suitable participants/care givers who could be given the 
invitation letter.  If there is interest in taking part, the investigator will go on to 
provided information sheets and offer verbal explanations of what the study 
involves. 
If the patient lacks capacity to give informed consent to participate in the study, the 
research team will seek advice form a nominated consultee.  The nominated 
consultee will be given a Consultee Information Sheet (CIS). 
If the patient consents or the nominated consultee confirms that in his/her opinion 
the patient would be willing to participate in the study, the research team will obtain 
consent/consultee agreement.  Consent/Consultee Agreement will be obtained >24 
hours after provision of the PIS/CIS. 
We will record the numbers of patients who decline participation, and any reasons 
given. 
The Chief Investigator will then provide an overview of the AGP system by way of 
introduction.  Participants will also be given a fridge magnet with contact numbers 
as a reminder/aide memoire.  
In case of discharge from hospital prior to the potential participant consenting, the 
Chief Investigator will also hand out a pre-paid envelope, contact telephone number 
and reply slip stating that the trial team can contact the patient/carer to discuss 
recruitment into the trial.  Consent would then take place at the first home visit. 
No financial or non-financial incentives are offered to participants. 
5.9.2 Retention 
Within a month from discharge back home (or usual place of care), the Chief 
Investigator will contact the participants/the nominated consultee to check 
willingness to continue with the study.  If the participant is willing (or the nominated 
consultee confirms agreement), the PI will carry out a home visit, in order to supply 
the AGP system, provide refresher training and fit the sensor. 
Following fitting of the sensor, participants will receive a follow-up telephone call 
after one week to check on progress and willingness to continue with the study. A 
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note will be made of any issues for potential follow up at the 2nd home visit interview 
to ensure continuity. 
Participants will have the right to withdraw from the study at any time without giving 
reason. Identifiable data already collected with consent will be retained and used in 
the study. 
 
5.10 Data Collection, Management and Analysis 
5.10.1 Data Collection Methods 
Each participant will be given a unique trial Participant Identification Number (PIN). 
The preferred method of data collection is direct online entry of data by trial staff 
onto the central database, stored on servers based at the University of East Anglia. 
Data may be entered onto paper Case Record Forms (CRFs) prior to entry onto the 
database (but this is not essential).  
Data collection, data entry and queries raised by a member of the trial team will be 
conducted in line with the University of East Anglia’s Data Management Standard 
Operating Procedure. 
Baseline data (demographics, gender, age, medical history, medications) will be 
collected by medical case note review.  
Quantitative data will be collected by downloading reports from the AGP system.  
These reports will capture the blood glucose readings during the two-week period 
when the AGP system was being used. 
Qualitative data will be collected by means of one in depth interviews with 
participants and/or carers. The interview will take place after the two-week period 
of wearing the AGP system and will explore the experiences and acceptability of its 
use in this patient population and/or their carers where appropriate.  An iterative 
topic guide will be prepared in advance to ensure key areas of importance both to 
the study and to the participants are followed up and reflect issues that may have 
arisen. 
A sample topic guide is included in Appendix X with indicative questions and prompts. 
It will be a guide to discussion to ensure key areas are covered. The interview will 
take place at the participant’s home or a location of their choosing and will last up to 
one hour.  The interview and will be audio-recorded and transcribed in full.   
Participant identification logs, screening logs and enrolment logs will be kept at the 
trial site in a locked cabinet within a secured room. Clinical trial team members will 
receive trial protocol training. Regular central monitoring will assess data quality and 
completeness during progression of the trial. All data will be handled in accordance 
with the Data Protection Act 1998. 
5.10.2 Data Management 
All data will be stored in a database on a secure server, provided and maintained by 
the University. The server environment is protected by a firewall and is patched and 
maintained according to best practice. The physical location of the server is 
protected by CCTV and security door access. Access to the database will be 
controlled via unique, personally attributable (i.e. not generic) usernames, 
password protected, and accessible only to members of the trial team, and external 
regulators if requested.  
Data will be entered in the approved database by a member of the trial team.  The 
database software provides a number of features to help maintain data quality, 
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including; maintaining an audit trial, allowing custom validations on all data, 
allowing users to raise data query requests, and search facilities to identify 
validation failure/missing data. After completion of the trial the database will be 
retained on the servers of University for on-going analysis. 
The identification, screening and enrolment logs, linking participant identifiable 
data to the pseudoanonymised Participant Identification Number (PIN), will be 
stored securely at the database, with access controlled on a per-user basis. Access 
to identifiable and pseudoanonymised data will be stored separately within the 
database and permissioned accordingly.  
Participant contact details will be collected by a member of the research team at 
the time that the participant calls to express an interest in being part of the study. 
Interviews will be recorded by the investigators. Interviews will be transcribed, 
coded and anonymised by members of the research team at the University of East 
Anglia after the interview has taken place. Typed data will be kept on a password 
protected University-owned computer.  Data may be accessed only by the research 
team who may listen to recordings or read about them to check the work.  After 
completion of the trial the personal data will be stored for 12 months and 
pseudoanonymised data for 10 years. Paper documents will be stored in a locked 
filling cabinet and electronic data on the university secure server. 
5.10.3 Analysis plan 
This study is a single-centre medical device study to determine the feasibility and 
acceptability of the use of an AGP system for two weeks in PWDD. 
5.10.3.1 Statistical Analysis Plan (SAP) 
Baseline characteristics for each participant will be presented in a Table.  For 
categorical variables, the number and percentage will be presented.  For continuous 
variables, the mean (and standard deviation) or median (and interquartile range) will 
be presented depending on the distribution.   
5.10.3.2. Statistical Methods  
Feasibility outcomes (quantitative) 
 Hours of captured glucose data will be presented with numbers and 
percentages. 
 Participant eligibility: how many patients with memory problems and 
diabetes are potentially eligible? 
 Participant recruitment: how many patients are subsequently enrolled in the 
study? 
 Participant retention:  what proportion of participants will take part until the 
end of the study?  For withdrawals, what are the reasons? 
 How many hours of glucose data will successfully be recorded? 
 Do participants find the use of the AGP system acceptable? 
 Are there any adverse events? 
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Patient outcomes (qualitative) 
One semi-structured face-to-face interviews will take place during the study period. 
Topics for discussion are likely (but not exclusively) to include: factors that have had 
an impact on the acceptability of the AGP System including design and usability; 
and, the impact of the device on daily life and routines including physical, 
emotional and social health; current and perceived practical, emotional and 
theoretical issues with wearing the device and the associated health monitoring. In 
addition, we will gather participants’ views on the quality and quantity of 
communication received concerning information, explanations and on-going and 
follow-up care needs; and, recommendations for inclusion in the design of future 
patient and carer-facing information and explanations. 
An interpretive inductive approach will be used based on the six phases outlined by 
Braun and Clarke (17): Data familiarisation, initial coding, themes identification, 
review, definition and, reporting. 
5.11 Data Monitoring 
5.11.1 Data Monitoring Committee 
This feasibility study looking in to the acceptability of the use of AGP system in older 
people with memory problems and diabetes minimal or no risks.  The device simply 
enables glucose concentrations to be recorded in a less invasive and more frequent 
manner than conventional finger-prick testing. This study does not involve delivery 
of a therapeutic intervention that exerts physiological effect.  The medical device has 
already received CE mark/approval for the adult population with diabetes and can 
be purchased from the Freestyle Libre website 
(https://www.freestylelibre.co.uk/libre/), and, depending on local clinical 
commissioning groups (CCG) may also now be available on prescription (since 
November 2017). 
A recent feasibility and acceptability study of the device in children showed that 
about 60% of the participants were willing to wear the sensor again.  Five out of 46 
participants complained of pain while wearing the sensor.  In 16 out of 46, the sensor 
lasted for less than two weeks.  Four out of those 16 rejected wearing the sensor 
again.  One child developed a pustule at the insertion site (18). 
Any adverse events reports will be assessed by the Trial Steering Committee.  
Therefore, the trial team submit that a separate data monitoring committee is not 
necessary. 
 
5.11.2 Data Monitoring for Harm 
5.11.2.1 Safety reporting 
Definitions of harm of the EU Directive 2001/20/EC Article 2 based on the principles 
of ICH GCP apply to this trial.  
Table 1: Adverse Event Definitions 
Adverse Event (AE) Any untoward medical occurrence in a patient or 
clinical trial participant administered a medicinal 
product and which does not necessarily have a causal 
relationship with this product. 
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Adverse Reaction (AR) Any untoward and unintended response to an 
investigational medicinal product related to any dose 
administered 
Unexpected Adverse 
Reaction (UAR) 
An adverse reaction, the nature or severity of which 
is not consistent with the applicable product 
information (eg Investigator’s Brochure for an 
unauthorised product or summary of product 
characteristics (SPC) for an authorised product. 
Serious Adverse Event 
(SAE) or Serious Adverse 
Reaction (SAR) 
Any AE or AR that: 
 results in death  
 is life threatening*  
 requires hospitalisation or prolongs existing 
hospitalisation** 
 results in persistent or significant disability or 
incapacity 
 or is another important medical condition*** 
* the term life threatening here refers to an event in which the patient is at risk of 
death at the time of the event; it does not refer to an event that might 
hypothetically cause death if it was more severe (eg a silent myocardial infarction) 
** Hospitalisation is defined as an in-patient admission, regardless of length of 
stay, even if the hospitalisation is a precautionary measure for continued 
observation. Hospitalisation for pre-existing conditions (including elective 
procedures that have not worsened) do not constitute an SAE 
*** Medical judgement should be exercised in deciding whether an AE or AR is 
serious in other situations. Important AEs or ARs that may not be immediately life 
threatening or result in death or hospitalisation, but may seriously jeopardise the 
participant by requiring intervention to prevent one of the other outcomes listed 
in the table  
 
Adverse events include: 
 an exacerbation of a pre-existing illness 
 an increase in the frequency or intensity of a pre-existing episodic event or 
condition 
 continuous persistent disease or a symptom present at baseline that worsens 
following use of the device 
Adverse events do NOT include: 
 Medical or surgical procedures: the condition that leads to the procedure is 
the adverse event. 
 Pre-existing disease or a condition present before treatment that does not 
worsen. 
 Hospitalisation where no untoward or unintended response has occurred e.g. 
elective cosmetic surgery. 
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5.11.3  Investigator responsibilities relating to safety reporting 
All non-serious AEs and ARs, whether expected or not, should be recorded in the 
patient’s medical notes and reported in the toxicity (symptoms) section of the 
Follow-up Form. SAEs and SARs should be notified immediately the investigator 
becomes aware of the event (in no circumstance should this notification take longer 
than 24 hours). 
5.11.3.1 Seriousness assessment  
When an AE or AR occurs, the investigator responsible for the care of the participant 
must first assess whether or not the event is serious using the definition given in 
Table 1. If the event is classified as ‘serious’ then an SAE form must be completed 
and notification sent within one working day. 
5.11.3.2 Causality 
The investigator must assess the causality of all serious events or reactions in relation 
to the trial therapy using the definitions in Table 2.  
Table 2: Causality definitions 
Relationship Description Event type 
Unrelated There is no evidence of 
any causal relationship 
Unrelated SAE 
Unlikely to be related There is little evidence to 
suggest that there is a 
causal relationship (eg 
the event did not occur 
within a reasonable time 
after administration of 
the trial medication). 
There is another 
reasonable explanation 
for the event (eg the 
participant’s clinical 
condition or other 
concomitant treatment) 
Unrelated SAE 
Possibly related There is some evidence to 
suggest a causal 
relationship (eg because 
the event occurs within a 
reasonable time after 
administration of the trial 
medication). However, 
the influence of other 
factors may have 
contributed to the event 
(eg the participant’s 
clinical condition or other 
concomitant treatment)  
SAR 
Probably related There is evidence to 
suggest a causal 
SAR 
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relationship and the 
influence of other factors 
is unlikely 
Definitely related There is clear evidence to 
suggest a causal 
relationship and other 
possible contributing 
factors can be ruled out. 
SAR 
 
If an SAE is considered to be related to trial treatment, and treatment is discontinued, 
interrupted or the dose modified, refer to the relevant Interventions sections of the 
protocol. 
5.11.4 Trial Team  
The Trial Team will be set up to assist with developing the design, co-ordination and 
day to day operational issues in the management of the trial, including budget 
management. The membership, frequency of meetings, activity (including trial 
conduct and data review) and authority will be covered in the TMT terms of 
reference. 
 
5.11.5 Trial Steering Committee 
The Independent Trial Steering Committee (TSC) is the independent group 
responsible for oversight of the trial in order to safeguard the interests of trial 
participants. The TSC provides advice to the Chief Investigator, the funder and 
sponsor on all aspects of the trial through its independent Chair. The membership, 
frequency of meetings, activity (including trial conduct and data review) and 
authority will be covered in the TSC terms of reference. 
5.11.6 Trial Sponsor 
The role of the sponsor is to take on responsibility for securing the arrangements to: 
initiate, manage and finance the trial.  
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6 Ethics and Dissemination 
6.1 Research Ethics Approval 
Before initiation of the trial, the protocol, all informed consent/declaration forms 
and any material given to the prospective participant/consultee will have been 
approved by the relevant REC. Any subsequent amendments to these documents will 
be submitted for further approval.  
The rights of the participant to refuse to participate in the trial without giving a 
reason will be respected.  The participant remains free to change their mind at any 
time about the protocol treatment and follow-up without giving a reason and 
without prejudicing their further treatment. 
6.2 Protocol Amendments 
The chief investigator is responsible for communicating any regulatory approved 
substantial protocol amendments (e.g. changes to eligibility criteria, outcomes, 
sample size calculations, analyses) to all principal investigators in all participating 
centres, trial registries, journals and regulators.  Relevant parties will be informed by 
postal letter containing an amended version of the protocol for storing in the trial 
master file.      
6.3 Consent or Consultation 
Patients will be provided with a Patient Information Sheet (PIS) and given time to 
read it fully. Following a discussion with a medical qualified investigator or suitably 
trained and authorised delegate, any questions will be satisfactorily answered and if 
the participant is willing to participate, written informed consent will be obtained.  
There will be a minimum of 24 hours between provision of the PIS  to the participant 
and seeking informed consent. Members of the trial team seeking consent will be 
fully trained in Good Clinical Practice (GCP). During the consent process, it will be 
made completely and unambiguously clear to participants they are free to refuse to 
participate in all or any aspect of the trial, at any time and for any reason, without 
incurring any penalty or affecting their treatment.  
 
A number of potential participants for this feasibility study may not have the 
decisional capacity to give informed consent. Here they are, or are judged, as being 
unable to understand information given to them, or to use it to make an informed 
decision about participation.  As we are investigating the use of a medical device in 
patients who either have memory problems (or dementia), these patients may well 
benefit from participation in the trial. In such situations, the consultation process will 
take place in accordance with the Mental Capacity Act (MCA) (this is a Non-CTIMP 
study).  An appropriate person will be found to consult with, in order to make a 
decision about whether the potential participant should be included in the research.  
The consultee will not consent on behalf of the participant – they will provide advice 
which will be taken into account by the research team.  In the first instance, a 
personal consultee will be sought for consultation.  If a personal consultee cannot be 
found, an appropriate professional who is not connected to the research will be 
nominated to act as consultee. 
 
The consultee will be informed about all aspects of the study and provided with a 
Consultee Information Sheet (CIS).  The information given to a consultee will clarify 
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their legal obligations under the MCA.  Following a discussion with a medical qualified 
investigator or suitably trained and authorised delegate, any questions will be 
satisfactorily answered.   If the consultee advises that in their opinion the potential 
participant would have no objection to taking part in the study, they will be asked to 
sign the Consultee Declaration Form (CDF).  There will be a minimum of 24 hours 
between provision of the CIS and seeking the consultee’s advice. 
 
If during the trial, the participant is judged to have regained capacity, their consent 
will be sought.           
 
Consent will be re-sought if new information becomes available that affects the 
participants’ consent in any way. These changes will be documented in a revision to 
the PIS/CIS and the participant/consultee asked to sign an updated 
consent/declaration form. Changes will be approved by the ethics committee prior 
to their use.  
A copy of the approved consent form and declaration form is available from the trial 
team.  
6.4 Confidentiality 
All patients will be recorded on an identification log with pseudoanymised identifiers 
of initials and hospital number. This log, in both a paper and computer form, will be 
compiled by trial research staff and stored in either locked cabinets in swipe card 
access officers and on hospital or university password access computers in swipe card 
access offices.  All potential participants are allocated a participant identification 
number (PIN) to replace their name. Personal information is collected by trial staff 
trained in the principals of Good Clinical Practice. Only members of the trial teams in 
each centre will have access to the e-database, identification and screening logs.  
6.5 Declaration of Interests 
The investigators named on the protocol have no financial or other competing 
interests that impact on their responsibilities towards the scientific value or potential 
publishing activities associated with the trial.  
6.6 Indemnity 
UEA holds insurance to cover participants for injury caused by their participation in 
the clinical trial. Participants may be able to claim compensation if they can prove 
that UEA has been negligent. However, as this clinical trial is being carried out in a 
hospital, the hospital continues to have a duty of care to the participant in the clinical 
trial. UEA does not accept liability for any breach in the hospital’s duty of care, or any 
negligence on the part of hospital employees. This applies whether the hospital is an 
NHS Trust or not.  This does not affect the participant’s right to seek compensation 
via the non-negligence route.  
 
Participants may also be able to claim compensation for injury caused by 
participation in this clinical trial without the need to prove negligence on the part of 
UEA or another party.  Participants who sustain injury and wish to make a claim for 
compensation should do so in writing in the first instance to the Chief Investigator, 
who will pass the claim to UEA’s insurers, via the Sponsor’s office. 
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Hospitals selected to participate in this clinical trial shall provide clinical negligence 
insurance cover for harm caused by their employees and a copy of the relevant 
insurance policy or summary shall be provided to UEA, upon request. 
 
6.7 Finance 
The EAGLE study is part of an Alzheimer’s Society doctoral fellowship (Grant number 
324 (AS-CTF-16-001)). It is not expected that any further external funding will be 
sought. 
6.8 Archiving 
The investigators agree to archive and/or arrange for secure storage of trial materials 
and records for a minimum of 5 years after the close of the trial. 
6.9 Access to Data 
Access to the final trial dataset will be granted to the: chief investigator, trial 
statistician, chair persons of the TSC and any regulatory authorities. Access by any 
other parties will require approval from the CI and chairperson of the TSC. Requests 
for access to trial data will be considered, and approved in writing where appropriate, 
after formal application to the TSC.  
6.10 Ancillary and Post-trial Care 
Following completion of the trial, Flash Glucose Monitoring would not be prescribed 
to participants using research funding.  This feasibility study   does not have the 
objective of demonstrating benefit.  Patients and carers will have to go through 
conventional funding channels if they wish to continue using the medical device. 
6.11 Publication Policy 
6.11.1 Trial Results 
The Chief Investigator will co-ordinate the writing of abstracts and full publications 
and send these to all co-investigators before submission to scientific meetings and 
peer review journals for comments and approval. The full publication detailing the 
primary and secondary outcomes will be first submitted within 12 months after the 
last participant has completed follow-up. Following full publication, relevant papers 
will be sent to the appropriate patient groups, and participants who have requested 
this.    
6.11.2 Authorship 
Any trial related publications will include co-investigators, who in the opinion of the 
Chief Investigator, have made a significant contribution to the: design, conduct, 
analysis, funding application and report writing of the trial.    
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7 Protocol Amendments 
This is the second version of the protocol.   
November 2017 amendment: change to the selection criteria to exclude patients 
with obvious signs of cellulitis, bruising, bleeding, and skin tears to the upper arm. 
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Appendix 3 Patient Information Sheet 
 
 
 
 
 
EAGLE study 
Flash glucose monitoring in older patients with diabetes and memory 
problems 
Patient Information Sheet 
 
We would like to invite you to take part in the EAGLE research study run by 
the University of East Anglia. Before you decide whether you would like to 
take part, you need to know why the study is being done and what it is you 
would have to do. Please take time to read the following information 
carefully which you may wish to discuss with friends and relatives. Please 
contact us if you would like more information using the details below. 
 
What is the purpose of this research project? 
Diabetes and memory problems are common conditions that can occur 
together in older people.  People with memory problems can have 
difficulty in managing and monitoring their diabetes, especially their blood 
sugars. Medication for diabetes can provoke excessively low blood sugars 
(aside-effect commonly known as 'hypos') needing recognition and 
treatment. 
 
New technology (flash glucose monitoring) may help in keeping a closer 
eye on blood sugars. Small (coin-sized) sensors (fitted for 1-2 weeks) can 
constantly record sugar levels. Patients (or carers) do not need to 
remember, or recognize when to do finger prick testing. So far, no one has 
tested this technology to help patients with memory problems and 
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diabetes.  There are some pictures of the device are attached to this 
leaflet. 
 
This study will explore whether people aged 65 and older with memory 
problems and diabetes can tolerate wearing the flash glucose monitoring 
system for two weeks to help monitor blood sugar levels.  We will recruit 
up to 20 patients for this study.  Potential participants will be identified 
and invited whilst they are in hospital (the Norfolk and Norwich University 
Hospital). 
Why have I been chosen? 
You have been invited to take part as you have diabetes and memory 
problem.  This study is about finding out whether people with diabetes and 
memory problems can tolerate wearing the flash glucose monitor system 
and make recordings for two weeks.  This medical device is already publicly 
available for use in adults and children with diabetes.   However, so far, no 
one has looked specifically at how adults with diabetes AND memory 
problems would tolerate and wear the device at home. 
 
Do I have to take part? 
No, it is up to you to decide. If you decide to take part and then change 
your mind, you can stop at any time. Whether or not you take part, you 
will still have access to the usual medical services. If you decide not to take 
part, it will not in any way harm or affect the medical care you receive. 
 
What will happen if you agree to take part? 
Each patient will be shown how to use the flash glucose monitoring 
system, which will be worn about one month AFTER discharge from 
hospital.  This will give you enough time to recover from your last hospital 
admission and get back into your normal day to day routines.  We would 
like you to wear this medical device for two weeks.  A member of the 
research team will visit you either at your home or other convenient place, 
in order to give you the device and show how it is used.  Prior to giving you 
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the device, a member of the research team will check the skin of your 
upper arms (this is where the device will be fitted) to make sure that there 
are no signs of bleeding, infection, skin tears or bruises.  Should any of this 
be apparent, then it will not be possible for you to take part in the study. 
The visit should take no more than one hour. 
 
After the two weeks of using the device, the research team will visit you 
either at your home or other convenient place, to pick up the device and to 
talk about your experiences.  This visit should last no more than an hour. 
 
What should I do if I wish to take part? 
If you might be interested in taking part in the study, and would like to find 
out more, please call or email using the details below. We will arrange the 
initial meeting, to answer any questions you may have and ask you to 
complete a consent form. At this meeting, the researcher will give you an 
initial overview and hands-on demonstration of the medical device. 
 
What will I have to do? 
The research team will contact you about one month after your discharge 
from hospital to check if you are still willing to take part in the study.  If 
you are, then we will arrange to visit you at home (or other preferred 
place) at a convenient time to give you the flash glucose system, fit the 
sensor, provide refresher training and answer any questions you may have. 
 
You will wear the sensor for two weeks (the lifetime of one sensor), which 
will typically need to be swiped with a reader three times a day (for 
instance, before or after meals). 
After one week, the research team will telephone you to check how you 
are getting on with wearing the device and whether issues/questions have 
arisen. 
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After the two weeks, the research team will contact you to arrange a 
convenient place and time to pick up the device and speak to you about 
your experiences.  This meeting should last no more than one hour. 
 
The research team will make audio recordings of the study visits and 
telephone follow-up to ensure that any concerns, questions and adverse 
events are documented. 
 
During the time when you wear the device, the research team would like 
you to continue with the management of your diabetes as per normal and 
not to make any changes (unless advised to do so by a healthcare 
professional). 
 
What are the possible disadvantages of taking part? 
 The research team will visit you twice for up to an hour on each 
visit. 
 You may feel worried about being able see blood sugar readings all 
the time.  If you have any concerns at all, you will be able to contact 
the research team or your GP.   
 You may experience discomfort when the sensor is fitted. 
 You may experience a mild skin reaction where the sensor is fitted. 
 
What are the possible benefits of taking part? 
 You will potentially be able to get detailed information about blood 
sugar levels over a two-week period.  
 Medical professionals will be able to analyze the information 
collected and make decisions on your treatment plan, if need be. 
 You may be able to pick up trends of high or low sugars, that can be 
used to inform your doctors so that they can any adjustments to 
the treatment as they see fit. 
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What happens when the research stops? 
The study will help shed light on whether people with diabetes and 
memory problems can tolerate wearing and making recordings with the 
flash glucose device.  It may pave the way to bigger studies to improve 
management and safety in people with memory problems and diabetes.   
If you decide that you wish to continue using the device, it is available for 
purchase form the manufacturer’s website at: 
https://www.freestylelibre.co.uk/libre/.  It may also be possible to obtain 
it on prescription, but this will depend on the local primary care guidelines. 
 
Involvement of your GP 
If you decide to take part in the study, we will send a letter to your GP 
practice to let them know.  After the study finishes and if we pick up any 
results that may require adjustment of your medications, we will write to 
your GP practice to update them. 
 
What if there is a problem? 
If you want to withdraw from the study, you can do so at any time without 
giving a reason. If you withdraw, your information collected can be 
removed before it is analyzed by the research team, but not if you 
withdraw after it has been analyzed. If you have a complaint about the 
study or how you have been treated, please contact the research team.  
You can also contact the Norfolk and Norwich University Hospital Trust’s 
Patient Advice and Liaison Service (PALS).  Their contact details are: 
Complaints and Legal Services Department 
Norfolk and Norwich University Hospitals 
NHS Foundation Trust 
Colney Lane 
Norwich NR4 7UY 
Tel: 01603 289684 or 01603 289686 
Email: complaints-team@nnuh.nhs.uk 
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If you have any concerns about your blood sugar readings, you can contact 
the research team or your GP for further advice.  If you have any concerns 
about the device itself, please contact the research team. 
 
Will my taking part in the research be kept confidential? 
Yes, all data by the research team will stay confidential. All data collected 
for the study will be stored and anonymized. Data will be stored securely 
on password-protected computers accessible only to the study team. With 
regard to the audio recording, a member of the research team will type 
this up, code and anonymize it.  This process will be carried out on a 
University-owned computer.  The audio recording will be stored for a 
period of 12 months and then erased by a member of the research team.   
 Anonymized data will be stored for a period of 10 years, in line with 
current data archiving policy at the University of East Anglia. Disposal of 
data after this period of time will be carried out securely, by using data 
shredders.  
 
Anonymized data will be used in reporting the results of the study at 
conferences and in academic journals. By giving consent, you agree for this 
information to be collected. 
 
 
What will happen if I do not want to carry on with the research? 
You can withdraw from the study at any point without any adverse 
consequences.  You do not have to give any reason for withdrawing. 
 
What will happen with the results of the study? 
The results will be used to help improve the management of diabetes in 
people with memory problems. We will write up results for the funder 
(Alzheimer’s Society), publications and conferences, as well as for the 
general public. You can request a copy of the full results, which we will 
send after the study has finished. 
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Will I receive any payment for being in this study? 
There is no payment for taking part. 
 
Who is organizing and funding the research? 
The research is funded by the Alzheimer’s Society.  
Patient and public representatives have been involved at all stages of the 
development and review process. The research is sponsored by the 
University of East Anglia, which has appropriate insurance in place, to 
cover research activities. 
 
Who has reviewed the study? 
This research has been looked at by an independent group of people, 
called a Research Ethics Committee, to protect your safety, rights, 
wellbeing and dignity (Ref: 17/EE/0388).  
 
What to do next 
The research team will contact you in the next few days to see whether 
you are interested in taking part in the study.  Alternatively, please contact 
the research team using the contact details below. 
 
Contact details 
Dr Katharina Mattishent (researcher) 
Tel: 07547886634 
email: K.Mattishent@uea.ac.uk 
 
 
 
Thank you for taking the time to read this information leaflet about the 
EAGLE study 
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Appendix 4 Consent Form  
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Appendix 5 Ethics approval 
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Appendix 6 Indicative Topic Guide 
The aim is to derive a more holistic account of the user and carers 
individual experience. 
Some baseline descriptors will be needed in advance such as the level of 
awareness of the device (cognitive health), living circumstances and 
environment 
Areas for discussion to include: 
 
Acceptability 
Tell me a bit about how you have got on with (wearing) the device? 
Prompt for comfort, design & functionality issues: 
Did you notice it physically? 
In what ways, if any, did it change your day to day activities? 
Were there any particular positive / negative aspects of the device? 
Ease of use, wearablity, comfort, visibility, obtrusiveness, damage, 
inconvenience, stigma? 
 
Exploration of expectations 
What were your expectations of (wearing) the AGP device? (Contrast user 
and carer views) 
Did it the device meet any expectations you had of using the AGP device? 
 
Effectiveness 
What was the experience of users/carers of scanning the device? 
Was there any immediate or longer term consequences for the user and 
their diabetes health? 
 
Consequences 
Impact on wider health and wellbeing  
‘Thinking about other aspects of your health and wellbeing can you tell me 
a bit about your health in general?’ 
Prompt for: 
Overall impact of the device (positive and negative)  
Any specific areas mentioned e.g. did you feel the device made any 
difference to your symptoms/experiences of living with diabetes, 
dementia, co-morbidities, anxiety, & self-care etc 
Impact on more personal and social aspects of life and wellbeing 
Effect on day to day activities, social life, personal implications of 
wearing and managing the device? 
Where any elements of the device reassuring or discouraging and if so – 
who to (user and / or carers)? 
 
Overall 
What would you say to others considering this device? 
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Appendix 7 FreeStyle Libre Pictorial Guide 
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Appendix 8 ISAC Protocol 
 
 
 
 
 
 
Study Title: Hypoglycaemia and serious adverse events in older people 
living with diabetes and dementia – a population-based cohort study 
 
Short title: Hypoglycaemia and serious adverse events in older people with 
diabetes and dementia  
Date and Version No: November 2017 v3 
 
Chief Investigator: Professor Yoon K Loke, Norwich Medical School, University of 
East Anglia 
Email: Y.Loke@uea.ac.uk  
 
 
Investigators:  Dr Katharina Mattishent, Alzheimer’s Society Clinical Research 
Fellow, Norwich Medical School, University of East Anglia; Older 
People’s Medicine Registrar, Norfolk and Norwich University 
Hospital 
Email: K.Mattishent@uea.ac.uk 
Dr George Savva, Senior Lecturer in Applied Statistics, University 
of East Anglia 
Email: g.savva@uea.ac.uk 
Dr Kathryn Richardson, Research Fellow in Statistics, University 
of East Anglia 
Email: Kathryn.Richardson@uea.ac.uk 
 
 
  
Funder:  Alzheimer’s Society 
Host organisations: University of East Anglia, Norfolk and Norwich University Hospital 
Foundation Trust 
  
Signature of Chief Investigator:  
 
Confidentiality Statement: This document contains confidential 
information that must not be disclosed to anyone other than the 
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Investigator Team, host organisation, and members of the Independent 
Scientific Advisory Committee, unless authorised to do so 
A. Lay summary 
Diabetes and dementia are common illnesses that can occur together in 
older people. Diabetes UK estimate that approximately 5 million people 
will have diabetes in the next 10 years, whereas Alzheimer’s UK estimate 
that over 1 million people will have dementia.  Currently, 1 in 5 patients 
with dementia also have diabetes.  
 
Medication to control blood sugar can provoke low blood sugars 
(hypoglycaemia; a particularly serious side-effect that may cause serious 
long-term harm).  Although dementia is significantly associated with 
hypoglycaemia, there is currently little evidence regarding long-term 
consequences of hypoglycaemia in patients with diabetes and dementia. 
We will analyse healthcare data from the Clinical Practice Research 
Datalink to determine serious complications associated with 
hypoglycaemia (falls or fractures, use of emergency healthcare and 
hospitalization, heart attacks, and death) in patients with diabetes and 
dementia compared to those with only diabetes. 
 
Understanding the potentially serious consequences of hypoglycaemia is 
crucial in helping patients, carers and doctors make decisions on choice, 
intensity and monitoring of medication for diabetes and concomitant 
dementia.  
 
 The results will provide valuable evidence for national guidance and co-
ordination of health and social care policy (e.g. provision of meals at the 
appropriate time) for vulnerable patients with diabetes and dementia. 
 
B. Technical summary 
Background: Treatment of diabetes in older people with dementia is 
challenging, as clinicians try to achieve a comfortable balance between the 
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pursuit of tight blood sugar control (in accordance with national targets), 
against pragmatism and avoidance of serious side-effects, such as 
hypoglycaemia.  There is a paucity of evidence regarding risk of 
hypoglycaemia in patients with diabetes and dementia, and the 
relationship between hypoglycaemia and serious adverse events (falls or 
fractures, use of emergency healthcare and hospitalization, heart attacks, 
and death). 
Objectives: To describe serious (medically recorded) hypoglycaemic events 
in older people with multimorbidity (diabetes and dementia), and to 
determine risk of associated serious adverse events after serious 
(medically recorded)  hypoglycaemia (falls or fractures, use of emergency 
healthcare and hospitalization, heart attacks, and death).  For ease of 
reference, all mention of hypoglycaemia is intended to mean serious 
(medically recorded) hypoglycaemia. 
Methods Population-based cohort of patients with diabetes (± dementia) 
based on CPRD with linkage to Hospital episode statistics, and Office for 
National Statistics datasets. 
Data Analysis Kaplan-Meier survival curves will be used to display the 
survival curve for each adverse outcome after incident exposure to a 
hypoglycaemic event.  The association between hypoglycaemic exposure 
and serious subsequent adverse event, will be evaluated using Cox 
proportional hazard regression models with adjustment for appropriate 
confounders to estimate a Hazard Ratio and 95% confidence interval.  
C. Objectives, Specific Aims and Rationale 
Objectives 
To quantify the consequences of the problem of hypoglycaemia in older 
people with multimorbidity (dementia and diabetes), focusing on extent of 
associated serious complications (falls or fractures, use of emergency 
healthcare and hospitalization, heart attacks, and death) during follow-up 
after a hypoglycaemic event.   
Specific Aims 
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1. In older patients with dementia and diabetes, what is the risk of 
serious adverse events (such as falls, fractures, cardiovascular 
events, use of emergency services, and death) following 
hypoglycaemia, compared to similar patients who do not have 
hypoglycaemic events? 
2. Does hypoglycaemia in older patients with comorbid dementia and 
diabetes carry any greater risk of serious adverse events, as 
compared to hypoglycaemia in patients with diabetes who do not 
have a comorbid diagnosis of dementia? 
Rationale 
Current NICE guidelines do not specifically address the management of 
patients with diabetes and dementia.  There has yet to be a 
unified/systematic approach to the management of this vulnerable patient 
group, and care pathways do not take account of the special circumstances 
and additional burden (such as the accompanying behavioural and 
psychological symptoms of dementia) in such patients (1).  Several 
governmental and international professional bodies have highlighted the 
urgent need for more evidence into the management of diabetes and 
dementia(2) . 
 
This study will look at the occurrence of hypoglycaemic episodes in older 
patients with dementia and diabetes and likelihood of subsequent serious 
adverse events associated with hypoglycaemia. This will guide a holistic 
approach that takes into account shared clinician and patient decision-
making on type of medication, intensity of therapy, awareness of adverse 
effects, additional supervision of timing and type of meal, and 
comprehensiveness of monitoring for dangerous sugar levels. 
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D. Background 
Diabetes and dementia are becoming more prevalent in the ageing UK 
population.  By 2025 there will be around 5 million people with diabetes in 
the UK, more than one million with dementia and around 200,000 with 
both dementia and diabetes (3, 4). 
 
People living with diabetes and dementia (PLwDD) may not recognize signs 
and symptoms of abnormal blood sugars, or are not able to vocalize their 
problems, thus leading to delays in getting treatment. Decreased food 
intake or inability to adjust drug doses accounts for more than half of 
hypoglycaemia episodes in older patients (5), which means that cognitive 
impairment or dementia can substantially increase the risk of 
hypoglycaemia. 
 
Hypoglycaemia is a growing burden with wide implications for healthcare 
professionals, patients, carers and healthcare service utilization. Munshi et 
al. detected 102 hypoglycaemic episodes over a 3-day period through 
continuous glucose monitoring in 40 patients (without dementia), mean age 
73 years (6). East Midlands Ambulance Trust responded to 523 call outs for 
severe hypoglycaemia over a 3-month period (mean age 76 years for the 
non-insulin treated patients), with projected annual call out costs of over 
£235,000(7) .  This is mirrored by evidence in older people elsewhere where 
a 10-fold increase in risk of hypoglycaemic episodes needing hospital 
admission has been observed over the last decade (8) (9) .  This upsurge has 
been attributed to increased intensity of medical treatment, as well as 
greater co-morbidities and frailty. 
 
The National Institute of Health Research (NIHR) has acknowledged the 
evidence gaps in managing this vulnerable group and commissioned a realist 
synthesis to identify theories, frameworks, and processes of care for PLwDD 
(1).  The NIHR commissioning brief emphasized the high priority of this topic 
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whereby “Individualised diabetes care for people with dementia has been 
advocated that considers not only the complications of acute 
hypoglycaemia and hyperglycaemia but also quality of life and carer 
support.”    
 
The American Geriatrics Society (AGS) has also highlighted the lack of 
evidence in patients with diabetes and dementia. They remarked that older 
people were often excluded from trials in diabetes, and so, guidelines are 
not based on reliable evidence in this group.  The AGS has called for more 
research “to better understand the risks and benefits of tighter glycaemic 
control among older patients and those with comorbidities” because of 
“Increasing observational evidence … that clinicians often do not 
differentiate treatments for older patients who differ widely in health 
status” (2). 
 
Current NICE guidelines do not specifically address the management of 
patients with diabetes and dementia.  There has yet to be a 
unified/systematic approach to the management of PLwDD, and care 
pathways do not take account of the special circumstances and additional 
burden (such as the accompanying behavioural and psychological symptoms 
of dementia) in such patients (1). 
 
Current research has highlighted the urgent need to investigate the 
understanding of the magnitude of hypoglycaemia in people with dementia 
and diabetes, which will inform guidance about safer management and 
treatment decisions.   
 
Our database study will examine the occurrence of hypoglycaemic events in 
PLwDD, and the association between hypoglycaemia and subsequent 
serious adverse events, such as falls or fractures, use of emergency 
healthcare and hospitalization, heart attacks, and death. This will guide a 
holistic approach that takes into account shared clinician and patient 
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decision-making on type of medication, intensity of therapy, awareness of 
adverse effects, additional supervision of timing and type of meal, and 
comprehensiveness of monitoring for dangerous sugar levels. 
E. Study Type 
Descriptive and hypothesis testing 
F. Study Design 
Retrospective cohort study 
G. Sample Size 
Our power calculation is based on the within group analysis for Aim 1 (ability 
to detect an increased risk in fractures following hypoglycaemic episodes) - 
our feasibility request to CPRD has identified prevalence of 22 984 people 
with diabetes and dementia (1990-2013), of which about 55% 
(approximately 12 000 patients) may have linkage to Full HES and ONS.  
Patients with dementia have a baseline fracture rate of 6% per year reported 
by Wang et al. (10) and a relative risk increase of 2.0 for fractures identified 
from our systematic review to be clinically important in those with 
hypoglycaemia. (11) Recent published data found that proportion of 
patients with diabetes and dementia affected by severe hypoglycaemia is 8 
in a 100, thus potentially giving 960 patients with hypoglycaemia, and 9600 
without hypoglycaemia (1:10 matching). (12) Based on these estimates, our 
study has >99% power to detect a clinically important relative risk increase 
of 2.0 for fracture between groups (alpha 0.05) i.e. absolute increase in 
fractures from 6% in the non-hypoglycaemic group to 12% in the 
hypoglycaemic group. 
We have also conducted a more conservative estimate, where if there was 
only half the number of eligible patients with hypoglycaemia, and a halving 
of the baseline fracture rate of 3%, then for 480 hypoglycaemic patients with 
diabetes and dementia, and 4800 non-hypoglycaemic controls, we have 
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83% power of detecting an absolute increase in fractures from 3% to 6%. 
H. Data Linkage 
We will define the study population using CPRD (time period April 1997-
latest available dataset).   
HES Admitted Patient Care and HES Accident &Emergency (from April 
2006) data will be used to supplement the available CPRD GOLD data on 
serious adverse events (including hypoglycaemia, fall, fractures and 
cardiovascular events) that triggered visits to hospital. We recognize that 
HES linkage covers only approx. 55% of patients from April 1997 until the 
most current data extraction date.   
ONS Death Registration Data will be used to supplement the available 
CPRD GOLD data to identify deaths after the exposure, and cause of death 
related to falls, fractures and cardiovascular events. We recognize that 
ONS linkage covers only approx. 55% of patients from January 1998 until 
the most current data extraction date. Our analysis of mortality will be 
based on this smaller subset of patients.   
Index of Multiple Deprivation Data will also be used as one of the 
covariates that we are considering for addressing confounding in the data 
analysis. 
Patients are only eligible for linkage if they (i) registered at a participating 
English practice prior to the transfer of identifiers to the trusted third party 
for matching, (ii) had a valid identifier for linkage (NHS number plus at 
least one other of date of birth, postcode, gender), (iii) had not opted out 
or dissented from CPRD or the linkage scheme.   
I. Study population 
Inclusion criteria: Any adult (aged over 50 years) with a new or existing 
diagnosis of diabetes (Type 1 or Type 2) with at least three months of 
registration in CPRD following the date the practice became ‘up to 
standard’.  The study entry date will be the date of first-ever prescription 
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(from April 1997 onwards) of any oral or injectable glucose-lowering drug 
(see Appendix 1). Eligible participants have to have HES linked data 
available.   
 
The index date will be defined as the first recorded hypoglycaemia 
exposure dated on/after April 1997 following initiation of a glucose 
lowering agent. Only patients who are 65 years and older at the time of 
the index hypoglycaemia exposure will be included. 
Hypoglycaemia is almost never seen in patients with diabetes who are not 
on glucose lowering drugs (except in the context of terminal illness). Thus, 
we can be fairly certain that we have constructed a cohort that is very 
unlikely to have a significant past history of hypoglycaemia, and any 
recorded hypoglycaemia on follow-up are incident exposures. It is unlikely 
(in this study population age >50 years) that we would enrol patients who 
are being initiated on metformin therapy solely for polycystic ovarian 
syndrome. 
 
Follow-up: Up to five years from the index date, loss from database, death, 
or permanent cessation of glucose-lowering drugs, whichever is the earlier.   
During follow-up after hypoglycaemia exposure, participants who were 
originally classified as (Diabetes but No Dementia) will additionally be 
censored at 6 months prior to the first date of them receiving a subsequent 
dementia diagnosis and/or prescription of dementia drug. 
 
Please see Appendix 2 for Read codes that have been validated in previous 
CPRD studies for diabetes mellitus, as well as dementia. 
J. Selection of comparison group(s) or controls  
From the study population (any adult aged over 50 years) with a new or 
existing diagnosis of diabetes in CPRD), we will extract three groups (see 
Appendix 1): 
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 Group 1: Diabetes + Dementia + no medically recorded 
hypoglycaemic events at the time of the index date (assigned the 
same index date as matched patient in Group 2) 
 Group 2: Diabetes + Dementia + medically recorded hypoglycaemic 
event as index date. If the patient has diabetes first and then 
dementia, then hypoglycaemia should be assessed after dementia 
date; if the patient has dementia first and then develops diabetes 
then then hypoglycaemia should be assessed after diabetes date 
 Group 3: Diabetes + no Dementia + medically recorded 
hypoglycaemic event as the index date  
 
Aim 1: This will be a comparison of adverse outcomes in patients with 
diabetes and dementia, based on no recorded exposure (Group 1) or 
exposure (Group 2) to hypoglycaemia. Patients will be eligible for selection 
into Group 1 or Group 2 from the later of their first prescription of an oral 
or injectable glucose-lowering drug, and the first of (1) a first diagnosis of 
dementia, or (2) a first prescription of a drug used in the treatment of 
dementia (e.g. donepezil, galantamine, memantine, or rivastigmine) (13).  
Group 2 patients (hypo exposure) will be matched to each patient in Group 
1 (never hypos) on ratio of up to 1:10, based on year of birth (+/- 3 years), 
gender, country, index of multiple deprivation quintile, availability of linked 
data, year of glucose-lowering drug initiation, year of meeting the dementia 
definition, and any diabetes complications. 
 
Aim 2: adverse outcomes after hypoglycaemia exposure - this will be a 
comparison between Group 2 and Group 3 (see Appendix 1).  We will match 
patients with diabetes and dementia (Group 2) with those who have no 
diagnosis of dementia (Group 3) on ratio of up to 1:10, based on year of 
birth (+/- 3 years), gender, country, index of multiple deprivation quintile, 
availability of linked data, year of glucose-lowering drug initiation, index 
date year, and any diabetes complications. 
In a sensitivity analysis of the hazard of serious adverse events after 
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hypoglycaemia exposure, we will evaluate the impact in Group 3 of 
classifying patients into the dementia Group 2 if they fulfilled the above-
mentioned dementia diagnosis criteria for up to 6 months after the 
hypoglycaemia exposure. This takes into account the time frame for 
development of dementia (which is usually a gradual process and would 
likely have been already present in the preceding 6 months), and the fact 
that dementia itself may have been a triggering factor for hypoglycaemia. 
K. Exposures, outcomes and covariates 
Exposure of interest: occurrence of hypoglycaemia 
We will ascertain the occurrence of acute episodes of hypoglycaemia 
recorded on CPRD, and/or the Hospital Episode Statistics (HES) database 
for the study participants. We recognize that capture of hypoglycaemia is 
incomplete if based on CPRD alone. HES data substantially improves 
capture of hypoglycaemia events, because it records all hospital 
admissions and emergency attendances at NHS hospitals in England.  The 
incident exposure will be considered as the first medically recorded 
hypoglycaemia in the period after first prescription of glucose-lowering 
drug. 
 
 
Outcomes of interest: serious adverse events after occurrence of 
hypoglycaemia 
The primary outcome will be falls and/or fractures. Secondary outcomes will 
be emergency healthcare and hospitalization, cardiovascular events (acute 
coronary syndrome, stroke), and overall mortality.   
 
For the emergency healthcare and hospitalisation, we will initially use Full 
HES to analyse all cause hospital admission and then select out admission 
with one of the serious adverse events and/or hypoglycaemia recorded as 
the cause. 
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HES Admitted Patient Care data will be used in the primary analysis. ONS 
Death Registration Data and HES Accident & Emergency Data will form 
sensitivity analyses from 1998 and 2006 respectively for the subgroups of 
patients who have such linkage.   
 
Co-variates 
We will extract information on a wide range of patient characteristics, 
including duration of dementia and diabetes, medications, co-morbid 
conditions (hypertension, peripheral vascular disease, valvular heart 
disease, cardiovascular disease, chronic kidney disease, atrial fibrillation), 
complications (severe kidney failure, amputation, blindness), body mass 
index, HbA1C, hypertension, and any other risk factors that may influence 
adverse outcomes.  
 
Choice of confounders will subsequently be specifically tailored to the 
established risk factors for the particular outcome under investigation.  This 
will be guided by a comprehensive literature search and consensus with 
clinical experts within the research team. For instance, confounders for 
cardiovascular events will include cholesterol and blood pressure whereas 
evaluation of falls/fracture risk may be affected by corticosteroid use, 
osteoporosis, and history of excess alcohol use (this is not an exhaustive list).   
L. Data/Statistical analysis 
First, we will describe the patient characteristics of the groups 1, 2 and 3.  
 
Aim 1 and 2: to estimate the association between the timing of a severe 
hypoglycaemic episode and serious adverse events, we will use Cox 
proportional hazard regression models with adjustment for appropriate 
confounders to generate Hazard Ratios and 95% confidence intervals for 
each outcome. We will also adjust for all covariates we have matched the 
cohorts upon to allow for differing matching ratios. We will test the 
proportional hazards assumption and if it is not met, we will consider 
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splitting the follow-up time, or apply a different modelling technique. 
The first analysis will compare Groups 1 and 2.  The second analysis will 
compare Groups 2 and 3. 
For aim 1, we will also carry out a sensitivity analysis for multiple recorded 
hypoglycaemic events (e.g. those with 2 hypoglycaemic events, or ≥3 events 
as compared to referent group who have no hypoglycaemia).  We will carry 
out analyses using CPRD Gold and HES Admitted Patient Care data, Read 
Codes alone, HES alone and, finally, HES Accident & Emergency Data alone. 
Analyses will be performed with SPSS 22 (IBM) and STATA software 
(StataCorp LP, College Station, TX).  Statistical significance will be defined 
as p<0.05. 
 
M. Plan for addressing confounding  
We will use multivariable regression models which include the 
confounders that have been identified (please also see Section K). 
 
N. Plan for addressing missing data 
We anticipate that there will be missing data, which will include 
incomplete recording of outcomes as well as confounding variables, such 
as HbA1C or cholesterol. 
We will explore the possibility of whether data may be missing at random 
(by comparing the characteristics of those with and without missing data) 
and decide whether to impute or conduct a complete case analysis. We 
would prefer to impute where feasible to maintain the cohort size and 
reduce potential bias due to missing data. 
 
O. Limitations of the study design, data sources and analytic 
methods 
Hypoglycaemia events are recorded in CPRD only if the patient presents to 
the GP with hypoglycaemia, or the GP codes a prior hypoglycaemia event 
reported to them by the patient or from a secondary care source. In 
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practice, this is uncommon and there are relatively few events in the CPRD 
database with a Read code for hypoglycaemia.  To resolve this issue, we 
will also use HES to capture data on patients admitted to hospital with 
recorded hypoglycaemia, which is linked with CPRD. The use of HES will 
retrieve hypoglycaemia exposure that are more severe or symptomatic – 
this is advantageous for our study because we believe that more severe 
hypoglycaemia has a potentially greater magnitude of association with 
long-term serious consequences. This approach has been successfully used 
in a recent CPRD-based cohort study of cardiovascular events associated 
with hypoglycaemic events recorded in insulin-treated patients. (14) 
Missing data will be another limitation (see Section N). 
Residual confounding will always be a possible limitation, for example 
frailty which has not been captured on CPRD or severity of dementia (we 
will adjust for dementia duration).  
 
P. Patient user group involvement 
The research protocol has been seen by three members of the Alzheimer’s 
Research Network and their input and comments has been instrumental in 
finalizing this project.  They will also be members of the Advisory 
Committee who will meet six-monthly and provide input in the running of 
the project. 
 
 
Q. Plans for disseminating and communicating study results, 
including the presence or absence of any restrictions on the 
extent and timing of publication 
Patients and carers: Findings will be disseminated through meetings with 
the Alzheimer’s Society, Diabetes UK and Age UK. We will extend this 
through webinars and materials for the websites of these charities. 
Healthcare professionals: We have regular contact with medical journalists 
who prepare articles for the mainstream healthcare press such as Pulse 
(for GPs), and Pharmacy Journal. We will use these channels to 
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disseminate our findings to clinicians involved in patient care. 
Policy makers: Findings will be submitted to three separate NICE Guideline 
Groups (multimorbidity, dementia, and diabetes). 
Scientific community: Presentations at annual British Geriatrics Society and 
Alzheimer’s Society conferences, and submission for publication in peer-
reviewed journals. 
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Appendix 1 – schematic representation of cohort study 
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Appendix 2 – READ Codes 
 
Dementia (based on Imfeld et al.) (13) 
E00, E02y1, E041, Eu00, Eu01, Eu02, Eu041, F110, F111, F112, F116, Fyu3000 
Diabetes (based on Khunti et al.) (14) 
C10+ 
Hypoglycaemia (based on Khunti et al.) (14) 
C11..00, C111.00, C111000, C111100, C111z00, C112.00, C112000, C112100, 
C112z00, C116.00, C116000, C11y100, Cyu3000, F374500 
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Amendments to the Protocol, November 2017 
Section I Study population 
Inclusion criteria: Eligible participants have to have HES linked data available 
(April 1997 to March 2016) 
 
Follow-up: Up to five years from the index date, loss from database, death, 
or end of available HES linkage (31 March 2016), whichever is the earlier.   
 
We have added ICD-10 codes to Appendix 2 for dementia. Dementia 
diagnosis from HES, where available, will also be accepted if the patient does 
not have a CPRD Read code for dementia. 
 
Section H Data linkage 
HES Admitted Patient Care and HES Accident &Emergency (from April 
2007) data will be used to supplement the available CPRD GOLD data on 
serious adverse events (including hypoglycaemia, fall, fractures and 
cardiovascular events) that triggered visits to hospital. 
 
Section J Selection of comparison groups and controls 
Aim 1: This will be a comparison of adverse outcomes in patients with 
diabetes and dementia, based on no recorded exposure (Group 1) or 
exposure (Group 2) to hypoglycaemia. Patients will be eligible for selection 
into Group 1 or Group 2 from the later of their first prescription of an oral 
or injectable glucose-lowering drug, and the first of (1) a first diagnosis of 
dementia, or (2) a first prescription of a drug used in the treatment of 
dementia (e.g. donepezil, galantamine, memantine, or rivastigmine). 
Aim 2: adverse outcomes after hypoglycaemia exposure - this will be a 
comparison between Group 2 and Group 3 (see Appendix 1).   
Section K Exposures, outcomes and covariates 
Co-variates 
We will extract information on a wide range of patient characteristics, 
including year of birth, gender, country, index of multiple deprivation 
  333 
quintile, year of glucose-lowering drug initiation, duration of dementia and 
diabetes, medications, co-morbid conditions (hypertension, peripheral 
vascular disease, valvular heart disease, cardiovascular disease, chronic 
kidney disease, atrial fibrillation), complications (severe kidney failure, 
amputation, blindness), body mass index, HbA1C, hypertension, and any 
other risk factors that may influence adverse outcomes.  
 
 
Appendix 2 
 
ICD 10 codes for dementia 
F00, F01, F02, F03, G30, G31.0 or G31.1 
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Appendix 9 Cover letter to ISAC with proposed amendments 
Dear ISAC Secretariat 
 
Protocol 16_184: “Hypoglycaemia and serious adverse events in older 
people living with diabetes and dementia – a population-based cohort 
study” 
Justification for amendments to Protocol 
 
We enclose proposed amendments to the above protocol.  The 
amendments are listed at the end of the document in the section headed 
‘amendments’.  No changes have been made to the already approved 
protocol or application form. 
 
The justifications for the amendments are as follows: 
Proposed amendment Justifications  
Section I Study population 
Inclusion criteria: Eligible 
participants have to have HES 
linked data available (April 1997 
to March 2016) 
 
Follow-up:  
We would like to remove ‘or 
permanent cessation of glucose-
lowering drugs’ from the follow-
up period and include ‘or end of 
available HES linkage (31 March 
2016)’ 
 
 
 
We have added ICD-10 codes to 
Appendix 2 for dementia. 
Dementia diagnosis from HES, 
where available, will also be 
accepted if the patient does not 
have a CPRD Read code for 
dementia.  
 
We have added the HES availability 
dates to the inclusion criteria. 
 
 
 
On reflection, the cessation of 
glucose-lowering drugs after the 
index date is not relevant, as we are 
not investigating adverse events from 
drugs.  Instead, we are interested in 
adverse events following 
hypoglycaemic event(s). 
 
 
Brown et al’s 2016 paper showed that 
dementia recorded in routinely 
collected NHS hospital admission 
data (HES) has 85% diagnostic 
agreement with a GP survey, and is 
sufficiently reliable for 
epidemiological research.  The 
authors looked at CPRD, GP surveys 
and HES records1. 
 
Section H Data Linkage 
HES Admitted Patient Care and 
HES Accident &Emergency (from 
April 2007) 
 
We have corrected a typographical 
error and realise that the HES A&E 
data does not start until April 2007. 
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Section J Selection of 
comparison groups and 
controls 
Aim 1: This will be a comparison 
of adverse outcomes in patients 
with diabetes and dementia, 
based on no recorded exposure 
(Group 1) or exposure (Group 2) 
to hypoglycaemia. Patients will 
be eligible for selection into 
Group 1 or Group 2 from the 
later of their first prescription of 
an oral or injectable glucose-
lowering drug, and the first of (1) 
a first diagnosis of dementia, or 
(2) a first prescription of a drug 
used in the treatment of 
dementia (e.g. donepezil, 
galantamine, memantine, or 
rivastigmine). 
 
We have decided to adjust for 
covariates, rather than match and 
have removed the matching criteria 
previously listed in Aim 1.  We 
assessed feasibility of matching, but 
this resulted in substantial loss of 
power.  For example, cohort one 
included just under 10500 
unmatched patient IDs, which was 
reduced to just under 4000 when 
matched 1:3 on sex and age +/- 2 
years. 
 
We will instead transfer the matching 
criteria to the covariates (section K). 
Section K. Exposures, outcomes, 
covariates 
Co-variates 
We will extract information on a 
wide range of patient 
characteristics, including year of 
birth, gender, index of multiple 
deprivation quintile, year of 
glucose-lowering drug initiation, 
duration of dementia and 
diabetes, medications, co-
morbid conditions 
(hypertension, peripheral 
vascular disease, valvular heart 
disease, cardiovascular disease, 
chronic kidney disease, atrial 
fibrillation), complications 
(severe kidney failure, 
amputation, blindness), body 
mass index, HbA1C, 
hypertension, and any other risk 
factors that may influence 
adverse outcomes.  
 
The items that were previously in the 
matching criteria are now considered 
to be covariates in the adjusted 
analysis (see above). 
Appendix 2 
ICD 10 codes for dementia 
Please see justification for Section I 
amendment above 
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F00, F01, F02, F03, G30, G31.0 or 
G31.1 
 
 
1 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5084368/ (last accessed 20 November 2017) 
 
We would be grateful if our proposed amendments could be considered 
and approved. 
 
Your sincerely 
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Appendix 10 ISAC approvals 
ISAC EVALUATION OF PROTOCOLS FOR RESEARCH 
INVOLVING CPRD DATA 
 
FEEDBACK TO APPLICANTS 
 
CONFIDENTIAL                                                                       by e-mail 
PROTOCOL NO: 16_184R 
PROTOCOL TITLE:  Hypoglycaemia and serious adverse events in older people living 
with diabetes and dementia – a population-based cohort study 
APPLICANT:  Professor Yoon K Loke, Professor of Medicine and  Pharmacology, 
University of East Anglia, Norwich NR4 7TJ. 
Email: y.loke@uea.ac.uk 
APPROVED  
  
APPROVED WITH 
COMMENTS  
(resubmission not required)  
  
REVISION/ 
RESUBMISSION 
REQUESTED  
  
REJECTED  
 
 
INSTRUCTIONS: 
Please include your response/s to the Reviewer’s feedback below only if you are required to 
Revise/ Resubmit your protocol.  
Protocols with an outcome of ‘Approved’ or ‘Approved with comments’ do not require 
resubmission to the ISAC. 
 
REVIEWER  COMMENTS: 
Protocol 16_184R has been approved. 
 
DATE OF ISAC FEEDBACK: 14/03/2017 
DATE OF APPLICANT 
FEEDBACK: 
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ISAC EVALUATION OF PROTOCOLS FOR RESEARCH 
INVOLVING CPRD DATA 
 
FEEDBACK TO APPLICANTS 
CONFIDENTIAL                                                                       by e-mail 
PROTOCOL NO: 16_184RA 
PROTOCOL TITLE:  Hypoglycaemia and serious adverse events in older people living with 
diabetes and dementia – a population-based cohort study 
APPLICANT:  Professor Yoon K Loke, Professor of Medicine and  Pharmacology, 
University of East Anglia, Norwich NR4 7TJ. 
Email: y.loke@uea.ac.uk  
APPROVED  
  
APPROVED WITH 
COMMENTS  
(resubmission not required)  
  
REVISION/ 
RESUBMISSION 
REQUESTED  
  
REJECTED  
 
 
INSTRUCTIONS: 
Please include your response/s to the Reviewer’s feedback below only if you are required to 
Revise/ Resubmit your protocol.  
Protocols with an outcome of ‘Approved’ or ‘Approved with comments’ do not require 
resubmission to the ISAC. 
 
REVIEWER  COMMENTS: 
Please note that Section H Data linkage recorded under amended protocol section does not make 
mention the use of HES data to further identify dementia cases although this has been outlined 
(and supported) in the cover letter.  Please update this section accordingly.  
 
Suggestion only 
The low yield on matching is likely due to the large number of matching variables initially 
proposed. Matching may be improved by simply matching on practice, year of birth and gender 
with the remaining variables included in the model as covariates. As matching will no longer be 
undertaken it is unclear what is the start of follow-up for patients without a record of 
hypoglycaemia. The study could perhaps be implemented as a time-dependent analysis where 
patients with a record of hypoglycaemia are unexposed up to the time of their hypoglycaemia 
diagnosis and then exposed thereafter; patients without a history of hypoglycaemia remain 
unexposed through the study.  
 
DATE OF ISAC FEEDBACK: 18/12/2017 
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Appendix 11 Codes used to generate dataset for CPRD study 
In accordance with good practice for reporting of electronic healthcare studies, the entirety of the code files will be stored on a publicly accessible site for 
full transparency of reporting. 
https://clinicalcodes.rss.mhs.man.ac.uk/medcodes/article/75/ 
 
Drugs used for dementia Product codes: 9966, 62925, 7329, 36976, 60107, 56771, 11751, 68845, 5334, 53922, 11546, 10255, 38976, 
5616, 68792, 61385, 63226, 20140, 60723, 61476, 65501, 24088, 58780, 11752, 68802, 68494, 11635, 
68493, 48443, 56600, 53882, 9854, 55928, 65761, 59993, 37188, 2931, 39363, 6225, 66899, 63217, 39362, 
11654, 56631, 63405, 65333, 61920, 62780, 48482, 39240, 59330, 66934, 55720, 37957, 63951, 57139, 
61618, 60192, 11837, 29288, 62867, 11827, 35088, 61921, 37444, 62868, 10187, 58969, 65573, 53842, 
11716, 60493, 58937, 18587, 65534, 36848, 56709, 67593, 59871, 2930, 35179, 7361, 56421, 18800, 4597, 
61676, 5247, 5400, 58947, 62164, 57171, 63360, 14309, 48015, 18062, 57627, 58709, 9786, 20404, 37132, 
64982, 18556, 48442 
 
Dementia Read codes:  Eu00200, Eu00112, Eu00100, Eu00000, Eu00.00, E004.11, E004.00, E002100, E002000, 
E001.00, E000.00, E00..12, E00..11, 6AB..00, 66h..00, Eu00z00, Eu00z11, Eu01.00, Eu01300, Eu01z00, 
Eu02.00, Eu02300, Eu02500, Eu02z00, Eu02z14, F110.00, F110000, F110100, F112.00, F116.00 
ICD 9/10 codes: 290, F00-F03, G30, G31.0 or G31.1, G31.83 
 
Hypoglycemia Read codes: C112100, C11y100, C116.00, C110z00, C112z00, C116000, C112000, C112.00, C110.00 
ICD9/10: 251.0, 251.1, 251.2, E249.8 and E250.8, E10.64, E11.64, E16.0, E16.1, E16.2 
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Fracture codes 
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  342 
 
 
  343 
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Cardiovascular codes
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Falls 
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Appendix 12 Steps used when cleaning CPRD data and assumptions made when categories needed to be allocated 
Generating covariates 
Covariate What is the problem with data as extracted, such that we 
can't use it directly in Cox Regression? 
What should the correct formatted data look like? 
HbA1C Extracted values date back from index date to years before, 
and may not reflect recent ones 
Only HbA1C in 18-months prior to index date should be keyed into 
analysis. 
BMI Extracted values date back from index date to years before, 
and may not reflect recent ones 
Only BMI in 18-months prior to index date should be keyed into analysis. 
Smoking Extracted values provide dates available for non-smoker, ex-
smoker, current smoker 
Need to generate variables representing smoking status (yes/no) 
ETOH Extracted values provide dates available for ETOH user and 
non-user 
Need to generate variables representing ETOH status (yes/no) 
Diabetes duration Extracted values include participants with index date PRIOR 
to date of first diabetes drug 
Only participants with index date AFTER commencing drug therapy 
should be keyed into analysis 
History of MI Hx of MI is a confounder for future cardiovascular events Need to generate variable representing history of MI prior to index_date 
Ethnicity  Ethnicity is coded as a string variable Need to convert to a numerical variable 
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Generating outcomes 
Outcome What is the problem with data as extracted, such that 
we can't use it directly in Cox Regression? 
What should the correct formatted data look like? 
MI Some MI recorded on CPRD/HES after date of death on 
ONS. 
If MI is coded in both CPRD and ONS then we re-allocate first-MI date to 
match ONS date of death. 
 
Stroke Some Stroke recorded on CPRD/HES after date of death 
on ONS. 
If Stroke is coded in both CPRD and ONS, then we re-allocate first stroke 
date to match ONS date of death. 
  
CV data Need to construct composite of MI or stroke Date of first MI or stroke, whichever is earlier 
Death date before 
1998 
ONS linkage only starts from 1 Jan 1998 Patients with index date before Jan 1998 need to have their CPRD death 
status checked, and the date entered into date of death 
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Appendix 13 Reporting of hypoglycaemia incidence  
Study ID Reporting of hypoglycaemia incidence 
Bedenis 2014140 Total 1066; at least one episode of severe hypoglycaemia n=87 
Bonds 2010137 Total n=10194; patients with at least one hypoglycaemic event requiring assistance n=703 
Cha 2016141 Total n=1260; severe hypoglycaemia n=85 
Chiba 2015142 Total n=211; hypoglycaemia in patients with falls 22/62 (35%) 
Chin 2016143 Total n=1957; participants with hypoglycaemia n=118; no hypoglycaemia n=1839 
Cukierman-Yaffe 2019144 Severe hypoglycaemia n=427; no severe hypoglycaemia n=11068 
Davis 2019145 Rate of severe hypoglycemia in the intensive treatment group was 10.3 per 100 patient-years compared with 3.7 per 100 patient-
years in the standard treatment group; at least one severe hypoglcyaemic event n=268 
Duckworth 2011146 9 episodes per 100 patient years in intensive arm 
Escalada 2016147 Total n=31035; hypoglycaemia group n=3066 
Freemantle 2016148 Total of 175 (6.6%) participants reported at least one severe hypoglycaemic event, and 1508 (53.7%) reported at least one 
symptomatic hypoglycaemic event 
Goto 2016149 58223 with T2DM; 128 (0.2%) patients experienced severe hypoglycemia 
Haroon 2015150 Total cohort 225045; secondary analysis hospitalizations or ED visits for hypoglycaemia during follow-up as a risk factor for dementia 
– total number of hypoglycaemic episodes not reported. 
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Heller 2017151 5380 patients with type 2 diabetes; any reported hypoglycaemia n=354 
Hsu 2013152 1,844 hypoglycemic events among 77,611 new type 2 diabetic patients from 1998 to 2009. The incidence of hypoglycemia was 
2.38% (1,844/77,611). 
Hung 201772 Total cohort n=5173; 2588 patients with severe hypoglcyaemia 
Johnston 2011154 Total n=860845; 27,065 (3.1%) had hypoglycaemic events during the evaluation period  
Johnston 2012153 361 210 included patients; 16 936 had hypoglycaemic events during the evaluation period 
Kacharoo 2015155 21,613 hypoglycemia patients were matched with 21,613 non-hypoglycemic patients 
Khunti 2015122 3,260 patients with type 1 diabetes and 10,422 patients with type 2 diabetes included; during follow-up, 573 patients (18%) with 
type 1 diabetes and 1,463 patients (14%) with type 2 diabetes experienced 
hypoglycemia. 
Kong 2014 (CKD) 156 Cohort of 8,767 type 2 diabetic patients; on enrolment, 209 patients had severe hypoglycaemia and 194 developed 
severe hypoglycaemia during follow-up. 
Lee 2018 (CV mortality) 71 1,209 participants with diagnosed diabetes; 195 participants with at least one severe hypoglycemic episode 
Lee 2018 (dementia) 68 2001 participants with diabetes; 63 had history of severe hypoglcyaemia (3.1%) 
Leong 2016157 Three percent of patients (n = 285) had previous hypoglycemia 
Lin 201370 15 404 diabetic subjects; 2% (n = 289) of participants had at least one episode of hypoglycaemia in a 3-year period 
Lu 2015158 Diabetes with hypoglycaemia group n=31049; Diabetes without hypoglycaemia group n=31049 
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Majumdar 2013159 Cohort included 85,810 patients; 440 patients (0.5%) had severe hypoglycemia associated with hospitalization 
Mattishent 2019160 1679 participants had a medically recorded hypoglycaemic episode 
McCoy 2012161 625 (61.7%) reported any hypoglycaemia, and 76 (7.5%) reported severe hypoglycaemia. 
Mehta 2017 162 5.7% (n = 3,018) had at least one hypoglycaemia episode during the follow-up period; 0.8% (n = 503) had two episodes; and 0.5% (n 
= 314) had more than two episodes 
Mellbin 2013164 3518 participants had at least one episode of hypoglycaemia. Of these 2614 (74.3%) occurred in the glargine group and 904 (25.7%) 
in the standard group.   
Of the 472 participants with at least one episode of severe hypoglycaemia, 76.1% (359) occurred in the glargine group and 23.9% 
(113) in the standard group with an estimated annual incidence of 0.9 and 0.3%, respectively. 
Ntouva 2019163 14147 patients in the exposed cohort (patients with a documented hypoglycaemic event at index date) 
Pieber 2018165 Severe hypoglycaemia prior to all-cause mortality n=38; 7.32 events per 100 patient-years 
Rajpathak 2015166 Documented hypoglycaemia during follow-up period n=1056; no documented hypoglycaemia n=25334 
Rathmann 2013167 Hypoglycaemic episodes (≥1) were documented in 0.18% patients with DPP-4 and in 1.00% with SU  
Signorovitch 2013168 A total of N=5582 people with claims for hypoglycaemia and N=27 910 with no such claims were included. 
Standl 2018169 Severe hypoglycaemic episodes were uncommon and unassociated with sitagliptin therapy (N = 160 [2.2%],0.78/100 patient-years 
vs. N = 143 [1.9%], 0.70/100 patient-years for placebo 
Whitmer 200969 At least 1 episode of hypoglycaemia was diagnosed in 1465 patients (8.8%) 
Yaffe 2013170 During the 12-year follow-up period, 61 participants (7.8%) had a reported hypoglycemic event, 
Zhao 2012171 The analytical population consisted of 44,261 patients, including 761 patients in the hypoglycemia group and 43,500 in the control 
group. The incidence rate of hypoglycemia events was calculated as 3.57/100 patient-years 
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Zhao 2015172 A total of 4215 patients with hypoglycaemia were identified and 4215 non-hypoglycaemia patients were match to the 
hypoglycaemia patients 
Zinman 2018173 4.3% (n=180) participants who used insulin at baseline had had severe hypoglycaemia 
Zoungas 2010174 During a median follow-up period of 5 years, 231 patients (2.1%) had at least one severe hypoglycemic episode; 150 had been 
assigned to intensive glucose control (2.7% of the 5571 patients in that group), and 81 had been assigned to standard glucose 
control (1.5% of the 5569 patients in that group). 
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Appendix 14 Pooled Odds Ratios for different associations using fixed and random effects methods 
 
 
 
 Pooled Odds Ratios – fixed effect Pooled Odds Ratios – random effect I2 
Association between hypoglycaemia and mortality 1.86 (95% CI 1.78 to 1.94) 2.02 (95% CI 1.75 to 2.32) 86% 
Association between hypoglycaemia and dementia 1.62 (95% CI 1.54 to 1.71) 1.55 (95% CI 1.33 to 1.79) 70% 
Association between hypoglycaemia and falls  1.54 (95% CI 1.45 to 1.63) 1.78 (95% CI 1.44 to 2.21) 87% 
Association between hypoglycaemia and fractures 1.51 (95% CI 1.43 to 1.58) 1.68 (95% CI 1.37 to 2.07) 91% 
Association between hypoglycaemia and 
macrovascular events 
1.80 (95% CI 1.71 to 1.91) 1.81 (95% CI 1.69 to 1.95) 10% 
Association between hypoglycaemia and 
microvascular events 
1.77 (95% CI 1.49 to 2.10) 1.77 (95% CI 1.49 to 2.10) 0% 
